WO2016134320A1 - Bicyclic heterocycles as fgfr inhibitors - Google Patents

Bicyclic heterocycles as fgfr inhibitors Download PDF

Info

Publication number
WO2016134320A1
WO2016134320A1 PCT/US2016/018787 US2016018787W WO2016134320A1 WO 2016134320 A1 WO2016134320 A1 WO 2016134320A1 US 2016018787 W US2016018787 W US 2016018787W WO 2016134320 A1 WO2016134320 A1 WO 2016134320A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
difluoro
dimethoxyphenyl
pyrazol
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/018787
Other languages
French (fr)
Inventor
Liang Lu
Bo Shen
Alexander Sokolsky
Xiaozhao Wang
Liangxing Wu
Wenqing Yao
Yingda YE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55442925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2016134320(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to ES16706767T priority Critical patent/ES2751669T3/en
Priority to HK18106492.0A priority patent/HK1246794B/en
Priority to UAA201709221A priority patent/UA121669C2/en
Priority to CN201680011332.7A priority patent/CN107438607B/en
Priority to MYPI2017001121A priority patent/MY197720A/en
Priority to BR112017017418-9A priority patent/BR112017017418B1/en
Priority to MX2017010673A priority patent/MX373169B/en
Priority to NZ734586A priority patent/NZ734586B2/en
Priority to CR20170390A priority patent/CR20170390A/en
Priority to MX2020004108A priority patent/MX388991B/en
Priority to EA201791866A priority patent/EA038045B1/en
Priority to AU2016219822A priority patent/AU2016219822B2/en
Priority to SG11201706287PA priority patent/SG11201706287PA/en
Priority to JP2017544021A priority patent/JP6689871B2/en
Priority to EP19187640.8A priority patent/EP3617205B1/en
Priority to KR1020177026449A priority patent/KR102632018B1/en
Priority to CA2976790A priority patent/CA2976790C/en
Priority to CN202110062229.8A priority patent/CN113004278B/en
Priority to EP16706767.7A priority patent/EP3259269B9/en
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of WO2016134320A1 publication Critical patent/WO2016134320A1/en
Priority to IL253691A priority patent/IL253691B/en
Priority to PH12017501481A priority patent/PH12017501481B1/en
Anticipated expiration legal-status Critical
Priority to CONC2017/0008795A priority patent/CO2017008795A2/en
Priority to AU2020250211A priority patent/AU2020250211B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
  • the Fibroblast Growth Factor Receptors are receptor tyrosine kinases that bind to fibroblast growth factor (FGF) ligands.
  • FGF fibroblast growth factor
  • FGFR 1-4 FGFR proteins that are capable of binding ligands and are involved in the regulation of many physiological processes including tissue development, angiogenesis, wound healing, and metabolic regulation.
  • the receptors Upon ligand binding, the receptors undergo dimerization and phosphorylation leading to stimulation of the protein kinase activity and recruitment of many intracellular docking proteins. These interactions facilitate the activation of an array of intracellular signaling pathways including Ras-MAPK, AKT-PI3K, and phospholipase C that are important for cellular growth, proliferation and survival (Reviewed in Eswarakumar et al. Cytokine & Growth Factor Reviews, 2005).
  • FGFR or activating mutations in the FGFRs can lead to tumor development, progression, and resistance to conventional cancer therapies.
  • genetic alterations including gene amplification, chromosomal translocations and somatic mutations that lead to ligand- independent receptor activation have been described.
  • Large scale DNA sequencing of thousands of tumor samples has revealed that components of the FGFR pathway are among the most frequently mutated in human cancer. Many of these activating mutations are identical to germline mutations that lead to skeletal dysplasia syndromes.
  • Mechanisms that lead to aberrant ligand-dependent signaling in human disease include overexpression of FGFs and changes in FGFR splicing that lead to receptors with more promiscuous ligand binding abilities (Reviewed in Knights and Cook Pharmacology & Therapeutics, 2010; Turner and Grose, Nature Reviews Cancer, 2010). Therefore, development of inhibitors targeting FGFR may be useful in the clinical treatment of diseases that have elevated FGF or FGFR activity.
  • carcinomas e.g., bladder, breast, cervical, colorectal, endometrial, gastric, head and neck, kidney, liver, lung, ovarian, prostate
  • hematopoietic malignancies e.g., multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, acute myelogenous leukemia, non- Hodgkin lymphoma, myeloproliferative neoplasms, and Waldenstrom's Macroglubulinemia
  • other neoplasms e.g., glioblastoma, melanoma, and rhabdosarcoma.
  • FGFR activation has also been implicated in skeletal and chondrocyte disorders including, but not limited to, achrondroplasia and craniosynostosis syndromes.
  • the FGFR4-FGF19 signaling axis specifically, has been implicated in the pathogenesis of a number of cancers including hepatocellular carcinoma (Heinzle et al, Cur. Pharm. Des. 2014, 20:2881). Ectopic expression of FGF19 in transgenic mice was shown to lead to tumor formation in the liver and a neutralizing antibody to FGF 19 was found to inhibit tumor growth in mice. In addition, overexpression of FGFR4 has been observed in a multiple tumor types including hepatocellular carcinoma, colorectal, breast, pancreatic, prostate, lung, and thyroid cancers. Furthermore, activating mutations in FGFR4 have been reported in rhabdomyosarcoma (Taylor et al. JCI 2009,1 19:3395). Targeting FGFR with selective small molecule inhibitors may therefore prove beneficial in the treatment of cancers and other diseases.
  • the present disclosure relates to compounds having Formula ( ⁇ ):
  • compositions comprising a compound of Formula ( ⁇ ), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.
  • the present disclosure provides methods for inhibiting an FGFR3 and/or FGFR4 enzyme.
  • the method includes contacting the enzyme with a compound of Formula ( ⁇ ), or a pharmaceutically acceptable salt thereof or a composition comprising compounds of Formula ( ⁇ ).
  • the present disclosure provides a method for treating a disease associated with abnormal activity or expression of an FGFR enzyme, such as an FGFR3 and/or an FGFR4.
  • the method includes administering an effective amount of a compound of Formula ( ⁇ ), or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of Formula ( ⁇ ), to a patient in need thereof.
  • the present disclosure provides compounds of Formula ( ⁇ ) for use in treating a disease associated with abnormal activity or expression of an FGFR3 and/or FGFR4 enzyme.
  • the present disclosure provides a method for treating a disorder mediated by an FGFR3 and/or FGFR4 enzyme, or a mutant thereof, in a patient in need thereof.
  • the method includes administering to the patient a compound as described herein or pharmaceutically acceptable salts thereof or a composition comprising a compound as described herein.
  • the present disclosure provides the use of compounds of Formula ( ⁇ ) in the preparation of a medicament for use in therapy.
  • the present disclosure provides a compound having Formula ( ⁇ ):
  • ring A is a Ce- ⁇ aryl or 5- to 10-membered heteroaryl having carbon and 1 to 4 heteroatoms as ring members selected from O, N, and S, wherein the N and S are each optionally oxidized;
  • each R 12 is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, OR a , SR a , C(0)R a , C(0)NR a R a , C(0)OR a , OC(0)R a , OC(0)NR a R a , NR a R a , NR a OR a , NR a C(0)R a , NR a C(0)OR a
  • heterocycloalkyl ring phenyl or 5 to 6-membered heteroaryl ring, wherein the
  • heterocycloalkyl or heteroaryl has 1 -2 heteroatoms as ring members selected from O, N, and S;
  • each R a is independently selected from H, Ci-6 alkyl, Ci -4 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci
  • R a substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • each R c is independently selected from H, Ci-6 alkyl, Ci -4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-iocycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of R c are each optionally substituted with 1, 2, 3, 4, or 5 independently selected R f substituents;
  • R c substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • each R d is independently selected from C1-4 alkyl, C1-4 haloalkyl, halo, CN, OR e , SR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NR e R e , NR e C(0)R e ,
  • each R f is independently selected from Ci-4 alkyl, Ci -4 haloalkyl, halo, CN, OR s , SR S , C(0)R8, C(0)NRsRs, C(0)ORs, OC(0)Rs, OC(0)NR «Re NR g R g , NR g C(0)Rs,
  • each R j is independently selected from halo, Ci -4 alkyl, Ci -4 haloalkyl, CN, 0R k , SR k , C(0)R k , C(0)NR k R k , C(0)OR k , OC(0)R k , OC(0)NR k R k , NR k R k , NR k C(0)R k ,
  • each R e , R s , R 1 or R k is independently selected from H, Ci -4 alkyl, C6-ioaryl, C1-4 haloalkyl, C 2 -4 alkenyl, and C 2 -4 alkynyl, wherein the C1-4 alkyl, C6-ioaryl, C 2 -4 alkenyl or C 2 -4 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, di(Ci-4 alkyl)amino, Ci-4 haloalkyl, and Ci-4 haloalkoxy;
  • R e substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R s substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R 1 substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • X 1 is -CR 10 R n - or -NR 7 -
  • X 2 is N or CR 6 ;
  • R 13 is H, CN, NR c4 R d4 , OR 1 or -C(0)NHR e , wherein R 1 is C1-3 alkyl or C1-3 haloalkyl; R 2 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy; R 3 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
  • R 14 is H, CN, NR c4 R d4 , OR 4 or -C(0)NHRs, wherein R 4 is C1-3 alkyl or C1-3 haloalkyl; R 5 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
  • R 6 is selected from H, halo, CN, OR a4 , SR a4 , C(0)NR c4 R d4 , OC(0)NR c4 R d4 , NR c4 R d4 , NR c4 C(0)R M , NR c4 C(0)OR a4 , NR c4 C(0)NR c4 R d4 , NR c4 S(0)R M , NR c4 S(0)2R M ,
  • R 7 is selected from H, C(0)NR c4 R d4 , S(0)R M , S(0)NR c4 R d4 , S(0) 2 R M ,
  • R 10 and R 11 are each independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, a 5-10 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-10 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl groups of R 10 and R 11 are each optionally substituted with 1, 2, or 3, R 10A ;
  • R 10 and R 11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group or a 4-, 5-, 6-, 7-, 8-, 9-, or 10- membered heterocycloalkyl group; wherein said 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group and 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group are each optionally substituted with 1, 2, 3 or 4 R 10A ;
  • NR c4 C( NR e4 )NR c4 R d4 , NR c4 R d4 , NR c4 C(0)R M , NR c4 C(0)OR a4 , NR c4 C(0)NR c4 R d4 , NR c4 S(0)R M , NR c4 S(0) 2 R M , NR c4 S(0) 2 NR c4 R d4 , S(0)R M , S(0)NR c4 R d4 , S(0)2R M ,
  • each R a4 , R b4 , R c4 , and R d4 is independently selected from H, Ci -4 alkyl, C2-4 alkenyl,
  • R 04 and R d4 together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group which is optionally substituted with 1, 2 or 3 substituents independently selected from R 19 ;
  • each R e4 is independently H or Ci -4 alkyl
  • each R 19 is independently selected from halo, CN, NO2, OR a9 , SR a9 , C(0)R b9 , C(0)NR c9 R d9 , C(0)OR a9 , OC(0)R b9 , OC(0)NR c9 R d9 , NR c9 R d9 , NR c9 C(0)R b9 , NR c9 C(0)OR a9 , NR c9 C(0)NR c9 R d9 , NR c9 S(0)R b9 , NR c9 S(0) 2 R b9 , NR c9 S(0) 2 NR c9 R d9 , S(0)R b9 , S(0)NR c9 R d9 , S(0)R b9 , S(0)NR c9 R d9 , S(0)R b9 , S(0)NR c9 R d9 , S(0) 2 R b9 , S(0)NR c9
  • each R a9 , R c9 , and R d9 is independently selected from H and C1-4 alkyl;
  • each R b9 is independently C1-4 alkyl
  • n 0, 1, 2 or 3.
  • the present disclosure provides a compound having Formula
  • ring A is a C6-10 aryl or 5 to 6-membered heteroaryl having carbon and 1 to 4 heteroatoms as ring members selected from O, N, and S;
  • each R 12 is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5- 10 membered heteroaryl, 4- 10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5- 10 membered heteroaryl)-Ci-4 alkyl-, (4- 10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, N0 2 , OR a , SR a , C(0)R a , C(0)NR a R a , C(0)OR a , OC(0)R a , OC(0)NR a R a , NR a R a , NR a OR a , NR a C(0)R a , NR a C
  • heterocycloalkyl ring phenyl or 5 to 6-membered heteroaryl ring, wherein the
  • heterocycloalkyl or heteroaryl has 1 -2 heteroatoms as ring members selected from O, N, and S;
  • each R a is independently selected from H, Ci-6 alkyl, Ci -4 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein Ci-6 alkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-
  • R a substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • each R c is independently selected from H, Ci-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 independently selected R f substituents; or any two R c substituents attached to the same
  • each R d is independently selected from C1-4 alkyl, C1-4 haloalkyl, halo, CN, OR e , SR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NR e R e , NR e C(0)R e ,
  • each R f is independently selected from Ci-4 alkyl, Ci -4 haloalkyl, halo, CN, OR ⁇ , SR ⁇ ,
  • each R j is independently selected from halo, Ci -4 alkyl, Ci -4 haloalkyl, CN, OR k , SR k , C(0)R k , C(0)NR k R k , C(0)OR k , OC(0)R k , OC(0)NR k R k , NR k R k , NR k C(0)R k ,
  • each R e , R g , R 1 or R k is independently selected from H, Ci -4 alkyl, C6-ioaryl, C1-4 haloalkyl, C 2 -4 alkenyl, and C 2 -4 alkynyl, wherein the C1-4 alkyl, C6-ioaryl, C 2 -4 alkenyl or C 2 -4 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci -4 alkyl, C1-4 alkoxy, Ci -4 alkylthio, Ci -4 alkylamino, di(Ci-4 alkyl)amino, Ci-4 haloalkyl, and Ci-4 haloalkoxy;
  • R 1 substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • X 1 is -CR 10 R n - or -NR 7 -
  • X 2 is N or CR 6 ;
  • R 1 is Ci-3 alkyl or C1-3 haloalkyl
  • R 2 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
  • R 3 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
  • R 4 is Ci-3 alkyl or C1-3 haloalkyl
  • R 5 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
  • R 6 and R 7 are each independently selected from H, halo, CN, OR a4 , SR a4 ,
  • R 10 and R 11 are each independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, a 5-10 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-10 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl groups of R 10 and R 11 are each optionally substituted with 1, 2, or 3, R 10A ;
  • R 10 and R 11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group or a 4-, 5-, 6-, 7-, 8-, 9-, or 10- membered heterocycloalkyl group; wherein said 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group and 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group are each optionally substituted with 1, 2, 3 or 4 R 10A ;
  • NR c4 C( NR e4 )NR c4 R d4 , NR c4 R d4 , NR c4 C(0)R M , NR c4 C(0)OR a4 , NR c4 C(0)NR c4 R d4 , NR c4 S(0)R M , NR c4 S(0) 2 R M , NR c4 S(0) 2 NR c4 R d4 , S(0)R M , S(0)NR c4 R d4 , S(0)2R M ,
  • each R a4 , R b4 , R c4 , and R d4 is independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of R a4 , R b4 , R c4 , and R d4 are each optionally substituted with 1, 2, or 3 substituents independently selected from R 19 ;
  • R 04 and R d4 together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group which is optionally substituted with 1, 2 or 3 substituents independently selected from R 19 ;
  • each R e4 is independently H or C1-4 alkyl
  • each R 19 is independently selected from halo, CN, NO2, OR a9 , SR a9 , C(0)R b9 , C(0)NR c9 R d9 , C(0)OR a9 , OC(0)R b9 , OC(0)NR c9 R d9 , NR c9 R d9 , NR c9 C(0)R b9 ,
  • each R a9 , R c9 , and R d9 is independently selected from H and C1-4 alkyl;
  • each R b9 is independently Ci -4 alkyl
  • n 0, 1, 2 or 3.
  • ring A is a Ce- ⁇ aryl or 5 to 6-membered heteroaryl having carbon and 1 to 4 heteroatoms as ring members selected from O, N, and S;
  • each R 12 is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, OR a , SR a , C(0)R a , C(0)NR a R a , C(0)OR a , OC(0)R a , OC(0)NR a R a , NR a R a , NROR a , NR a C(0)R a , NR a C(0)OR a ,
  • heterocycloalkyl ring phenyl or 5 to 6-membered heteroaryl ring, wherein the
  • heterocycloalkyl or heteroaryl have 1-2 heteroatoms as ring members selected from O, N, and S;
  • each R a is independently selected from H, Ci-6 alkyl, Ci -4 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein Ci-6 alkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci
  • R a substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • each R c is independently selected from H, Ci-6 alkyl, Ci -4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-iocycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 independently selected R f substituents;
  • R c substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • each R d is independently selected from C1-4 alkyl, C1-4 haloalkyl, halo, CN, OR e , SR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NR e R e , NR e C(0)R e ,
  • each R f is independently selected from Ci-4 alkyl, Ci -4 haloalkyl, halo, CN, OR ⁇ , SR ⁇ ,
  • each R j is independently selected from halo, Ci -4 alkyl, Ci-4 haloalkyl, CN, OR k , SR k , C(0)R k , C(0)NR k R k , C(0)OR k , OC(0)R k , OC(0)NR k R k , NR k R k , NR k C(0)R k ,
  • each R e , R s , R 1 or R k is independently selected from H, Ci -4 alkyl, C6-ioaryl, Ci-4 haloalkyl, C 2 -4 alkenyl, and C 2 -4 alkynyl, wherein the Ci-4 alkyl, C6-ioaryl, C 2 -4 alkenyl or C 2 -4 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci -4 alkyl, Ci-4 alkoxy, Ci -4 alkylthio, Ci -4 alkylamino, di(Ci-4 alkyl)amino, Ci-4 haloalkyl, and Ci-4 haloalkoxy;
  • R e substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R s substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R 1 substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • X 1 is -CR 10 R n - or -NR 7 -
  • X 2 is N or CR 6 ;
  • R 1 is Ci-3 alkyl or C1-3 haloalkyl
  • R 2 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
  • R 3 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
  • R 4 is Ci-3 alkyl or C1-3 haloalkyl
  • R 5 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
  • R 6 is selected from H, halo, CN, OR a4 , SR a4 , C(0)NR c4 R d4 , OC(0)NR c4 R d4 , NR c4 R d4 , NR c4 C(0)R M , NR c4 C(0)OR a4 , NR c4 C(0)NR c4 R d4 , NR c4 S(0)R M , NR c4 S(0) 2 R M ,
  • R 7 is selected from H, C(0)NR c4 R d4 , S(0)R M , S(0)NR c4 R d4 , S(0 R b4 ,
  • R 10 and R 11 are each independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, a 5-10 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-10 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- ⁇ aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl groups of R 10 and R 11 are each optionally substituted with 1, 2, or 3, R 10A ;
  • R 10 and R 11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group or a 4-, 5-, 6-, 7-, 8-, 9-, or 10- membered heterocycloalkyl group; wherein said 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group and 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group are each optionally substituted with 1, 2, 3 or 4 R 10A ;
  • NR c4 C( NR e4 )NR c4 R d4 , NR c4 R d4 , NR c4 C(0)R M , NR c4 C(0)OR a4 , NR c4 C(0)NR c4 R d4 , NR c4 S(0)R M , NR c4 S(0) 2 R M , NR c4 S(0) 2 NR c4 R d4 , S(0)R M , S(0)NR c4 R d4 , S(0)2R M ,
  • each R a4 , R b4 , R c4 , and R d4 is independently selected from H, Ci -4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of R a4 , R b4 , R c4 , and R d4 are each optionally substituted with 1, 2, or 3 substituents independently selected from R 19 ;
  • R 04 and R d4 together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group which is optionally substituted with 1, 2 or 3 substituents independently selected from R 19 ;
  • each R e4 is independently H or Ci -4 alkyl
  • each R 19 is independently selected from halo, CN, NO2, OR a9 , SR a9 , C(0)R b9 ,
  • each R a9 , R c9 , and R d9 is independently selected from H and C1-4 alkyl;
  • each R b9 is independently C1-4 alkyl
  • n 0, 1, 2 or 3.
  • the present disclosure provides a compound having Formula (I):
  • heterocycloalkyl ring phenyl or 5 to 6-membered heteroaryl ring, wherein the
  • heterocycloalkyl or heteroaryl have 1-2 heteroatoms as ring members selected from O, N, and S;
  • each R a is independently selected from H, Ci-6 alkyl, Ci -4 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein Ci-6 alkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-
  • R a substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • each R c is independently selected from H, Ci-6 alkyl, Ci -4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 independently selected R f substituents;
  • each R d is independently selected from C1-4 alkyl, C1-4 haloalkyl, halo, CN, OR e , SR e , C(0)R e , C(0)NR e R e , C(0)OR e , OC(0)R e , OC(0)NR e R e , NR e R e , NR e C(0)R e ,
  • each R f is independently selected from C1-4 alkyl, Ci -4 haloalkyl, halo, CN, OR s , SR S , C(0)R8, C(0)NR3 ⁇ 4s, C(0)ORs, OC(0)Rs, OC(0)NR «R ⁇ % NR3 ⁇ 4s, NR S C(0)RS,
  • each R j is independently selected from halo, Ci -4 alkyl, C1-4 haloalkyl, CN, 0R k , SR k , C(0)R k , C(0)NR k R k , C(0)OR k , OC(0)R k , OC(0)NR k R k , NR k R k , NR k C(0)R k ,
  • each R e , R g , R 1 or R k is independently selected from H, Ci -4 alkyl, C6-ioaryl, C1-4 haloalkyl, C 2 -4 alkenyl, and C 2 -4 alkynyl, wherein the C1-4 alkyl, C6-ioaryl, C 2 -4 alkenyl or C 2 -4 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci -4 alkyl, C1-4 alkoxy, Ci -4 alkylthio, Ci -4 alkylamino, di(Ci-4 alkyl)amino, Ci-4 haloalkyl, and Ci-4 haloalkoxy;
  • R e substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R s substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R 1 substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • X 1 is -CR 10 R n - or -NR 7 - X 2 is N or CR 6 ;
  • R 1 is Ci-3 alkyl or C1-3 haloalkyl
  • R 2 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
  • R 3 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
  • R 4 is Ci-3 alkyl or C1-3 haloalkyl
  • R 5 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
  • R 6 and R 7 are each independently selected from H, halo, CN, 0R a4 , SR a4 ,
  • R 10 and R 11 are each independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, a 5-10 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-10 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl groups of R 10 and R 11 are each optionally substituted with 1, 2, or 3, R 10A ;
  • R 10 and R 11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group or a 4-, 5-, 6-, 7-, 8-, 9-, or 10- membered heterocycloalkyl group; wherein said 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group and 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group are each optionally substituted with 1, 2, 3 or 4 R 10A ;
  • each R 10A is independently selected from halo, CN, NO2, OR a4 , SR a4 , C(0)R M ,
  • NR c4 C( NR e4 )NR c4 R d4 , NR c4 R d4 , NR c4 C(0)R M , NR c4 C(0)OR a4 , NR c4 C(0)NR c4 R d4 , NR c4 S(0)R M , NR c4 S(0) 2 R M , NR c4 S(0) 2 NR c4 R d4 , S(0)R M , S(0)NR c4 R d4 , S(0)2R M ,
  • each R a4 , R b4 , R c4 , and R d4 is independently selected from H, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of R a4 , R b4 , R c4 , and R d4 are each optionally substituted with 1, 2, or 3 substituents independently selected from R 19 ;
  • R 04 and R d4 together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group which is optionally substituted with 1, 2 or 3 substituents independently selected from R 19 ;
  • each R e4 is independently H or Ci -4 alkyl
  • each R 19 is independently selected from halo, CN, NO2, OR a9 , SR a9 , C(0)R b9 ,
  • each R a9 , R c9 , and R d9 is independently selected from H and C1-4 alkyl;
  • each R b9 is independently C1-4 alkyl
  • n 0, 1, 2 or 3.
  • R 7 is selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl groups of R 7 are each optionally substituted with 1, 2, or 3 substituents independently selected from R 10A .
  • R 7 is Ci-6 alkyl, phenyl, benzyl, C3-6 cycloalkyl, C3-10 cycloalkyl-Ci-4 alkyl-, 4- to 10-membered heterocycloalkyl, (4-10 membered
  • R 7 is Ci-6 alkyl, cyclopropylmethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-fluorobenzyl, tetrahydrofuran-3-yl, (3-methylisoxazol-5-yl)methyl, (tetrahydro-2H-pyran- 4-yl)methyl, (5-cyclopropylisoxazol-3-yl)methyl, 5-methylisoxazol-3-yl)methyl, 4- fluorophenyl, (l-ethylpyrazol-4-yl)methyl, benzothiazol-6-yl, l-methyl-5-oxopyrrolidin-3-yl, 1 -acetylpiperidin-4-yl, 2,3 -dihydro- 1 ,4-benzodioxin-6-ylmethyl, 1 -t- butoxycarbonylpiperidin-4-yl, 4-cyanophenyl, 4-pyr
  • R 7 is Ci-6 alkyl, cyclopropylmethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-fluorobenzyl, (3-methylisoxazol-5-yl)methyl, (5- cyclopropylisoxazol-3-yl)methyl, 4-fluorophenyl, (l-ethylpyrazol-4-yl)methyl, 1- acetylpiperidin-4-yl, 2,3-dihydro-l,4-benzodioxin-6-ylmethyl, 1-t-butoxycarbonylpiperidin- 4-yl, 4-cyanophenyl, 4-pyrimidinyl, 2-pyrimidinyl, 5-pyrimidinyl, l-methylpyrazol-3-yl, (l,5-dimethylpyrazol-4-yl)methyl, or (5-methyl-l,3,4-oxadiazol-2-yl)methyl.
  • R 7 is Ci-6 alkyl, cyclopropylmethyl, cyclopentyl, 4- fluorobenzyl, tetrahydrofuran-3-yl, (3-methylisoxazol-5-yl)methyl, (tetrahydro-2H-pyran-4- yl)methyl, (5-cyclopropylisoxazol-3-yl)methyl, 5-methylisoxazol-3-yl)methyl, 4- fluorophenyl, (l-ethylpyrazol-4-yl)methyl, benzothiazol-6-yl, l-methyl-5-oxopyrrolidin-3-yl, l-acetylpiperidin-4-yl, 2,3-dihydro-l,4-benzodioxin-6-ylmethyl, 4-cyanophenyl, 4- pyrimidinyl, (l,5-dimethylpyrazol-4-yl)methyl, or (5-methyl-l,3,4-oxadia
  • R 7 is methyl, isopropyl, pyridazin-4-yl, (2-methoxypyridin-4- yl)methyl, (6-methoxypyridin-3-yl)methyl, 3-cyanophenyl, pyrimidin-5-yl, isoquinolin-7-yl, 4-methylcarbamoylbenzyl, (5-ethylisoxazol-3-yl)methyl, pyrimidin-4-ylmethyl, 3-cyano-4- fluorophenyl, (5-ethyl-l,3,4-oxadiazol-2-yl)methyl, (2-methylpyridin-4-yl)methyl, pyridin-4- ylmethyl, pyrazin-2-yl, l-(methylsulfonyl)piperidin-4-yl, (1 -methyl- lH-pyrazol-4-yl)methyl, 3,4-difluorobenzyl, 2-cyano-5-pyridyl,
  • compounds of Formula ( ⁇ ) or (I) have selective inhibitory activity on FGFR4 enzyme or any mutant thereof over other FGFR enzymes. In other embodiments, compounds of Formula ( ⁇ ) or (I) have selective inhibitory activity on FGFR3 enzyme or any mutant thereof over other FGFR enzymes. In other embodiments, compounds of Formula ( ⁇ ) or (I) have selective dual inhibitory activity on both FGFR3 and FGFR4 enzymes or any mutant thereof.
  • ring A is C6-io aryl. In certain instances, ring A is phenyl. In one instance, ring A is 1 -naphthyl or 2-naphthyl.
  • ring A is phenyl and two adjacent R 12 substituents on the phenyl ring taken together with the carbon atoms to which they are attached form a fused 3 to 7-membered cycloalkyl. In some instances, ring A is phenyl and two adjacent R 12 substituents on the phenyl ring taken together with the carbon atoms to which they are attached form a fused cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
  • ring A is phenyl and two adjacent R 12 substituents on the phenyl ring taken together with the carbon atoms to which they are attached form a fused 4 to 6-membered heterocycloalkyl.
  • ring A is phenyl and two adjacent R 12 substituents on the phenyl ring taken together with the carbon atoms to which they are attached form a fused 2-oxetanyl, 2-tetrahydrofuranyl, 3- tetrahydrofuranyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 1, 1- dioxotetrahydrothiophen-2-yl, l, l-dioxotetrahydrothiophen-3-yl, 2-tetrahydropyranyl, 3- tetrahydropyranyl, 4-tetrahydropyranyl, 3,6-dihydro-2H-pyranyl, 3,4-dihydro-2H-pyranyl, 1- azetidinyl, 2-azetidinyl, 3-azetidinyl, 1 -pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl,
  • ring A is 5-membered heteroaryl.
  • ring A is 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, thiophenyl, thiazolyl, isoxazolyl, isothiazolyl, or furanyl.
  • ring A is pyrazolyl or imidazolyl.
  • ring A is pyrazolyl.
  • ring A is 4-pyrazolyl.
  • ring A is 5-membered heteroaryl selected from 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 1-pyrazolyl, 3-pyrazolyl, 4- pyrazolyl, 1 -imidazolyl, 2-imidazolyl, 4-imidazolyl, 2-oxazolyl, 4- oxazolyl, 5-oxazolyl, 2- thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3- isothiazolyl, 4- isothiazolyl, 5-isothiazolyl, 1 ,2,3-triazol- 1 -yl, 1 ,2,3-triazol-2-yl, 1 ,2,3-triazol-3-yl, 1 ,2,3- triazol-4-yl, 1 ,2,3-triazol-5-yl, 1 ,2,4-
  • ring A is 6-membered heteroaryl. In certain embodiments, ring A is selected from pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, and triazinyl.
  • ring A is 6-membered heteroaryl selected from 2-pyridyl, 3 -pyridyl, 4-pyridyl, 2-pyrazinyl, 3- pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5 -pyrimidinyl, l,2,3-triazin-4-yl, l,2,3-triazin-5-yl, l,3,5-triazin-2-yl, l,2,4-triazin-3-yl, l,2,4-triazin-5-yl, and l,2,4-triazin-6- yl-
  • ring A is pyridyl.
  • ring A is phenyl or 6-membered heteroaryl.
  • ring A is phenyl or pyridyl.
  • j or each of which is optionally substituted with 1 or 2 R 12 substituents defined herein.
  • ring A is bstituted with R 12 as defined herein.
  • ring A is optionally substituted with R 12
  • ring A is
  • ring A is , optionally substituted with R 12 .
  • ring A is
  • R 13 is H, CN, NR c4 R d4 , OR 1 or - C(0)NHR e , wherein R 1 is Ci-3 alkyl or Ci-3 haloalkyl and R 14 is H, CN, NR ⁇ 4 , OR 4 or - C(0)NHR s , wherein R 4 is C1-3 alkyl or C1-3 haloalkyl.
  • R 13 is OR 1 and R 14 is OR 4 .
  • R 13 is -C(0)NHR e and R 14 is OR 4 .
  • R 13 is H, CN, NR c4 R d4 , OR 1 or - C(0)NHR e , wherein R 1 is Ci-3 alkyl or Ci-3 haloalkyl and R 14 is H, CN, NR ⁇ 4 , OR 4 or - C(0)NHR s , wherein R 4 is C1-3 alkyl or C1-3 haloalkyl.
  • R 13 is OR 1 and R 14 is OR 4 .
  • R 13 and R 14 are each OCH3. In other embodiments, R 13 is -C(0)NHR e and R 14 is OR 4 . In some embodiments, R 13 and R 14 are each independently selected form Ci -4 alkyl-NHC(O)- and OCH3. In one embodiment, R 13 is -C(0)NHCi-6 alkyl and R 14 is OR 4 . In another embodiment, R 13 is -C(0)NHCi-6alkyl and R 14 is OCH3. In another embodiment, R 13 is -C(0)NHCH 3 and R 14 is OCH3. In some embodiments, R 13 is H and R 14 is CN, NR ⁇ 4 , OR 4 or -C(0)NHRs.
  • R 2 and R 5 are each independently H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy. In other embodiments, R 2 and R 5 are each independently halogen. In some instances, R 2 and R 5 are halogen. In a preferred embodiment, R 2 and R 5 are F.
  • R 1 and R 4 are each independently C1-3 alkyl or C1-3 haloalkyl. In some instances, R 1 and R 4 are each
  • R 1 and R 4 are each independently methyl, ethyl, propyl, CF3, CF2H or CFH2. In a preferred embodiment, R 1 and R 4 are CH3.
  • R 3 is H, halo, C1-3 alkyl, Ci-3 haloalkyl, CN, or C1-3 alkoxy. In some instances, R 3 is H, F, CI, Ci-3alkyl, CF3, CF3O, CFH2, CHF2, OCFH2 or OCHF2. In a preferred embodiment, R 3 is H.
  • R 10 and R 11 are each independently Ci-6 alkyl. In some instances, R 10 and R 11 are methyl. In some embodiments, R 10 and R 11 taken together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group, which is optionally substituted with 1 or 2
  • R 10A groups independently selected R 10A groups.
  • R 10 and R 11 taken together with the carbon atom to which they are attached form cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, each of which is optionally substituted with from 1-3 R 10A groups.
  • R 10 and R 11 together with the carbon atom to which they are attached form a cyclopropyl, optionally substituted with 1 or 2 independently selected R 10A groups.
  • R 10 and R 11 are H.
  • R 10 and R 11 are each independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2 or 3 substituents independently selected from R 10A .
  • R 10 and R 11 taken together with the carbon atom to which they are attached form 4-, 5-, 6-, or 7-membered
  • R 10 and R 11 together with the carbon atom to which they are attached form 2-oxetanyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2 -tetrahydropyranyl, 3- tetrahydropyranyl, 4-tetrahydropyranyl, 3,6-dihydro-2H-pyranyl, 3,4-dihydro-2H-pyranyl, 1- azetidinyl, 2-azetidinyl, 3-azetidinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1- piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1 -piperazinyl, 2-piperazinyl, 4- morpholinyl, 3-morpholinyl or 2-morpholinyl, 1-azepany
  • R 10A is halo, CN, Ci-6 alkyl, C3-6 cycloalkyl, -C(0)R b4 , or -C(0)OR b4 ; or two R 10A substituents attached to the adjacent ring atoms of the aryl or heteroaryl ring of R 7 are optionally taken together with the atoms to which they are attached form a 5- to 6-membered heterocycloalkyl ring having 1-2 heteroatoms as ring members independently selected from O, N and S, wherein the nitrogen and sulfur atoms are each optionally oxidized.
  • R 10A is F, CI, CH3, Ci- 6 alkyl, CN, -C(0)Ci-4 alkyl or - C(0)OCi-4 alkyl; or two R 10A substituents attached to the adjacent ring atoms of the aryl or heteroaryl ring of R 7 are optionally taken together with the atoms to which they are attached form a tetrahydrofuran, tetrahydropyran, 1,4-dioxane, morpholine, tetrahydrothiopyran or tetrahydrothiophene ring, each of which is optionally substituted with 1 or 2 R 19 substituents.
  • R 10A is F, CH3, CN, -C(0)CH3, or cyclopropyl.
  • R 10 and R 11 together with the carbon atom to which they are attached form a cyclopropyl.
  • X 1 is -CR 10 R n - or -NR 7 -.
  • X 1 is -CR 10 R U -. In another embodiment, X 1 is -NR 7 -. In some instances, X 1 is CH2 or NH.
  • X 1 is NR 7 , wherein R 7 is Ci-6 alkyl, phenyl, benzyl, C3-6 cycloalkyl, C3-10 cycloalkyl-Ci-4 alkyl-, 4- to 10-membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, 5- to 10-membered heteroaryl, or (5- to 10-membered heteroaryl)-Ci-4 alkyl-, each of which is optionally substituted with 1, 2, or 3 independently selected R 10A substituents; or two R 10A substituents attached to the adjacent ring atoms of the aryl or heteroaryl ring of R 7 are taken together with the atoms to which they are attached form a fused C5-6 cycloalkyl ring or a fused 5 to 6- membered heterocycloalkyl ring having 1-2 heteroatoms as ring members independently selected from O, N and
  • R 10A is halo, CN, Ci ealkyl, C3- 6cycloalkyl, -C(0)R M or -C(0)OR M ; or two R 10A substituents attached to the adjacent ring atoms of the aryl or heteroaryl ring of R 7 are taken together with the atoms to which they are attached form a 5- to 6-membered heterocycloalkyl ring having 1-2 heteroatoms as ring members independently selected from O, N and S, wherein the nitrogen and sulfur atoms are each optionally oxidized.
  • R 10A is F, CI, CH3, Ci-6 alkyl, CN, -C(0)Ci-4 alkyl or -C(0)OCi-4 alkyl; or two R 10A substituents attached to the adjacent ring atoms of the aryl or heteroaryl ring of R 7 are taken together with the atoms to which they are attached form a tetrahydrofuran, tetrahydropyran, 1,4-dioxane, morpholine, tetrahydrothiopyran, or tetrahydrothiophene ring, each of which is optionally substituted with 1 or 2 R 19 substituents.
  • X 1 is NR 7 , wherein R 7 is Ci-6 alkyl, cycloproprylmethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4- fluorobenzyl, (3-methylisoxazol-5-yl)methyl, (5-cyclopropylisoxazol-3-yl)methyl, 4- fluorophenyl, (l-ethylpyrazol-4-yl)methyl, l-acetylpiperidin-4-yl, 2,3-dihydro-l,4- benzodioxin-6-ylmethyl, l-t-butoxycarbonylpiperidin-4-yl, 4-cyanophenyl, 4-pyrimidinyl, 2- pyrimidinyl, 5-pyrimidinyl, l-methylpyrazol-3-yl, (l,5-dimethylpyrazol-4-yl)methyl or (5
  • X 2 is N or CR 6 . In other embodiments, X 2 is N or CH. In one preferred embodiment, X 2 is N. In another preferred embodiment, X 2 is CH.
  • each R 12 is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, OR a , SR a , C(0)R a , C(0)NR a R a , C(0)OR a , OC(0)R a , OC(0)NR a R a , NR a R a , NROR a , NR a C(0)R a , NR
  • each R 12 is independently selected from F, CI, CN, CH3, CH2CH3, NH2, OCH3, -C(0)NH(Ci-4 alkyl), NHC(0)CH 3 , NHS(0) 2 CH 3 , NHS(0) 2 R a , C(0)R a , -CH 2 C(0)R a , -CH 2 CH 2 R a , morpholinosulfonyl, imidazolyl, 4-morpholinyl, (3- cyanopyrrolidin-l-yl)methyl, 2-cyanoprop-2-yl, 1-cyanocyclobutyl, 1 -cyanocyclopropyl, benzyl, pyridylmethyl, l,l-dioxothiolan-3-yl, l-methylsulfonylazetidin-3-yl, l-acetyl-3- (cyanomethyl)azetidin-3-yl, and -CH2-(4-morpholinyl), wherein R
  • each R 12 is independently selected from F, CI, CN, CH3, CH2CH3, NH2, -C(0)NH(Ci- 4 alkyl), NHC(0)CH 3 , NHS(0) 2 CH 3 , C(0)R a , -CH 2 C(0)R a , - CH2CH2R a , morpholinosulfonyl, imidazolyl, 4-morpholinyl, (3-cyanopyrrolidin-l-yl)methyl, 2-cyanoprop-2-yl, 1-cyanocyclobutyl, pyridylmethyl, l,l-dioxothiolan-3-yl, l-acetyl-3- (cyanomethyl)azetidin-3-yl, and -CH2-(4-morpholinyl), wherein R a is 4-morpholinyl.
  • each R 12 is independently NH2, CH3, F, CN, 1-piperidinyl, 1 -piperazinyl. or 4-morpholinyl.
  • each R 12 is independently selected from -NH2, -NHOH, - NHOR a , -NHR a , -NHC(0)R a , -NHC(0)NHR a , -NHS(0) 2 R a , -C(0)R a , -S(0) 2 R a , Ci- 6 alkyl, Ci ealkoxy, Ci ehaloalkyl, Ci- 4 haloalkoxy, halo, CN, C3-6cycloalkyl, phenyl-Ci- 4 alkyl, 5-6 membered heteroaryl, 5- to 6-membered heteroaryl-Ci- 4 alkyl, 4 to 6-membered
  • heterocycloalkyl and (4-10 membered heterocycloalkyl)-Ci- 4 alkyl-, wherein the Ci-6 alkyl, C3-6cycloalkyl, phenyl-Ci- 4 alkyl, 5-6 membered heteroaryl, 4 to 6-membered
  • heterocycloalkyl and (4-10 membered heterocycloalkyl)-Ci- 4 alkyl- is optionally substituted with from 1-3 R b ; and Ci e alkoxy or Ci- 4 haloalkoxy is optionally substituted by 1-3 R d .
  • each R 12 is independently F, CI, CN, CH3, NH2, OCH3, NHS(0) 2 R a , C(0)R a , -CH 2 C(0)R a , imidazoyl, 4-morpholinyl, -CH 2 -(4-morpholinyl), (3- cyanopyrrolidin-l-yl)methyl, 1-cycano-l -methyl-ethyl, 1-cyanocyclobutyl, 1- cyanocyclopropyl, benzyl, l,l-dioxothiolan-3-yl, l-methylsulfonylazetidin-3-yl, l-acetyl-3- (cyanomethyl)azetidin-3-yl and -CH2-(4-morpholinyl), wherein R a is 4-morpholinyl.
  • each R 12 is independently F, CI, CN, CH3, NH2, OCH3, NHS(0)2R a , C(0)R a , imidazoyl, 4-morpholinyl, and -CH2-(4-morpholinyl), wherein R a is 4- morpholinyl.
  • R 12 is H, methyl, ethyl, CN, cyanomethyl, 2-cyanoethyl, 1- cyanocyclobutyl, 3-morpholinopropyl, l-(methylsulfonyl)pyrrolidin-3-yl, (1-
  • the subscript n is 0, 1, or 2. In some embodiments, the subscript n is 0. In some embodiments, the subscript n is 1. In another embodiment, the subscript n is 2. In another embodiment, the subscript n is 3.
  • Ring A is phenyl or a 6-membered heteroaryl ring
  • R 10 and R 11 are Ci-e alkyl
  • R 10 and R 11 together with the carbon atom to which they are attached form a a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group, which is optionally substituted with 1 or 2 independently selected R 10A groups.
  • each R 12 is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, C6-10 aryl, C 3 -
  • each R b is independently selected from halo, Ci -4 alkyl, Ci -4 haloalkyl, CN, N0 2 , OR c ,
  • NR c C(0)OR c NR c C(0)NR c R c , NR c S(0)R c , NR c S(0) 2 R c , NR c S(0) 2 NR c R c , S(0)R c ,
  • each R c is independently selected from H and Ci-6 alkyl
  • n 0, 1, 2, or 3.
  • X 1 is CR 10 R n ;
  • X 2 is CH
  • Ring A is phenyl or a 6-membered heteroaryl ring
  • R 10 and R 11 are Ci-e alkyl; alternatively, R 10 and R 11 together with the carbon atom to which they are attached form a a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group, which is optionally substituted with 1 or 2 independently selected R 10A groups.
  • each R 12 is independently selected from halo, CN, NR a R a , NROR a , NHC(0)R a , NHS(0) 2 R a , C(0)R a , S(0) 2 R a , OR a , Ci-e alkyl, Ci-e haloalkyl, 5-6 membered heteroaryl, and 4 to 6-membered heterocycloalkyl, wherein said Ci-6 alkyl, 5-6 membered heteroaryl, or 4 to 6- membered heterocycloalkyl is optionally substituted with from 1-3 R b ;
  • each R b is independently selected from halo, Ci -4 alkyl, Ci -4 haloalkyl, CN, NO2, OR c , SR C , C(0)R c , C(0)NR c R c , C(0)OR c , OC(0)R c , OC(0)NR c R c , NR C R C , NR c C(0)R c ,
  • NR c C(0)OR c NR c C(0)NR c R c , NR c S(0)R c , NR c S(0) 2 R c , NR c S(0) 2 NR c R c , S(0)R c ,
  • each R c is independently selected from H and Ci-6 alkyl
  • n 0, 1, 2, or 3.
  • X 1 is CR 10 R n ;
  • X 2 is CH
  • Ring A is phenyl or pyridyl
  • R 10 and R 11 are Ci-6 alkyl
  • R 10 and R 11 together with the carbon atom to which they are attached form a a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group, which is optionally substituted with 1 or 2 independently selected R 10A groups;
  • each R 12 is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, (4-6 membered heterocycloalkyl)-Ci- 2 alkyl-, CN, OR a , C(0)R a , NR a R a , NR a S(0) 2 R a , and S(0) 2 R a ;
  • each R a is independently selected from H, Ci-6 alkyl, C1-4 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl; and
  • n 0, 1, 2, or 3.
  • ring A is a 5-6 membered heteroaryl ring, then ring A is connected by a carbon atom to the moiety below at the point indicated by the wavy line:
  • compounds of Formula ( ⁇ ) or (I) have subformula (la):
  • variables ring A, R 1 , R 2 , R 3 , R 4 , R 5 , R 10 , R 11 , R 12 , X 2 and n are as defined in any embodiment of compounds of Formula ( ⁇ ) or (I).
  • ring A is a C6-10 aryl or a 5 to 6-membered heteroaryl having carbon and 1 to 4 heteroatoms as ring members selected from O, N and S;
  • each R 12 is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, OR a , SR a , C(0)R a , C(0)NR a R a , C(0)OR a , OC(0)R a , OC(0)NR a R a , NR a R a , NR a OR a , NR a C(0)R a , NR a C(0)OR a
  • each R a is independently selected from H, Ci-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-iocycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- is optionally substituted with 1, 2, 3, 4, or 5 R d substituents independently selected from C1-4 alkyl, Ci-4 haloalkyl,
  • each R c is independently selected from H, Ci-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
  • heterocycloalkyl C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-iocycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- is optionally substituted with 1, 2, 3, 4, or 5 R f substituents independently selected from C1-4 alkyl, Ci-4 haloalkyl,
  • Ci-e alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 Ri substituents independently selected from halo, C1-4 alkyl, Ci- 4 haloalkyl, CN, 0R k , SR k , C(0)R k , C(0)NR k R k , C(0)OR k , OC(0)R k ,
  • R e substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R s substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • R 1 substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected R h substituents;
  • each R e , R s , R 1 or R k is independently selected from H, C1-4 alkyl, C6-ioaryl, C1-4 haloalkyl, C 2 - 4 alkenyl, and C 2 - 4 alkynyl, wherein the Ci- 4 alkyl, C6-ioaryl, C 2 - 4 alkenyl or C 2 - 4 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci- 4 alkyl, Ci- 4 alkoxy, Ci- 4 alkylthio, Ci- 4 alkylamino, di(Ci- 4 alkyl)amino, Ci-4 haloalkyl, and Ci- 4 haloalkoxy;
  • X 2 is N or CR 6 ;
  • R 1 is Ci-3 alkyl or C1-3 haloalkyl
  • R 2 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy
  • R 3 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy
  • R 4 is Ci-3 alkyl or C1-3 haloalkyl
  • R 5 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
  • R 6 is H, halo, CN, OR a4 , SR a4 , C(0)NR c4 R d4 , OC(0)NR c4 R d4 , NR c4 R d4 , NR c4 C(0)R M , NR c4 C(0)OR a4 , NR c4 C(0)NR c4 R d4 , NR c4 S(0)R M , NR c4 S(0) 2 R b4 , NR c4 S(0) 2 NR c4 R d4 ,
  • heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl groups of R 6 are each optionally substituted with 1, 2, or 3 substituents independently selected from R 10A ;
  • R 10 is selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-10 aryl, C3- 10 cycloalkyl, a 5-10 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-10 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl groups of R 10 are each optionally substituted with 1, 2, 3, or 4 R 10A ;
  • each R 10A is independently selected from halo, CN, NO2, OR a4 , SR a4 , C(0)R M ,
  • NR c4 C( NR e4 )NR c4 R d4 , NR c4 R d4 , NR c4 C(0)R M , NR c4 C(0)OR a4 , NR c4 C(0)NR c4 R d4 , NR c4 S(0)R M , NR c4 S(0) 2 R M , NR c4 S(0) 2 NR c4 R d4 , S(0)R M , S(0)NR c4 R d4 , S(0)2R M ,
  • each R a4 , R b4 , R c4 , and R d4 are independently selected from H, Ci -4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci -4 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of R a4 , R b4 , R c4 , and R d4 are each optionally substituted with 1, 2, or 3 substituents independently selected from R 19 ;
  • R 04 and R d4 together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group which is optionally substituted with 1, 2 or 3 substituents independently selected from R 19 ;
  • each R e4 is independently H or Ci -4 alkyl
  • R 11 is selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2 or 3 substituents independently selected from R 19 ;
  • R 10 and R 11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group or a 4-, 5-, 6-, 7-, 8-, 9-, or 10- membered heterocycloalkyl group; wherein said 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group and 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group are each optionally substituted with 1, 2, 3 or 4 R 10A ;
  • each R 19 is independently selected from halo, CN, NO2, OR a9 , SR a9 , C(0)R b9 , C(0)NR c9 R d9 , C(0)OR a9 , OC(0)R b9 , OC(0)NR c9 R d9 , NR c9 R d9 , NR c9 C(0)R b9 ,
  • each R a9 , R c9 , and R d9 is independently selected from H and C1-4 alkyl;
  • each R b9 is independently Ci -4 alkyl
  • compounds of Formula (la) have selective inhibitory activity on FGFR4 enzyme or any mutant thereof. In other embodiments, compounds of Formula (la) have selective inhibitory activity on FGFR3 enzyme or any mutant thereof. In other embodiments, compounds of Formula (la) have selective inhibitory activity on both FGFR3 and FGFR4 enzyme or any mutant thereof. In some embodiments, compounds of Formula ( ⁇ ) or (I) have subformula (lb):
  • R 7 is H, halo, CN, or Ci-6 alkyl. In one embodiment, R 7 is H or Ci-6 alkyl.
  • compounds of Formula ( ⁇ ) or (I) have subformula (Ic):
  • R 2 is F or CI
  • R 5 is F or CI
  • R 10 is selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-10 aryl, C3- 10 cycloalkyl, a 5-10 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-10 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl groups of R 10 are each optionally substituted with 1, 2, 3, or 4 R 10A ;
  • NR c4 C( NR e4 )NR c4 R d4 , NR c4 R d4 , NR c4 C(0)R M , NR c4 C(0)OR a4 , NR c4 C(0)NR c4 R d4 , NR c4 S(0)R M , NR c4 S(0) 2 R M , NR c4 S(0) 2 NR c4 R d4 , S(0)R M , S(0)NR c4 R d4 , S(0)2R M ,
  • each R a4 , R b4 , R c4 , and R d4 is independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl groups of R a4 , R b4 , R c4 , and R d4 are each optionally substituted with 1, 2, or 3 substituents independently selected from R 19 ;
  • R 04 and R d4 together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group which is optionally substituted with 1, 2 or 3 substituents s independently selected from R 19 ;
  • R e4 is H or Ci- 4 alkyl
  • R 11 is selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl;
  • R 10 and R 11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group or a 4-, 5-, 6-, or 7-membered heterocycloalkyl group; wherein said 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group and 4-, 5-, 6-, or 7-membered heterocycloalkyl group are each optionally substituted with 1, 2, 3 or 4
  • each R 19 is independently selected from halo, CN, NO2, OR a9 , SR a9 , C(0)R b9 , C(0)NR c9 R d9 , C(0)OR a9 , OC(0)R b9 , OC(0)NR c9 R d9 , NR c9 R d9 , NR c9 C(0)R b9 , NR c9 C(0)OR a9 , NR c9 C(0)NR c9 R d9 , NR c9 S(0)R b9 , NR c9 S(0) 2 R b9 , NR c9 S(0) 2 NR b9 , NR c9 S(0) 2 NR c9 R d9 , S(0)R b9 , S(0)NR c9 R d9 , S(0) 2 R b9 , S(0)NR c9 R d9 , S(0) 2 R b9 , S(0)NR c9 R d9
  • each R a9 , R c9 , and R d9 are independently selected from H and Ci-4 alkyl;
  • R b9 is Ci-4 alkyl.
  • X 2 is N.
  • X 2 is CR 6 .
  • R 6 is H, halo, CN, or Ci-6 alkyl. In some embodiments, R 6 is H.
  • R 6 is Ci-6 alkyl. In some embodiments, R 6 is methyl. In some embodiments, R 6 is halo. In some embodiments, R 6 is CN.
  • R 1 is C1-3 alkyl. In some embodiments, R 1 is methyl.
  • R 2 is halo. In some embodiments, R 2 is fluoro. In some embodiments, R 2 is chloro.
  • R 3 is H.
  • R 4 is C1-3 alkyl. In some embodiments, R 4 is methyl.
  • R 5 is halo. In some embodiments, R 5 is fluoro. In some embodiments, R 5 is chloro.
  • R 2 is fluoro and R 5 is fluoro. In some embodiments, R 2 is chloro and R 5 is chloro.
  • R 1 is C1-3 alkyl; R 2 is halo; R 3 is H; R 4 is C1-3 alkyl; and R 5 is halo.
  • R 1 is C1-3 alkyl; R 2 is F; R 3 is H; R 4 is C1-3 alkyl; and R 5 is F.
  • R 1 is methyl; R 2 is F; R 3 is H; R 4 is methyl; and R 5 is F.
  • R 1 is C1-3 alkyl; R 2 is CI; R 3 is H; R 4 is C1-3 alkyl; and R 5 is CI.
  • R 1 is methyl; R 2 is CI; R 3 is H; R 4 is methyl; and R 5 is CI.
  • R 10 is Ci-6 alkyl. In some embodiments, R 10 is methyl. In some embodiments, R 11 is Ci-6 alkyl. In some embodiments, R 11 is methyl.
  • R 10 and R 11 are each Ci-6 alkyl. In some embodiments, R 10 and R 11 are each methyl.
  • R 10 and R 11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group. In some embodiments, R 10 and R 11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, or 6- membered cycloalkyl group. In some embodiments, R 10 and R 11 together with the carbon atom to which they are attached form a 3-, 4-, or 5-membered cycloalkyl group.
  • R 10 and R 11 together with the carbon atom to which they are attached form a cyclopropyl group. In some embodiments, R 10 and R 11 together with the carbon atom to which they are attached form a cyclobutyl group. In some embodiments, R 10 and R 11 together with the carbon atom to which they are attached form a cyclopentyl group. In some embodiments, R 10 and R 11 together with the carbon atom to which they are attached form a cyclohexyl group. In some embodiments, R 10 and R 11 together with the carbon atom to which they are attached form a cycloheptyl group.
  • R 10 and R 11 together with the carbon atom to which they are attached form a cyclopropyl group optionally substituted by 1 or 2 R 10A .
  • R 10 and R 11 together with the carbon atom to which they are attached form a cyclobutyl group optionally substituted by 1 or 2 R 10A . In some embodiments, R 10 and R 11 together with the carbon atom to which they are attached form a cyclopentyl group optionally substituted by 1 or 2 R 10A . In some embodiments, R 10 and R 11 together with the carbon atom to which they are attached form a cyclohexyl group optionally substituted by 1 or 2 R 10A .
  • R 10 and R 11 together with the carbon atom to which they are attached form 4-, 5-, 6-, or 7-membered heterocycloalkyl group.
  • R 10 and R 11 together with the carbon atom to which they are attached form a tetrahydropyranyl group, a tetrahydrofuranyl group, tetrahydrothiophene group, a pyrrolidinyl group, or a piperidinyl group. In some embodiments, R 10 and R 11 together with the carbon atom to which they are attached form a tetrahydropyranyl group. In some embodiments, R 10 and R 11 together with the carbon atom to which they are attached form a tetrahydropyranyl group optionally substituted by 1 or 2 R 10A . In some embodiments, R 10 and R 11 together with the carbon atom to which they are attached form a
  • R 10 and R 11 together with the carbon atom to which they are attached form a tetrahydrofuranyl group optionally substituted by R 10A .
  • R 10 and R 11 together with the carbon atom to which they are attached form an azetidinyl group.
  • R 10 and R 11 together with the carbon atom to which they are attached form an azetidinyl group optionally substituted by R 10A .
  • compounds of Formula ( ⁇ ), (I) or (la) have sub Formula (Id):
  • compounds of Formula ( ⁇ ), (I) or (la) have sub Formula (Ie):
  • compounds of Formula ( ⁇ ), (I), (la) or (Ie) have sub Formula
  • compounds of Formula ( ⁇ ), (I), (Ie) or (If) have sub Formula
  • ring A, R 10 , R 11 , X, R 12 and n are as defined in any embodiment of compounds of Formula ( ⁇ ) or (I) as described herein.
  • X 2 is N.
  • X 2 is CH.
  • ring A is phenyl.
  • ring A is 5-membered heteroaryl selected from 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl, 1- imidazolyl, 2-imidazolyl, 4-imidazolyl, 2-oxazolyl, 4- oxazolyl, 5-oxazolyl, 2-thiazolyl, 4- thiazolyl, 5-thiazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3- isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, 1 ,2,3-triazol- 1 -yl, 1 ,2,3-triazol-2-yl, 1 ,2,3-triazol-3-yl, 1 ,2,3-triazol-4-yl, 1 ,2,3-triazol-5-yl, 1 ,2,4-triazol-l -yl, 1 ,2,2,4-
  • ring A is 2-pyridyl, 3-pyridyl or 4-pyridyl.
  • each R 12 is independently selected from Ek, CH3, F, CN, 1 -piperidinyl, methylcarbamoyl, 1 -piperazinyl or 4- morpholinyl.
  • the subscript n is 0. In one embodiment, the subscript n is 1. In another embodiment, the subscript n is 2. In another embodiment, the subscript n is 3.
  • compounds of Formula ( ⁇ ) or (I) have sub Formula (Ih):
  • X 1 , ring A, R 12 and n are as defined in any embodiment of compounds of Formula ( ⁇ ) or (I) as described herein.
  • X 1 is -CR 10 R n - or -NR 7 -.
  • X 1 is -CR 10 R n -, where R 10 and R 11 taken together form a C3-6 cycloalkyl ring.
  • R 10 and R 11 taken together form a cyclopropyl ring.
  • X 1 is -NR 7 -.
  • R 7 is Ci-6 alkyl.
  • R 7 is ethyl.
  • ring A is phenyl or 3-pyridyl.
  • ring A is 4-pyrazolyl.
  • compounds of Formula ( ⁇ ) have sub Formula (Ih):
  • R 13 , R 14 , X 1 , ring A, R 12 and n are as defined in any embodiment of compounds of formula ( ⁇ ) or (I) as described herein.
  • R 13 is -C(0)NHCi-6 alkyl and R 14 is OCH3.
  • X 1 is -CR 10 R n - or -NR 7 -.
  • X 1 is -CR 10 R n -, where R 10 and R 11 taken together form a C3-6 cycloalkyl ring.
  • R 10 and R 11 taken together form a cyclopropyl ring.
  • X 1 is - NR 7 -.
  • Ci-6 alkyl is specifically intended to individually disclose methyl, ethyl, C3 alkyl, CA alkyl, C5 alkyl, and Ce alkyl.
  • aryl, heteroaryl, cycloalkyl, and heterocycloalkyl rings are described. Unless otherwise specified, these rings can be attached to the rest of the molecule at any ring member as permitted by valency.
  • a pyridine ring or “pyridinyl” may refer to a pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl ring.
  • n-membered where n is an integer typically describes the number of ring- forming atoms in a moiety where the number of ring-forming atoms is n.
  • piperidinyl is an example of a 6-membered heterocycloalkyl ring
  • pyrazolyl is an example of a 5-membered heteroaryl ring
  • pyridyl is an example of a 6-membered heteroaryl ring
  • 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.
  • each variable can be a different moiety independently selected from the group defining the variable.
  • the two R groups can represent different moieties independently selected from the group defined for R.
  • the phrase "optionally substituted" means unsubstituted or substituted.
  • substituted means that a hydrogen atom is replaced by a non-hydrogen group. It is to be understood that substitution at a given atom is limited by valency.
  • G-j where i and j are integers, employed in combination with a chemical group, designates a range of the number of carbon atoms in the chemical group with i-j defining the range.
  • Ci-6 alkyl refers to an alkyl group having 1, 2, 3, 4, 5, or 6 carbon atoms.
  • alkyl refers to a saturated hydrocarbon group that may be straight-chain or branched.
  • the alkyl group contains 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, w-pentyl, 2-methyl-l -butyl, 3- pentyl, w-hexyl, 1,2,2-trimethylpropyl, and the like.
  • the alkyl group is methyl, ethyl, or propyl.
  • alkenyl employed alone or in combination with other terms, refers to an alkyl group having one or more carbon-carbon double bonds. In some embodiments, the alkenyl moiety contains 2 to 6 or 2 to 4 carbon atoms.
  • Example alkenyl groups include, but are not limited to, ethenyl, w-propenyl, isopropenyl, w-butenyl, sec-butenyl, and the like.
  • alkynyl employed alone or in combination with other terms, refers to an alkyl group having one or more carbon-carbon triple bonds. In some embodiments, the alkynyl moiety contains 2 to 6 or 2 to 4 carbon atoms.
  • Example alkynyl groups include, but are not limited to, ethynyl, propyn-l-yl, propyn-2-yl, and the like.
  • halo or halogen, employed alone or in combination with other terms, includes fluoro, chloro, bromo, and iodo. In some embodiments, halo is F or CI. In some embodiments, halo is F.
  • haloalkyl employed alone or in combination with other terms, refers to an alkyl group having up to the full valency of halogen atom substituents, which may either be the same or different.
  • the halogen atoms are fluoro atoms.
  • the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • Example haloalkyl groups include CF3, C2F5, CHF2, CCb, CHCI2, C2CI5, and the like.
  • alkoxy employed alone or in combination with other terms, refers to a group of formula -O-alkyl.
  • the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • Example alkoxy groups include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t-butoxy, and the like. In some embodiments, alkoxy is methoxy.
  • haloalkoxy employed alone or in combination with other terms, refers to a group of formula -0-(haloalkyl).
  • the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
  • An example haloalkoxy group is -OCF3.
  • amino employed alone or in combination with other terms, refers to amino
  • alkylamino employed alone or in combination with other terms, refers to a group of formula -NH(alkyl). In some embodiments, the alkylamino group has 1 to 6 or 1 to 4 carbon atoms.
  • Example alkylamino groups include methylamino, ethylamino, propylamino (e.g., n-propylamino and isopropylamino), and the like.
  • dialkylamino employed alone or in combination with other terms, refers to a group of formula -N(alkyl)2.
  • Example dialkylamino groups include dimethylamino, diethylamino, dipropylamino (e.g., di(n-propyl)amino and
  • each alkyl group independently has 1 to 6 or 1 to 4 carbon atoms.
  • alkylthio employed alone or in combination with other terms, refers to a group of formula -S-alkyl. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
  • cycloalkyl employed alone or in combination with other terms, refers to a non-aromatic cyclic hydrocarbon including cyclized alkyl and alkenyl groups.
  • Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3, or 4 fused, bridged, or spiro rings) ring systems.
  • cycloalkyl moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyclopentane, cyclohexene, cyclohexane, and the like, or pyrido derivatives of cyclopentane or cyclohexane. Ring- forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo. Cycloalkyl groups also include cycloalkylidenes.
  • cycloalkyl also includes bridgehead cycloalkyl groups (e.g., non-aromatic cyclic hydrocarbon moieties containing at least one bridgehead carbon, such as admantan-l-yl) and spirocycloalkyl groups (e.g., non-aromatic hydrocarbon moieties containing at least two rings fused at a single carbon atom, such as spiro [2.5] octane and the like).
  • the cycloalkyl group has 3 to 10 ring members, or 3 to 7 ring members, or 3 to 6 ring members.
  • the cycloalkyl group is monocyclic or bicyclic.
  • the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is a C3-7 monocyclic cycloalkyl group.
  • Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, tetrahydronaphthalenyl,
  • the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • heterocycloalkyl refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene or alkynylene groups as part of the ring structure, which has at least one heteroatom ring member independently selected from nitrogen, sulfur, oxygen, and phosphorus.
  • Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused, bridged, or spiro rings) ring systems.
  • the heterocycloalkyl group is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen. Also included in the definition of
  • heterocycloalkyl are moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the non-aromatic heterocycloalkyl ring, for example, 1,2,3,4-tetrahydro-quinoline and the like.
  • Heterocycloalkyl groups can also include bridgehead heterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least one bridgehead atom, such as azaadmantan- 1 -yl and the like) and spiroheterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least two rings fused at a single atom, such as [l,4-dioxa-8-aza-spiro[4.5]decan-N-yl] and the like).
  • bridgehead heterocycloalkyl groups e.g., a heterocycloalkyl moiety containing at least one bridgehead atom, such as azaadmantan- 1 -yl and the like
  • spiroheterocycloalkyl groups e.g., a heterocycloalkyl moiety containing at least two rings fused at a single atom, such as [l,4-d
  • the heterocycloalkyl group has 3 to 10 ring-forming atoms, 4 to 10 ring- forming atoms, or 3 to 8 ring forming atoms. In some embodiments, the heterocycloalkyl group has 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 heteroatoms, or 1 to 2 heteroatoms.
  • the carbon atoms or heteroatoms in the ring(s) of the heterocycloalkyl group can be oxidized to form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized.
  • the heterocycloalkyl portion is a C2-7 monocyclic heterocycloalkyl group.
  • the heterocycloalkyl group is a morpholine ring, pyrrolidine ring, piperazine ring, piperidine ring, dihydropyran ring, tetrahydropyran ring, tetrahyropyridine, azetidine ring, or tetrahydrofuran ring.
  • aryl refers to a monocyclic or poly cyclic (e.g., having 2 fused rings) aromatic hydrocarbon moiety, such as, but not limited to, phenyl, 1-naphthyl, 2-naphthyl, and the like. In some embodiments, aryl groups have from 6 to 10 carbon atoms or 6 carbon atoms. In some embodiments, the aryl group is a monocyclic or bicyclic group. In some embodiments, the aryl group is phenyl or naphthyl.
  • heteroaryl employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., having 2 or 3 fused rings) aromatic hydrocarbon moiety, having one or more heteroatom ring members independently selected from nitrogen, sulfur and oxygen.
  • the heteroaryl group is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen.
  • Example heteroaryl groups include, but are not limited to, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, pyrrolyl, azolyl, quinolinyl, isoquinolinyl, benzisoxazolyl, imidazo[l,2-b]thiazolyl or the like.
  • the carbon atoms or heteroatoms in the ring(s) of the heteroaryl group can be oxidized to form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized, provided the aromatic nature of the ring is preserved.
  • the heteroaryl group is a 5 to 10 membered heteroaryl group. In another embodiment the heteroaryl group is a 5 to 6 membered heteroaryl group.
  • the compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated.
  • Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. Resolution of racemic mixtures of compounds can be carried out by methods known in the art.
  • An example method includes fractional recrystallizaion using a chiral resolving acid which is an optically active, salt-forming organic acid.
  • Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids.
  • resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2- diaminocyclohexane, and the like.
  • Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine).
  • an optically active resolving agent e.g., dinitrobenzoylphenylglycine
  • Suitable elution solvent composition can be determined by one skilled in the art.
  • Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton.
  • Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge.
  • Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4-triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole.
  • Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
  • Compounds of the invention also include all isotopes of atoms occurring in the intermediates or final compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include tritium and deuterium.
  • compound as used herein is meant to include all stereoisomers, geometric iosomers, tautomers, and isotopes of the structures depicted.
  • All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g., in the form of hydrates and solvates) or can be isolated.
  • the compounds of the invention, or salts thereof are substantially isolated.
  • substantially isolated is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected.
  • Partial separation can include, for example, a composition enriched in the compounds of the invention.
  • Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the invention, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • the present invention also includes pharmaceutically acceptable salts of the compounds described herein.
  • pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form.
  • examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts of the present invention include the non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred.
  • non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred.
  • ACN acetonitrile
  • an ex vivo cell can be part of a tissue sample excised from an organism such as a mammal.
  • an in vitro cell can be a cell in a cell culture.
  • an in vivo cell is a cell living in an organism such as a mammal.
  • contacting refers to the bringing together of indicated moieties in an in vitro system or an in vivo system.
  • "contacting" the FGFR4 enzyme with a compound of the invention includes the administration of a compound of the present invention to an individual or patient, such as a human, having FGFR, as well as, for example, introducing a compound of the invention into a sample containing a cellular or purified preparation containing the FGFR4 enzyme.
  • the term "individual” or “patient,” used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
  • the phrase "therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
  • treating or “treatment” refers to 1) preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease; 2) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology), or 3) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/
  • the reactions for preparing compounds of the invention can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis.
  • suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature.
  • a given reaction can be carried out in one solvent or a mixture of more than one solvent.
  • suitable solvents for a particular reaction step can be selected by the skilled artisan.
  • Reactions can be monitored according to any suitable method known in the art.
  • product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., l H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.
  • spectroscopic means such as nuclear magnetic resonance spectroscopy (e.g., l H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry
  • chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.
  • HPLC high performance liquid chromatography
  • Dichloropyrimidine 8 can be prepared by the methods described in Scheme 2.
  • Lactam 11 can be prepared by the treatment of compounds 10 with a strong base, such as NaH or CS2CO3 in DMF, and followed by an acid, such as HCl, mediated decarboxylation.
  • a-Substituted lactam 12 can be obtained by treating compound 11 with a base, such as NaH or CS2CO3 in DMF or acetonitrile, and followed by the addition of halides R 10 X and/or R U X (X is halo such as CI, Br, or I).
  • Chloride 12 can be converted to compound 13, wherein M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., M is B(OH)2, Sn(Bu)3, or ZnBr), under standard Suzuki conditions ⁇ e.g., in the presence of a palladium catalyst, such as, but not limited to, [l, l'-bis(di-cyclohexylphosphino)ferrocene]dichloropalladium(II) and a bicarbonate or carbonate base ⁇ , or standard Stille conditions [e.g., in the presence of a palladium catalyst, such as, but not limited to, Pd(dba)2] or standard Negishi conditions [e.g., in the presence of a palladium catalyst, such as, but not limited to,
  • Compound 16 can be synthesized following the procedure shown in Scheme 4. Therefore, compound 9 is first treated with triphosgene in the presence of a base such as pyridine, and then with amine R 7 NH2 in the presence of another base (e.g. DIPEA) to afford urea compound 14. Upon treatment with a proper base (e.g. CS2CO3), cyclization of 14 takes place to generate cyclic urea 15, which can then be converted to compound 16, wherein M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., M is B(OH)2, Sn(Bu)3, or ZnBr).
  • a proper base e.g. CS2CO3
  • M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., M is B(OH)2, Sn(Bu)3, or ZnBr).
  • the coupling reaction to yield 16 can occur under standard Suzuki conditions ⁇ e.g., in the presence of a palladium catalyst, such as, but not limited to, [l, l '-bis(di- cyclohexylphosphino)ferrocene]dichloropalladium(II) and a bicarbonate or carbonate base ⁇ , or standard Stille conditions [e.g., in the presence of a palladium catalyst, such as, but not limited to, Pd(dba)2] or standard Negishi conditions [e.g., in the presence of a palladium catalyst, such as, but not limited to, tetrakis(triphenylphosphine)palladium(0)].
  • a palladium catalyst such as, but not limited to, [l, l '-bis(di- cyclohexylphosphino)ferrocene]dichloropalladium(II) and a bicarbonate or carbonate base ⁇
  • Compound 21 can be prepared according to the synthetic procedures described in Scheme 5. The reductive amination of aldehyde 18 with aniline 17 can afford compound 19. Compound 19 is treated with triphosgene in the presence of a base such as triethylamine to afford urea 20. Compound 20 can then be converted to compound 21, wherein M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., M is B(OH)2, Sn(Bu)3, or ZnBr).
  • M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., M is B(OH)2, Sn(Bu)3, or ZnBr).
  • the coupling reaction to yield 21 can occur under standard Suzuki conditions ⁇ e.g., in the presence of a palladium catalyst, such as, but not limited to, [l,l '-bis(di- cyclohexylphosphino)ferrocene]dichloropalladium(II) and a bicarbonate or carbonate base ⁇ , or standard Stille conditions [e.g., in the presence of a palladium catalyst, such as, but not limited to, Pd(dba)2] or standard Negishi conditions [e.g., in the presence of a palladium catalyst, such as, but not limited to, tetrakis(triphenylphosphine)palladium(0)].
  • a palladium catalyst such as, but not limited to, [l,l '-bis(di- cyclohexylphosphino)ferrocene]dichloropalladium(II) and a bicarbonate or carbonate base ⁇
  • Ester 1 can be reduced to the corresponding aldehyde 2 using DIBAL-H.
  • the reductive amination of this aldehyde with aniline 17 can afford compound 22.
  • Compound 22 is then converted to 23, wherein M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., M is B(OH)2, Sn(Bu)3, or ZnBr).
  • the coupling reaction to yield 23 can occur under standard Suzuki conditions ⁇ e.g., in the presence of a palladium catalyst, such as, but not limited to, [l,l '-bis(di-cyclohexylphosphino)ferrocene]dichloropalladium(II) and a bicarbonate or carbonate base ⁇ , or standard Stille conditions [e.g., in the presence of a palladium catalyst, such as, but not limited to, Pd(dba)2] or standard Negishi conditions [e.g., in the presence of a palladium catalyst, such as, but not limited to,
  • Compound 23 can undergo Buchwald coupling with amine R 7 NH2 under standard conditions ⁇ e.g., in the presence of a palladium catalyst, such as, but not limited to, (2'-aminobiphenyl-2-yl)(chloro)[dicyclohexyl(2',6'- diisopropoxybiphenyl-2-yl)phosphoranyl]palladium and a base, such as, but not limited to, cesium carbonate or sodium tert-butoxide ⁇ then cyclized with triphosgene in the presence of a base such as triethylamine to provide compound 21.
  • a palladium catalyst such as, but not limited to, (2'-aminobiphenyl-2-yl)(chloro)[dicyclohexyl(2',6'- diisopropoxybiphenyl-2-yl)phosphoranyl]palladium
  • a base such as, but not limited to, cesium carbonate or sodium tert
  • Compounds of the present disclosure can inhibit the activity of the FGFR enzyme.
  • the compounds of the disclosure can be used to selectivly inhibit the activity of an FGFR3 and/or FGFR4 enzyme in a cell or in an individual or patient in need of inhibition of the enzyme by administering an inhibiting amount of a compound of the disclosure to the cell, individual, or patient.
  • the compounds of the disclosure are selective for the enzyme
  • the compounds of the disclosure have selective inhibitory activity for the FGFR4 enzyme over FGFR1, FGFR2, and FGFR3. In some embodiments, the compounds of the disclosure are selective for the enzyme FGFR4 over VEGFR2. In some embodiments, the selectivity is 2- fold or more, 3-fold or more, 5-fold or more, 10-fold or more, 25-fold or more, 50-fold or more, or 100-fold or more.
  • the compounds of the disclosure have selective inhibitory activity for the enzyme FGFR3 over one or more of FGFR1 and/or FGFR2 and/or FGFR4. In some embodiments, the compounds of the disclosure are selective for the enzyme FGFR3 over FGFR1 and FGFR2. In certain embodiments, the compounds of the disclosure are selective for the enzyme FGFR3 over FGFR1. In certain embodiments, the compounds of the disclosure are selective for the enzyme FGFR3 over FGFR4. In some embodiments, the compounds of the disclosure are selective for the enzyme FGFR3 over VEGFR2.
  • the selectivity of the compounds of the present disclosure for FGFR3 over FGFR1 and/or FGFR2 and/or FGFR4 is 2-fold or more, 3-fold or more, 5-fold or more, 10- fold or more, 25-fold or more, 50-fold or more, or 100-fold or more.
  • the compounds of the disclosure are useful in the treatment of various diseases associated with abnormal expression or activity of the FGFR3 and/or FGFR4 enzyme or FGFR ligands.
  • Compounds which inhibit FGFR will be useful in providing a means of preventing the growth or inducing apoptosis in tumors, particularly by inhibiting angiogenesis. It is therefore anticipated that the compounds will prove useful in treating or preventing proliferative disorders such as cancers. In particular tumours with activating mutants of receptor tyrosine kinases or upregulation of receptor tyrosine kinases may be particularly sensitive to the inhibitors.
  • the FGFR4, or a mutant thereof activity is inhibited irreversibly. In certain embodiments, FGFR4, or a mutant thereof, activity is inhibited irreversibly by covalently modifying Cys 552 of FGFR4.
  • the disclosure provides a method for treating a FGFR4- mediated disorder in a patient in need thereof, comprising the step of administering to said patient an effective amount of a compound according to the invention, or a pharmaceutically acceptable composition thereof.
  • the compounds of the disclosure are useful in the treatment of various diseases associated with abnormal expression or activity of the FGFR3 enzyme or FGFR ligands.
  • the disclosure provides a method for treating a FGFR3- mediated disorder in a patient in need thereof, comprising the step of administering to said patient an effective amount of a compound according to the invention, or a pharmaceutically acceptable composition thereof.
  • Examplary cancers include bladder cancer, breast cancer, cervical cancer, colorectal cancer, cancer of the small intestine, colon cancer, rectal cancer, cacncer of the anus, endometrial cancer, gastric cancer, head and neck cancer (e.g., cancers of the larynx, hypopharynx, nasopharynx, oropharynx, lips, and mouth), kidney cancer, liver cancer (e.g., hepatocellular carcinoma, cholangiocellular carcinoma), lung cancer (e.g., adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas, parvicellular and non-parvicellular carcinoma, bronchial carcinoma, bronchial adenoma, pleuropulmonary blastoma), ovarian cancer, prostate cancer, testicular cancer, uterine cancer, esophageal cancer, gall bladder cancer, pancreatic cancer (e.g.
  • exocrine pancreatic carcinoma stomach cancer, thyroid cancer, parathyroid cancer, skin cancer (e.g., squamous cell carcinoma, Kaposi sarcoma, Merkel cell skin cancer), and brain cancer (e.g., astrocytoma, medulloblastoma,
  • cancers include hematopoietic malignancies such as leukemia or lymphoma, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, cutaneous T-cell lymphoma, acute myelogenous leukemia, Hodgkin's or non- Hodgkin's lymphoma, myeloproliferative neoplasms (e.g., polycythemia vera, essential thrombocythemia, and primary myelofibrosis), Waldenstrom's Macroglubulinemia, hairy cell lymphoma, chronic myelogenic lymphoma, acute lymphoblastic lymphoma, AIDS-related lymphomas, and Burkitt's lymphoma.
  • leukemia or lymphoma multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, cutaneous T-cell lympho
  • cancers treatable with the compounds of the disclosure include tumors of the eye, glioblastoma, melanoma, rhabdosarcoma, lymphosarcoma, and osteosarcoma.
  • Compounds of the disclosure can also be useful in the inhibition of tumor metastisis.
  • the present disclosure provides a method for treating hepatocellular carcinoma in a patient in need thereof, comprising the step of administering to a patient a compound of Formula ( ⁇ ) or (I) or a compouind as disclosed herein, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of
  • the present disclosure provides a method for treating
  • Rhabdomyosarcoma esophageal cancer, breast cancer, or cancer of a head or neck, in a patient in need thereof, comprising the step of administering to the patient a compound
  • the present disclosure provides a method of treating cancer, wherein the cancer is selected from hepatocellular cancer, breast cancer, bladder cancer, colorectal cancer, melanoma, mesothelioma, lung cancer, prostate cancer, pancreatic cancer, testicular cancer, thyroid cancer, squamous cell carcinoma, glioblastoma, neuroblastoma, uterine cancer, and rhabdosarcoma.
  • the cancer is selected from hepatocellular cancer, breast cancer, bladder cancer, colorectal cancer, melanoma, mesothelioma, lung cancer, prostate cancer, pancreatic cancer, testicular cancer, thyroid cancer, squamous cell carcinoma, glioblastoma, neuroblastoma, uterine cancer, and rhabdosarcoma.
  • the compounds of the invention are useful in the treatment of skeletal and chondrocyte disorders including, but not limited to, achrondroplasia, hypochondroplasia, dwarfism, thanatophoric dysplasia (TD) (clinical forms TD I and TD II), Apert syndrome, Crouzon syndrome, Jackson- Weiss syndrome, Beare-Stevenson cutis gyrate syndrome, Pfeiffer syndrome, and craniosynostosis syndromes.
  • achrondroplasia hypochondroplasia
  • dwarfism dwarfism
  • thanatophoric dysplasia (TD) (clinical forms TD I and TD II)
  • Apert syndrome Crouzon syndrome
  • Jackson- Weiss syndrome Beare-Stevenson cutis gyrate syndrome
  • Pfeiffer syndrome and craniosynostosis syndromes.
  • the present disclosure provides a method for treating a patient suffering from a skeletal and chondrocyte disorder including, but not limiting to, achrondroplasia, hypochondroplasia, dwarfism, thanatophoric dysplasia (TD) (clinical forms TD I and TD II), Apert syndrome, Crouzon syndrome, Jackson- Weiss syndrome, Beare-Stevenson cutis gyrate syndrome, Pfeiffer syndrome, and craniosynostosis syndromes.
  • achrondroplasia hypochondroplasia
  • dwarfism dwarfism
  • thanatophoric dysplasia (TD) clinical forms TD I and TD II
  • Apert syndrome Crouzon syndrome
  • Jackson- Weiss syndrome Beare-Stevenson cutis gyrate syndrome
  • Pfeiffer syndrome and craniosynostosis syndromes.
  • the method includes administering to the patient in need thereof an effective amount of a compound Formula ( ⁇ ) or (I) or a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of Formula ( ⁇ ) or (I) or a compound as disclosed herein.
  • the compounds of the invention can also be useful in the treatment of
  • hypophosphatemia disorders including, for example, X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, autosomal dominant hypophosphatemic rickets, and tumor-induced osteromalacia.
  • the present disclosure provides a method for treating a patient suffering from a hypophosphatemia disorder including, but not limiting to, X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, autosomal dominant hypophosphatemic rickets, and tumor- induced osteromalacia.
  • the method includes administering to the patient in need thereof an effective amount of a compound Formula ( ⁇ ) or (I) or a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of Formula ( ⁇ ) or (I) or a compound as disclosed herein.
  • the compounds of the invention may further be useful in the treatment of fibrotic diseases, such as where a disease symptom or disorder is characterized by fibrosis.
  • fibrotic diseases include liver cirrhosis, glomerulonephritis, pulmonary fibrosis, systemic fibrosis, rheumatoid arthritis, and wound healing.
  • One or more additional pharmaceutical agents or treatment methods such as, for example, anti-viral agents, chemotherapeutics or other anti-cancer agents, immune enhancers, immunosuppressants, radiation, anti-tumor and anti-viral vaccines, cytokine therapy (e.g., IL2, GM-CSF, etc.), and/or tyrosine kinase inhibitors can be used in combination with the compounds of Formula ( ⁇ ) or (I) or a compound as described herein for treatment of FGFR- associated diseases, disorders or conditions.
  • the agents can be combined with the present compounds in a single dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.
  • Suitable antiviral agents contemplated for use in combination with the compounds of the present disclosure can comprise nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors ( RTIs), protease inhibitors and other antiviral drugs.
  • NRTIs nucleoside and nucleotide reverse transcriptase inhibitors
  • RTIs non-nucleoside reverse transcriptase inhibitors
  • protease inhibitors and other antiviral drugs.
  • Example suitable NRTIs include zidovudine (AZT); didanosine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil
  • Typical suitable NNRTIs include nevirapine (BI-RG-587); delaviradine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721; AG-1549; MKC-442 (l-(ethoxy-methyl)-5-(l-methylethyl)-6-(phenylmethyl)- (2,4(lH,3H)-pyrimidinedione); and (+)-calanolide A ( SC-675451) and B.
  • Typical suitable protease inhibitors include saquinavir (Ro 31-8959); ritonavir (ABT-538); indinavir (MK- 639); nelfnavir (AG-1343); amprenavir (141W94); lasinavir (BMS-234475); DMP-450; BMS-2322623; ABT-378; and AG-1 549.
  • Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside and Yissum Project No.11607.
  • Suitable agents for use in combination with the compounds of the present invention for the treatment of cancer include chemotherapeutic agents, targeted cancer therapies, immunotherapies or radiation therapy.
  • Compounds of this invention may be effective in combination with anti-hormonal agents for treatment of breast cancer and other tumors.
  • anti-estrogen agents including but not limited to tamoxifen and toremifene, aromatase inhibitors including but not limited to letrozole, anastrozole, and exemestane, adrenocorticosteroids (e.g. prednisone), progestins (e.g. megastrol acetate), and estrogen receptor antagonists (e.g. fulvestrant).
  • Suitable anti-hormone agents used for treatment of prostate and other cancers may also be combined with compounds of the present invention.
  • anti-androgens including but not limited to flutamide, bicalutamide, and nilutamide, luteinizing hormone-releasing hormone (LHRH) analogs including leuprolide, goserelin, triptorelin, and histrelin, LHRH antagonists (e.g. degarelix), androgen receptor blockers (e.g. enzalutamide) and agents that inhibit androgen production (e.g.
  • Compounds of the present invention may be combined with or in sequence with other agents against membrane receptor kinases especially for patients who have developed primary or acquired resistance to the targeted therapy.
  • These therapeutic agents include inhibitors or antibodies against EGFR, Her2, VEGFR, c-Met, Ret, IGFR1, or Flt-3 and against cancer-associated fusion protein kinases such as Bcr-Abl and EML4-Alk.
  • Inhibitors against EGFR include gefitinib and erlotinib, and inhibitors against EGFR/Her2 include but are not limited to dacomitinib, afatinib, lapitinib and neratinib.
  • Antibodies against the EGFR include but are not limited to cetuximab, panitumumab and necitumumab.
  • Inhibitors of c- Met may be used in combination with FGFR inhibitors. These include onartumzumab, tivantnib, and INC-280.
  • Agents against Abl (or Bcr-Abl) include imatinib, dasatinib, nilotinib, and ponatinib and those against Alk (or EML4-ALK) include crizotinib.
  • Angiogenesis inhibitors may be efficacious in some tumors in combination with
  • FGFR inhibitors include antibodies against VEGF or VEGFR or kinase inhibitors of VEGFR.
  • Antibodies or other therapeutic proteins against VEGF include bevacizumab and aflibercept.
  • Inhibitors of VEGFR kinases and other anti-angiogenesis inhibitors include but are not limited to sunitinib, sorafenib, axitinib, cediranib, pazopanib, regorafenib, brivanib, and vandetanib.
  • agents targeting components of these pathways have been combined with receptor targeting agents to enhance efficacy and reduce resistance.
  • agents that may be combined with compounds of the present invention include inhibitors of the PI3K-AKT-mTOR pathway, inhibitors of the Raf-MAPK pathway, inhibitors of JAK-STAT pathway, and inhibitors of protein chaperones and cell cycle progression.
  • Agents against the PI3 kinase include but are not limited topilaralisib, idelalisib, buparlisib.
  • Inhibitors of mTOR such as rapamycin, sirolimus, temsirolimus, and everolimus may be combined with FGFR inhibitors.
  • Other suitable examples include but are not limited to vemurafenib and dabrafenib (Raf inhibitors) and trametinib, selumetinib and GDC-0973 (MEK inhibitors).
  • Inhibitors of one or more JAKs e.g., ruxolitinib, baricitinib, tofacitinib), Hsp90 (e.g., tanespimycin), cyclin dependent kinases (e.g., palbociclib), HDACs (e.g., panobinostat), PARP (e.g., olaparib), and proteasomes (e.g., bortezomib, carfilzomib) can also be combined with compounds of the present invention.
  • the JAK inhibitor is selective for JAK1 over JAK2 and JAK3.
  • Suitable agents for use in combination with the compounds of the present invention include chemotherapy combinations such as platinum-based doublets used in lung cancer and other solid tumors (cisplatin or carboplatin plus gemcitabine; cisplatin or carboplatin plus docetaxel; cisplatin or carboplatin plus paclitaxel; cisplatin or carboplatin plus pemetrexed) or gemcitabine plus paclitaxel bound particles (Abraxane®).
  • chemotherapy combinations such as platinum-based doublets used in lung cancer and other solid tumors (cisplatin or carboplatin plus gemcitabine; cisplatin or carboplatin plus docetaxel; cisplatin or carboplatin plus paclitaxel; cisplatin or carboplatin plus pemetrexed) or gemcitabine plus paclitaxel bound particles (Abraxane®).
  • Suitable chemotherapeutic or other anti-cancer agents include, for example, alkylating agents (including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes) such as uracil mustard, chlormethine, cyclophosphamide (CytoxanTM), ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide.
  • alkylating agents including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes
  • alkylating agents including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoure
  • Suitable agents for use in combination with the compounds of the present invention include: dacarbazine (DTIC), optionally, along with other chemotherapy drugs such as carmustine (BCNU) and cisplatin; the "Dartmouth regimen," which consists of DTIC, BCNU, cisplatin and tamoxifen; a combination of cisplatin, vinblastine, and DTIC; or temozolomide.
  • DTIC dacarbazine
  • BCNU carmustine
  • cisplatin the "Dartmouth regimen” which consists of DTIC, BCNU, cisplatin and tamoxifen
  • a combination of cisplatin, vinblastine, and DTIC or temozolomide.
  • Compounds according to the invention may also be combined with immunotherapy drugs, including cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF).
  • cytokines such as interferon alpha, interleukin 2, and tumor necrosis
  • Suitable chemotherapeutic or other anti-cancer agents include, for example, antimetabolites (including, without limitation, folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors) such as methotrexate, 5-fluorouracil, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate,
  • antimetabolites including, without limitation, folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors
  • Suitable chemotherapeutic or other anti-cancer agents further include, for example, certain natural products and their derivatives (for example, vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins) such as vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, ara- C, paclitaxel (TAXOLTM), mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, interferons (especially IFN-a), etoposide, and teniposide.
  • certain natural products and their derivatives for example, vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins
  • vinblastine vincristine, vindesine
  • bleomycin dactinomycin
  • daunorubicin daunor
  • cytotoxic agents include navelbene, CPT-11, anastrazole, letrazole,
  • capecitabine reloxafine
  • cyclophosphamide ifosamide
  • droloxafine droloxafine
  • cytotoxic agents such as epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes such as cis-platin and carboplatin; biological response modifiers; growth inhibitors; antihormonal therapeutic agents; leucovorin; tegafur; and haematopoietic growth factors.
  • anti-cancer agent(s) include antibody therapeutics such as trastuzumab
  • anti-cancer agents also include those that block immune cell migration such as antagonists to chemokine receptors, including CCR2 and CCR4.
  • Other anti-cancer agents also include those that augment the immune system such as adjuvants or adoptive T cell transfer.
  • Anti-cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines and recombinant viruses.
  • the compounds of the invention can be administered in the form of pharmaceutical compositions which refers to a combination of a compound of the invention, or its pharmaceutically acceptable salt, and at least one pharmaceutically acceptable carrier.
  • compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated.
  • Administration may be topical (including ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), ocular, oral or parenteral.
  • Methods for ocular delivery can include topical administration (eye drops), subconjunctival, periocular or intravitreal injection or introduction by balloon catheter or ophthalmic inserts surgically placed in the conjunctival sac.
  • Parenteral administration includes intravenous, intraarterial, subcutaneous,
  • compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
  • This invention also includes pharmaceutical compositions which contain, as the active ingredient, one or more of the compounds of the invention above in combination with one or more pharmaceutically acceptable carriers.
  • the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container.
  • an excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10 % by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
  • the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose.
  • the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
  • the compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
  • compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 to about 30 mg, of the active ingredient.
  • unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
  • the active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
  • the principal active ingredient is mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of a compound of the present invention.
  • a solid pre-formulation composition containing a homogeneous mixture of a compound of the present invention.
  • the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • This solid pre-formulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of the present invention.
  • the tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
  • liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
  • compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
  • the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
  • the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
  • Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner
  • compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.
  • compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration.
  • the pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
  • the therapeutic dosage of the compounds of the present invention can vary according to, for example, the particular use for which the treatment is made, the manner of
  • a compound of the invention in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration.
  • the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral
  • Some typical dose ranges are from about 1 ⁇ g/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day.
  • the dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose- response curves derived from in vitro or animal model test systems.
  • the compounds of the invention can also be formulated in combination with one or more additional active ingredients which can include any pharmaceutical agent such as anti- viral agents, vaccines, antibodies, immune enhancers, immune suppressants, antiinflammatory agents and the like.
  • Another aspect of the present invention relates to fluorescent dye, spin label, heavy metal or radio-labeled compounds of the invention that would be useful not only in imaging but also in assays, both in vitro and in vivo, for localizing and quantitating the FGFR enzyme in tissue samples, including human, and for identifying FGFR enzyme ligands by inhibition binding of a labeled compound.
  • the present invention includes FGFR enzyme assays that contain such labeled compounds.
  • the present invention further includes isotopically-labeled compounds of the invention.
  • An “isotopically” or “radio-labeled” compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring).
  • Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to 2 H (also written as D for deuterium), 3 H (also written as T for tritium), n C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 18 F, 35 S, 36 C1, 82 Br, 75 Br, 76 Br, 77 Br, 123 I, 124 I, 125 I and 131 I.
  • the radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound.
  • a “radio-labeled” or “labeled compound” is a compound that has incorporated at least one radionuclide.
  • the radionuclide is selected from the group consisting of 3 H, 14 C, 125 1 , 35 S and 82 Br.
  • Synthetic methods for incorporating radio-isotopes into organic compounds are applicable to compounds of the invention and are well known in the art.
  • a radio-labeled compound of the invention can be used in a screening assay to identify/evaluate compounds.
  • a newly synthesized or identified compound i.e., test compound
  • a test compound can be evaluated for its ability to reduce binding of the radio-labeled compound of the invention to the FGFR4 enzyme. Accordingly, the ability of a test compound to compete with the radio-labeled compound for binding to the FGFR4 enzyme directly correlates to its binding affinity.
  • kits useful for example, in the treatment or prevention of FGFR-associated diseases or disorders, obesity, diabetes and other diseases referred to herein which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention.
  • kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art.
  • Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.
  • Preparatory LC-MS purifications of some of the compounds prepared were performed on Waters mass directed fractionation systems.
  • the basic equipment setup, protocols, and control software for the operation of these systems have been described in detail in the literature. See e.g. "Two-Pump At Column Dilution Configuration for Preparative LC-MS", K. Blom, J. Combi. Chem., 4, 295 (2002); "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi.
  • Typical preparative reverse- phase high performance liquid chromatography (RP-HPLC) column conditions are as follows:
  • pH 2 purifications: Waters SunfireTM Cis 5 ⁇ particle size, 19 x 100 mm column, eluting with mobile phase A: 0.1% TFA (trifluoroacetic acid) in water and mobile phase B: acetonitrile; the flow rate was 30 mL/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [see “Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate used with the 30 x 100 mm column was 60 mL/minute.
  • pH 10 purifications: Waters XBridge Cis 5 ⁇ particle size, 19 x 100 mm column, eluting with mobile phase A: 0.15% NH4OH in water and mobile phase B: acetonitrile; the flow rate was 30 mL/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [See “Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate used with 30 x 100 mm column was 60 mL/minute.
  • Step 2 N-[ ( 4, 6-dichloropyridin-3-yl)methyl]-2, 6-difluoro-i, 5 -dimethoxy aniline
  • Step 3 ethyl 3-[[(4, 6-dichloropyridin-3-yl)methyl](2, 6-difluoro-3,5- dimethoxyphenyl) amino] -3-oxopropanoate
  • Step 4 ethyl 6-chloro-2-(2, 6-difluoro-3,5-dimethoxyphenyl)-3-oxo-l,2,3,4-tetrahydro-2, 7- naphthyridine-4-carboxylate
  • Step 1 N-(5-(2'-(2, 6-difluoro-i, 5-dimethoxyphenyl)-3 '-oxo-2 ', 3 '-dihydro-l ⁇ - spiro[cyclopropane-l,4'-[2 ]naphthyndine]-6'-yl)pyndin-3-yl)acetamide
  • Step 2 6'-(5-aminopyridin-3-yl)-2 '-(2, 6-difluoro-i, 5-dimethoxyphenyl)-l ⁇ - spiro [cyclopropane- 1 ,4'-[2, 7] naphthyridin] -3 '(2'H)-one
  • Step 1 6-methyl-5-( 4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)pyridin-3-amine
  • Step 2 6'-(5-amino-2-methylpyridin-3-yl)-2'-(2, 6-difluoro-3,5-dimethoxyphenyl)-l 'H- spiro [cyclopropane- 1 ,4'-[2, 7] naphthyridin] -3 '(2'H)-one
  • Step l 5-(2'-(2, 6-difluoro-3, 5-dimethoxyphenyl)-3 '-oxo-2 ', 3 '-dihydro-1 ⁇ - spirof cyclopropane- 1, 4 '-[2, 7] naphthyridine] -6'-yl)nicotinaldehyde
  • Step 2 2'-(2, 6-difluoro-3, 5-dimethoxyphenyl)-6'-(5-(morpholinomethyl)pyridin-3-yl)-l ⁇ - spiro [cyclopropane- 1 ,4'-[2, 7] naphthyridin] -3 '(2'H)-one
  • Step 1 7-chloro-3-(2, 6-difluoro-3, 5-dimethoxyphenyl)-l-ethyl-3, 4-dihydropyrido [ 4, 3- d]pyrimidin-2(lH)-one
  • Step 2 3-(2, 6-difluoro-i, 5-dimethoxyphenyl)-l-ethyl- 7-phenyl-i, 4-dihydropyrido[ 4, 3- d]pyrimidin-2( lH)-one
  • [4,3-d]pyrimidin-2(lH)-one (35.0 mg, 0.0912 mmol), sodium carbonate (19.3 mg, 0.18 mmol), phenylboronic acid (16.7 mg, 0.14 mmol), and Pd-127 (6.9 mg, 0.0091 mmol) in tert- butyl alcohol (1.0 mL) and water (1.0 mL) was first degassed with nitrogen, and then stirred and heated at 90 °C for 3 hours. The resulting mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3 x 1.5 mL). The combined organic layers were dried over Na2S0 4 , and concentrated.
  • Step 6 3-( ⁇ [ 6-chloro-4-(ethylamino)pyridin-3-yl]methyl ⁇ amino)-2-fluoro-5-methoxy-N- methylbenzamide
  • Step 7 3-(7-chloro-l-ethyl-2-oxo-l,2-dihydropyrido[4,3-d]pyrimidin-3(4H)-yl)-2-fluoro-5- methoxy-N-methylbenzamide
  • Step 8 3-(7-( 6-( l-cyanocyclobutyl)pyridin-3-yl)-l-ethyl-2-oxo-l, 2-dihydropyrido[ 4, 3- d]pyrimidin-3(4H)-yl)-2-fluoro-5-methoxy-N-methylbenzamide
  • Step 1 N- ⁇ [ 4-chloro-6-( 1, 3-dimethyl-lH-pyrazol-4-yl)pyridin-3-ylJmethyl ⁇ -2, 6-difluoro-3, 5- dimethoxy aniline
  • Step 2 N-(cyclopropylmethyl)-5-((2,6-difluoro-3,5-dimethoxyphenylamino)methyl)-2-(l,3- dimethyl-lH-pyrazol-4-yl)pyridin-4-amine
  • Step 3 l-(cyclopropylmethyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH- pyrazol-4-yl)-3, 4-dihydropyrido[ 4, 3-d]pyrimidin-2( lH)-one
  • Step 1 tert-butyl 4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)- 2-oxo-3,4-dihydropyrido[4,3-d]pyrimidin-l(2H)-yl)piperidine-l-carboxylate
  • Step 2 3-(2, 6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-(piperidin- 4-yl)-3, 4-dihydropyrido[ 4, 3-
  • Step 3 l-( l-acetylpiperidin-4-yl)-3-(2, 6-difluoro-3, 5-dimethoxyphenyl)- 7-( 1, 3 -dimethyl- 1H- pyrazol-4-yl)-3, 4-dihydropyrido[ 4, 3-d]pyrimidin-2( lH)-one
  • LCMS calculated for C27H31F2N6O4 [M+H] + m/z: 541.2; Found: 541.2.
  • Step 1 3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(3-methyl-lH-pyrazol-4-yl)-3,4- dihydropyridof 4, 3-d]pyrimidin- -one
  • Step 1 3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(3-methyl-lH-pyrazol-4-yl)-3,4- dihydropyrido[ 4, 3-d]pyrimidin-2( lH)-one
  • Step 2 3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(3-methyl-l-(pyridin-3-ylmethyl)-lH- pyrazol-4-yl)-3, 4-dihydropyrido[ 4, 3-d]pyrimidin-2( lH)-one
  • Step 1 3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(3-methyl-lH-pyrazol-4-yl)-3,4- dihydropyridof 4, 3-d]pyrimidin- -one
  • Step 2 3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(3-methyl-l-(2-morphoUno-2- oxoethyl)-lH-pyrazol-4-yl)-3, 4-dihydropyrido[ 4, 3-d]pyrimidin-2(lH)-one
  • Step 1 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(3-methyl-lH-pyrazol-4-yl)-l 'H- spiro [cyclopropane- 1 ,4'-[2, 7] naphthyridin] -3 '(2'H)-one
  • Step 1 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(3-methyl-lH-pyrazol-4-yl)-l 'H- spiro [cyclopropane- 1 ,4'-[2, 7] naphthyridin] -3 '(2'H)-one
  • Step 2 2'-(2, 6-difluoro-i, 5-dimethoxyphenyl)-6'-[l-( 1, l-dioxidotetrahydro-3-thienyl)-3- methyi-lH ⁇ yrazoi-4-yiJ-l 2'-dihydro-3'H-spiro[cyciopropane-l,4'-[2, 7JnaphthyridinJ-3'- one
  • Step 1 tert-butyl 3-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazol-l- yl)azetidine-l-carboxylate
  • Step 2 tert-butyl 3-(4-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro-l 'H- spiro [cyclopropane- 1 ,4'-[2, 7] ' naphthyridinej '-6'-yl)-lH-pyrazol-l-yl)azetidine-l-carboxylate
  • This compound was prepared using procedures analogous to those for example 1, step 7, with tert-butyl 3-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazol-l- yl)azetidine- 1 -carboxylate replacing (5-amino-2-methylphenyl)boronic acid.
  • the crude product was used directly in the next step without further purification.
  • Step 3 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(l-(l-(methylsulfonyl)azetidin-3-yl)-lH- pyrazol-4-yl)-l'H-spiro[cyclopropane-l,4'-[2, 7]naphthyndin]-3'(2'H)-one
  • Step 1 tert-butyl 3-(cyanomethyl)-3-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazol-l-yl)azetidine-l -carboxylate
  • Step 2 tert-butyl 3-(cyanomethyl)-3-(4-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'- dihydro-l ⁇ -spirof cyclopropane- 1, 4 '-[2, 7] naphthyridine] -6'-yl)-lH-pyrazol-l-yl)azetidine-l- carboxylate
  • This compound was prepared using procedures analogous to those for example 1, step 7, with tert-butyl 3-(cyanomethyl)-3-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazol-l-yl)azetidine-l-carboxylate replacing (5-amino-2-methylphenyl)boronic acid.
  • the crude product was used directly in the next step without further purification.
  • Step 3 2-( l-acetyl-3-( 4-(2'-(2, 6-difluoro-3, 5-dimethoxyphenyl)-3 '-oxo-2 ', 3 '-dihydro-l ⁇ - spiro[cyclopropane-l ,4'-[2 7j ' naphthyridine] '-6'-yi)-lH-pyrazoi-l-yi)azetidin-3-yi)acetonitriie tert-Butyl 3-(cyanomethyl)-3-(4-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'- dihy dro- 1 ⁇ -spiro [cyclopropane- 1,4'- [2,7]naphthyridine]-6'-yl)- 1 H-pyrazol- 1 -yl)azetidine- 1 - carboxylate
  • Step 1 Preparation of tert-butyl 4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl- lH-pyrazol-4-yl)-2-oxo-3, 4-dihydropyrido[ 4, 3-d]pyrimidin-l(2H)-yl)piperidine-l- carboxylate
  • Step 1 tert-butyl 4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)- 2-oxo-3, 4-dihydropyrido[ 4, 3-d]pyrimidin-l(2H)-yl)phenylcarbamate
  • Step 2 Preparation of l-(4-aminophenyl)-3-(2, 6-difluoro-3,5-dimethoxyphenyl)-7-(l,3- dimethyl-lH-pyrazol-4-yl)-3, 4- -2(lH)-one.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 and/or FGFR4 enzyme and are useful in the treatment of FGFR-associated diseases.

Description

BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
FIELD OF THE INVENTION
The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
BACKGROUND OF INVENTION
The Fibroblast Growth Factor Receptors (FGFR) are receptor tyrosine kinases that bind to fibroblast growth factor (FGF) ligands. There are four FGFR proteins (FGFR 1-4) that are capable of binding ligands and are involved in the regulation of many physiological processes including tissue development, angiogenesis, wound healing, and metabolic regulation. Upon ligand binding, the receptors undergo dimerization and phosphorylation leading to stimulation of the protein kinase activity and recruitment of many intracellular docking proteins. These interactions facilitate the activation of an array of intracellular signaling pathways including Ras-MAPK, AKT-PI3K, and phospholipase C that are important for cellular growth, proliferation and survival (Reviewed in Eswarakumar et al. Cytokine & Growth Factor Reviews, 2005).
Aberrant activation of this pathway either through overexpression of FGF ligands or
FGFR or activating mutations in the FGFRs can lead to tumor development, progression, and resistance to conventional cancer therapies. In human cancer, genetic alterations including gene amplification, chromosomal translocations and somatic mutations that lead to ligand- independent receptor activation have been described. Large scale DNA sequencing of thousands of tumor samples has revealed that components of the FGFR pathway are among the most frequently mutated in human cancer. Many of these activating mutations are identical to germline mutations that lead to skeletal dysplasia syndromes. Mechanisms that lead to aberrant ligand-dependent signaling in human disease include overexpression of FGFs and changes in FGFR splicing that lead to receptors with more promiscuous ligand binding abilities (Reviewed in Knights and Cook Pharmacology & Therapeutics, 2010; Turner and Grose, Nature Reviews Cancer, 2010). Therefore, development of inhibitors targeting FGFR may be useful in the clinical treatment of diseases that have elevated FGF or FGFR activity. The cancer types in which FGF/FGFRs are implicated include, but are not limited to: carcinomas (e.g., bladder, breast, cervical, colorectal, endometrial, gastric, head and neck, kidney, liver, lung, ovarian, prostate); hematopoietic malignancies (e.g., multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, acute myelogenous leukemia, non- Hodgkin lymphoma, myeloproliferative neoplasms, and Waldenstrom's Macroglubulinemia); and other neoplasms (e.g., glioblastoma, melanoma, and rhabdosarcoma). In addition to a role in oncogenic neoplasms, FGFR activation has also been implicated in skeletal and chondrocyte disorders including, but not limited to, achrondroplasia and craniosynostosis syndromes.
The FGFR4-FGF19 signaling axis, specifically, has been implicated in the pathogenesis of a number of cancers including hepatocellular carcinoma (Heinzle et al, Cur. Pharm. Des. 2014, 20:2881). Ectopic expression of FGF19 in transgenic mice was shown to lead to tumor formation in the liver and a neutralizing antibody to FGF 19 was found to inhibit tumor growth in mice. In addition, overexpression of FGFR4 has been observed in a multiple tumor types including hepatocellular carcinoma, colorectal, breast, pancreatic, prostate, lung, and thyroid cancers. Furthermore, activating mutations in FGFR4 have been reported in rhabdomyosarcoma (Taylor et al. JCI 2009,1 19:3395). Targeting FGFR with selective small molecule inhibitors may therefore prove beneficial in the treatment of cancers and other diseases.
SUMMARY OF INVENTION
In one aspect, the present disclosure relates to compounds having Formula (Γ):
Figure imgf000004_0001
or a pharmaceutically acceptable salt thereof, wherein constituent variables are defined herein. In another aspect, the present disclosure provides pharmaceutical compositions comprising a compound of Formula (Γ), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.
In another aspect, the present disclosure provides methods for inhibiting an FGFR3 and/or FGFR4 enzyme. The method includes contacting the enzyme with a compound of Formula (Γ), or a pharmaceutically acceptable salt thereof or a composition comprising compounds of Formula (Γ).
In another aspect, the present disclosure provides a method for treating a disease associated with abnormal activity or expression of an FGFR enzyme, such as an FGFR3 and/or an FGFR4. The method includes administering an effective amount of a compound of Formula (Γ), or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of Formula (Γ), to a patient in need thereof.
In yet another aspect, the present disclosure provides compounds of Formula (Γ) for use in treating a disease associated with abnormal activity or expression of an FGFR3 and/or FGFR4 enzyme.
In another aspect, the present disclosure provides a method for treating a disorder mediated by an FGFR3 and/or FGFR4 enzyme, or a mutant thereof, in a patient in need thereof. The method includes administering to the patient a compound as described herein or pharmaceutically acceptable salts thereof or a composition comprising a compound as described herein.
In another aspect, the present disclosure provides the use of compounds of Formula (Γ) in the preparation of a medicament for use in therapy.
DETAILED DESCRIPTION
Compounds
In one aspect, the present disclosure provides a compound having Formula (Γ):
Figure imgf000006_0001
or a pharmaceutically acceptable salt thereof, wherein:
ring A is a Ce-ιο aryl or 5- to 10-membered heteroaryl having carbon and 1 to 4 heteroatoms as ring members selected from O, N, and S, wherein the N and S are each optionally oxidized;
each R12 is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, ORa, SRa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NRaRa, NRaORa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa, NRaC(=NRa)NRaRa,
NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, or 4 independently selected Rb substituents; or two adjacent R12 substituents on ring A taken together with the atoms to which they are attached form a fused 5- or 6-membered cycloalkyl ring, 5 to 6-membered
heterocycloalkyl ring, phenyl or 5 to 6-membered heteroaryl ring, wherein the
heterocycloalkyl or heteroaryl has 1 -2 heteroatoms as ring members selected from O, N, and S;
each Ra is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Ra are each optionally substituted with 1, 2, 3, 4, or 5 independently selected Rd substituents;
or any two Ra substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each Rb is independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc, and S(0)2NRCRC; wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rb are each optionally substituted with 1, 2, 3, 4, or 5 independently selected Rf substituents;
each Rc is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-iocycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rc are each optionally substituted with 1, 2, 3, 4, or 5 independently selected Rf substituents;
or any two Rc substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each Rd is independently selected from C1-4 alkyl, C1-4 haloalkyl, halo, CN, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NReRe, NReC(0)Re,
NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC(=NRe)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe; each Rf is independently selected from Ci-4 alkyl, Ci-4 haloalkyl, halo, CN, ORs, SRS, C(0)R8, C(0)NRsRs, C(0)ORs, OC(0)Rs, OC(0)NR«Re NRgRg, NRgC(0)Rs,
RSC(0) RSRS, NRsC(0)ORs, C(=NRs)NRsRs, NRsC(=NRs)NRsRs, S(0)Re, S(0)NRsRs, S(0)2Rs, NR¾(0)2Rs, NR¾(0)2NR¾s, and S(0)2NR¾s;
each Rh is independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-6 haloalkyl, halo, CN, OR1, SR1, C(0)R, C(0)NRR, C(0)OR, OC(0)R, OC(0)NRR, NR'R', NRC(0)R, NRC^NRR, NRC(0)OR, C(=NR1)NRiR1, NRC^NR NRR, S(0)R, S(0)NRR, S(0)2R, NRS(0)2R, NRiS(0)2NRiRi, and S(0)2NRiRi, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, Ce-ιο aryl, and 5-6 membered heteroaryl of Rh are optionally substituted by 1, 2, or 3 independentlys selected R> substituents;
each Rj is independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, CN, 0Rk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk, OC(0)Rk, OC(0)NRkRk, NRkRk, NRkC(0)Rk,
NRkC(0)NRkRk, NRkC(0)OR, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk, NRkS(0)2NRkRk, and S(0)2NRkRk;
each Re, Rs, R1 or Rk is independently selected from H, Ci-4 alkyl, C6-ioaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C6-ioaryl, C2-4 alkenyl or C2-4 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, di(Ci-4 alkyl)amino, Ci-4 haloalkyl, and Ci-4 haloalkoxy;
or any two Re substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rs substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R1 substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
X1 is -CR10Rn- or -NR7-
X2 is N or CR6;
R13 is H, CN, NRc4Rd4, OR1 or -C(0)NHRe, wherein R1 is C1-3 alkyl or C1-3 haloalkyl; R2 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy; R3 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R14 is H, CN, NRc4Rd4, OR4 or -C(0)NHRs, wherein R4 is C1-3 alkyl or C1-3 haloalkyl; R5 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R6 is selected from H, halo, CN, ORa4, SRa4, C(0)NRc4Rd4, OC(0)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, NRc4S(0)RM, NRc4S(0)2RM,
NRc4S(0)2NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM, S(0)2NRc4Rd4, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl groups of R6 are each optionally substituted with 1, 2, or 3 substituents independently selected from R10A;
R7 is selected from H, C(0)NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM,
S(0)2NRc4Rd4, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, 5- to 10-membered heteroaryl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, 4- to 10-membered heterocycloalkyl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl- C1-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)- C1-4 alkyl-; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5- to 10-membered heteroaryl, 4-7 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- groups of R7 are each optionally substituted with 1, 2, or 3 substituents independently selected from R10A; or two R10A substituents attached to the adjacent ring atoms of the aryl or heteroaryl ring of R7, taken together with the atoms to which they are attached, form a fused C5-6 cycloalkyl ring or a fused 5- to 6-membered heterocycloalkyl ring having 1-2 heteroatoms as ring members independently selected from O, N and S, wherein the nitrogen and sulfur atoms are each optionally oxidized and the fused C5-6 cycloalkyl ring or fused 5 to 6-membered heterocycloalkyl is optionally substituted with 1 or 2 independently selected R19 groups;
R10 and R11 are each independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, a 5-10 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-10 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl groups of R10 and R11 are each optionally substituted with 1, 2, or 3, R10A;
alternatively, R10 and R11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group or a 4-, 5-, 6-, 7-, 8-, 9-, or 10- membered heterocycloalkyl group; wherein said 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group and 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group are each optionally substituted with 1, 2, 3 or 4 R10A;
each R10A is independently selected from halo, CN, NO2, ORa4, SRa4, C(0)RM, C(0)NRc4Rd4, C(0)ORa4, OC(0)RM, OC(0)NRc4Rd4, C(=NRe4)NRc4Rd4,
NRc4C(=NRe4)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, NRc4S(0)RM, NRc4S(0)2RM, NRc4S(0)2NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM,
S(0)2NRc4Rd4, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1 , 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of R10A are each optionally substituted with 1, 2, or 3 substituents independently selected from R19;
each Ra4, Rb4, Rc4, and Rd4 is independently selected from H, Ci-4 alkyl, C2-4 alkenyl,
C2-4 alkynyl, Ci-4 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of Ra4, Rb4, Rc4, and Rd4 are each optionally substituted with 1, 2, or 3 substituents independently selected from R19;
alternatively, R04 and Rd4 together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group which is optionally substituted with 1, 2 or 3 substituents independently selected from R19;
each Re4 is independently H or Ci-4 alkyl;
each R19 is independently selected from halo, CN, NO2, ORa9, SRa9, C(0)Rb9, C(0)NRc9Rd9, C(0)ORa9, OC(0)Rb9, OC(0)NRc9Rd9, NRc9Rd9, NRc9C(0)Rb9, NRc9C(0)ORa9, NRc9C(0)NRc9Rd9, NRc9S(0)Rb9, NRc9S(0)2Rb9, NRc9S(0)2NRc9Rd9, S(0)Rb9, S(0)NRc9Rd9, S(0)2Rb9, S(0)2NRc9Rd9, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3- 6cycloalkyl and Ci-4 haloalkyl; wherein the Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6- cycloalkyl and C1-4 haloalkyl of R19 are each further optionally substituted with 1 or 2 R20 substituents independently selected from H, halo, CN, N02, OR\ SR\ C(0)R\ C(0)NRiRi, C(0)ORi, OC(0)Ri, OC(0)NRiRi, NRqRq, NR< (0)Ri, NRiC(0)ORi, NR< (0)NRiRi, NR¾(0)Ri, NR¾(0)2Ri, NR¾(0)2NRiRi, S(0)Ri, S(0)NRiRi, S(0)2Ri, S(0)2NRiRi, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6cycloalkyl and C1-4 haloalkyl, wherein each Rq is independently H or Ci-4alkyl;
each Ra9, Rc9, and Rd9 is independently selected from H and C1-4 alkyl;
each Rb9 is independently C1-4 alkyl; and
the subscript n is 0, 1, 2 or 3.
In some embodiments, the present disclosure provides a compound having Formula
Figure imgf000011_0001
or a pharmaceutically acceptable salt thereof, wherein:
ring A is a C6-10 aryl or 5 to 6-membered heteroaryl having carbon and 1 to 4 heteroatoms as ring members selected from O, N, and S;
each R12 is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5- 10 membered heteroaryl, 4- 10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5- 10 membered heteroaryl)-Ci-4 alkyl-, (4- 10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, N02, ORa, SRa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NRaRa, NRaORa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa, NRaC(=NRa)NRaRa, NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, or 4 independently selected Rb substituents; or two adjacent R12 substituents on ring A taken together with the atoms to which they are attached form a fused 5- or 6-membered cycloalkyl ring, 5- to 6-membered
heterocycloalkyl ring, phenyl or 5 to 6-membered heteroaryl ring, wherein the
heterocycloalkyl or heteroaryl has 1 -2 heteroatoms as ring members selected from O, N, and S;
each Ra is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein Ci-6 alkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Ra are each optionally substituted with 1, 2, 3, 4, or 5 independently selected Rd substituents;
or any two Ra substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each Rb is independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, CN, N02, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC,
NRCC(=NRC)NRCRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc, and S(0)2NRcRc;
each Rc is independently selected from H, Ci-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 independently selected Rf substituents; or any two Rc substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents, wherein the Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl or 5-6 membered heteroaryl as Rh is optionally substituted with 1, 2, or 3 independently selected R> substituents;
each Rd is independently selected from C1-4 alkyl, C1-4 haloalkyl, halo, CN, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NReRe, NReC(0)Re,
NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC(=NRe)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe;
each Rf is independently selected from Ci-4 alkyl, Ci-4 haloalkyl, halo, CN, OR§, SR§,
C(0)R8, C(0)NR¾s, C(0)ORs, OC(0)Rs, OC(0)NRSR<% NR¾s, NRSC(0)RS,
RsC(0) R¾s, RsC(0)ORs, C(=NRs)NR¾s, NRsC(=NRs)NR¾s, S(0)Re, S(0)NR¾s, S(0)2Rs, NR¾(0)2Rs, NR¾(0)2NR¾s, and S(0)2NR¾s;
each Rh is independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, Ci-6 haloalkyl, halo, CN, OR1, SR1, C(0)R, C^N , C(0)OR, OC(0)R, OC^N , NRR, N C^ , N C^N , N CCO , C(=NR1)NRiR1, N C^NR N , S(0)R, S(0)NR1Ri, S(0)2R, RiS(0)2Ri, R'S^ R'R1, and 8(0)2Ν^^, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 independentlys selected Rj substituents;
each Rj is independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, CN, ORk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk, OC(0)Rk, OC(0)NRkRk, NRkRk, NRkC(0)Rk,
NRkC(0)NRkRk, NRkC(0)OR, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk, NRkS(0)2NRkRk, and S(0)2NRkRk;
each Re, Rg, R1 or Rk is independently selected from H, Ci-4 alkyl, C6-ioaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C6-ioaryl, C2-4 alkenyl or C2-4 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-4 alkyl, C1-4 alkoxy, Ci-4 alkylthio, Ci-4 alkylamino, di(Ci-4 alkyl)amino, Ci-4 haloalkyl, and Ci-4 haloalkoxy;
or any two Re substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents; or any two Rs substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R1 substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
X1 is -CR10Rn- or -NR7-
X2 is N or CR6;
R1 is Ci-3 alkyl or C1-3 haloalkyl;
R2 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R3 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R4 is Ci-3 alkyl or C1-3 haloalkyl;
R5 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R6 and R7 are each independently selected from H, halo, CN, ORa4, SRa4,
C(0)NRc4Rd4, OC(0)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, NRc4S(0)RM, NRc4S(0)2RM, NRc4S(0)2NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM, S(0)2NRc4Rd4, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl groups of R6 and R7 are each optionally substituted with 1, 2, or 3 substituents independently selected from R10A;
R10 and R11 are each independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, a 5-10 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-10 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl groups of R10 and R11 are each optionally substituted with 1, 2, or 3, R10A;
alternatively, R10 and R11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group or a 4-, 5-, 6-, 7-, 8-, 9-, or 10- membered heterocycloalkyl group; wherein said 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group and 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group are each optionally substituted with 1, 2, 3 or 4 R10A;
each R10A is independently selected from halo, CN, N02, ORa4, SRa4, C(0)RM, C(0)NRc4Rd4, C(0)ORa4, OC(0)RM, OC(0)NRc4Rd4, C(=NRe4)NRc4Rd4,
NRc4C(=NRe4)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, NRc4S(0)RM, NRc4S(0)2RM, NRc4S(0)2NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM,
S(0)2NRc4Rd4, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1 , 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of R10A are each optionally substituted with 1, 2, or 3 substituents independently selected from R19;
each Ra4, Rb4, Rc4, and Rd4 is independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of Ra4, Rb4, Rc4, and Rd4 are each optionally substituted with 1, 2, or 3 substituents independently selected from R19;
alternatively, R04 and Rd4 together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group which is optionally substituted with 1, 2 or 3 substituents independently selected from R19;
each Re4 is independently H or C1-4 alkyl;
each R19 is independently selected from halo, CN, NO2, ORa9, SRa9, C(0)Rb9, C(0)NRc9Rd9, C(0)ORa9, OC(0)Rb9, OC(0)NRc9Rd9, NRc9Rd9, NRc9C(0)Rb9,
NRc9C(0)ORa9, NRc9C(0)NRc9Rd9, NRc9S(0)Rb9, NRc9S(0)2Rb9, NRc9S(0)2NRc9Rd9, S(0)Rb9, S(0)NRc9Rd9, S(0)2Rb9, S(0)2NRc9Rd9, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, and C1-4 haloalkyl; wherein the C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, and C1-4 haloalkyl are each further optionally substituted with 1 or 2 R20 substituents independently selected from H, halo, CN, NO2, OR\ SR\ C(0)R¾, C(0)NRiRi, C(0)ORi, OC(0)Ri, OC(0)NRiRi, NRqRq, NRiC(0)Ri, NRiC(0)ORi, NRiC(0)NRiRi, NRqS(0)Rq, NRqS(0)2Rq, NRqS(0)2NRqRq, S(0)Rq, S(0)NRqRq, S(0)2Rq, S(0)2 RqRq, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl and C1-4 haloalkyl, wherein each R is independently H or Ci-4alkyl;
each Ra9, Rc9, and Rd9 is independently selected from H and C1-4 alkyl;
each Rb9 is independently Ci-4 alkyl; and
the subscript n is 0, 1, 2 or 3.
In some embodiments of compounds of Formula (Γ) or (I):
ring A is a Ce-ιο aryl or 5 to 6-membered heteroaryl having carbon and 1 to 4 heteroatoms as ring members selected from O, N, and S;
each R12 is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, ORa, SRa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NRaRa, NRORa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa, NRaC(=NRa)NRaRa,
NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, or 4 independently selected Rb substituents; or two adjacent R12 substituents on ring A taken together with the atoms to which they are attached form a fused 5- or 6-membered cycloalkyl ring, 5 to 6-membered
heterocycloalkyl ring, phenyl or 5 to 6-membered heteroaryl ring, wherein the
heterocycloalkyl or heteroaryl have 1-2 heteroatoms as ring members selected from O, N, and S;
each Ra is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein Ci-6 alkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- as Ra are each optionally substituted with 1, 2, 3, 4, or 5 independently selected Rd substituents;
or any two Ra substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each Rb is independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, CN, NO2, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC,
NRCC(=NRC)NRCRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc, and S(0)2NRcRc;
each Rc is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-iocycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 independently selected Rf substituents;
or any two Rc substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each Rd is independently selected from C1-4 alkyl, C1-4 haloalkyl, halo, CN, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NReRe, NReC(0)Re,
NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC(=NRe)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe;
each Rf is independently selected from Ci-4 alkyl, Ci-4 haloalkyl, halo, CN, OR§, SR§,
C(0)R8, C(0)NR¾s, C(0)ORs, OC(0)Rs, OC(0)NR«R<% NR¾s, NRSC(0)RS,
NRsC(0)NR¾s, NRsC(0)ORs, C(=NRs)NR¾s, NRsC(=NRs)NR¾s, S(0)R8, S(0)NR¾s, S(0)2Rs, NR¾(0)2Rs, NR¾(0)2NR¾s, and S(0)2NR¾s;
each Rh is independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, 5-6 membered heteroaryl, Ci-6 haloalkyl, halo, CN, OR1, SR1, C(0)R;, C^NR'R1, C(0)OR, OC(0)R, OC C NRR, NRR, NRiC(0)Ri, Ν^Ο(0)Ν^^, R'CCO R1, C(=NR1)NRiR1, R^ R^ R'R1, S(0)R, S(0)NR1Ri, S(0)2R, RiS(0)2Ri, R'S^ R'R1, and 8(0)2Ν^^, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, Ce-ιο aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 independentlys selected R substituents;
each Rj is independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, CN, ORk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk, OC(0)Rk, OC(0)NRkRk, NRkRk, NRkC(0)Rk,
NRkC(0)NRkRk, NRkC(0)ORi, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk, NRkS(0)2NRkRk, and S(0)2NRkRk;
each Re, Rs, R1 or Rk is independently selected from H, Ci-4 alkyl, C6-ioaryl, Ci-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the Ci-4 alkyl, C6-ioaryl, C2-4 alkenyl or C2-4 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-4 alkyl, Ci-4 alkoxy, Ci-4 alkylthio, Ci-4 alkylamino, di(Ci-4 alkyl)amino, Ci-4 haloalkyl, and Ci-4 haloalkoxy;
or any two Re substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rs substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R1 substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
X1 is -CR10Rn- or -NR7-
X2 is N or CR6;
R1 is Ci-3 alkyl or C1-3 haloalkyl;
R2 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R3 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R4 is Ci-3 alkyl or C1-3 haloalkyl;
R5 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R6 is selected from H, halo, CN, ORa4, SRa4, C(0)NRc4Rd4, OC(0)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, NRc4S(0)RM, NRc4S(0)2RM,
NRc4S(0)2NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM, S(0)2NRc4Rd4, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl having carbon and 1, 2, or 3 heteroatoms independently selected from , O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl groups of R6 are each optionally substituted with 1, 2, or 3 substituents independently selected from R10A;
R7 is selected from H, C(0)NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0 Rb4,
S(0)2NRc4Rd4, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl groups of R7 are each optionally substituted with 1, 2, or 3 substituents independently selected from R10A;
R10 and R11 are each independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, a 5-10 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-10 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl groups of R10 and R11 are each optionally substituted with 1, 2, or 3, R10A;
alternatively, R10 and R11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group or a 4-, 5-, 6-, 7-, 8-, 9-, or 10- membered heterocycloalkyl group; wherein said 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group and 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group are each optionally substituted with 1, 2, 3 or 4 R10A;
each R10A is independently selected from halo, CN, NO2, ORa4, SRa4, C(0)RM, C(0)NRc4Rd4, C(0)ORa4, OC(0)RM, OC(0)NRc4Rd4, C(=NRe4)NRc4Rd4,
NRc4C(=NRe4)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, NRc4S(0)RM, NRc4S(0)2RM, NRc4S(0)2NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM,
S(0)2NRc4Rd4, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of R10A are each optionally substituted with 1, 2, or 3 substituents independently selected from R19;
each Ra4, Rb4, Rc4, and Rd4 is independently selected from H, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of Ra4, Rb4, Rc4, and Rd4 are each optionally substituted with 1, 2, or 3 substituents independently selected from R19;
alternatively, R04 and Rd4 together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group which is optionally substituted with 1, 2 or 3 substituents independently selected from R19;
each Re4 is independently H or Ci-4 alkyl;
each R19 is independently selected from halo, CN, NO2, ORa9, SRa9, C(0)Rb9,
C(0)NRc9Rd9, C(0)ORa9, OC(0)Rb9, OC(0)NRc9Rd9, NRc9Rd9, NRc9C(0)Rb9,
NRc9C(0)ORa9, NRc9C(0)NRc9Rd9, NRc9S(0)Rb9, NRc9S(0)2Rb9, NRc9S(0)2NRc9Rd9, S(0)Rb9, S(0)NRc9Rd9, S(0)2Rb9, S(0)2NRc9Rd9, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3- 6cycloalkyl and C1-4 haloalkyl; wherein C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6cycloalkyl and Ci-4 haloalkyl are each further optionally substituted with 1 or 2 R20 substituents independently selected from H, halo, CN, NO2, ORi, SRi, C(0)Ri, C(0)NRiRi, C(0)ORi, OC(0)Ri, OC(0)NRiRi, NRqRq, NR< (0)Ri, NR< (0)ORi, NRiC(0)NRiRi, NR¾(0)Ri, NR¾(0)2Rq, NR¾(0)2NRiRi, S(0)Ri, S(0)NRiRi, S(0)2Rq, S(0)2NRiRi, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6cycloalkyl and C1-4 haloalkyl, wherein each R is independently H or Ci-4alkyl
each Ra9, Rc9, and Rd9 is independently selected from H and C1-4 alkyl;
each Rb9 is independently C1-4 alkyl; and
the subscript n is 0, 1, 2 or 3.
In one aspect, the present disclosure provides a compound having Formula (I):
Figure imgf000021_0001
6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, ORa, SRa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NRaRa, NRaORa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa, NRaC(=NRa)NRaRa,
NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, or 4 independently selected Rb substituents; or two adjacent R12 substituents on ring A taken together with the atoms to which they are attached form a fused 5- or 6-membered cycloalkyl ring, 5 to 6-membered
heterocycloalkyl ring, phenyl or 5 to 6-membered heteroaryl ring, wherein the
heterocycloalkyl or heteroaryl have 1-2 heteroatoms as ring members selected from O, N, and S;
each Ra is independently selected from H, Ci-6 alkyl, Ci-4haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein Ci-6 alkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- as Ra are each optionally substituted with 1, 2, 3, 4, or 5 independently selected Rd substituents;
or any two Ra substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each Rb is independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, CN, NO2, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC,
NRCC(=NRC)NRCRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc, and S(0)2NRcRc;
each Rc is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 independently selected Rf substituents;
or any two Rc substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents, wherein the Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl or 5-6 membered heteroaryl as Rh is optionally substituted with 1, 2, or 3 independently selected R> substituents;
each Rd is independently selected from C1-4 alkyl, C1-4 haloalkyl, halo, CN, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NReRe, NReC(0)Re,
NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC(=NRe)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe;
each Rf is independently selected from C1-4 alkyl, Ci-4 haloalkyl, halo, CN, ORs, SRS, C(0)R8, C(0)NR¾s, C(0)ORs, OC(0)Rs, OC(0)NR«R<% NR¾s, NRSC(0)RS,
NRsC(0)NR¾s, NRsC(0)ORs, C(=NRs)NR¾s, NRsC(=NRs)NR¾s, S(0)R8, S(0)NR¾s, S(0)2Rs, NR¾(0)2Rs, NR¾(0)2NRSRS, and S(0)2NRSRS;
each Rh is independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-6 haloalkyl, halo, CN, OR1, SR1, C(0)R C^NR , 0(0)0^, 00(0)^, 00(0) Κ¾;, NR'R', Ν^Ο(Ο)^, ^0(0) ^;, ^0(0)0^, 0(= ^) ^^, NR ^NR NR , S^R1, S^NR , SiO^R1, NR^CO^R1, NR^CO^NRiR1, and δ(0)2 ^^, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, Ce-ιο aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 independentlys selected R> substituents;
each Rj is independently selected from halo, Ci-4 alkyl, C1-4 haloalkyl, CN, 0Rk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk, OC(0)Rk, OC(0)NRkRk, NRkRk, NRkC(0)Rk,
NRkC(0)NRkRk, NRkC(0)ORi, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk, NRkS(0)2NRkRk, and S(0)2NRkRk;
each Re, Rg, R1 or Rk is independently selected from H, Ci-4 alkyl, C6-ioaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C6-ioaryl, C2-4 alkenyl or C2-4 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-4 alkyl, C1-4 alkoxy, Ci-4 alkylthio, Ci-4 alkylamino, di(Ci-4 alkyl)amino, Ci-4 haloalkyl, and Ci-4 haloalkoxy;
or any two Re substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rs substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R1 substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
X1 is -CR10Rn- or -NR7- X2 is N or CR6;
R1 is Ci-3 alkyl or C1-3 haloalkyl;
R2 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R3 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R4 is Ci-3 alkyl or C1-3 haloalkyl;
R5 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R6 and R7 are each independently selected from H, halo, CN, 0Ra4, SRa4,
C(0)NRc4Rd4, OC(0)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, NRc4S(0)RM, NRc4S(0)2RM, NRc4S(0)2NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM, S(0)2NRc4Rd4, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl having carbon and 1, 2, or 3 heteroatoms independently selected from , O and S, and a 4-7 membered heterocycloalkyl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl groups of R6 and R7 are each optionally substituted with 1, 2, or 3 substituents independently selected from R10A;
R10 and R11 are each independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, a 5-10 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-10 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl groups of R10 and R11 are each optionally substituted with 1, 2, or 3, R10A;
alternatively, R10 and R11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group or a 4-, 5-, 6-, 7-, 8-, 9-, or 10- membered heterocycloalkyl group; wherein said 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group and 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group are each optionally substituted with 1, 2, 3 or 4 R10A;
each R10A is independently selected from halo, CN, NO2, ORa4, SRa4, C(0)RM,
C(0)NRc4Rd4, C(0)ORa4, OC(0)RM, OC(0)NRc4Rd4, C(=NRe4)NRc4Rd4,
NRc4C(=NRe4)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, NRc4S(0)RM, NRc4S(0)2RM, NRc4S(0)2NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM,
S(0)2NRc4Rd4, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1 , 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of R10A are each optionally substituted with 1, 2, or 3 substituents independently selected from R19;
each Ra4, Rb4, Rc4, and Rd4 is independently selected from H, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of Ra4, Rb4, Rc4, and Rd4 are each optionally substituted with 1, 2, or 3 substituents independently selected from R19;
alternatively, R04 and Rd4 together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group which is optionally substituted with 1, 2 or 3 substituents independently selected from R19;
each Re4 is independently H or Ci-4 alkyl;
each R19 is independently selected from halo, CN, NO2, ORa9, SRa9, C(0)Rb9,
C(0)NRc9Rd9, C(0)ORa9, OC(0)Rb9, OC(0)NRc9Rd9, NRc9Rd9, NRc9C(0)Rb9,
NRc9C(0)ORa9, NRc9C(0)NRc9Rd9, NRc9S(0)Rb9, NRc9S(0)2Rb9, NRc9S(0)2NRc9Rd9, S(0)Rb9, S(0)NRc9Rd9, S(0)2Rb9, S(0)2NRc9Rd9, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, and Ci-4 haloalkyl;
each Ra9, Rc9, and Rd9 is independently selected from H and C1-4 alkyl;
each Rb9 is independently C1-4 alkyl; and
the subscript n is 0, 1, 2 or 3.
In some embodiments, R7 is selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl groups of R7 are each optionally substituted with 1, 2, or 3 substituents independently selected from R10A.
In some embodiments, R7 is Ci-6 alkyl, phenyl, benzyl, C3-6 cycloalkyl, C3-10 cycloalkyl-Ci-4 alkyl-, 4- to 10-membered heterocycloalkyl, (4-10 membered
heterocycloalkyl)-Ci-4 alkyl-, 5- to 10-membered heteroaryl, or (5- to 10-membered heteroaryl)-Ci-4 alkyl-, each of which is optionally substituted with 1, 2, or 3 independently selected R10A substituents; or two R10A substituents attached to the adjacent ring atoms of the aryl or heteroaryl ring of R7 are optionally taken together with the atoms to which they are attached form a fused C5-6 cycloalkyl ring or a fused 5 to 6-membered heterocycloalkyl ring having 1 -2 heteroatoms as ring members independently selected from O, N and S, wherein the nitrogen and sulfur atoms are each optionally oxidized and the fused C5-6 cycloalkyl ring or fused 5 to 6-membered heterocycloalkyl is optionally substituted with 1 or 2 independently selected R19 groups.
R7 is Ci-6 alkyl, cyclopropylmethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-fluorobenzyl, tetrahydrofuran-3-yl, (3-methylisoxazol-5-yl)methyl, (tetrahydro-2H-pyran- 4-yl)methyl, (5-cyclopropylisoxazol-3-yl)methyl, 5-methylisoxazol-3-yl)methyl, 4- fluorophenyl, (l-ethylpyrazol-4-yl)methyl, benzothiazol-6-yl, l-methyl-5-oxopyrrolidin-3-yl, 1 -acetylpiperidin-4-yl, 2,3 -dihydro- 1 ,4-benzodioxin-6-ylmethyl, 1 -t- butoxycarbonylpiperidin-4-yl, 4-cyanophenyl, 4-pyrimidinyl, 2-pyrimidinyl, 5-pyrimidinyl, l-methylpyrazol-3-yl, l-methylpyrazol-4-yl, (l,5-dimethylpyrazol-4-yl)methyl, or (5-methyl- l,3,4-oxadiazol-2-yl)methyl.
In some embodiments, R7 is Ci-6 alkyl, cyclopropylmethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-fluorobenzyl, (3-methylisoxazol-5-yl)methyl, (5- cyclopropylisoxazol-3-yl)methyl, 4-fluorophenyl, (l-ethylpyrazol-4-yl)methyl, 1- acetylpiperidin-4-yl, 2,3-dihydro-l,4-benzodioxin-6-ylmethyl, 1-t-butoxycarbonylpiperidin- 4-yl, 4-cyanophenyl, 4-pyrimidinyl, 2-pyrimidinyl, 5-pyrimidinyl, l-methylpyrazol-3-yl, (l,5-dimethylpyrazol-4-yl)methyl, or (5-methyl-l,3,4-oxadiazol-2-yl)methyl.
In some embodiments, R7 is Ci-6 alkyl, cyclopropylmethyl, cyclopentyl, 4- fluorobenzyl, tetrahydrofuran-3-yl, (3-methylisoxazol-5-yl)methyl, (tetrahydro-2H-pyran-4- yl)methyl, (5-cyclopropylisoxazol-3-yl)methyl, 5-methylisoxazol-3-yl)methyl, 4- fluorophenyl, (l-ethylpyrazol-4-yl)methyl, benzothiazol-6-yl, l-methyl-5-oxopyrrolidin-3-yl, l-acetylpiperidin-4-yl, 2,3-dihydro-l,4-benzodioxin-6-ylmethyl, 4-cyanophenyl, 4- pyrimidinyl, (l,5-dimethylpyrazol-4-yl)methyl, or (5-methyl-l,3,4-oxadiazol-2-yl)methyl.
In some embodiments, R7 is methyl, isopropyl, pyridazin-4-yl, (2-methoxypyridin-4- yl)methyl, (6-methoxypyridin-3-yl)methyl, 3-cyanophenyl, pyrimidin-5-yl, isoquinolin-7-yl, 4-methylcarbamoylbenzyl, (5-ethylisoxazol-3-yl)methyl, pyrimidin-4-ylmethyl, 3-cyano-4- fluorophenyl, (5-ethyl-l,3,4-oxadiazol-2-yl)methyl, (2-methylpyridin-4-yl)methyl, pyridin-4- ylmethyl, pyrazin-2-yl, l-(methylsulfonyl)piperidin-4-yl, (1 -methyl- lH-pyrazol-4-yl)methyl, 3,4-difluorobenzyl, 2-cyano-5-pyridyl, 2-methylbenzo[d]oxazol-6-yl, 4-(lH-pyrazol-l- yl)phenyl, 3-cyano-5-fluorophenyl, 5-cyano-2-pyridyl, oxazol-5-ylmethyl, 4-cyano-5- methoxyphenyl, (5-methyloxazol-2-yl)methyl, cyclopropyl, pyrimidin-5-ylmethyl, pyrazin-2- ylmethyl, pyridin-3-yl, 6-methylpyrazin-2-yl, pyridazin-3-ylmethyl, 3-(l-methyl-lH-l,2,3- triazol-5-yl)phenyl, 1-cyanocyclopropyl, 2-pyridyl, (5-isopropylisoxazol-3-yl)methyl, pyridin-2-ylmethyl, (2-methylthiazol-4-yl)methyl, (l-methyl-5-oxopyrrolidin-3-yl)methyl, 4- (cyanomethyl)phenyl, 4-(methylsulfonyl)phenyl, 3 -fluorophenyl, 1 -methyl- lH-pyrazol-3-yl, ( 1,3 -dimethyl- lH-pyrazol-4-yl)methyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 4- methoxyphenyl, pyrimidin-2-yl, 5-ethylpyrazin-2-yl, 5-methylpyrazin-2-yl, (tetrahydrofuran- 3-yl)methyl, 3 -methoxyphenyl, 2-fluorophenyl, 3-(methylsulfamoyl)phenyl, 5- methoxypyrazin-2-yl, 4-(dimethylcarbamoyl)phenyl, 2-(l -methyl- lH-pyrazol-4-yl)ethyl, 5- methyl- 1 ,3 ,4-oxadiazol-2-yl, (2-ethoxypyridin-4-yl)methyl, ( 1 -methyl-2-oxo- 1,2- dihydropyridin-4-yl)methyl, ( 1 -methyl- 1 H-benzo[d] [ 1 ,2,3 ]triazol-5-yl)methyl, 2-oxoindolin- 5-yl, 2-methyl-3-oxoisoindolin-5-yl, (2-methylpyrimidin-4-yl)methyl, 1- (methylcarboxy)piperidin-4-yl, 4-(methoxycarbonylamino)phenyl, (1-cyclopropyl-lH- pyrazol-4-yl)methyl, ( 1 -cyanomethyl- 1 H-pyrazol-4-yl)methyl, ( 1 -cyclopropylmethyl- 1 H- pyrazol-4-yl)methyl, (l-(2,2-difluoroethyl)-lH-pyrazol-4-yl)methyl, lH-pyrazol-4-yl, 1- cyclopropyl-lH-pyrazol-4-yl, 1 -ethyl- lH-pyrazol-4-yl, 1 -propyl- lH-pyrazol-4-yl, 1H- indazol-6-yl, lH-indazol-5-yl, pyrimidin-4-yl, cyclobutyl, 3-pyridyl, 2-methoxyethyl, cyclopropylmethyl, ethyl, 4-cyanophenyl, (1 -ethyl- lH-pyrazol-4-yl)methyl, (5-methyl-l,3,4- oxadiazol-2-yl)methyl, or 1 -methyl- lH-pyrazol-4-yl.
In some embodiments, compounds of Formula (Γ) or (I) have selective inhibitory activity on FGFR4 enzyme or any mutant thereof over other FGFR enzymes. In other embodiments, compounds of Formula (Γ) or (I) have selective inhibitory activity on FGFR3 enzyme or any mutant thereof over other FGFR enzymes. In other embodiments, compounds of Formula (Γ) or (I) have selective dual inhibitory activity on both FGFR3 and FGFR4 enzymes or any mutant thereof.
In some embodiments of compounds of Formula (Γ) or (I), ring A is C6-io aryl. In certain instances, ring A is phenyl. In one instance, ring A is 1 -naphthyl or 2-naphthyl.
In some embodiments of compounds of Formula (Γ) or (I), ring A is phenyl and two adjacent R12 substituents on the phenyl ring taken together with the carbon atoms to which they are attached form a fused 3 to 7-membered cycloalkyl. In some instances, ring A is phenyl and two adjacent R12 substituents on the phenyl ring taken together with the carbon atoms to which they are attached form a fused cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
In some embodiments of compounds of Formula (Γ) or (I), ring A is phenyl and two adjacent R12 substituents on the phenyl ring taken together with the carbon atoms to which they are attached form a fused 4 to 6-membered heterocycloalkyl. In some instances, ring A is phenyl and two adjacent R12 substituents on the phenyl ring taken together with the carbon atoms to which they are attached form a fused 2-oxetanyl, 2-tetrahydrofuranyl, 3- tetrahydrofuranyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 1, 1- dioxotetrahydrothiophen-2-yl, l, l-dioxotetrahydrothiophen-3-yl, 2-tetrahydropyranyl, 3- tetrahydropyranyl, 4-tetrahydropyranyl, 3,6-dihydro-2H-pyranyl, 3,4-dihydro-2H-pyranyl, 1- azetidinyl, 2-azetidinyl, 3-azetidinyl, 1 -pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-oxo- pyrrolidin-l-yl, 2-oxo-pyrrolidin-3-yl, 2-oxo-pyrrolidin-4-yl, 2-oxo-pyrrolidin-5-yl, 1- piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2-oxo-piperidin-l-yl, 2-oxo-piperidin- 3-yl, 2-oxo-piperidin-4-yl, 2-oxo-piperidin-5-yl, 2-oxo-piperidin-6-yl, 1 -piperazinyl, 2- piperazinyl, 4-morpholinyl, 3-morpholinyl or 2-morpholinyl.
In some embodiments of compounds of Formula (Γ) or (I), ring A is 5-membered heteroaryl. In some embodiments, ring A is 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, thiophenyl, thiazolyl, isoxazolyl, isothiazolyl, or furanyl. In some embodiments, ring A is pyrazolyl or imidazolyl. In some embodiments, ring A is pyrazolyl. In some embodiments, ring A is 4-pyrazolyl.
In some embodiments of compounds of Formula (Γ) or (I), ring A is 5-membered heteroaryl selected from 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 1-pyrazolyl, 3-pyrazolyl, 4- pyrazolyl, 1 -imidazolyl, 2-imidazolyl, 4-imidazolyl, 2-oxazolyl, 4- oxazolyl, 5-oxazolyl, 2- thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3- isothiazolyl, 4- isothiazolyl, 5-isothiazolyl, 1 ,2,3-triazol- 1 -yl, 1 ,2,3-triazol-2-yl, 1 ,2,3-triazol-3-yl, 1 ,2,3- triazol-4-yl, 1 ,2,3-triazol-5-yl, 1 ,2,4-triazol-l -yl, 1 ,2,4-triazol-2-yl, l,2,4-triazol-3-yl, 1 ,2,4- triazol-4-yl, l,2,4-triazol-5-yl, 1 -oxa-2,3-diazol-4-yl, 1 -oxa-2,3-diazol-5-yl, l-oxa-2,4-diazol-
3- yI, 1 - oxa-2,4-diazol-5-yl, 1 -oxa-2,5-diazol-3-yl, 1 -oxa-2,5-diazol-4-yl, 1 -thia-2,3-diazol-
4- yl, 1 -thia-2,3- diazol-5-yl, 1 -thia-2,4-diazol-3-yl, 1 -thia-2,4-diazol-5-yl, 1 -thia-2,5-diazol- 3-yl, 1 -thia-2,5-diazol-4- yl, 1-tetrazolyl, 3-tetrazolyl, 1 H-5-tetrazolyl, 3H-5-tetrazolyl, 2- furanyl, 3-furanyl, 2-thiopenyl, and 3-thiophenyl.
In some embodiments of compounds of Formula (Γ) or (I), ring A is 6-membered heteroaryl. In certain embodiments, ring A is selected from pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, and triazinyl. In some embodiments of compounds of Formula (Γ) or (I), ring A is 6-membered heteroaryl selected from 2-pyridyl, 3 -pyridyl, 4-pyridyl, 2-pyrazinyl, 3- pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5 -pyrimidinyl, l,2,3-triazin-4-yl, l,2,3-triazin-5-yl, l,3,5-triazin-2-yl, l,2,4-triazin-3-yl, l,2,4-triazin-5-yl, and l,2,4-triazin-6- yl- In some embodiments, ring A is pyridyl. In other embodiments, ring A is phenyl or 6-membered heteroaryl. In other embodiments, ring A is phenyl or pyridyl.
In some embodiments,
Figure imgf000029_0001
j or , each of which is optionally substituted with 1 or 2 R12 substituents defined herein.
In some embodiments, ring A is bstituted with R12 as defined herein.
In some embodiments, ring A is optionally substituted with R 12
In some embodiments, ring A is
In some embodiments, ring A is
Figure imgf000029_0002
, optionally substituted with R12.
In some embodiments, ring A is
Figure imgf000029_0003
In some embodiments of compounds of Formula (Γ), R13 is H, CN, NRc4Rd4, OR1 or - C(0)NHRe, wherein R1 is Ci-3 alkyl or Ci-3 haloalkyl and R14 is H, CN, NR^4, OR4 or - C(0)NHRs, wherein R4 is C1-3 alkyl or C1-3 haloalkyl. In other embodiments, R13 is OR1 and R14 is OR4. In other embodiments, R13 is -C(0)NHRe and R14 is OR4. In other
embodiments, R13 and R14 are each OCH3. In other embodiments, R13 is -C(0)NHRe and R14 is OR4. In some embodiments, R13 and R14 are each independently selected form Ci-4 alkyl-NHC(O)- and OCH3. In one embodiment, R13 is -C(0)NHCi-6 alkyl and R14 is OR4. In another embodiment, R13 is -C(0)NHCi-6alkyl and R14 is OCH3. In another embodiment, R13 is -C(0)NHCH3 and R14 is OCH3. In some embodiments, R13 is H and R14 is CN, NR^4, OR4 or -C(0)NHRs.
In some embodiments of compounds of Formula (Γ) or (I), R2 and R5 are each independently H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy. In other embodiments, R2 and R5 are each independently halogen. In some instances, R2 and R5 are halogen. In a preferred embodiment, R2 and R5 are F.
In some embodiments of compounds of Formula (Γ) or (I), R1 and R4 are each independently C1-3 alkyl or C1-3 haloalkyl. In some instances, R1 and R4 are each
independently C1-3 alkyl. In other instances, R1 and R4 are each independently methyl, ethyl, propyl, CF3, CF2H or CFH2. In a preferred embodiment, R1 and R4 are CH3.
In some embodiments of compounds of Formula (Γ) or (I), R3 is H, halo, C1-3 alkyl, Ci-3 haloalkyl, CN, or C1-3 alkoxy. In some instances, R3 is H, F, CI, Ci-3alkyl, CF3, CF3O, CFH2, CHF2, OCFH2 or OCHF2. In a preferred embodiment, R3 is H.
In some embodiments of compounds of Formula (Γ) or (I), R10 and R11 are each independently Ci-6 alkyl. In some instances, R10 and R11 are methyl. In some embodiments, R10 and R11 taken together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group, which is optionally substituted with 1 or 2
independently selected R10A groups. In some instances, R10 and R11 taken together with the carbon atom to which they are attached form cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, each of which is optionally substituted with from 1-3 R10A groups. In a preferred embodiment, R10 and R11 together with the carbon atom to which they are attached form a cyclopropyl, optionally substituted with 1 or 2 independently selected R10A groups. In some embodiments, R10 and R11 are H. In certain embodiments, R10 and R11 are each independently selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2 or 3 substituents independently selected from R10A.
In some embodiments of compounds of Formula (Γ) or (I), R10 and R11 taken together with the carbon atom to which they are attached form 4-, 5-, 6-, or 7-membered
heterocycloalkyl group, which is optionally substituted with 1 or 2 independently selected R10A groups. In some instances, R10 and R11 together with the carbon atom to which they are attached form 2-oxetanyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2 -tetrahydropyranyl, 3- tetrahydropyranyl, 4-tetrahydropyranyl, 3,6-dihydro-2H-pyranyl, 3,4-dihydro-2H-pyranyl, 1- azetidinyl, 2-azetidinyl, 3-azetidinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1- piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1 -piperazinyl, 2-piperazinyl, 4- morpholinyl, 3-morpholinyl or 2-morpholinyl, 1-azepanyl, 2-azepanyl, 3-azepanyl, 4- azepanyl, 2-oxepanyl, 3-oxepanyl or 4-oxepanyl, each of which is optionally substituted with 1 or 2 independently selected R10A. In some embodiments, R10A is halo, CN, Ci-6 alkyl, C3-6 cycloalkyl, -C(0)Rb4, or -C(0)ORb4; or two R10A substituents attached to the adjacent ring atoms of the aryl or heteroaryl ring of R7 are optionally taken together with the atoms to which they are attached form a 5- to 6-membered heterocycloalkyl ring having 1-2 heteroatoms as ring members independently selected from O, N and S, wherein the nitrogen and sulfur atoms are each optionally oxidized.
In some embodiments, R10A is F, CI, CH3, Ci-6 alkyl, CN, -C(0)Ci-4 alkyl or - C(0)OCi-4 alkyl; or two R10A substituents attached to the adjacent ring atoms of the aryl or heteroaryl ring of R7 are optionally taken together with the atoms to which they are attached form a tetrahydrofuran, tetrahydropyran, 1,4-dioxane, morpholine, tetrahydrothiopyran or tetrahydrothiophene ring, each of which is optionally substituted with 1 or 2 R19 substituents.
In some embodiments, R10A is F, CH3, CN, -C(0)CH3, or cyclopropyl.
In some embodiments, R10 and R11 together with the carbon atom to which they are attached form a cyclopropyl.
In some embodiments of compounds of Formula (Γ) or (I), X1 is -CR10Rn- or -NR7-.
In one embodiment, X1 is -CR10RU-. In another embodiment, X1 is -NR7-. In some instances, X1 is CH2 or NH.
In some embodiments of compounds of Formula (Γ) or (I), X1 is NR7, wherein R7 is Ci-6 alkyl, phenyl, benzyl, C3-6 cycloalkyl, C3-10 cycloalkyl-Ci-4 alkyl-, 4- to 10-membered heterocycloalkyl, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, 5- to 10-membered heteroaryl, or (5- to 10-membered heteroaryl)-Ci-4 alkyl-, each of which is optionally substituted with 1, 2, or 3 independently selected R10A substituents; or two R10A substituents attached to the adjacent ring atoms of the aryl or heteroaryl ring of R7 are taken together with the atoms to which they are attached form a fused C5-6 cycloalkyl ring or a fused 5 to 6- membered heterocycloalkyl ring having 1-2 heteroatoms as ring members independently selected from O, N and S, wherein the nitrogen and sulfur atoms are each optionally oxidized; and wherein one or two ring atoms in the fused C5-6 cycloalkyl ring or fused 5 to 6- membered heterocycloalkyl are optionally replaced by a carbonyl group, and the fused C5-6 cycloalkyl ring or fused 5 to 6-membered heterocycloalkyl is optionally substituted with 1 or 2 independently selected R19 groups. In some instances, R10A is halo, CN, Ci ealkyl, C3- 6cycloalkyl, -C(0)RM or -C(0)ORM; or two R10A substituents attached to the adjacent ring atoms of the aryl or heteroaryl ring of R7 are taken together with the atoms to which they are attached form a 5- to 6-membered heterocycloalkyl ring having 1-2 heteroatoms as ring members independently selected from O, N and S, wherein the nitrogen and sulfur atoms are each optionally oxidized. In other instances, R10A is F, CI, CH3, Ci-6 alkyl, CN, -C(0)Ci-4 alkyl or -C(0)OCi-4 alkyl; or two R10A substituents attached to the adjacent ring atoms of the aryl or heteroaryl ring of R7 are taken together with the atoms to which they are attached form a tetrahydrofuran, tetrahydropyran, 1,4-dioxane, morpholine, tetrahydrothiopyran, or tetrahydrothiophene ring, each of which is optionally substituted with 1 or 2 R19 substituents.
In some embodiments of compounds of Formula (Γ) or (I), X1 is NR7, wherein R7 is Ci-6 alkyl, cycloproprylmethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4- fluorobenzyl, (3-methylisoxazol-5-yl)methyl, (5-cyclopropylisoxazol-3-yl)methyl, 4- fluorophenyl, (l-ethylpyrazol-4-yl)methyl, l-acetylpiperidin-4-yl, 2,3-dihydro-l,4- benzodioxin-6-ylmethyl, l-t-butoxycarbonylpiperidin-4-yl, 4-cyanophenyl, 4-pyrimidinyl, 2- pyrimidinyl, 5-pyrimidinyl, l-methylpyrazol-3-yl, (l,5-dimethylpyrazol-4-yl)methyl or (5- methyl-l,3,4-oxadiazol-2-yl)methyl.
In some embodiments of compounds of Formula (Γ) or (I), X2 is N or CR6. In other embodiments, X2 is N or CH. In one preferred embodiment, X2 is N. In another preferred embodiment, X2 is CH.
In some embodiments of compounds of Formula (Γ) or (I), each R12 is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, ORa, SRa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NRaRa, NRORa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2 or 3 Rb substituents.
In some embodiments, each R12 is independently selected from F, CI, CN, CH3, CH2CH3, NH2, OCH3, -C(0)NH(Ci-4 alkyl), NHC(0)CH3, NHS(0)2CH3, NHS(0)2Ra, C(0)Ra, -CH2C(0)Ra, -CH2CH2Ra, morpholinosulfonyl, imidazolyl, 4-morpholinyl, (3- cyanopyrrolidin-l-yl)methyl, 2-cyanoprop-2-yl, 1-cyanocyclobutyl, 1 -cyanocyclopropyl, benzyl, pyridylmethyl, l,l-dioxothiolan-3-yl, l-methylsulfonylazetidin-3-yl, l-acetyl-3- (cyanomethyl)azetidin-3-yl, and -CH2-(4-morpholinyl), wherein Ra is 4-morpholinyl. In some embodiments, each R12 is independently selected from F, CI, CN, CH3, CH2CH3, NH2, -C(0)NH(Ci-4 alkyl), NHC(0)CH3, NHS(0)2CH3, C(0)Ra, -CH2C(0)Ra, - CH2CH2Ra, morpholinosulfonyl, imidazolyl, 4-morpholinyl, (3-cyanopyrrolidin-l-yl)methyl, 2-cyanoprop-2-yl, 1-cyanocyclobutyl, pyridylmethyl, l,l-dioxothiolan-3-yl, l-acetyl-3- (cyanomethyl)azetidin-3-yl, and -CH2-(4-morpholinyl), wherein Ra is 4-morpholinyl.
In some embodiments of compounds of Formula (Γ) or (I), each R12 is independently NH2, CH3, F, CN, 1-piperidinyl, 1 -piperazinyl. or 4-morpholinyl.
In some embodiments, each R12 is independently selected from -NH2, -NHOH, - NHORa, -NHRa, -NHC(0)Ra, -NHC(0)NHRa, -NHS(0)2Ra, -C(0)Ra, -S(0)2Ra, Ci-6 alkyl, Ci ealkoxy, Ci ehaloalkyl, Ci-4haloalkoxy, halo, CN, C3-6cycloalkyl, phenyl-Ci-4alkyl, 5-6 membered heteroaryl, 5- to 6-membered heteroaryl-Ci-4alkyl, 4 to 6-membered
heterocycloalkyl, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C3-6cycloalkyl, phenyl-Ci-4alkyl, 5-6 membered heteroaryl, 4 to 6-membered
heterocycloalkyl, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- is optionally substituted with from 1-3 Rb; and Ci e alkoxy or Ci-4haloalkoxy is optionally substituted by 1-3 Rd.
In some embodiments, each R12 is independently F, CI, CN, CH3, NH2, OCH3, NHS(0)2Ra, C(0)Ra, -CH2C(0)Ra, imidazoyl, 4-morpholinyl, -CH2-(4-morpholinyl), (3- cyanopyrrolidin-l-yl)methyl, 1-cycano-l -methyl-ethyl, 1-cyanocyclobutyl, 1- cyanocyclopropyl, benzyl, l,l-dioxothiolan-3-yl, l-methylsulfonylazetidin-3-yl, l-acetyl-3- (cyanomethyl)azetidin-3-yl and -CH2-(4-morpholinyl), wherein Rais 4-morpholinyl.
In some embodiments, each R12 is independently F, CI, CN, CH3, NH2, OCH3, NHS(0)2Ra, C(0)Ra, imidazoyl, 4-morpholinyl, and -CH2-(4-morpholinyl), wherein Ra is 4- morpholinyl.
In some embodiments, R12 is H, methyl, ethyl, CN, cyanomethyl, 2-cyanoethyl, 1- cyanocyclobutyl, 3-morpholinopropyl, l-(methylsulfonyl)pyrrolidin-3-yl, (1-
(methylsulfonyl)piperidin-4-yl)ethyl, (4-methoxypiperidin-l-yl)ethyl, 2-morpholinoethyl, 2- morpholino-2-oxoethyl, dimethylamino, (3-methoxypyrrolidin-l-yl)ethyl, (l,l-dioxido-l,2- thiazinan-3-yl)methyl, l-methylpyrrolidin-3-yl, (dimethylamino)ethyl, 2-(piperidin-4- yl)ethyl, (l-(methylsulfonyl)azetidin-3-yl)methyl, (l-acetylazetidin-3-yl)methyl, 1- acetylpyrrolidin-3-yl, (tetrahydro-2H-pyran-4-yl)methyl, ethylcarbamoyl,
cyclopropylcarbamoyl, (2-hydroxyethyl)carbamoyl, propylcarbamoyl, isopropylcarbamoyl, 1-cycanocyclopropyl, carbamoyl, morpholino, 1-cyanomethylpyrrolidin-l-yl, or pyridin-3- ylmethyl. In some embodiments, the subscript n is 0, 1, or 2. In some embodiments, the subscript n is 0. In some embodiments, the subscript n is 1. In another embodiment, the subscript n is 2. In another embodiment, the subscript n is 3.
In some embodiments:
Ring A is phenyl or a 6-membered heteroaryl ring;
R10 and R11 are Ci-e alkyl;
alternatively, R10 and R11 together with the carbon atom to which they are attached form a a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group, which is optionally substituted with 1 or 2 independently selected R10A groups.
each R12 is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, C6-10 aryl, C3-
10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, ORa, C(0)Ra, C(0)NRaRa, C(0)ORa, NRaRa, NRORa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1-3 independently selected Rb substituents;
each Rb is independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, CN, N02, ORc,
SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, NRCRC, NRcC(0)Rc,
NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2Rc, and S(0)2NRcRc; and
each Rc is independently selected from H and Ci-6 alkyl; and
subscript n is 0, 1, 2, or 3.
In some embodiments:
X1 is CR10Rn;
X2 is CH;
Ring A is phenyl or a 6-membered heteroaryl ring;
R10 and R11 are Ci-e alkyl; alternatively, R10 and R11 together with the carbon atom to which they are attached form a a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group, which is optionally substituted with 1 or 2 independently selected R10A groups.
each R12 is independently selected from halo, CN, NRaRa, NRORa, NHC(0)Ra, NHS(0)2Ra, C(0)Ra, S(0)2Ra, ORa, Ci-e alkyl, Ci-e haloalkyl, 5-6 membered heteroaryl, and 4 to 6-membered heterocycloalkyl, wherein said Ci-6 alkyl, 5-6 membered heteroaryl, or 4 to 6- membered heterocycloalkyl is optionally substituted with from 1-3 Rb;
each Rb is independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, CN, NO2, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, NRCRC, NRcC(0)Rc,
NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2Rc, and S(0)2NRcRc;
each Rc is independently selected from H and Ci-6 alkyl; and
subscript n is 0, 1, 2, or 3. In some embodiments:
X1 is CR10Rn;
X2 is CH;
Ring A is phenyl or pyridyl;
R10 and R11 are Ci-6 alkyl;
alternatively, R10 and R11 together with the carbon atom to which they are attached form a a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group, which is optionally substituted with 1 or 2 independently selected R10A groups;
each R12 is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, (4-6 membered heterocycloalkyl)-Ci-2 alkyl-, CN, ORa, C(0)Ra, NRaRa, NRaS(0)2Ra, and S(0)2Ra;
each Ra is independently selected from H, Ci-6 alkyl, C1-4 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl; and
subscript n is 0, 1, 2, or 3. In some embodiments, when ring A is a 5-6 membered heteroaryl ring, then ring A is connected by a carbon atom to the moiety below at the point indicated by the wavy line:
Figure imgf000036_0001
Subformulas
In some embodiments, compounds of Formula (Γ) or (I) have subformula (la):
Figure imgf000036_0002
or a pharmaceutically acceptable salt thereof, wherein the variables ring A, R1, R2, R3, R4, R5, R10, R11, R12, X2 and n are as defined in any embodiment of compounds of Formula (Γ) or (I).
In some embodiments of compounds of Formula (la):
ring A is a C6-10 aryl or a 5 to 6-membered heteroaryl having carbon and 1 to 4 heteroatoms as ring members selected from O, N and S;
each R12 is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, ORa, SRa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NRaRa, NRaORa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa, NRaC(=NRa)NRaRa,
NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, or 4 Rb substituents independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, CN, N02, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0 NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc, and S(0)2NRcRc; or two adjacent R12 substituents on ring A taken together with the atoms to which they are attached form a fused 5- or 6-member cycloalkyl ring, 5 to 6-membered heterocycloalkyl ring, phenyl or 5 to 6-membered heteroaryl ring, wherein the heterocycloalkyl or heteroaryl have 1-2 heteroatoms as ring members selected from O, N and S;
each Ra is independently selected from H, Ci-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-iocycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- is optionally substituted with 1, 2, 3, 4, or 5 Rd substituents independently selected from C1-4 alkyl, Ci-4 haloalkyl, halo, CN, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NReRe, NReC(0)Re, NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC(=NRe)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe;
each Rc is independently selected from H, Ci-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-iocycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- is optionally substituted with 1, 2, 3, 4, or 5 Rf substituents independently selected from C1-4 alkyl, Ci-4 haloalkyl, halo, CN, OR SR§, C(0)R C(0)NR¾s, C(0)ORs, OC(0)Rs, OC(0)NRsRs, NRgRg, NRgC(0)Rs, NRsC(0)NRsRs, NRsC(0)ORs, C(=NRs)NRsRs,
Figure imgf000037_0001
S(0)Rs, S(0)NRsRs, S(0)2Rs, NR¾(0)2Rs, NR¾(0)2NRsRs, and S(0)2NR¾s; or any two Ra attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 Rh substituents independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-6 haloalkyl, halo, CN, OR', SR C(0)R CCC NR'R1, 0(0)0^, 00(0)^, 00(0) ^;, NR'R', ^Ο(Ο)^,
^Ο(0) ^^, ^0(0)0^, C^ R R , ^Ο(= ^) ^^, S^R1, S^NR , SiO^R1, R^CO^R1, NR^O^NRiR1, and SCO^NR , wherein said Ci-e alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 Ri substituents independently selected from halo, C1-4 alkyl, Ci-4haloalkyl, CN, 0Rk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk, OC(0)Rk,
OC(0)NRkRk, NRkRk, NRkC(0)Rk, NRkC(0)NRkRk, NRkC(0)ORi, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk, NRkS(0)2NRkRk, and S(0)2NRkRk;
or any two Rc attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Re substituents together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rs substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R1 substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each Re, Rs, R1 or Rk is independently selected from H, C1-4 alkyl, C6-ioaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the Ci-4 alkyl, C6-ioaryl, C2-4 alkenyl or C2-4 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-4 alkyl, Ci-4 alkoxy, Ci-4 alkylthio, Ci-4 alkylamino, di(Ci-4 alkyl)amino, Ci-4 haloalkyl, and Ci-4haloalkoxy;
X2 is N or CR6;
R1 is Ci-3 alkyl or C1-3 haloalkyl;
R2 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy; R3 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R4 is Ci-3 alkyl or C1-3 haloalkyl;
R5 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R6 is H, halo, CN, ORa4, SRa4, C(0)NRc4Rd4, OC(0)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, NRc4S(0)RM, NRc4S(0)2Rb4, NRc4S(0)2NRc4Rd4,
S(0)RM, S(0)NRc4Rd4, S(0)2RM, S(0)2NRc4Rd4, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered
heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl groups of R6 are each optionally substituted with 1, 2, or 3 substituents independently selected from R10A;
R10 is selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-10 aryl, C3- 10 cycloalkyl, a 5-10 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-10 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl groups of R10 are each optionally substituted with 1, 2, 3, or 4 R10A;
each R10A is independently selected from halo, CN, NO2, ORa4, SRa4, C(0)RM,
C(0)NRc4Rd4, C(0)ORa4, OC(0)RM, OC(0)NRc4Rd4, C(=NRe4)NRc4Rd4,
NRc4C(=NRe4)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, NRc4S(0)RM, NRc4S(0)2RM, NRc4S(0)2NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM,
S(0)2NRc4Rd4, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of R10A are each optionally substituted with 1, 2, or 3 substituents independently selected from R19;
each Ra4, Rb4, Rc4, and Rd4 are independently selected from H, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci-4 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of Ra4, Rb4, Rc4, and Rd4 are each optionally substituted with 1, 2, or 3 substituents independently selected from R19;
alternatively, R04 and Rd4 together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group which is optionally substituted with 1, 2 or 3 substituents independently selected from R19;
each Re4 is independently H or Ci-4 alkyl;
R11 is selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl; wherein said Ci-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2 or 3 substituents independently selected from R19;
alternatively, R10 and R11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group or a 4-, 5-, 6-, 7-, 8-, 9-, or 10- membered heterocycloalkyl group; wherein said 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group and 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group are each optionally substituted with 1, 2, 3 or 4 R10A;
each R19 is independently selected from halo, CN, NO2, ORa9, SRa9, C(0)Rb9, C(0)NRc9Rd9, C(0)ORa9, OC(0)Rb9, OC(0)NRc9Rd9, NRc9Rd9, NRc9C(0)Rb9,
NRc9C(0)ORa9, NRc9C(0)NRc9Rd9, NRc9S(0)Rb9, NRc9S(0)2Rb9, NRc9S(0)2NRc9Rd9,
S(0)Rb9, S(0)NRc9Rd9, S(0)2Rb9, S(0)2NRc9Rd9, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, and Ci-4 haloalkyl;
each Ra9, Rc9, and Rd9 is independently selected from H and C1-4 alkyl;
each Rb9 is independently Ci-4 alkyl; and
n as an integer is 0, 1, 2, or 3. In some embodiments, compounds of Formula (la) have selective inhibitory activity on FGFR4 enzyme or any mutant thereof. In other embodiments, compounds of Formula (la) have selective inhibitory activity on FGFR3 enzyme or any mutant thereof. In other embodiments, compounds of Formula (la) have selective inhibitory activity on both FGFR3 and FGFR4 enzyme or any mutant thereof In some embodiments, compounds of Formula (Γ) or (I) have subformula (lb):
Figure imgf000041_0001
or a pharmaceutically acceptable salt thereof, wherein the variables ring A, R1, R2, R3, R4, R5,R7, R12, X2 and n are as defined in any embodiment of compounds of Formula (Γ) or (I). In some embodiements, R7 is H, halo, CN, or Ci-6 alkyl. In one embodiment, R7 is H or Ci-6 alkyl.
In some embodiments, compounds of Formula (Γ) or (I) have subformula (Ic):
Figure imgf000041_0002
(Ic)
or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, R5, R10, R11, R12, X2 and n are as defined in any embodiment of compounds of Formula (Γ) or (I).
In some embodiments,
R2 is F or CI;
R5 is F or CI;
R10 is selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-10 aryl, C3- 10 cycloalkyl, a 5-10 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-10 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl groups of R10 are each optionally substituted with 1, 2, 3, or 4 R10A;
each R10A is independently selected from halo, CN, N02, ORa4, SRa4, C(0)RM, C(0)NRc4Rd4, C(0)ORa4, OC(0)RM, OC(0)NRc4Rd4, C(=NRe4)NRc4Rd4,
NRc4C(=NRe4)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, NRc4S(0)RM, NRc4S(0)2RM, NRc4S(0)2NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM,
S(0)2NRc4Rd4, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1 , 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl groups of R10a are each optionally substituted with 1, 2, or 3 substituents independently selected from R19;
each Ra4, Rb4, Rc4, and Rd4 is independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl groups of Ra4, Rb4, Rc4, and Rd4 are each optionally substituted with 1, 2, or 3 substituents independently selected from R19;
alternatively, R04 and Rd4 together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group which is optionally substituted with 1, 2 or 3 substituents s independently selected from R19;
Re4 is H or Ci-4 alkyl;
R11 is selected from Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-6 haloalkyl;
alternatively, R10 and R11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group or a 4-, 5-, 6-, or 7-membered heterocycloalkyl group; wherein said 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group and 4-, 5-, 6-, or 7-membered heterocycloalkyl group are each optionally substituted with 1, 2, 3 or 4
R1QA.
each R19 is independently selected from halo, CN, NO2, ORa9, SRa9, C(0)Rb9, C(0)NRc9Rd9, C(0)ORa9, OC(0)Rb9, OC(0)NRc9Rd9, NRc9Rd9, NRc9C(0)Rb9, NRc9C(0)ORa9, NRc9C(0)NRc9Rd9, NRc9S(0)Rb9, NRc9S(0)2Rb9, NRc9S(0)2NRc9Rd9, S(0)Rb9, S(0)NRc9Rd9, S(0)2Rb9, S(0)2NRc9Rd9, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl,C3- 6cycloalkyl and Ci-4 haloalkyl; wherein Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6cycloalkyl and Ci-4 haloalkyl are each further optionally substituted with 1 or 2 R20 substituents independently selected from H, halo, CN, N02, ORi, SRi, C(0)Ri, C(0)NRiRi, C(0)ORi, OC(0)Ri, OC(0)NRiRi, NRqRq, NR< (0)Ri, NR< (0)ORi, NRiC(0)NRiRi, NR¾(0)Ri, NR¾(0)2Ri, NR¾(0)2NRiRi, S(0)Ri, S(0)NRiRi, S(0)2Ri, S(0)2NRiRi, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6cycloalkyl and Ci-4 haloalkyl, wherein each Rq is independently H or Ci-4alkyl
each Ra9, Rc9, and Rd9 are independently selected from H and Ci-4 alkyl; and
Rb9 is Ci-4 alkyl.
In some embodiments, X2 is N.
In some embodiments, X2 is CR6.
In some embodiments, R6 is H, halo, CN, or Ci-6 alkyl. In some embodiments, R6 is H.
In some embodiments, R6 is Ci-6 alkyl. In some embodiments, R6 is methyl. In some embodiments, R6 is halo. In some embodiments, R6 is CN.
In some embodiments, R1 is C1-3 alkyl. In some embodiments, R1 is methyl.
In some embodiments, R2 is halo. In some embodiments, R2 is fluoro. In some embodiments, R2 is chloro.
In some embodiments, R3 is H.
In some embodiments, R4 is C1-3 alkyl. In some embodiments, R4 is methyl.
In some embodiments, R5 is halo. In some embodiments, R5 is fluoro. In some embodiments, R5 is chloro.
In some embodiments, R2 is fluoro and R5 is fluoro. In some embodiments, R2 is chloro and R5 is chloro.
In some embodiments, R1 is C1-3 alkyl; R2 is halo; R3 is H; R4 is C1-3 alkyl; and R5 is halo.
In some embodiments, R1 is C1-3 alkyl; R2 is F; R3 is H; R4 is C1-3 alkyl; and R5 is F. In some embodiments, R1 is methyl; R2 is F; R3 is H; R4 is methyl; and R5 is F.
In some embodiments, R1 is C1-3 alkyl; R2 is CI; R3 is H; R4 is C1-3 alkyl; and R5 is CI. In some embodiments, R1 is methyl; R2 is CI; R3 is H; R4 is methyl; and R5 is CI. In some embodiments, R10 is Ci-6 alkyl. In some embodiments, R10 is methyl. In some embodiments, R11 is Ci-6 alkyl. In some embodiments, R11 is methyl.
In some embodiments, R10 and R11 are each Ci-6 alkyl. In some embodiments, R10 and R11 are each methyl.
In some embodiments, R10 and R11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group. In some embodiments, R10 and R11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, or 6- membered cycloalkyl group. In some embodiments, R10 and R11 together with the carbon atom to which they are attached form a 3-, 4-, or 5-membered cycloalkyl group.
In some embodiments, R10 and R11 together with the carbon atom to which they are attached form a cyclopropyl group. In some embodiments, R10 and R11 together with the carbon atom to which they are attached form a cyclobutyl group. In some embodiments, R10 and R11 together with the carbon atom to which they are attached form a cyclopentyl group. In some embodiments, R10 and R11 together with the carbon atom to which they are attached form a cyclohexyl group. In some embodiments, R10 and R11 together with the carbon atom to which they are attached form a cycloheptyl group.
In some embodiments, R10 and R11 together with the carbon atom to which they are attached form a cyclopropyl group optionally substituted by 1 or 2 R10A. In some
embodiments, R10 and R11 together with the carbon atom to which they are attached form a cyclobutyl group optionally substituted by 1 or 2 R10A. In some embodiments, R10 and R11 together with the carbon atom to which they are attached form a cyclopentyl group optionally substituted by 1 or 2 R10A. In some embodiments, R10 and R11 together with the carbon atom to which they are attached form a cyclohexyl group optionally substituted by 1 or 2 R10A.
In some embodiments, R10 and R11 together with the carbon atom to which they are attached form 4-, 5-, 6-, or 7-membered heterocycloalkyl group.
In some embodiments, R10 and R11 together with the carbon atom to which they are attached form a tetrahydropyranyl group, a tetrahydrofuranyl group, tetrahydrothiophene group, a pyrrolidinyl group, or a piperidinyl group. In some embodiments, R10 and R11 together with the carbon atom to which they are attached form a tetrahydropyranyl group. In some embodiments, R10 and R11 together with the carbon atom to which they are attached form a tetrahydropyranyl group optionally substituted by 1 or 2 R10A. In some embodiments, R10 and R11 together with the carbon atom to which they are attached form a
tetrahydrofuranyl group. In some embodiments, R10 and R11 together with the carbon atom to which they are attached form a tetrahydrofuranyl group optionally substituted by R10A. In some embodiments, R10 and R11 together with the carbon atom to which they are attached form an azetidinyl group. In some embodiments, R10 and R11 together with the carbon atom to which they are attached form an azetidinyl group optionally substituted by R10A.
In some embodiments, compounds of Formula (Γ), (I) or (la) have sub Formula (Id):
Figure imgf000045_0001
(Id)
or a pharmaceutically acceptable salt thereof, wherein X2, R1, R2, R3, R4, R5, R10, R11, R12 and n are as defined in any embodiment of Formula (Γ) or (I) as described herein.
In some embodiments, compounds of Formula (Γ), (I) or (la) have sub Formula (Ie):
Figure imgf000045_0002
or a pharmaceutically acceptable salt thereof, wherein ring A, R2, R3, R^, R^, R^, R^2, X2 and n are as defined in any embodiment of Formula (Γ) or (I) as described herein.
In some embodiments, compounds of Formula (Γ), (I), (la) or (Ie) have sub Formula
(If):
Figure imgf000046_0001
(if)
or a pharmaceutically acceptable salt thereof, wherein ring A, R3, R10, R11, R12, X2 and n are as defined in any embodiment of compounds of Formula (Γ) or (I) as described herein.
In some embodiments, compounds of Formula (Γ), (I), (Ie) or (If) have sub Formula
(Ig):
Figure imgf000046_0002
(Ig)
or a pharmaceutically acceptable salt thereof, wherein ring A, R10, R11, X, R12 and n are as defined in any embodiment of compounds of Formula (Γ) or (I) as described herein. In some embodiments of compounds of Formula (Ie), X2 is N. In other embodiments, X2 is CH. In one embodiment, ring A is phenyl. In another embodiment, ring A is 5-membered heteroaryl selected from 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl, 1- imidazolyl, 2-imidazolyl, 4-imidazolyl, 2-oxazolyl, 4- oxazolyl, 5-oxazolyl, 2-thiazolyl, 4- thiazolyl, 5-thiazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3- isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, 1 ,2,3-triazol- 1 -yl, 1 ,2,3-triazol-2-yl, 1 ,2,3-triazol-3-yl, 1 ,2,3-triazol-4-yl, 1 ,2,3-triazol-5-yl, 1 ,2,4-triazol-l -yl, 1 ,2,4-triazol-2-yl, l,2,4-triazol-3-yl, 1 ,2,4- triazol-4-yl, l,2,4-triazol-5-yl, 1 -oxa-2,3-diazol-4-yl, 1 -oxa-2,3-diazol-5-yl, l-oxa-2,4-diazol-3-yI, 1 - oxa- 2,4-diazol-5-yl, 1 -oxa-2,5-diazol-3-yl, 1 -oxa-2,5-diazol-4-yl, 1 -thia-2,3-diazol-4-yl, 1 -thia- 2,3- diazol-5-yl, 1 -thia-2,4-diazol-3-yl, 1 -thia-2,4-diazol-5-yl, 1 -thia-2,5-diazol-3-yl, 1 -thia- 2,5-diazol-4- yl, 1 -tetrazolyl, 3-tetrazolyl, 1 H-5-tetrazolyl, 3H-5-tetrazolyl, 2-furanyl, 3- furanyl, 2-thiopenyl or 3- thiophenyl. In other embodiments, ring A is 2-pyridyl, 3-pyridyl or 4-pyridyl. In some embodiements of compounds of Formula (Ie), each R12 is independently selected from Ek, CH3, F, CN, 1 -piperidinyl, methylcarbamoyl, 1 -piperazinyl or 4- morpholinyl. In one embodiment, the subscript n is 0. In one embodiment, the subscript n is 1. In another embodiment, the subscript n is 2. In another embodiment, the subscript n is 3.
In some embodiments compounds of Formula (Γ) or (I) have sub Formula (Ih):
Figure imgf000047_0001
The variables X1, ring A, R12 and n are as defined in any embodiment of compounds of Formula (Γ) or (I) as described herein. In certain instances, X1 is -CR10Rn- or -NR7-. In some instances, X1 is -CR10Rn-, where R10 and R11 taken together form a C3-6 cycloalkyl ring. In one embodiment, R10 and R11 taken together form a cyclopropyl ring. In other instances, X1 is -NR7-. In one embodiment, R7 is Ci-6 alkyl. In one embodiment, R7 is ethyl. In some instances, ring A is phenyl or 3-pyridyl. In one instance, ring A is 4-pyrazolyl.
In some embodiments, compounds of Formula (Γ) have sub Formula (Ih):
Figure imgf000047_0002
The variables R13, R14, X1, ring A, R12 and n are as defined in any embodiment of compounds of formula (Γ) or (I) as described herein. In some instances, R13 is -C(0)NHCi-6 alkyl and R14 is OCH3. In certain instances, X1 is -CR10Rn- or -NR7-. In some instances, X1 is -CR10Rn-, where R10 and R11 taken together form a C3-6 cycloalkyl ring. In one embodiment, R10 and R11 taken together form a cyclopropyl ring. In other instances, X1 is - NR7-.
It is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.
Definitions
At various places in the present specification, substituents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual subcombination of the members of such groups and ranges.
For example, the term "Ci-6 alkyl" is specifically intended to individually disclose methyl, ethyl, C3 alkyl, CA alkyl, C5 alkyl, and Ce alkyl.
At various places in the present specification various aryl, heteroaryl, cycloalkyl, and heterocycloalkyl rings are described. Unless otherwise specified, these rings can be attached to the rest of the molecule at any ring member as permitted by valency. For example, the term "a pyridine ring" or "pyridinyl" may refer to a pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl ring.
The term "n-membered" where n is an integer typically describes the number of ring- forming atoms in a moiety where the number of ring-forming atoms is n. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, pyridyl is an example of a 6-membered heteroaryl ring, and 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.
For compounds of the invention in which a variable appears more than once, each variable can be a different moiety independently selected from the group defining the variable. For example, where a structure is described having two R groups that are simultaneously present on the same compound, the two R groups can represent different moieties independently selected from the group defined for R. As used herein, the phrase "optionally substituted" means unsubstituted or substituted.
As used herein, the term "substituted" means that a hydrogen atom is replaced by a non-hydrogen group. It is to be understood that substitution at a given atom is limited by valency.
As used herein, the term "G-j," where i and j are integers, employed in combination with a chemical group, designates a range of the number of carbon atoms in the chemical group with i-j defining the range. For example, Ci-6 alkyl refers to an alkyl group having 1, 2, 3, 4, 5, or 6 carbon atoms.
As used herein, the term "alkyl," employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chain or branched. In some embodiments, the alkyl group contains 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, w-pentyl, 2-methyl-l -butyl, 3- pentyl, w-hexyl, 1,2,2-trimethylpropyl, and the like. In some embodiments, the alkyl group is methyl, ethyl, or propyl.
As used herein, "alkenyl," employed alone or in combination with other terms, refers to an alkyl group having one or more carbon-carbon double bonds. In some embodiments, the alkenyl moiety contains 2 to 6 or 2 to 4 carbon atoms. Example alkenyl groups include, but are not limited to, ethenyl, w-propenyl, isopropenyl, w-butenyl, sec-butenyl, and the like.
As used herein, "alkynyl," employed alone or in combination with other terms, refers to an alkyl group having one or more carbon-carbon triple bonds. In some embodiments, the alkynyl moiety contains 2 to 6 or 2 to 4 carbon atoms. Example alkynyl groups include, but are not limited to, ethynyl, propyn-l-yl, propyn-2-yl, and the like.
As used herein, "halo" or "halogen", employed alone or in combination with other terms, includes fluoro, chloro, bromo, and iodo. In some embodiments, halo is F or CI. In some embodiments, halo is F.
As used herein, the term "haloalkyl," employed alone or in combination with other terms, refers to an alkyl group having up to the full valency of halogen atom substituents, which may either be the same or different. In some embodiments, the halogen atoms are fluoro atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Example haloalkyl groups include CF3, C2F5, CHF2, CCb, CHCI2, C2CI5, and the like.
As used herein, the term "alkoxy," employed alone or in combination with other terms, refers to a group of formula -O-alkyl. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Example alkoxy groups include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t-butoxy, and the like. In some embodiments, alkoxy is methoxy.
As used herein, "haloalkoxy," employed alone or in combination with other terms, refers to a group of formula -0-(haloalkyl). In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. An example haloalkoxy group is -OCF3.
As used herein, "amino," employed alone or in combination with other terms, refers
As used herein, the term "alkylamino," employed alone or in combination with other terms, refers to a group of formula -NH(alkyl). In some embodiments, the alkylamino group has 1 to 6 or 1 to 4 carbon atoms. Example alkylamino groups include methylamino, ethylamino, propylamino (e.g., n-propylamino and isopropylamino), and the like.
As used herein, the term "dialkylamino," employed alone or in combination with other terms, refers to a group of formula -N(alkyl)2. Example dialkylamino groups include dimethylamino, diethylamino, dipropylamino (e.g., di(n-propyl)amino and
di(isopropyl)amino), and the like. In some embodiments, each alkyl group independently has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "alkylthio," employed alone or in combination with other terms, refers to a group of formula -S-alkyl. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "cycloalkyl," employed alone or in combination with other terms, refers to a non-aromatic cyclic hydrocarbon including cyclized alkyl and alkenyl groups. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3, or 4 fused, bridged, or spiro rings) ring systems. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyclopentane, cyclohexene, cyclohexane, and the like, or pyrido derivatives of cyclopentane or cyclohexane. Ring- forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo. Cycloalkyl groups also include cycloalkylidenes. The term "cycloalkyl" also includes bridgehead cycloalkyl groups (e.g., non-aromatic cyclic hydrocarbon moieties containing at least one bridgehead carbon, such as admantan-l-yl) and spirocycloalkyl groups (e.g., non-aromatic hydrocarbon moieties containing at least two rings fused at a single carbon atom, such as spiro [2.5] octane and the like). In some embodiments, the cycloalkyl group has 3 to 10 ring members, or 3 to 7 ring members, or 3 to 6 ring members. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is a C3-7 monocyclic cycloalkyl group. Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, tetrahydronaphthalenyl,
octahydronaphthalenyl, indanyl, and the like. In some embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
As used herein, the term "heterocycloalkyl," employed alone or in combination with other terms, refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene or alkynylene groups as part of the ring structure, which has at least one heteroatom ring member independently selected from nitrogen, sulfur, oxygen, and phosphorus. Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused, bridged, or spiro rings) ring systems. In some embodiments, the heterocycloalkyl group is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen. Also included in the definition of
heterocycloalkyl are moieties that have one or more aromatic rings (e.g., aryl or heteroaryl rings) fused (i.e., having a bond in common with) to the non-aromatic heterocycloalkyl ring, for example, 1,2,3,4-tetrahydro-quinoline and the like. Heterocycloalkyl groups can also include bridgehead heterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least one bridgehead atom, such as azaadmantan- 1 -yl and the like) and spiroheterocycloalkyl groups (e.g., a heterocycloalkyl moiety containing at least two rings fused at a single atom, such as [l,4-dioxa-8-aza-spiro[4.5]decan-N-yl] and the like). In some embodiments, the heterocycloalkyl group has 3 to 10 ring-forming atoms, 4 to 10 ring- forming atoms, or 3 to 8 ring forming atoms. In some embodiments, the heterocycloalkyl group has 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 heteroatoms, or 1 to 2 heteroatoms. The carbon atoms or heteroatoms in the ring(s) of the heterocycloalkyl group can be oxidized to form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized. In some embodiments, the heterocycloalkyl portion is a C2-7 monocyclic heterocycloalkyl group. In some embodiments, the heterocycloalkyl group is a morpholine ring, pyrrolidine ring, piperazine ring, piperidine ring, dihydropyran ring, tetrahydropyran ring, tetrahyropyridine, azetidine ring, or tetrahydrofuran ring. As used herein, the term "aryl," employed alone or in combination with other terms, refers to a monocyclic or poly cyclic (e.g., having 2 fused rings) aromatic hydrocarbon moiety, such as, but not limited to, phenyl, 1-naphthyl, 2-naphthyl, and the like. In some embodiments, aryl groups have from 6 to 10 carbon atoms or 6 carbon atoms. In some embodiments, the aryl group is a monocyclic or bicyclic group. In some embodiments, the aryl group is phenyl or naphthyl.
As used herein, the term "heteroaryl," employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., having 2 or 3 fused rings) aromatic hydrocarbon moiety, having one or more heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl group is a monocyclic or bicyclic group having 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, sulfur and oxygen. Example heteroaryl groups include, but are not limited to, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, pyrrolyl, azolyl, quinolinyl, isoquinolinyl, benzisoxazolyl, imidazo[l,2-b]thiazolyl or the like. The carbon atoms or heteroatoms in the ring(s) of the heteroaryl group can be oxidized to form a carbonyl, an N-oxide, or a sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized, provided the aromatic nature of the ring is preserved. In one embodiment the heteroaryl group is a 5 to 10 membered heteroaryl group. In another embodiment the heteroaryl group is a 5 to 6 membered heteroaryl group.
The compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. Resolution of racemic mixtures of compounds can be carried out by methods known in the art. An example method includes fractional recrystallizaion using a chiral resolving acid which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids. Other resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2- diaminocyclohexane, and the like.
Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.
Compounds of the invention also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4-triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
Compounds of the invention also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium.
The term, "compound," as used herein is meant to include all stereoisomers, geometric iosomers, tautomers, and isotopes of the structures depicted.
All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g., in the form of hydrates and solvates) or can be isolated.
In some embodiments, the compounds of the invention, or salts thereof, are substantially isolated. By "substantially isolated" is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the compounds of the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the invention, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The present invention also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred. Lists of suitable salts are found in Remington 's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.
The following abbreviations may be used herein: AcOH (acetic acid); AC2O (acetic anhydride); aq. (aqueous); atm. (atmosphere(s)); Boc (?-butoxycarbonyl); br (broad); Cbz (carboxybenzyl); calc. (calculated); d (doublet); dd (doublet of doublets); DCM
(dichloromethane); DEAD (diethyl azodicarboxylate); DIAD (N,N'-diisopropyl
azidodicarboxylate); DIPEA (N,N-diisopropylethylamine); DMF (N,N-dimethylformamide); Et (ethyl); EtOAc (ethyl acetate); g (gram(s)); h (hour(s)); HATU (N,N,N',N'-tetramethyl-0- (7-azabenzotriazol-l-yl)uronium hexafluorophosphate); HC1 (hydrochloric acid); HPLC (high performance liquid chromatography); Hz (hertz); J (coupling constant); LCMS (liquid chromatography - mass spectrometry); m (multiplet); M (molar); mCPBA (3- chloroperoxybenzoic acid); MgS04 (magnesium sulfate); MS (Mass spectrometry); Me
(methyl); MeCN (acetonitrile); MeOH (methanol); mg (milligram(s)); min. (minutes(s)); mL (milliliter(s)); mmol (millimole(s)); N (normal); NaHCCb (sodium bicarbonate); NaOH (sodium hydroxide); a2S04 (sodium sulfate); NH4C1 (ammonium chloride); NH4OH (ammonium hydroxide); nM (nanomolar); NMR (nuclear magnetic resonance spectroscopy); OTf (trifluoromethanesulfonate); Pd (palladium); Ph (phenyl); pM (picomolar); PMB (para- methoxybenzyl), POCb (phosphoryl chloride); RP-HPLC (reverse phase high performance liquid chromatography); s (singlet); t (triplet or tertiary); TBS (tert-butyldimethylsilyl); tert (tertiary); tt (triplet of triplets); t-Bu (tert-butyl); TFA (trifluoroacetic acid); THF
(tetrahydrofuran); μg (microgram(s)); μΐ., (microliter(s)); μΜ (micromolar); wt% (weight percent).
As used herein, the term "cell" is meant to refer to a cell that is in vitro, ex vivo or in vivo. In some embodiments, an ex vivo cell can be part of a tissue sample excised from an organism such as a mammal. In some embodiments, an in vitro cell can be a cell in a cell culture. In some embodiments, an in vivo cell is a cell living in an organism such as a mammal.
As used herein, the term "contacting" refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example, "contacting" the FGFR4 enzyme with a compound of the invention includes the administration of a compound of the present invention to an individual or patient, such as a human, having FGFR, as well as, for example, introducing a compound of the invention into a sample containing a cellular or purified preparation containing the FGFR4 enzyme.
As used herein, the term "individual" or "patient," used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
As used herein, the phrase "therapeutically effective amount" refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. As used herein the term "treating" or "treatment" refers to 1) preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease; 2) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology), or 3) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology).
Synthesis
Compounds of the invention, including salts thereof, can be prepared using known organic synthesis techniques and according to various possible synthetic routes.
The reactions for preparing compounds of the invention can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.
Preparation of compounds of the invention can involve the protection and
deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3rd. Ed., Wiley & Sons, Inc., New York (1999), which is incorporated herein by reference in its entirety.
Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., lH or 13C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography. The expressions, "ambient temperature," "room temperature," and "r.t", as used herein, are understood in the art, and refer generally to a temperature, e.g. a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a temperature from about 20 °C to about 30 °C.
Compounds as disclosed herein can be prepared by one skilled in the art according to preparatory routes known in the literature. Example synthetic methods for preparing compounds of the invention are provided in the Schemes below.
Scheme 1
Figure imgf000057_0001
The synthesis of compound 4 is outlined in Scheme 1. Ester 1 can be reduced to the corresponding aldehyde 2 using DIBAL-H. The reductive amination on this aldehyde with aniline 3 can afford dichloropyridine 4.
Scheme 2
Figure imgf000057_0002
8
Dichloropyrimidine 8 can be prepared by the methods described in Scheme 2.
Treatment of 5-(hydroxymethyl)pyrimidine-2,4(lH,3H)-dione with POCb can afford trichloride 6, which can be converted to iodide 7 using Nal. Compound 7 can be coupled with aniline 3, in the presence of a base such as, z'PnNEt, CS2CO3, or NaH, to give dichloropyrimidine 8.
Scheme 3
Figure imgf000058_0001
The synthesis of compound 13 is outlined in Scheme 3. Compound 9 can be treated with ethyl 3-chloro-3-oxopropanoate and NaH in THF to provide amide 10. Lactam 11 can be prepared by the treatment of compounds 10 with a strong base, such as NaH or CS2CO3 in DMF, and followed by an acid, such as HCl, mediated decarboxylation. a-Substituted lactam 12 can be obtained by treating compound 11 with a base, such as NaH or CS2CO3 in DMF or acetonitrile, and followed by the addition of halides R10X and/or RUX (X is halo such as CI, Br, or I). Chloride 12 can be converted to compound 13, wherein M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., M is B(OH)2, Sn(Bu)3, or ZnBr), under standard Suzuki conditions {e.g., in the presence of a palladium catalyst, such as, but not limited to, [l, l'-bis(di-cyclohexylphosphino)ferrocene]dichloropalladium(II) and a bicarbonate or carbonate base}, or standard Stille conditions [e.g., in the presence of a palladium catalyst, such as, but not limited to, Pd(dba)2] or standard Negishi conditions [e.g., in the presence of a palladium catalyst, such as, but not limited to,
tetrakis(triphenylphosphine)palladium(0)].
Scheme 4
Figure imgf000059_0001
Compound 16 can be synthesized following the procedure shown in Scheme 4. Therefore, compound 9 is first treated with triphosgene in the presence of a base such as pyridine, and then with amine R7NH2 in the presence of another base (e.g. DIPEA) to afford urea compound 14. Upon treatment with a proper base (e.g. CS2CO3), cyclization of 14 takes place to generate cyclic urea 15, which can then be converted to compound 16, wherein M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., M is B(OH)2, Sn(Bu)3, or ZnBr). The coupling reaction to yield 16 can occur under standard Suzuki conditions {e.g., in the presence of a palladium catalyst, such as, but not limited to, [l, l '-bis(di- cyclohexylphosphino)ferrocene]dichloropalladium(II) and a bicarbonate or carbonate base}, or standard Stille conditions [e.g., in the presence of a palladium catalyst, such as, but not limited to, Pd(dba)2] or standard Negishi conditions [e.g., in the presence of a palladium catalyst, such as, but not limited to, tetrakis(triphenylphosphine)palladium(0)]. Scheme 5
Figure imgf000060_0001
Compound 21 can be prepared according to the synthetic procedures described in Scheme 5. The reductive amination of aldehyde 18 with aniline 17 can afford compound 19. Compound 19 is treated with triphosgene in the presence of a base such as triethylamine to afford urea 20. Compound 20 can then be converted to compound 21, wherein M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., M is B(OH)2, Sn(Bu)3, or ZnBr). The coupling reaction to yield 21 can occur under standard Suzuki conditions {e.g., in the presence of a palladium catalyst, such as, but not limited to, [l,l '-bis(di- cyclohexylphosphino)ferrocene]dichloropalladium(II) and a bicarbonate or carbonate base}, or standard Stille conditions [e.g., in the presence of a palladium catalyst, such as, but not limited to, Pd(dba)2] or standard Negishi conditions [e.g., in the presence of a palladium catalyst, such as, but not limited to, tetrakis(triphenylphosphine)palladium(0)]. Scheme 6
Figure imgf000061_0001
Compound 21 can be synthesized using an alternative procedure shown in Scheme 6.
Ester 1 can be reduced to the corresponding aldehyde 2 using DIBAL-H. The reductive amination of this aldehyde with aniline 17 can afford compound 22. Compound 22 is then converted to 23, wherein M is a boronic acid, boronic ester or an appropriately substituted metal (e.g., M is B(OH)2, Sn(Bu)3, or ZnBr). The coupling reaction to yield 23 can occur under standard Suzuki conditions {e.g., in the presence of a palladium catalyst, such as, but not limited to, [l,l '-bis(di-cyclohexylphosphino)ferrocene]dichloropalladium(II) and a bicarbonate or carbonate base}, or standard Stille conditions [e.g., in the presence of a palladium catalyst, such as, but not limited to, Pd(dba)2] or standard Negishi conditions [e.g., in the presence of a palladium catalyst, such as, but not limited to,
tetrakis(triphenylphosphine)palladium(0)]. Compound 23 can undergo Buchwald coupling with amine R7NH2 under standard conditions {e.g., in the presence of a palladium catalyst, such as, but not limited to, (2'-aminobiphenyl-2-yl)(chloro)[dicyclohexyl(2',6'- diisopropoxybiphenyl-2-yl)phosphoranyl]palladium and a base, such as, but not limited to, cesium carbonate or sodium tert-butoxide} then cyclized with triphosgene in the presence of a base such as triethylamine to provide compound 21.
Methods of Use
Compounds of the present disclosure can inhibit the activity of the FGFR enzyme. For example, the compounds of the disclosure can be used to selectivly inhibit the activity of an FGFR3 and/or FGFR4 enzyme in a cell or in an individual or patient in need of inhibition of the enzyme by administering an inhibiting amount of a compound of the disclosure to the cell, individual, or patient.
In some embodiments, the compounds of the disclosure are selective for the enzyme
FGFR4 over one or more of FGFR1, FGFR2, and/or FGFR3. In some embodiments, the compounds of the disclosure have selective inhibitory activity for the FGFR4 enzyme over FGFR1, FGFR2, and FGFR3. In some embodiments, the compounds of the disclosure are selective for the enzyme FGFR4 over VEGFR2. In some embodiments, the selectivity is 2- fold or more, 3-fold or more, 5-fold or more, 10-fold or more, 25-fold or more, 50-fold or more, or 100-fold or more.
In some embodiments, the compounds of the disclosure have selective inhibitory activity for the enzyme FGFR3 over one or more of FGFR1 and/or FGFR2 and/or FGFR4. In some embodiments, the compounds of the disclosure are selective for the enzyme FGFR3 over FGFR1 and FGFR2. In certain embodiments, the compounds of the disclosure are selective for the enzyme FGFR3 over FGFR1. In certain embodiments, the compounds of the disclosure are selective for the enzyme FGFR3 over FGFR4. In some embodiments, the compounds of the disclosure are selective for the enzyme FGFR3 over VEGFR2. In some embodiments, the selectivity of the compounds of the present disclosure for FGFR3 over FGFR1 and/or FGFR2 and/or FGFR4 is 2-fold or more, 3-fold or more, 5-fold or more, 10- fold or more, 25-fold or more, 50-fold or more, or 100-fold or more.
As selective FGFR3 and/or FGFR4 inhibitors, the compounds of the disclosure are useful in the treatment of various diseases associated with abnormal expression or activity of the FGFR3 and/or FGFR4 enzyme or FGFR ligands. Compounds which inhibit FGFR will be useful in providing a means of preventing the growth or inducing apoptosis in tumors, particularly by inhibiting angiogenesis. It is therefore anticipated that the compounds will prove useful in treating or preventing proliferative disorders such as cancers. In particular tumours with activating mutants of receptor tyrosine kinases or upregulation of receptor tyrosine kinases may be particularly sensitive to the inhibitors.
In certain embodiments, the FGFR4, or a mutant thereof, activity is inhibited irreversibly. In certain embodiments, FGFR4, or a mutant thereof, activity is inhibited irreversibly by covalently modifying Cys 552 of FGFR4.
In certain embodiments, the disclosure provides a method for treating a FGFR4- mediated disorder in a patient in need thereof, comprising the step of administering to said patient an effective amount of a compound according to the invention, or a pharmaceutically acceptable composition thereof.
As selective FGFR3 inhibitors, the compounds of the disclosure are useful in the treatment of various diseases associated with abnormal expression or activity of the FGFR3 enzyme or FGFR ligands.
In certain embodiments, the disclosure provides a method for treating a FGFR3- mediated disorder in a patient in need thereof, comprising the step of administering to said patient an effective amount of a compound according to the invention, or a pharmaceutically acceptable composition thereof.
In certain embodiments, compounds of the disclosure are useful in the treatment of cancer. Examplary cancers include bladder cancer, breast cancer, cervical cancer, colorectal cancer, cancer of the small intestine, colon cancer, rectal cancer, cacncer of the anus, endometrial cancer, gastric cancer, head and neck cancer (e.g., cancers of the larynx, hypopharynx, nasopharynx, oropharynx, lips, and mouth), kidney cancer, liver cancer (e.g., hepatocellular carcinoma, cholangiocellular carcinoma), lung cancer (e.g., adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas, parvicellular and non-parvicellular carcinoma, bronchial carcinoma, bronchial adenoma, pleuropulmonary blastoma), ovarian cancer, prostate cancer, testicular cancer, uterine cancer, esophageal cancer, gall bladder cancer, pancreatic cancer (e.g. exocrine pancreatic carcinoma), stomach cancer, thyroid cancer, parathyroid cancer, skin cancer (e.g., squamous cell carcinoma, Kaposi sarcoma, Merkel cell skin cancer), and brain cancer (e.g., astrocytoma, medulloblastoma,
ependymoma, neuro-ectodermal tumors, pineal tumors).
Further example cancers include hematopoietic malignancies such as leukemia or lymphoma, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, cutaneous T-cell lymphoma, acute myelogenous leukemia, Hodgkin's or non- Hodgkin's lymphoma, myeloproliferative neoplasms (e.g., polycythemia vera, essential thrombocythemia, and primary myelofibrosis), Waldenstrom's Macroglubulinemia, hairy cell lymphoma, chronic myelogenic lymphoma, acute lymphoblastic lymphoma, AIDS-related lymphomas, and Burkitt's lymphoma.
Other cancers treatable with the compounds of the disclosure include tumors of the eye, glioblastoma, melanoma, rhabdosarcoma, lymphosarcoma, and osteosarcoma.
Compounds of the disclosure can also be useful in the inhibition of tumor metastisis.
In some embodiments, the present disclosure provides a method for treating hepatocellular carcinoma in a patient in need thereof, comprising the step of administering to a patient a compound of Formula (Γ) or (I) or a compouind as disclosed herein, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of
Formula (Γ) or (I) or a compound as disclosed herein.
In some embodiments, the present disclosure provides a method for treating
Rhabdomyosarcoma, esophageal cancer, breast cancer, or cancer of a head or neck, in a patient in need thereof, comprising the step of administering to the patient a compound
Formula (Γ) or (I) or a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of Formula (Γ) or (I) or a compound as disclosed herein.
In some embodiments, the present disclosure provides a method of treating cancer, wherein the cancer is selected from hepatocellular cancer, breast cancer, bladder cancer, colorectal cancer, melanoma, mesothelioma, lung cancer, prostate cancer, pancreatic cancer, testicular cancer, thyroid cancer, squamous cell carcinoma, glioblastoma, neuroblastoma, uterine cancer, and rhabdosarcoma.
In addition to oncogenic neoplasms, the compounds of the invention are useful in the treatment of skeletal and chondrocyte disorders including, but not limited to, achrondroplasia, hypochondroplasia, dwarfism, thanatophoric dysplasia (TD) (clinical forms TD I and TD II), Apert syndrome, Crouzon syndrome, Jackson- Weiss syndrome, Beare-Stevenson cutis gyrate syndrome, Pfeiffer syndrome, and craniosynostosis syndromes. In some embodiments, the present disclosure provides a method for treating a patient suffering from a skeletal and chondrocyte disorder including, but not limiting to, achrondroplasia, hypochondroplasia, dwarfism, thanatophoric dysplasia (TD) (clinical forms TD I and TD II), Apert syndrome, Crouzon syndrome, Jackson- Weiss syndrome, Beare-Stevenson cutis gyrate syndrome, Pfeiffer syndrome, and craniosynostosis syndromes. The method includes administering to the patient in need thereof an effective amount of a compound Formula (Γ) or (I) or a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of Formula (Γ) or (I) or a compound as disclosed herein.
The compounds of the invention can also be useful in the treatment of
hypophosphatemia disorders including, for example, X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, autosomal dominant hypophosphatemic rickets, and tumor-induced osteromalacia. In some embodiments, the present disclosure provides a method for treating a patient suffering from a hypophosphatemia disorder including, but not limiting to, X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, autosomal dominant hypophosphatemic rickets, and tumor- induced osteromalacia. The method includes administering to the patient in need thereof an effective amount of a compound Formula (Γ) or (I) or a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of Formula (Γ) or (I) or a compound as disclosed herein.
The compounds of the invention may further be useful in the treatment of fibrotic diseases, such as where a disease symptom or disorder is characterized by fibrosis. Example fibrotic diseases include liver cirrhosis, glomerulonephritis, pulmonary fibrosis, systemic fibrosis, rheumatoid arthritis, and wound healing. Combination Therapy
One or more additional pharmaceutical agents or treatment methods such as, for example, anti-viral agents, chemotherapeutics or other anti-cancer agents, immune enhancers, immunosuppressants, radiation, anti-tumor and anti-viral vaccines, cytokine therapy (e.g., IL2, GM-CSF, etc.), and/or tyrosine kinase inhibitors can be used in combination with the compounds of Formula (Γ) or (I) or a compound as described herein for treatment of FGFR- associated diseases, disorders or conditions. The agents can be combined with the present compounds in a single dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.
Suitable antiviral agents contemplated for use in combination with the compounds of the present disclosure can comprise nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors ( RTIs), protease inhibitors and other antiviral drugs. Example suitable NRTIs include zidovudine (AZT); didanosine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil
[bis(POM)-PMEA]; lobucavir (BMS-180194); BCH-10652; emitricitabine [(-)-FTC]; beta-L- FD4 (also called beta-L-D4C and named beta-L-2', 3'-dicleoxy-5-fluoro-cytidene); DAPD, ((- )-beta-D-2,6,-diamino-purine dioxolane); and lodenosine (FddA). Typical suitable NNRTIs include nevirapine (BI-RG-587); delaviradine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721; AG-1549; MKC-442 (l-(ethoxy-methyl)-5-(l-methylethyl)-6-(phenylmethyl)- (2,4(lH,3H)-pyrimidinedione); and (+)-calanolide A ( SC-675451) and B. Typical suitable protease inhibitors include saquinavir (Ro 31-8959); ritonavir (ABT-538); indinavir (MK- 639); nelfnavir (AG-1343); amprenavir (141W94); lasinavir (BMS-234475); DMP-450; BMS-2322623; ABT-378; and AG-1 549. Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside and Yissum Project No.11607.
Suitable agents for use in combination with the compounds of the present invention for the treatment of cancer include chemotherapeutic agents, targeted cancer therapies, immunotherapies or radiation therapy. Compounds of this invention may be effective in combination with anti-hormonal agents for treatment of breast cancer and other tumors. Suitable examples are anti-estrogen agents including but not limited to tamoxifen and toremifene, aromatase inhibitors including but not limited to letrozole, anastrozole, and exemestane, adrenocorticosteroids (e.g. prednisone), progestins (e.g. megastrol acetate), and estrogen receptor antagonists (e.g. fulvestrant). Suitable anti-hormone agents used for treatment of prostate and other cancers may also be combined with compounds of the present invention. These include anti-androgens including but not limited to flutamide, bicalutamide, and nilutamide, luteinizing hormone-releasing hormone (LHRH) analogs including leuprolide, goserelin, triptorelin, and histrelin, LHRH antagonists (e.g. degarelix), androgen receptor blockers (e.g. enzalutamide) and agents that inhibit androgen production (e.g.
abiraterone).
Compounds of the present invention may be combined with or in sequence with other agents against membrane receptor kinases especially for patients who have developed primary or acquired resistance to the targeted therapy. These therapeutic agents include inhibitors or antibodies against EGFR, Her2, VEGFR, c-Met, Ret, IGFR1, or Flt-3 and against cancer-associated fusion protein kinases such as Bcr-Abl and EML4-Alk. Inhibitors against EGFR include gefitinib and erlotinib, and inhibitors against EGFR/Her2 include but are not limited to dacomitinib, afatinib, lapitinib and neratinib. Antibodies against the EGFR include but are not limited to cetuximab, panitumumab and necitumumab. Inhibitors of c- Met may be used in combination with FGFR inhibitors. These include onartumzumab, tivantnib, and INC-280. Agents against Abl (or Bcr-Abl) include imatinib, dasatinib, nilotinib, and ponatinib and those against Alk (or EML4-ALK) include crizotinib.
Angiogenesis inhibitors may be efficacious in some tumors in combination with
FGFR inhibitors. These include antibodies against VEGF or VEGFR or kinase inhibitors of VEGFR. Antibodies or other therapeutic proteins against VEGF include bevacizumab and aflibercept. Inhibitors of VEGFR kinases and other anti-angiogenesis inhibitors include but are not limited to sunitinib, sorafenib, axitinib, cediranib, pazopanib, regorafenib, brivanib, and vandetanib.
Activation of intracellular signaling pathways is frequent in cancer, and agents targeting components of these pathways have been combined with receptor targeting agents to enhance efficacy and reduce resistance. Examples of agents that may be combined with compounds of the present invention include inhibitors of the PI3K-AKT-mTOR pathway, inhibitors of the Raf-MAPK pathway, inhibitors of JAK-STAT pathway, and inhibitors of protein chaperones and cell cycle progression.
Agents against the PI3 kinase include but are not limited topilaralisib, idelalisib, buparlisib. Inhibitors of mTOR such as rapamycin, sirolimus, temsirolimus, and everolimus may be combined with FGFR inhibitors. Other suitable examples include but are not limited to vemurafenib and dabrafenib (Raf inhibitors) and trametinib, selumetinib and GDC-0973 (MEK inhibitors). Inhibitors of one or more JAKs (e.g., ruxolitinib, baricitinib, tofacitinib), Hsp90 (e.g., tanespimycin), cyclin dependent kinases (e.g., palbociclib), HDACs (e.g., panobinostat), PARP (e.g., olaparib), and proteasomes (e.g., bortezomib, carfilzomib) can also be combined with compounds of the present invention. In some embodiments, the JAK inhibitor is selective for JAK1 over JAK2 and JAK3.
Other suitable agents for use in combination with the compounds of the present invention include chemotherapy combinations such as platinum-based doublets used in lung cancer and other solid tumors (cisplatin or carboplatin plus gemcitabine; cisplatin or carboplatin plus docetaxel; cisplatin or carboplatin plus paclitaxel; cisplatin or carboplatin plus pemetrexed) or gemcitabine plus paclitaxel bound particles (Abraxane®).
Suitable chemotherapeutic or other anti-cancer agents include, for example, alkylating agents (including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes) such as uracil mustard, chlormethine, cyclophosphamide (Cytoxan™), ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide.
Other suitable agents for use in combination with the compounds of the present invention include: dacarbazine (DTIC), optionally, along with other chemotherapy drugs such as carmustine (BCNU) and cisplatin; the "Dartmouth regimen," which consists of DTIC, BCNU, cisplatin and tamoxifen; a combination of cisplatin, vinblastine, and DTIC; or temozolomide. Compounds according to the invention may also be combined with immunotherapy drugs, including cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF).
Suitable chemotherapeutic or other anti-cancer agents include, for example, antimetabolites (including, without limitation, folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors) such as methotrexate, 5-fluorouracil, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate,
pentostatine, and gemcitabine.
Suitable chemotherapeutic or other anti-cancer agents further include, for example, certain natural products and their derivatives (for example, vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins) such as vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, ara- C, paclitaxel (TAXOL™), mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, interferons (especially IFN-a), etoposide, and teniposide.
Other cytotoxic agents include navelbene, CPT-11, anastrazole, letrazole,
capecitabine, reloxafine, cyclophosphamide, ifosamide, and droloxafine.
Also suitable are cytotoxic agents such as epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes such as cis-platin and carboplatin; biological response modifiers; growth inhibitors; antihormonal therapeutic agents; leucovorin; tegafur; and haematopoietic growth factors.
Other anti-cancer agent(s) include antibody therapeutics such as trastuzumab
(Herceptin), antibodies to costimulatory molecules such as CTLA-4, 4- IBB and PD-1, or antibodies to cytokines (IL-10, TGF-β, etc.).
Other anti-cancer agents also include those that block immune cell migration such as antagonists to chemokine receptors, including CCR2 and CCR4. Other anti-cancer agents also include those that augment the immune system such as adjuvants or adoptive T cell transfer.
Anti-cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines and recombinant viruses.
Methods for the safe and effective administration of most of these chemotherapeutic agents are known to those skilled in the art. In addition, their administration is described in the standard literature. For example, the administration of many of the chemotherapeutic agents is described in the "Physicians' Desk Reference" (PDR, e.g., 1996 edition, Medical Economics Company, Montvale, NJ), the disclosure of which is incorporated herein by reference as if set forth in its entirety.
Pharmaceutical Formulations and Dosage Forms
When employed as pharmaceuticals, the compounds of the invention can be administered in the form of pharmaceutical compositions which refers to a combination of a compound of the invention, or its pharmaceutically acceptable salt, and at least one pharmaceutically acceptable carrier. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated.
Administration may be topical (including ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), ocular, oral or parenteral. Methods for ocular delivery can include topical administration (eye drops), subconjunctival, periocular or intravitreal injection or introduction by balloon catheter or ophthalmic inserts surgically placed in the conjunctival sac. Parenteral administration includes intravenous, intraarterial, subcutaneous,
intraperitoneal, or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. This invention also includes pharmaceutical compositions which contain, as the active ingredient, one or more of the compounds of the invention above in combination with one or more pharmaceutically acceptable carriers. In making the compositions of the invention, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10 % by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.
The Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
The compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 to about 30 mg, of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
The active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these pre-formulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid pre-formulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of the present invention.
The tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
The liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
The compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner
The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.
The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
The therapeutic dosage of the compounds of the present invention can vary according to, for example, the particular use for which the treatment is made, the manner of
administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the invention in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral
administration. Some typical dose ranges are from about 1 μg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose- response curves derived from in vitro or animal model test systems.
The compounds of the invention can also be formulated in combination with one or more additional active ingredients which can include any pharmaceutical agent such as anti- viral agents, vaccines, antibodies, immune enhancers, immune suppressants, antiinflammatory agents and the like.
Labeled Compounds and Assay Methods
Another aspect of the present invention relates to fluorescent dye, spin label, heavy metal or radio-labeled compounds of the invention that would be useful not only in imaging but also in assays, both in vitro and in vivo, for localizing and quantitating the FGFR enzyme in tissue samples, including human, and for identifying FGFR enzyme ligands by inhibition binding of a labeled compound. Accordingly, the present invention includes FGFR enzyme assays that contain such labeled compounds.
The present invention further includes isotopically-labeled compounds of the invention. An "isotopically" or "radio-labeled" compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to 2H (also written as D for deuterium), 3H (also written as T for tritium), nC, 13C, 14C, 13N, 15N, 150, 170, 180, 18F, 35S, 36C1, 82Br, 75Br, 76Br, 77Br, 123I, 124I, 125I and 131I. The radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro FGFR enzyme labeling and competition assays, compounds that incorporate 3H, 14C, 82Br, 1251 , 131I, or 35S will generally be most useful. For radio-imaging applications UC, 18F, 1251, 1231, 124I, 1311, 75Br, 76Br or 77Br will generally be most useful.
It is understood that a "radio-labeled " or "labeled compound" is a compound that has incorporated at least one radionuclide. In some embodiments the radionuclide is selected from the group consisting of 3H, 14C, 1251 , 35S and 82Br.
Synthetic methods for incorporating radio-isotopes into organic compounds are applicable to compounds of the invention and are well known in the art.
A radio-labeled compound of the invention can be used in a screening assay to identify/evaluate compounds. In general terms, a newly synthesized or identified compound (i.e., test compound) can be evaluated for its ability to reduce binding of the radio-labeled compound of the invention to the FGFR4 enzyme. Accordingly, the ability of a test compound to compete with the radio-labeled compound for binding to the FGFR4 enzyme directly correlates to its binding affinity. Kits
The present invention also includes pharmaceutical kits useful, for example, in the treatment or prevention of FGFR-associated diseases or disorders, obesity, diabetes and other diseases referred to herein which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention. Such kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.
The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of non- critical parameters which can be changed or modified to yield essentially the same results. The compounds of the Examples were found to be inhibitors of one or more FGFR's as described below.
EXAMPLES
Experimental procedures for compounds of the invention are provided below.
Preparatory LC-MS purifications of some of the compounds prepared were performed on Waters mass directed fractionation systems. The basic equipment setup, protocols, and control software for the operation of these systems have been described in detail in the literature. See e.g. "Two-Pump At Column Dilution Configuration for Preparative LC-MS", K. Blom, J. Combi. Chem., 4, 295 (2002); "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi. Chem., 5, 670 (2003); and "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Combi. Chem., 6, 874-883 (2004). The compounds separated were typically subjected to analytical liquid chromatography mass spectrometry (LCMS) for purity check under the following conditions: Instrument; Agilent 1 100 series, LC/MSD, Column: Waters Sunfire™ Cis 5 μιη particle size, 2.1 x 5.0 mm, Buffers: mobile phase A: 0.025% TFA in water and mobile phase B: acetonitrile; gradient 2% to 80% of B in 3 minutes with flow rate 2.0 mL/minute.
Some of the compounds prepared were also separated on a preparative scale by reverse-phase high performance liquid chromatography (RP-HPLC) with MS detector or flash chromatography (silica gel) as indicated in the Examples. Typical preparative reverse- phase high performance liquid chromatography (RP-HPLC) column conditions are as follows:
pH = 2 purifications: Waters Sunfire™ Cis 5 μιη particle size, 19 x 100 mm column, eluting with mobile phase A: 0.1% TFA (trifluoroacetic acid) in water and mobile phase B: acetonitrile; the flow rate was 30 mL/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [see "Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate used with the 30 x 100 mm column was 60 mL/minute. pH = 10 purifications: Waters XBridge Cis 5 μιη particle size, 19 x 100 mm column, eluting with mobile phase A: 0.15% NH4OH in water and mobile phase B: acetonitrile; the flow rate was 30 mL/minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [See "Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate used with 30 x 100 mm column was 60 mL/minute.
Example 1
6'-(5-amino-2-methylphenyl)-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-l,H- spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2O)-one
Figure imgf000076_0001
Step 1: 4, 6-dichloronicotinaldehyde
Figure imgf000076_0002
To a stirred solution of 2,4-dichloro-5-carbethoxypyridine (10.0 g, 45.4 mmol) in methylene chloride (100.0 mL), diisobutylaluminum hydride in methylene chloride (50.0 mL, 1.0 M, 50.0 mmol) was added dropwise at -78°C. After 2 hours, the reaction was quenched with a saturated solution of Rochelle's salt. After stirring for 12 hours, the aqueous solution was extracted with DCM (3 x 150 mL). The combined organic layers were dried over a2S04 and concentrated in vacuo to afford the crude aldehyde (7.51 g, 42.9 mmol), which was used directly in the next step without further purification. LC-MS calculated for C6H4CI2NO
[M+H]+ m/z: 176.0; found 176.0.
Step 2: N-[ ( 4, 6-dichloropyridin-3-yl)methyl]-2, 6-difluoro-i, 5 -dimethoxy aniline
Figure imgf000076_0003
To a stirred solution of 2,6-difluoro-3,5-dimethoxyaniline (9.03 g, 47.7 mmol), sodium triacetoxyborohydride (38.0 g, 180 mmol) in methylene chloride (60 mL) / trifluoroacetic acid (30. mL), 4,6-dichloronicotinaldehyde (8.00 g, 45.5 mmol) was added in small portions at room temperature. After 1 hour, the volatiles were removed in vacuo and saturated aqueous NaHCC (200 mL) was added. The resulting mixture was extracted with DCM (3 x 150 mL). The organic layers were combined, dried over a2S04, and concentrated. The residue was purified on silica gel (eluting with 0 to 0-40% EtOAc in hexanes) to afford the desired product (15.0 g). LC-MS calculated for C14H13CI2F2N2O2 [M+H]+ m/z: 349.0; found 349.1.
Step 3: ethyl 3-[[(4, 6-dichloropyridin-3-yl)methyl](2, 6-difluoro-3,5- dimethoxyphenyl) amino] -3-oxopropanoate
Figure imgf000077_0001
To a stirred solution of N-[(4,6-dichloropyridin-3-yl)methyl]-2,6-difluoro-3,5- dimethoxyaniline (3.50 g, 10.0. mmol) in tetrahydrofuran (20 mL), NaH (60% w/w in mineral oil, 421 mg, 10.5 mmol) was added at room temperature. After 10 minutes, ethyl malonyl chloride (1.92 mL, 15.0 mmol) was added dropwise. After another 1 hour, the reaction was quenched with saturated aqueous NH4CI, and extracted with DCM (3x 100 mL). The organic layers were combined, dried over a2S04, and concentrated. The residue was purified on silica gel (eluting with 0 to 0-35% EtOAc in hexanes) to afford the desired product (4.20 g, 9.1 mmol). LC-MS calculated for C19H19CI2F2N2O5 [M+H]+ m/z: 463.1; found 463.1.
Step 4: ethyl 6-chloro-2-(2, 6-difluoro-3,5-dimethoxyphenyl)-3-oxo-l,2,3,4-tetrahydro-2, 7- naphthyridine-4-carboxylate
Figure imgf000077_0002
To a stirred solution of ethyl 3-[[(4,6-dichloropyridin-3-yl)methyl](2,6-difluoro-3,5- dimethoxyphenyl)amino] -3-oxopropanoate (1.50 g, 3.24 mmol) in DMF (15. mL) , NaH (60% w/w in mineral oil, 337 mg, 8.42 mmol) was added at room temperature. The resulting mixture was then warmed up to 110°C. After 5 hours, the reaction was cooled to room temperature, and saturated aqueous NH4CI (50 mL) was added to form precipitate. After filtration, the solid was dried in vacuo to give crude cyclized product (0.95 g, 2.23 mmol). LC-MS calculated for C19H18CIF2N2O5 [M+H]+ m/z: 427.1 ; found 427.0. Step 5: 6-chloro-2-(2, 6-difluoro-3,5-dimethoxyphenyl)-l,2-dihydro-2, 7-naphthyridin-3(4H)- one
Figure imgf000078_0001
To a stirred solution of ethyl 6-chloro-2-(2,6-difluoro-3,5-dimethoxyphenyl)-3-oxo- l,2,3,4-tetrahydro-2,7- naphthyridine-4-carboxylate (0.95 g, 2.23 mmol) in 1,4-dioxane (5 mL) hydrogen chloride (4.0 M in dioxane, 2 mL, 8 mmol) was added at room temperature. The resulting mixture was warmed up to 100°C. After 4 hours, the reaction was cooled to ambient temperature, quenched with saturated aqueous NaHCC , and extracted with DCM (3 x 100 mL). The organic layers were combined, dried over a2S04, and concentrated. The residue was purified on silica gel (eluting with 0 to 0-30% EtOAc in DCM) to afford the desired product (0.75 g, 2.12 mmol). LC-MS calculated for C16H14CIF2N2O3 [M+H]+ m/z: 355.1; found 355.1. Step 6: 6'-chloro-2'-(2, 6-difluoro-3,5-dimethoxyphenyl)-r,2'-dihydro-3'H- spirof cyclopropane- 1, 4 '-[2, 7]naph
Figure imgf000078_0002
To a stirred solution of 6-chloro-2-(2,6-difluoro-3,5-dimethoxyphenyl)-l,4-dihydro- 2,7-naphthyridin-3(2H)-one (1.50 g, 4.23 mmol) in DMF (10 mL), cesium carbonate (3.03 g, 9.30 mmol) and 1 -bromo-2-chloro-ethane (701 μί, 8.46 mmol) were added sequentially at room temperature. After 5 hours, the reaction was quenched with saturated aqueous NH4C1, and extracted with DCM (3 x75 mL). The organic layers were combined, dried over Na2S04, and concentrated. The residue was purified on silica gel (eluting with 0 to 0-50% EtOAc in hexanes) to afford the desired product (1.20 g, 3.15 mmol). LC-MS calculated for
C18H16CIF2N2O3 [M+H]+ m/z: 381.1; found 381.1. Step 7:6'-(5-amino-2-methylphenyl)-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-l 'H- spiro [cyclopropane- 1 ,4'-[2, 7] naphthyridin] -3 '(2'H)-one
A mixture of 6'-chloro-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-r,2'-dihydro-3'H- spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'-one (30.0 mg, 0.0788 mmol), (5-amino-2- methylphenyl)boronic acid (17.8 mg, 0.1 18 mmol), sodium carbonate (18.4 mg, 0.173 mmol), and [l, -bis(di-cyclohexylphosphino)ferrocene]dichloropalladium(II) (3.0 mg, 0.0039 mmol) in tert-butyl alcohol (3.0 mL) / water (3.0 mL) was stirred and heated at 90 °C. After 2 hours, the reaction mixture was quenched with saturated aq. NH4C1, extracted with methylene chloride. The combined organic layers were dried over a2S04, filtered, and concentrated to dryness under reduced pressure. The crude product was purified on prep- HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product (22 mg) as its TFA salt. LC-MS calculated for C25H24F2N3O3 [M+H]+m/z: 452.2; found 452.2.
Example 2
6'-(5-amino-4-fluoro-2-methylphenyl)-2 '-(2,6-difluoro-3,5-dimethoxyphenyl)-l Ή- spiro[cyclopropane-l,4'-[2,
Figure imgf000079_0001
This compound was prepared using procedures analogous to those for example 1, step 7, with 2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)aniline replacing (5-amino-2-methylphenyl)boronic acid. LCMS calculated for C25H23F3N3O3 [M+H]+ m/z: 470.2; Found: 470.2.
Example 3
4-amino-2-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3,-oxo-2,,3,-dihydro-l,H- spiro[cyclopropane-l,4'-[2,7]naphthyridine]-6'-yl)benzonitrile
Figure imgf000080_0001
This compound was prepared using procedures analogous to those for example I, step 7, with 4-amino-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzonitrile replacing (5- amino-2-methylphenyl)boronic acid. LCMS calculated for C25H21F2N4O3 [M+H]+ m/z:
463.2; Found: 463.2.
Example 4
e'- S-aminopyridin-S-y^- '-i ^-difluoro-S^-dimethoxypheny^-l'H-spiroIcyclopropane- 1,4'- [2,7] naphthyridin] -3 '(2 'H)-one
Figure imgf000080_0002
Step 1: N-(5-(2'-(2, 6-difluoro-i, 5-dimethoxyphenyl)-3 '-oxo-2 ', 3 '-dihydro-l Ή- spiro[cyclopropane-l,4'-[2 ]naphthyndine]-6'-yl)pyndin-3-yl)acetamide
Figure imgf000080_0003
This compound was prepared using procedures analogous to those for example I, step 7, with N-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-3-yl]acetamide replacing (5-amino-2-methylphenyl)boronic acid. LCMS calculated for C25H23F2N4O4 [M+H]+ m/z: 481.2; Found: 481.2.
Step 2: 6'-(5-aminopyridin-3-yl)-2 '-(2, 6-difluoro-i, 5-dimethoxyphenyl)-l Ή- spiro [cyclopropane- 1 ,4'-[2, 7] naphthyridin] -3 '(2'H)-one
To a stirred solution of N-{5-[2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'- dihydro-rH-spiro[cyclopropane-l,4'-[2,7]naphthyridin]-6'-yl]pyridin-3- yl}acetamide (0.048 g, 0.10 mmol) in ethanol (3.0 mL), potassium hydroxide (2.0 M in water, 0.15 mL, 0.30 mmol) was added at room temperature. The resulting mixture was heated at 60°C overnight. The reaction was quenched with saturated aqueous NH4CI and the volatiles were removed under reduced pressure. The residue was dissolved in methylene chloride and was washed with saturated aq. NH4CI. The organic layer was dried over a2S04, filtered, and concentrated to dryness under reduced pressure. The crude product was purified on prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product (26 mg) as its TFA salt LCMS calculated for C23H21F2N4O3 (M+H)+ m/z :439.2; Found: 439.2.
Example 5
'-i ^-difluoro-S^-dimethoxyphenyl^e'- S-fluoropyridin-S-y^-l'H-spiroIcyclopropane- 1,4'- [2,7] naphthyridin] -3 '(2 'H)-one
Figure imgf000081_0001
This compound was prepared using procedures analogous to those for example 1, step 7, with (5-fluoropyridin-3-yl)boronic acid replacing (5-amino-2-methylphenyl)boronic acid. LCMS calculated for C23H19F3N3O3 [M+H]+ m/z: 442.1; Found: 442.2. Example 6
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(5-morpholinopyridin-3-yl)-l,H- spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2,H)-one
Figure imgf000082_0001
This compound was prepared using procedures analogous to those for example 1, step 7, with 4-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-3-yl]morpholine replacing (5-amino-2-methylphenyl)boronic acid. LCMS calculated for C27H27F2N4O4 [M+H]+ m/z: 509.2; Found: 509.2.
Example 7
e'- S-amino- -meth l ridin-S- ^- '^^-difluoro-S^-dimethox hen ^-l'H- spiro[cyclopropane-l,4^2,7]naphthyridin]-3\2'H)-one
Figure imgf000082_0002
Step 1 : 6-methyl-5-( 4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)pyridin-3-amine
Figure imgf000082_0003
A stirred mixture of 5-bromo-6-methylpyridin-3-amine (0.100 g, 0.535 mmol), 4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[[l,3,2]dioxaborolanyl] (0.136 g, 0.535 mmol), [1, 1'- bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with dichloromethane (1 : 1) (42 mg, 0.051 mmol), and potassium acetate (0.150 g, 1.53 mmol) in 1,4-dioxane (5.0 mL) was heated at 110°C. After 2 hours, the reaction was quenched with saturated aqueous NH4CI, and extracted with DCM (3 x30 mL). The organic layers were combined, dried over a2S04, and concentrated. The crude product was used directly in the next step without further purification.
Step 2: 6'-(5-amino-2-methylpyridin-3-yl)-2'-(2, 6-difluoro-3,5-dimethoxyphenyl)-l 'H- spiro [cyclopropane- 1 ,4'-[2, 7] naphthyridin] -3 '(2'H)-one
This compound was prepared using procedures analogous to those for example I, step
7, with 6-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-3-amine replacing (5-amino-2-methylphenyl)boronic acid. LCMS calculated for C24H23F2N4O3 [M+H]+ m/z: 453.2; Found: 453.2. Example 8
S- '-i ^-difluoro-S^-dimethox phen ^-S'-oxo- '^'-dih dro-l'H-spiroIc clopropane- l,4'-[2,7]naphthyridine]-6'
Figure imgf000083_0001
This compound was prepared using procedures analogous to those for example 7, step 1 to 2, with 5-bromonicotinonitrile replacing 5-bromo-6-methylpyridin-3-amine in step 1. LCMS calculated for C24H19F2N4O3 [M+H]+ m/z: 449.1; Found: 449.1.
Example 9
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(pyridin-3-yl)-l'H-spiro[cyclopropane-l,4'- [2,7]naphthyridin]-3'(2'H)-on
Figure imgf000083_0002
This compound was prepared using procedures analogous to those for example I, step 7, with pyridin-3-ylboronic acid replacing (5-amino-2-methylphenyl)boronic acid. LCMS calculated for C23H20F2N3O3 [M+H]+ m/z: 424.2; Found: 424.2. Example 10
'-i ^-difluoro-S^-dimethox hen l^e'- S-methox ridin-S- ^-l'H- spiro[cyclopropane-l,4^2,7]naphthyridin]-3\2'H)-one
Figure imgf000084_0001
This compound was prepared using procedures analogous to those for example I, step 7, with 3-methoxy-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine replacing (5- amino-2-methylphenyl)boronic acid. LCMS calculated for C24H22F2N3O3 [M+H]+ m/z: 454.2; Found: 454.1.
Example 11
e'- S-chlorop ridin-S- ^- '-i ^-difluoro-S^-dimethox phen l)-!'!!- spiro[cyclopropane-l,4^2,7]naphthyridm]-3'(2'H)-one
Figure imgf000084_0002
This compound was prepared using procedures analogous to those for example 1, step 7, with 3-chloro-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine replacing (5-amino- 2-methylphenyl)boronic acid. LCMS calculated for C23H19CIF2N3O3 [M+H]+ m/z: 458.1 ; Found: 458.1. Example 12
6'-(5-(lH-imidazol-l-yl)pyridin-3-yl)-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-l,H- spiro[cyclopropane-l,4'-[2
Figure imgf000085_0001
This compound was prepared using procedures analogous to those for example 1, step
7, with 3-(lH-imidazol-l-yl)-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine replacing (5-amino-2-methylphenyl)boronic acid. LCMS calculated for C26H22F2N5O3
[M+H]+ m/z: 490.2; Found: 490.1. Example 13
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(5-(morpholine-4-carbonyl)pyridin-3-yl)-l,H- spiro[cyclopropane-l,4'-[
Figure imgf000085_0002
This compound was prepared using procedures analogous to those for example 1, step 7, with morpholino(5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanone replacing (5-amino-2-methylphenyl)boronic acid. LCMS calculated for C28H27F2N4O5
[M+H]+ m/z: 537.2; Found: 537.2.
Example 14
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(5-(morpholinosulfonyl)pyridin-3-yl)-l,H- spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2,H)-one
Figure imgf000086_0001
This compound was prepared using procedures analogous to those for example I, step 7, with 4-(5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-3-ylsulfonyl)morpholine replacing (5-amino-2-methylphenyl)boronic acid. LCMS calculated for C27H27F2N4O6S [M+H]+ m/z: 573.2; Found: 573.2.
Example 15
N-CS-C '-C ^-difluoro-S^-dimethox phen ^-S'-oxo- S'-dih dro-l'H- spiroIcyclopropane-l^'-t ^lnaphthyridinel-e'-y^pyridin-S-y^methanesulfonamide
Figure imgf000086_0002
This compound was prepared using procedures analogous to those for example 1, step 7, with N-(5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanesulfonamide replacing (5-amino-2-methylphenyl)boronic acid. LCMS calculated for C24H23F2N4O5S [M+H]+ m/z: 517.1 ; Found: 517.1.
Example 16
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(5-(morpholinomethyl)pyridin-3-yl)-l,H- spiro[cyclopropane-l,4^2,7]naphthyridm]-3'(2'H)-one
Figure imgf000087_0001
Step l:5-(2'-(2, 6-difluoro-3, 5-dimethoxyphenyl)-3 '-oxo-2 ', 3 '-dihydro-1 Ή- spirof cyclopropane- 1, 4 '-[2, 7] naphthyridine] -6'-yl)nicotinaldehyde
Figure imgf000087_0002
This compound was prepared using procedures analogous to those for example 1, step
7, with 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)nicotinaldehyde replacing (5-amino- 2-methylphenyl)boronic acid. LCMS calculated for C24H20F2N3O4 [M+H]+ m/z: 452.1;
Found: 452.1. Step 2: 2'-(2, 6-difluoro-3, 5-dimethoxyphenyl)-6'-(5-(morpholinomethyl)pyridin-3-yl)-l Ή- spiro [cyclopropane- 1 ,4'-[2, 7] naphthyridin] -3 '(2'H)-one
To a stirred solution of 5-[2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro- H-spiro[cyclopropane-l,4'-[2,7]naphthyridin]-6'-yl]nicotinaldehyde (20 mg, 0.04 mmol) and morpholine (7.7 \L, 0.088 mmol) in methylene chloride (5.0 mL), acetic
acid (0.198 mL, 3.49 mmol) was added at room temperature. After 15 minutes, sodium triacetoxyborohydride (18.7 mg, 0.0884 mmol) was added. After another 1 hour, the volatiles were removed and the residue was purified on prep-HPLC (pH = 2,
acetonitrile/water+TFA) to give the desired product (10 mg) as its TFA salt. LCMS calculated for C28H29F2N4O4 (M+H)+ m/z :523.2; Found: 523.2.
Example 17 '-i ^-difluoro-S^-dimethoxypheny^-e'-phenyl-l'H-spiroIcyclopropane-l^'- [2,7]naphthyridin]-3'(2'H)-one
Figure imgf000088_0001
This compound was prepared using procedures analogous to those for example 1, step 7, with phenylboronic acid replacing (5-amino-2-methylphenyl)boronic acid. LCMS calculated for C24H21F2N2O3 [M+H]+ m/z: 423.2; Found: 423.1.
Example 18
S- '-i ^-difluoro-S^-dimethox phen ^-S'-oxo- '^'-dih dro-l'H-spiroIc clopropane- 1,4'- [2,7] naphthyridine] -6'-yl)-N-methylpicolinamide
Figure imgf000088_0002
This compound was prepared using procedures analogous to those for example 1, step 7, with N-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)picolinamide replacing (5- amino-2-methylphenyl)boronic acid. LCMS calculated for C25H23F2N4O4 [M+H]+ m/z: 481.2; Found: 481.1.
Example 19
4-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro-l'H-spiro[cyclopropane- l,4'-[2,7]naphthyridine]-6'-yl)-N-methylbenzamide
Figure imgf000089_0001
This compound was prepared using procedures analogous to those for example I, step 7, with 4-(methylcarbamoyl)phenylboronic acid replacing (5-amino-2-methylphenyl)boronic acid. LCMS calculated for C26H24F2N3O4 [M+H]+ m/z: 480.2; Found: 480.2.
Example 20
5-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2,,3,-dihydro-l,H-spiro[cyclopropane- l,4'-[2,7]naphthyridine]-6'
Figure imgf000089_0002
This compound was prepared using procedures analogous to those for example I, step
7, with 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)picolinonitrile replacing (5-amino-2- methylphenyl)boronic acid. LCMS calculated for C24H19F2N4O3 [M+H]+ m z: 449.1; Found: 449.1. Example 21
2, -(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(l,3-dimethyl-lH-pyrazol-4-yl)-l',2,-dihydro-
3, H-spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3,-one
Figure imgf000090_0001
This compound was prepared using procedures analogous to those for example 1, step 7, with l,3-dimethyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole replacing (5-amino-2-methylphenyl)boronic acid. LCMS calculated for C23H23F2N4O3 [M+H]+ m/z: 441.2; Found: 441.2. *H NMR (500 MHz, dmso) δ 8.36 (s, 1H), 8.22 (s, 1H), 7.06 (t, J = 8.0 Hz, 1H), 7.03 (s, 1H), 4.92 (s, 2H), 3.89 (s, 6H), 3.78 (s, 3H), 2.40 (s, 3H), 1.71-1.73 (m, 2H), 1.55-1.57 (m, 2H). Example 22
3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-phenyl-3,4-dihydropyrido[4,3- d] pyrimidin-2 (1 H)-one
Figure imgf000090_0002
Step 1 : 7-chloro-3-(2, 6-difluoro-3, 5-dimethoxyphenyl)-l-ethyl-3, 4-dihydropyrido [ 4, 3- d]pyrimidin-2(lH)-one
Figure imgf000090_0003
To a solution of triphosgene (344 mg, 1.16 mmol) in CH2CI2 (12 mL, 190 mmol) at 0 first added pyridine (0.250 mL, 3.09 mmol). The mixture was then stirred at 0 °C for 10 minutes, and added a solution of N-[(4,6-dichloropyridin-3-yl)methyl]-2,6-difluoro-3,5- dimethoxy aniline (900 mg, 2.58 mmol) in CH2CI2 (8.0 mL). The reaction mixture was stirred at 0 °C for 1 hour, and added ethylamine in THF (2.0 M, 6.4 mL, 13 mmol), followed by N,N-diisopropylethylamine (920 μί, 5.3 mmol). The resulting mixture was then warmed to room temperature, stirred overnight, quenched with saturated NaHCC (aq) solution, and extracted with EtOAc (3 x 20 mL). The combined organic layers were dried over a2S04 and concentrated to give the crude intermediate which was used directly in the next step.
The crude intermediate obtained from previous step was first dissolved in DMF (20 mL), and added CS2CO3 (1.70 g, 5.2 mmol). The reaction mixture was then stirred at 95 °C for 5 hours until completion, cooled to room temperature, quenched with water, and extracted with EtOAc (3 x 20 mL). The combined organic layers were dried over Na2S04, and concentrated. The resulting material was purified via column chromatography (25% to 55% EtOAc in hexanes) to give the product as a slightly yellow solid. LC-MS calculated for C17H17CIF2N3O3 [M+H]+ m/z: 384.1 ; found 384.1.
Step 2: 3-(2, 6-difluoro-i, 5-dimethoxyphenyl)-l-ethyl- 7-phenyl-i, 4-dihydropyrido[ 4, 3- d]pyrimidin-2( lH)-one
A mixture of 7-chloro-3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-3,4- dihydropyrido
[4,3-d]pyrimidin-2(lH)-one (35.0 mg, 0.0912 mmol), sodium carbonate (19.3 mg, 0.18 mmol), phenylboronic acid (16.7 mg, 0.14 mmol), and Pd-127 (6.9 mg, 0.0091 mmol) in tert- butyl alcohol (1.0 mL) and water (1.0 mL) was first degassed with nitrogen, and then stirred and heated at 90 °C for 3 hours. The resulting mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3 x 1.5 mL). The combined organic layers were dried over Na2S04, and concentrated. The resulting material was purified via pH 2 preparative LC/MS (MeCN/water with TFA) to afford the product as a white solid (TFA salt). LC/MS calculated for C23H22F2N3O3 [M+H]+m/z: 426.2; found 426.1.
Example 23
3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(pyridin-3-yl)-3,4-dihydropyrido[4,3- d] pyrimidin-2 (1 H)-one
Figure imgf000092_0001
This compound was prepared using procedures analogous to those for example 22, step 2, with 3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine replacing phenylboronic acid. LC/MS calculated for C22H21F2N4O3 [M+H]+ m/z: 427.2; Found: 427.1.
Example 24
5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l,2,3,4-tetrahydropyrido[4,3- d]pyrimidin-7-yl)-N-met
Figure imgf000092_0002
This compound was prepared using procedures analogous to those for example 21, step 2, with N-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)picolinamide replacing phenyl boronic acid. LC/MS calculated for C24H24F2N5O4 [M+H]+ m/z: 484.2; Found: 484.1.
Example 25
(S)-l-(4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l,2,3,4- tetrahydropyrido[4,3-d]pyrimidin-7-yl)benzyl)pyrrolidine-3-carbonitrile
Figure imgf000093_0001
This compound was prepared using procedures analogous to those for example 22, step 2, with (S)-l-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzyl)pyrrolidine-3- carbonitrile replacing phenyl boronic acid. LC/MS calculated for C29H30F2N5O3 [M+H]+ m/z: 534.2; Found: 534.2.
Example 26
2-(5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l,2,3,4-tetrahydropyrido[4,3- d]pyrimidin-7-yl)pyridin-2- -2-methylpropanenitrile
Figure imgf000093_0002
This compound was prepared using procedures analogous to those for example 22, step 2, with 2-methyl-2-(5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl)propanenitrile replacing phenyl boronic acid. LC/MS calculated for C26H26F2N5O3 [M+H] m/z: 494.2; Found: 494.2.
Example 27
l-(5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l,2,3,4-tetrahydropyrido[4,3- d]pyrimidin-7-yl)pyridin-2-yl)cyclobutanecarbonitrile
Figure imgf000094_0001
This compound was prepared using procedures analogous to those for example 22, step 2, with l-(5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl)cyclobutanecarbonitrile replacing phenyl boronic acid. LC/MS calculated for
C27H26F2N5O3 [M+H]+ m/z: 506.2; Found: 506.2. XH NMR (600 MHz, DMSO) δ 9.34 - 9.32 (m, 1H), 8.55 (dd, J= 8.2, 2.4 Hz, 1H), 8.46 (s, 1H), 7.78 - 7.74 (m, 1H), 7.70 (s, 1H), 7.07 (t, J= 8.1 Hz, 1H), 4.85 (s, 2H), 4.06 (q, J= 6.8 Hz, 2H), 3.91 (s, 6H), 2.87 - 2.80 (m, 2H), 2.79 - 2.73 (m, 2H), 2.35 - 2.26 (m, 1H), 2.13 - 2.05 (m, 1H), 1.23 (t, J= 7.0 Hz, 3H). Example 28
3-(7-(6-(l-cyanocyclobutyl)pyridin-3-yl)-l-ethyl-2-oxo-l,2-dihydropyrido[4,3- d]pyrimidin-3(4H)-yl)-2-fluoro-5-methoxy-N-methylbenzamide
Figure imgf000094_0002
Step 1: 3-bromo-2-fluoro-5-iodobenzoic acid
Figure imgf000094_0003
To a mixture of 3-bromo-2-fluorobenzoic acid (1.50 g, 6.85 mmol) in sulfuric acid (5.0 mL) at 0 °C was added N-iodosuccinimide (1.62 g, 7.19 mmol) portionwise. The resulting mixture was warmed to room temperature, and kept stirring for 3 hours. The reaction mixture was then quenched with cold water, and the precipitate was collected by filtration, washed with cold water, and dried under vaccum to give the product as a white solid, which was used directly in the next step (2.36 g, 91%). LC-MS calculated for
C7H4BrFI02 [M+H]+ m/z: 344.8; found 344.7. Step 2: 3-bromo-2-fluoro-5-hydroxyb zoic acid
Figure imgf000095_0001
A mixture of 3-bromo-2-fluoro-5-iodobenzoic acid (2.15 g, 6.23 mmol), copper(I) oxide (130 mg, 0.94 mmol), and NaOH (1.25 g, 31.2 mmol) in water (20 mL) was stirred at 100 °C overnight. The reaction mixture was cooled to room temperature and filtered. The filtrate was acidified with 2 M HCl (aq) to ~pH 1, and extracted with EtOAc. The combined organic layers were dried over a2S04, and concentrated to give the product as a yellow solid, which was used directly in the next step (1.41 g, 96%). LC-MS calculated for
CvHsBrFOs [M+H]+ m/z: 234.9; found 234.9. Step 3: methyl 3-bromo-2-fluoro-5-methoxybenzoate
Figure imgf000095_0002
To a solution of 3-bromo-2-fluoro-5-hydroxybenzoic acid (4.88 g, 20.8 mmol) in N,N-dmethylformamide (20 mL) at room temperature was first added K2CO3 (8.60 g, 62.3 mmol), followed by Mel (2.84 mL, 45.6 mmol). The reaction mixture was stirred at 80 °C for 1 hour, cooled to room temperature, quenched with water, and extracted with EtOAc. The combined organic layers were dried over Na2S04, filtered and concentrated. The crude material was then purified using column chromatography (0% to 30% EtOAc in hexanes) to give the product as a yellow solid (4.87 g, 89%). LC-MS calculated for CgHgBrFOs [M+H]+ m/z: 263.0; found 263.0.
Step 4: 3-bromo-2-fluoro-5-methoxy-N-methylbenzamide
Figure imgf000096_0001
A mixture of methyl 3-bromo-2-fluoro-5-methoxybenzoate (200 mg, 0.76 mmol) in methanol (7.5 mL)/water (2.5 mL) at room temperature was added NaOH (152 mg, 3.80 mmol). The reaction mixture was stirred at room temperature for 2 hours, and 1.0 M HC1 in water (4.56 mL, 4.56 mmol) was added. The resulting mixture was extracted with EtOAc, and the combined organic layers were dried over a2S04, filtered and concentrated to give carboxylic acid intermediate, which was used directly in the next step.
The carboxylic acid obtained from previous step was dissolved in CH2CI2 (7.5 mL), and BOP reagent (404 mg, 0.912 mmol), 2.0 M Methylamine in THF (1.52 mL, 3.04 mmol), and Et3 (0.424 mL, 3.04 mmol) were added sequentially. The reaction mixture was stirred at room temperature for 3 hours before it was quenched with water, and extracted with CH2CI2. The combined organic layers were dried over Na2S04, filtered and concentrated. The residue was purified using column chromatography (0% to 50% EtOAc in hexanes) to give the product as a white solid. LC-MS calculated for CgHioBrFNC [M+H]+ m/z: 262.0; found 262.0.
Step 5: 3-amino-2-fluoro-5-methoxy- -methylbenzamide
Figure imgf000096_0002
A mixture of 3-bromo-2-fluoro-5-methoxy-N-methylbenzamide (205 mg, 0.78 mmol), benzophenone imine (157 \L, 0.94 mmol), (9,9-dimethyl-9H-xanthene-4, 5- diyl)bis(diphenylphosphine) (45 mg, 0.078 mmol), tris(dibenzylideneacetone)dipalladium(0) (36 mg, 0.039 mmol), and CS2CO3 (381 mg, 1.17 mmol) in 1,4-dioxane (3.0 mL) was purged with nitrogen, and stirred at 95°C for 24 hours. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc. The combined organic layers were dried over Na2S04, filtered and concentrated. The residue was purified using column chromatography (25% to 55% EtOAc in hexanes) to give the imine intermediate, which was used directly in the next step. The imine intermediate obtained from previous step was dissolved in THF (3.0 mL), and 1.0 M HC1 in water (1.0 mL, 1.0 mmol) was added. The reaction mixture was stirred at room temperature for 1 hour, neutralized with saturated NaHCC solution, and extracted with EtOAc. The combined organic layers were dried over Na2S04, filtered and concentrated. The residue was purified using column chromatography (0% to 10% MeOH in CH2CI2) to give the product as a yellow solid (132 mg, 85% over two steps). LC-MS calculated for
C9H12FN2O2 [M+H]+ m/z: 199.1 ; found 199.1.
Step 6: 3-( {[ 6-chloro-4-(ethylamino)pyridin-3-yl]methyl}amino)-2-fluoro-5-methoxy-N- methylbenzamide
Figure imgf000097_0001
To a solution of 3-amino-2-fluoro-5-methoxy-N-methylbenzamide (132 mg, 0.66 mmol) and 6-chloro-4-(ethylamino)nicotinaldehyde (147 mg, 0.80 mmol) in CH2CI2 (3.0 mL) at room temperature was first added trifluoroacetic acid (1.0 mL). The resulting mixture was stirred at room temperature for 15 minutes. NaBH(OAc)3 (21 1 mg, 1.00 mmol) was added in four portions over a period of 2 hours. The reaction mixture was then stirred at room temperature for additional 1 hour before it was quenched with saturated NaHCC solution, and extracted with EtOAc. The combined organic layers were dried over Na2S04, filtered and concentrated. The crude material was purified using column chromatography (0% to 60% EtOAc in hexanes) to give the product as a yellow solid (171 mg, 70%). LC-MS calculated for C17H21CIFN4O2 [M+H]+ m/z: 367.1 ; found 367.1.
Step 7: 3-(7-chloro-l-ethyl-2-oxo-l,2-dihydropyrido[4,3-d]pyrimidin-3(4H)-yl)-2-fluoro-5- methoxy-N-methylbenzamide
Figure imgf000097_0002
To a solution of 3-({[6-chloro-4-(ethylamino)pyridin-3-yl]methyl}amino)-2-fluoro-5- methoxy-N-methylbenzamide (131 mg, 0.36 mmol) in THF (5.0 mL) at room temperature was added Et3 (200 μΐ,, 1.4 mmol), followed by triphosgene (85 mg, 0.28 mmol) in THF (1.0 mL). The reaction mixture was stirred at room temperature for 2 hours. 1.0 M NaOH in water (1.4 mL, 1.4 mmol) was then added and the resulting mixture was stirred for another hour before it was extracted with EtOAc. The combined organic layers were dried over a2S04, filtered and concentrated. The residue was purified on column chromatography (0- 50% EtOAc in hexanes) to give the product as a colorless oil (137 mg, 98%). LC-MS calculated for C18H19CIFN4O3 [M+H]+ m/z: 393.1; found 393.1.
Step 8: 3-(7-( 6-( l-cyanocyclobutyl)pyridin-3-yl)-l-ethyl-2-oxo-l, 2-dihydropyrido[ 4, 3- d]pyrimidin-3(4H)-yl)-2-fluoro-5-methoxy-N-methylbenzamide
A mixture of 3-(7-chloro-l-ethyl-2-oxo-l,4-dihydropyrido[4,3-d]pyrimidin-3(2H)- yl)-2-fluoro-5-methoxy-N-methylbenzamide (20 mg, 0.051 mmol), [l,l'-bis(di- cyclohexylphosphino)ferrocene]dichloropalladium(II) (7.7 mg, 0.010 mmol), a2C03 (11 mg, 0.10 mmol), and l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]cyclobutanecarbonitrile (22 mg, 0.076 mmol) in water (1.0 mL)/t-BuOH (1.0 mL) was purged with nitrogen, and stirred at 100 °C for 3 hours. The reaction mixture was cooled to room temperature, and extracted with EtOAc. The combined organic layers were concentrated, and purified on prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the product as a white solid (TFA salt). LC-MS calculated for C28H28F 6O3 [M+H]+ m/z: 515.2; found 515.2. ¾ NMR (400 MHz, DMSO) δ 9.34 (d, J= 1.7 Hz, 1H), 8.56 (dd, J= 8.3, 2.3 Hz, 1H), 8.45 (s, 1H), 8.27 (s, 1H), 7.73 (d, J= 8.2 Hz, 1H), 7.67 (s, 1H), 7.26 (dd, J= 5.9, 3.2 Hz, 1H), 7.07 (dd, J= 4.9, 3.3 Hz, 1H), 4.87 (s, 3H), 4.05 (q, J= 6.7 Hz, 2H), 3.79 (s, 3H), 2.89 - 2.66 (m, 6H), 2.35 - 2.21 (m, 1H), 2.09 (ddd, J= 20.4, 9.0, 5.4 Hz, 1H), 1.23 (t, J = 6.9 Hz, 3H).
Example 29
l-(cyclopropylmethyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH- pyrazol-4-yl)-3,4-dihydropyrido [4,3-d] pyrimidin-2(lH)-one
Figure imgf000099_0001
Step 1 : N-{[ 4-chloro-6-( 1, 3-dimethyl-lH-pyrazol-4-yl)pyridin-3-ylJmethyl}-2, 6-difluoro-3, 5- dimethoxy aniline
Figure imgf000099_0002
N-[(4,6-dichloropyridin-3-yl)methyl]-2,6-difluoro-3,5-dimethoxyaniline (1.58 g, 4.52 mmol), l,3-dimethyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (1.00 g, 4.52 mmol) , tetrakis(triphenylphosphine)palladium(0) (520 mg, 0.45 mmol) and potassium carbonate (2.50 g, 18.1 mmol) in a vial were dissolved in a mixture of water (7.1 mL) and 1,4-dioxane (20 mL) The reaction mixture was then stirred at 120 °C overnight. The reaction mixture was quenched with saturated sodium bicarbonate solution and extracted three times with ethyl acetate. The combined extracts were dried over sodium sulfate and concentrated. The residue was purified on silica gel (50-100% ethyl acetate in hexanes) to afford the desired product (1.55 g, 31.6 mmol). LC-MS calculated for C19H19CIF2N4O2 [M+H]+ m/z: 409.1, found 409.1.
Step 2: N-(cyclopropylmethyl)-5-((2,6-difluoro-3,5-dimethoxyphenylamino)methyl)-2-(l,3- dimethyl-lH-pyrazol-4-yl)pyridin-4-amine
Figure imgf000100_0001
Conditions A:
A solution of N- { [4-chloro-6-( 1 ,3 -dimethyl- lH-pyrazol-4-yl)pyridin-3 -yljmethyl} - 2,6-difluoro-3,5-dimethoxyaniline (50.0 mg, 0.122 mmol), (2'-aminobiphenyl-2- yl)(chloro)[dicyclohexyl(2',6'-diisopropoxybiphenyl-2-yl)phosphoranyl]palladium (10 mg, 0.01 mmol), sodium tert-butoxide (21 mg, 0.22 mmol), and cyclopropyl methylamine(15.6 μΐ,, 0.183 mmol) in 1,4-dioxane (700 μΐ,) was heated at 90 °C for 2 hours. The reaction mixture was diluted with dichloromethane and filtered through a plug of Celite. The filtrate was concentrated and the residue used directly in the next step. LC-MS calculated for C23H28F2N5O2 [M+H]+ m/z: 444.2, found 444.2.
Conditions B:
A solution of N- { [4-chloro-6-( 1 ,3 -dimethyl- lH-pyrazol-4-yl)pyridin-3 -yljmethyl} - 2,6-difluoro-3,5-dimethoxyaniline (50.0 mg, 0.122 mmol), (2'-aminobiphenyl-2- yl)(chloro)[dicyclohexyl(2',6'-diisopropoxybiphenyl-2-yl)phosphoranyl]palladium (10 mg, 0.01 mmol), cesium carbonate (71 mg, 0.366 mmol), and cyclopropylmethylamine(15.6 μΐ,, 0.183 mmol) in tert-butanol (800 μΚ) was heated at 100 °C overnight. The reaction mixture was diluted with dichloromethane and filtered through a plug of Celite. The filtrate was concentrated and the residue used directly in the next step.
.Step 3: l-(cyclopropylmethyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH- pyrazol-4-yl)-3, 4-dihydropyrido[ 4, 3-d]pyrimidin-2( lH)-one
The crude residue from the previous step was dissolved in tetrahydrofuran (1.5 mL). Triethylamine (68.2 \L, 0.489 mmol) was added and the mixture cooled to 0 °C.
Triphosgene (36.3 mg, 0.122 mmol) was added in one portion and the reaction mixture stirred at room temperature for 1 hour, then quenched with 1 N NaOH and stirred an additional 1 hour at room temperature. The mixture was diluted with water and extracted with ethyl acetate three times. The combined organics were dried over sodium sulfate and concentrated. The crude product was purified on prep-HPLC (pH = 2,
acetonitrile/water+TFA) to give the desired product (22 mg) as its TFA salt. LC-MS calculated for C24H26F2N5O3 [M+H]+ m/z: 470.2, found 470.2.
Example 30
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-propyl-3,4- dihydropyrido[4,3-d]pyrimid -2(lH)-one
Figure imgf000101_0001
This compound was prepared using procedures analogous to those for example 29, step 2 (Condition A) and step 3, with w-propyl amine replacing cyclopropylmethylamine in step 2. LCMS calculated for C23H26F2N5O3 [M+H]+ m/z: 458.2; Found: 458.2.
Example 31
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-((5- methylisoxazol-3-yl)methyl)- -dihydropyrido[4,3-d]pyrimidin-2(lH)-one
Figure imgf000101_0002
This compound was prepared using procedures analogous to those for example 29, step 2 (Condition B) and step 3, with l-(5-methylisoxazol-3-yl)methanamine replacing cyclopropylmethylamine in step 2. LCMS calculated for C25H25F2N6O4 [M+H]+ m/z: 511.2; Found: 51 1.1. ¾ NMR (500 MHz, DMSO) δ 8.36 (s, 1H), 8.17 (s, 1H), 7.26 (s, 1H), 7.09 (t, J= 8.2 Hz, 1H), 6.13 (m, 1H), 5.23 (s, 2H), 4.87 (s, 2H), 3.90 (s, 6H), 3.82 (s, 3H), 2.36 (s, 3H), 2.32 (s, 3H).
Example 32
l-cyclopentyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)- 3,4-dihydropyrido[4,3-d]py
Figure imgf000102_0001
This compound was prepared using procedures analogous to those for example 29, step 2 (Condition A) and step 3, with cyclopentylamine replacing cyclopropylmethylamine in step 2. LCMS calculated for C25H28F2N5O3 [M+H]+ m/z: 484.2; Found: 484.2.
Example 33
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l- (tetrahydrofuran-3-yl)-3,4- (lH)-one
Figure imgf000102_0002
This compound was prepared using procedures analogous to those for example 29, step 2 (Condition A) and step 3, with tetrahydrofuran-3 -amine (HC1 salt) replacing cyclopropylmethylamine in step 2. LCMS calculated for C24H26F2N5O4 [M+H]+ m/z: 486.2; Found: 486.2.
Example 34 3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-(4- fluorobenzyl)-3,4-dihydropyr -d] pyrimidin-2(lH)-one
Figure imgf000103_0001
This compound was prepared using procedures analogous to those for example 29, step 2 (Condition A) and step 3, with 4-fluorobenzyl amine replacing
cyclopropylmethylamine in step 2. LCMS calculated for C27H25F3N5O3 [M+H]+ m/z: 524.2; Found: 524.1.
Example 35
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-((3- methylisoxazol-5-yl)methyl)- -dihydropyrido[4,3-d]pyrimidin-2(lH)-one
Figure imgf000103_0002
This compound was prepared using procedures analogous to those for example 29, step 2 (Condition B) and step 3, with l-(3-methylisoxazol-5-yl)methanamine replacing cyclopropylmethylamine in step 2. LCMS calculated for C25H25F2N6O4 [M+H]+ m/z: 511.2; Found: 51 1.2.
Example 36
l-((5-cyclopropylisoxazol-3-yl)methyl)-3-(2,6-difluoro-3,5-dimethoxyphen;
dimethyl-lH-pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one
Figure imgf000104_0001
This compound was prepared using procedures analogous to those for example 29, step 2 (Condition B) and step 3, with l-(5-cyclopropylisoxazol-3-yl)methanamine replacing cyclopropylmethylamine in step 2. LCMS calculated for C27H27F2N6O4 [M+H]+ m/z: 537.2; Found: 537.2.
Example 37
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-((tetrahydro- 2H-pyran-4-yl)methyl)-3,4-di 2(lH)-one
Figure imgf000104_0002
This compound was prepared using procedures analogous to those for example 29, step 2 (Condition A) and step 3, with l-(tetrahydro-2H-pyran-4-yl)methanamine replacing cyclopropylmethylamine in step 2. LCMS calculated for C26H30F2N5O4 [M+H]+ m/z: 514.2; Found: 514.2.
Example 38
3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-((2,3-dihydrobenzo[b][l,4]dioxin-6-yl)methyl)- 7-(l,3-dimethyl-lH-pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one
Figure imgf000105_0001
This compound was prepared using procedures analogous to those for example 29, step 2 (Condition B) and step 3, with l-(3,4-dihydro-2H-chromen-6-yl)methanamine replacing cyclopropylmethylamine in step 2. LCMS calculated for C29H28F2N5O5 [M+H]+ m/z: 564.2; Found: 564.2.
Example 39
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-((l-ethyl-lH- pyrazol-4-yl)methyl)-3,4-di H)-one
Figure imgf000105_0002
This compound was prepared using procedures analogous to those for example 29, step 2 (Condition B) and step 3, with 1-(1 -ethyl- lH-pyrazol-4-yl)methanamine replacing cyclopropylmethylamine in step 2. LCMS calculated for C26H28F2N7O3 [M+H]+ m/z: 524.2; Found: 524.1. ¾ NMR (600 MHz, DMSO) δ 8.39 (s, 1H), 8.25 (s, 1H), 7.73 (s, 1H), 7.45 (s, 1H), 7.32 (s, 1H), 7.11 (t, J= 8.2 Hz, 1H), 5.08 (s, 2H), 4.90 (s, 2H), 4.08 (q, J= 7.2 Hz, 2H), 3.93 (s, 6H), 3.86 (s, 3H), 2.29 (s, 3H), 1.31 (t, J= 7.3 Hz, 3H).
Example 40
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-(4- fluorophenyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one
Figure imgf000106_0001
This compound was prepared using procedures analogous to those for example 29, step 2 (Condition A) and step 3, with 4-fluoro aniline replacing cyclopropylmethylamine in step 2. LCMS calculated for C26H23F3N5O3 [M+H]+ m/z: 510.2; Found: 510.1. ¾ NMR (600 MHz, DMSO) δ 8.43 (s, 1H), 8.04 (s, 1H), 7.55 - 7.49 (m, 2H), 7.46 - 7.40 (m, 2H), 7.09 (t, J= 8.1 Hz, 1H), 6.28 (s, 1H), 4.99 (s, 2H), 3.91 (s, 6H), 3.77 (s, 3H), 2.1 1 (s, 3H).
Example 41
l-(l,3-benzothiazol-6-yl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH- pyrazol-4-yl)-3,4-dihydropyr -d] pyrimidin-2(lH)-one
Figure imgf000106_0002
This compound was prepared using procedures analogous to those for example 29, step 2 (Condition B) and step 3, with l,3-benzothiazol-6-amine replacing
cyclopropylmethylamine in step 2. LCMS calculated for C27H23F2N6O3S [M+H]+ m/z: 549.1 ; Found: 549.1.
Example 42
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-(l-methyl-5- oxopyrrolidin-3-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one
Figure imgf000107_0001
This compound was prepared using procedures analogous to those for example 29, step 2 (Condition B) and step 3, with 4-amino-l-methylpyrrolidin-2-one replacing cyclopropylmethylamine in step 2. LCMS calculated for C25H27F2N6O4 [M+H]+ m/z: 513.2; Found: 513.2.
Example 43
l-(l-acetylpiperidin-4-yl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH- pyrazol-4-yl)-3,4-dihydropyr -d] pyrimidin-2(lH)-one
Figure imgf000107_0002
Step 1: tert-butyl 4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)- 2-oxo-3,4-dihydropyrido[4,3-d]pyrimidin-l(2H)-yl)piperidine-l-carboxylate
Figure imgf000107_0003
This compound was prepared using procedures analogous to those for example 29, step 2 (Condition B) and step 3, with 4-amino-l-methylpyrrolidin-2-one replacing cyclopropylmethylamine in step 2. LCMS calculated for C30H37F2N6O5 [M+H]+ m/z: 599.3; Found: 599.2.
Step 2: 3-(2, 6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-(piperidin- 4-yl)-3, 4-dihydropyrido[ 4, 3-
Figure imgf000108_0001
To the crude residue from step 1 was added methanol (1 mL) and 4.0 M HC1 in 1,4- dioxane (1 mL). The reaction mixture stirred at room temperature for 1 hour, then concentrated. The crude product was purified on prep-HPLC (pH = 2,
acetonitrile/water+TFA) to give the desired product (24 mg) as its bis-TFA salt. LCMS calculated for C25H29F2N6O3 [M+H]+ m/z: 499.2; Found: 499.2.
Step 3: l-( l-acetylpiperidin-4-yl)-3-(2, 6-difluoro-3, 5-dimethoxyphenyl)- 7-( 1, 3 -dimethyl- 1H- pyrazol-4-yl)-3, 4-dihydropyrido[ 4, 3-d]pyrimidin-2( lH)-one
The product from step 2 (9.8 mg, 0.0135 mmol) was dissolved in methylene chloride (200 μΚ) and pyridine (5.5 μί, 0.0675 mmol) was added, followed by acetyl chloride (2.9xL, 0.0405 mmol). The mixture was stirred at room temperature overnight, then purified on prep-HPLC (pH = 2, acetonitrile/water+TFA) to give the desired product (5 mg) as its TFA salt. LCMS calculated for C27H31F2N6O4 [M+H]+ m/z: 541.2; Found: 541.2.
Example 44
4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-2-oxo-3,4- dihydropyrido[4,3-d]pyrimidin-l(2H)-yl)benzonitrile
Figure imgf000109_0001
This compound was prepared using procedures analogous to those for example 29, step 2 (Condition A) and step 3, with 4-aminobenzonitrile replacing cyclopropylmethylamine in step 2. LCMS calculated for C27H23F2N6O3 [M+H]+ m/z: 517.2; Found: 517.1. ¾ NMR (600 MHz, DMSO) δ 8.45 (s, 1H), 8.09 (d, J= 4.7 Hz, 2H), 8.03 (s, 1H), 7.72 (d, J= A J Hz, 2H), 7.10 (t, J= 8.2 Hz, 1H), 6.29 (s, 1H), 5.00 (s, 2H), 3.91 (s, 6H), 3.77 (s, 3H), 2.14 (s, 3H).
Example 45
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-pyrimidin-4- yl-3,4-dihydropyrido[4,3-d]p
Figure imgf000109_0002
This compound was prepared using procedures analogous to those for example 29, step 2 (Condition A) and step 3, with 5-aminopyrimidine replacing cyclopropylmethylamine in step 2. LCMS calculated for C24H22F2N7O3 [M+H]+ m/z: 494.2; Found: 494.1. ¾ NMR (600 MHz, DMSO) δ 9.32 (d, J= 0.9 Hz, 1H), 9.09 (d, J= 5.4 Hz, 1H), 8.46 (s, 1H), 8.07 (s, 1H), 7.85 (dd, J= 5.3, 1.3 Hz, 1H), 7.10 (t, J= 8.2 Hz, 1H), 6.70 (s, 1H), 4.98 (s, 2H), 3.91 (s, 6H), 3.76 (s, 3H), 2.24 (s, 3H).
Example 46
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-[(5-methyl- l,3,4-oxadiazol-2-yl)methyl]-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one
Figure imgf000110_0001
This compound was prepared using procedures analogous to those for example 29, step 2 (Condition B) and step 3, with l-(5-methyl-l,3,4-oxadiazol-2-yl)methanamine replacing cyclopropylmethylamine in step 2. LCMS calculated for C24H24F2N7O4 [M+H]+ m/z: 512.2; Found: 512.2. XH NMR (600 MHz, DMSO) δ 8.40 (s, 1H), 8.19 (s, 1H), 7.38 (s, 1H), 7.10 (t, J= 8.1 Hz, 1H), 5.45 (s, 2H), 4.89 (s, 2H), 3.90 (s, 6H), 3.83 (s, 3H), 2.48 (s, 3H), 2.36 (s, 3H).
Example 47
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-(l-methyl-lH- pyrazol-4-yl)-3,4-dihydropyr -d] pyrimidin-2(lH)-one
Figure imgf000110_0002
This compound was prepared using procedures analogous to those for example 29, step 2 (Condition B) and step 3, with 1 -methyl- lH-pyrazol-4-amine replacing
cyclopropylmethylamine in step 2. LCMS calculated for C24H24F2N7O3 [M+H]+ m/z: 496.2; Found: 496.2. ¾ NMR (600 MHz, DMSO) δ 8.46 (s, 1H), 8.14 (s, 1H), 8.03 (s, 1H), 7.61 (d, J= 0.7 Hz, 1H), 7.10 (t, J= 8.1 Hz, 1H), 6.70 (s, 1H), 4.97 (s, 2H), 3.92 (s, 3H), 3.92 (s, 6H), 3.81 (s, 3H), 2.22 (s, 3H). Example 48
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-[(l,5- dimethyl-lH-pyrazol-4-yl)methyl]-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one
Figure imgf000111_0001
This compound was prepared using procedures analogous to those for example 29, step 2 (Condition B) and step 3, with l-(l,5-dimethyl-lH-pyrazol-4-yl)methanamine replacing cyclopropylmethylamine in step 2. LCMS calculated for C26H28F2N7O3 [M+H]+ m/z: 524.2; Found: 524.2. XH NMR (600 MHz, DMSO) δ 8.37 (s, 1H), 8.23 (s, 1H), 7.28 (s, 1H), 7.26 (s, 1H), 7.10 (t, J= 8.2 Hz, 1H), 5.08 (s, 2H), 4.86 (s, 2H), 3.92 (s, 6H), 3.85 (s, 3H), 3.68 (s, 3H), 2.28 (s, 3H), 2.25 (s, 3H).
Example 49
3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(3-methyl-l-(2-morpholinoethyl)-lH- pyrazol-4-yl)-3,4-dihydr
Figure imgf000111_0002
Step 1: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(3-methyl-lH-pyrazol-4-yl)-3,4- dihydropyridof 4, 3-d]pyrimidin- -one
Figure imgf000111_0003
This compound was prepared using procedures analogous to those for example 22, step 2, with 3-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole replacing phenylboronic acid. LCMS calculated for C21H21F2N5O3 [M+H]+ m/z: 430.2; Found: 430.2. Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(3-methyl-l-(2-morpholinoethyl)-lH- pyrazol-4-yl)-3, 4-dihydropyrido[ 4, 3-d]pyrimidin-2( lH)-one
A mixture of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(3-methyl-lH-pyrazol- 4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one (170.0 mg, 0.3959 mmol), cesium carbonate (520.0 mg, 1.6 mmol), and 2-(4-morpholine)ethyl bromide hydrochloride (164.0 mg, 0.712 mmol) in acetonitrile (5.0 mL) was stirred and heated at 90 °C for 12 hours. The resulting mixture was cooled to room temperature, diluted with water, and extracted with
EtOAc (3 x 15 mL). The combined organic layers were dried over a2S04, and concentrated. The resulting material was purified via pH 2 preparative LC/MS (MeCN/water with TFA) to afford the product as a white solid (TFA salt). LC/MS calculated for C27H33F2N6O4
[M+H]+m/z: 543.2; found 543.2. ¾ NMR (500 MHz, dmso) δ 8.42 (s, 1H), 8.36 (s, 1H), 7.23 (s, 1H), 7.07 (t, J= 8.2 Hz, 1H), 4.80 (s, 2H), 4.55 (t, J= 6.6 Hz, 2H), 3.99 (q, J= 7.0 Hz, 2H), 3.89 (s, 6H), 3.64 (t, J= 6.6 Hz, 2H), 2.47 (s, 3H), 1.22 (t, J= 7.0 Hz, 3H). Note: the signals for the 8 protons on the morpholine were very broad and hidden in the baseline.
Example 50
3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(3-methyl-l-(pyridin-3-ylmethyl)-lH- pyrazol-4-yl)-3,4-dihydropyrido [4,3-d] pyrimidin-2(lH)-one
Figure imgf000112_0001
Step 1: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(3-methyl-lH-pyrazol-4-yl)-3,4- dihydropyrido[ 4, 3-d]pyrimidin-2( lH)-one
Figure imgf000113_0001
This compound was prepared using procedures analogous to those for example 22, step 2, with 3-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole replacing phenylboronic acid. LCMS calculated for C21H22F2N5O3 [M+H]+ m/z: 430.2; Found: 430.2.
Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(3-methyl-l-(pyridin-3-ylmethyl)-lH- pyrazol-4-yl)-3, 4-dihydropyrido[ 4, 3-d]pyrimidin-2( lH)-one
A mixture of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(3-methyl-lH-pyrazol-
4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one (20.0 mg, 0.0466 mmol), cesium carbonate (61.3 mg, 0.1883 mmol), and 3-(bromomethyl)pyridine hydrobromide (21.2 mg,
0.0838 mmol) in acetonitrile (0.6 mL) was stirred and heated at 90 °C for 12 hours. The resulting mixture was cooled to room temperature, diluted with water, and extracted with
EtOAc (3 x 2 mL). The combined organic layers were dried over a2S04, and concentrated.
The resulting material was purified via pH 2 preparative LC/MS (MeCN/water with TFA) to afford the product as a white solid (TFA salt). LC/MS calculated for C27H26F2N6O3
[M+H]+m/z: 521.2; found 521.2.
Example 51
3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(3-methyl-l-(2-morpholino-2-oxoethyl)- lH-pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one
Figure imgf000113_0002
Step 1: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(3-methyl-lH-pyrazol-4-yl)-3,4- dihydropyridof 4, 3-d]pyrimidin- -one
Figure imgf000114_0001
This compound was prepared using procedures analogous to those for example 22, step 2, with 3-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole replacing phenylboronic acid. LCMS calculated for C21H22F2N5O3 [M+H]+ m/z: 430.2; Found: 430.2.
Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(3-methyl-l-(2-morphoUno-2- oxoethyl)-lH-pyrazol-4-yl)-3, 4-dihydropyrido[ 4, 3-d]pyrimidin-2(lH)-one
A mixture of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(3-methyl-lH-pyrazol-
4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one (20.0 mg, 0.0466 mmol), cesium carbonate (61.3 mg, 0.1883 mmol), and 2-chloro-l-morpholinoethanone (13.7 mg, 0.0838 mmol) in acetonitrile (0.6 mL) was stirred and heated at 90 °C for 12 hours. The resulting mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3 x 2 mL). The combined organic layers were dried over a2S04, and concentrated. The resulting material was purified via pH 2 preparative LC/MS (MeCN/water with TFA) to afford the product as a white solid (TFA salt). LC/MS calculated for C27H31F2N6O5 [M+H]+m/z: 557.2; found 557.2. Example 52
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(3-methyl-l-(2-morpholinoethyl)-lH-pyrazol- 4-yl)-l'H-spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3,(2,H)-one
Figure imgf000115_0001
Step 1: 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(3-methyl-lH-pyrazol-4-yl)-l 'H- spiro [cyclopropane- 1 ,4'-[2, 7] naphthyridin] -3 '(2'H)-one
Figure imgf000115_0002
This compound was prepared using procedures analogous to those for example 1, step
7, with 3-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole replacing (5- amino-2-methylphenyl)boronic acid. LCMS calculated for C22H21F2N4O3 [M+H]+ m/z: 427.1; Found: 427.1. Step 2: 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(3-methyl-l-(2-morpholinoethyl)-lH- pyrazol-4-yl)-VH-spiro[cyclopropane-l,4'-[2, 7] naphthyridin] -3'(2'H)-one
A mixture of 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(3-methyl-lH-pyrazol-4-yl)- H-spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one (17.0 mg, 0.0399 mmol), cesium carbonate (40.0 mg, 0.1 mmol), and 2-(4-morpholine)ethyl bromide hydrochloride (23.0 mg, 0.1 mmol) in acetonitrile (0.5 mL) was stirred and heated at 90 °C for 12 hours. The resulting mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3 x 2 mL). The combined organic layers were dried over a2S04, and concentrated. The resulting material was purified via pH 2 preparative LC/MS (MeCN/water with TFA) to afford the product as a white solid (TFA salt). LC/MS calculated for C28H31F2N5O4 [M+H]+m/z: 540.2; found 540.2. ¾ NMR (400 MHz, DMSO) δ 8.41 (s, 1H), 8.36 (s, 1H), 7.14 - 6.98 (m, 2H), 4.94 (s, 2H), 4.49 (t, J= 6.4 Hz, 2H), 3.89 (s, 6H), 3.73 - 3.49 (m, 2H), 2.45 (s, 3H), 1.86 - 1.64 (m, 2H), 1.56 (q, J= 3.9 Hz, 2H). Example 53
'-C ^-difluoro-S^-dimethoxyphenyl^e'-Cl-ethyl-lH-imidazoM-yl^l'H- spiroIcyclopropane-l^'-^^naphthyridinl-S^'H^-one
Figure imgf000116_0001
This compound was prepared using procedures analogous to those for example 1, step 7, with l-ethyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-imidazole replacing (5- amino-2-methylphenyl)boronic acid. LCMS calculated for C23H23F2N4O3 [M+H]+ m/z: 441.2; Found: 441.2.
Example 54
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-[l-(l,l-dioxidotetrahydro-3-thienyl)-3-methyl- lH-pyrazol-4-yl] -1 ',2 '- 7] naphthyridin] -3 '-one
Figure imgf000116_0002
Step 1: 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(3-methyl-lH-pyrazol-4-yl)-l 'H- spiro [cyclopropane- 1 ,4'-[2, 7] naphthyridin] -3 '(2'H)-one
Figure imgf000117_0001
This compound was prepared using procedures analogous to those for example 1, step 7, with 3-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole replacing (5- amino-2-methylphenyl)boronic acid. LCMS calculated for C22H21F2N4O3 [M+H]+ m/z: 427.1; Found: 427.1.
Step 2: 2'-(2, 6-difluoro-i, 5-dimethoxyphenyl)-6'-[l-( 1, l-dioxidotetrahydro-3-thienyl)-3- methyi-lH^yrazoi-4-yiJ-l 2'-dihydro-3'H-spiro[cyciopropane-l,4'-[2, 7JnaphthyridinJ-3'- one
A mixture of 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(3-methyl-lH-pyrazol-4-yl)- rH-spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one (20.0 mg, 0.0469 mmol), cesium carbonate (40.0 mg, 0.1 mmol), and 3-Bromotetrahydrothiophene 1, 1-dioxide (23.0 mg, 0.12 mmol) in acetonitrile (0.6 mL) was stirred and heated at 90 °C for 12 hours. The resulting mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3 x 2 mL). The combined organic layers were dried over a2S04, and concentrated. The resulting material was purified via pH 2 preparative LC/MS (MeCN/water with TFA) to afford the product as a white solid (TFA salt). LC/MS calculated for C26H27F2N4O5S [M+H]+m/z: 545.2; found 545.2.
Example 55
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(l-(l-(methylsulfonyl)azetidin-3-yl)-lH- razoM- ^-l'H-s iroIc clo ro ane-l^'-^^Jna hth ridinJ-S '^-one
Figure imgf000118_0001
Step 1: tert-butyl 3-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazol-l- yl)azetidine-l-carboxylate
Figure imgf000118_0002
A mixture of 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (19.4 mg, 0.10 mmol), cesium carbonate (49.0 mg, 0.15 mmol), and tert-butyl 3-iodoazetidine-l- carboxylate (31.0 mg, 0.11 mmol) in acetonitrile (0.5 mL) was stirred and heated at 90 °C for 12 hours. The resulting mixture was cooled to room temperature, and the reaction was quenched with saturated aqueous NH4C1, and extracted with DCM (3x2 mL). The organic layers were combined, dried over a2S04, and concentrated. The crude product was used directly in the next step without further purification.
Step 2: tert-butyl 3-(4-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro-l 'H- spiro [cyclopropane- 1 ,4'-[2, 7] ' naphthyridinej '-6'-yl)-lH-pyrazol-l-yl)azetidine-l-carboxylate
Figure imgf000118_0003
This compound was prepared using procedures analogous to those for example 1, step 7, with tert-butyl 3-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazol-l- yl)azetidine- 1 -carboxylate replacing (5-amino-2-methylphenyl)boronic acid. The crude product was used directly in the next step without further purification. Step 3: 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(l-(l-(methylsulfonyl)azetidin-3-yl)-lH- pyrazol-4-yl)-l'H-spiro[cyclopropane-l,4'-[2, 7]naphthyndin]-3'(2'H)-one
tert-Butyl 3 -(4-(2'-(2,6-difluoro-3 ,5 -dimethoxyphenyl)-3 '-oxo-2',3 '-dihydro- 1 Ή- spiro[cyclopropane- 1 ,4'-[2,7]naphthyridine]-6'-yl)- IH-pyrazol- 1 -yl)azetidine- 1 -carboxylate was dissolved in hydrogen chloride solution, 4.0 M in dioxane (1 mL), and the resulting mixture was stirred at room temperature for 1 hour. The crude reaction mixture was concentrated, and then dissolved in DCM (0.6 mL). After cooling to 0 °C, triethylamine (0.023 mL, 0.16 mmol) and methanesulfonyl chloride (0.010 mL, 0.129 mmol) were added slowly into the reaction mixture. The resulting solution was stirred at room temperature for 1 hour. The reaction was quenched with aq. NaHCC , (2 mL) and extracted with EtOAc (3 x 2 mL). The combined organic layers were dried over a2S04, and concentrated. The resulting material was purified via pH 2 preparative LC/MS (MeCN/water with TFA) to afford the product as a white solid (TFA salt). LC/MS calculated for C25H26F2 405S [M+H]+m/z: 545.2; found 545.2.
Example 56
-Cl-acet l-S-C^C '-C ^-difluoro-S^-dimethox hen l^S'-oxo- S'-dih dro-l'H- spiro[cyclopropane-l,4'-[2,7]naphthyridine]-6'-yl)-lH-pyrazol-l-yl)azetidin-3- yl)acetonitrile
Figure imgf000119_0001
Step 1: tert-butyl 3-(cyanomethyl)-3-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazol-l-yl)azetidine-l -carboxylate
Figure imgf000119_0002
A mixture of 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (19.4 mg, 0.10 mmol), l,8-diazabicyclo[5.4.0]undec-7-ene (0.0313 mL, 0.209 mmol), and tert-butyl 3- (cyanomethylene)azetidine-l-carboxylate (19.4 mg, 0.10 mmol) in acetonitrile (0.5 mL) was stirred at room temperature for 12 hours. The resulting mixture was quenched with saturated aqueous NH4C1, and extracted with DCM (3x2 mL). The organic layers were combined, dried over a2S04, and concentrated. The crude product was used directly in the next step without further purification.
Step 2: tert-butyl 3-(cyanomethyl)-3-(4-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'- dihydro-l Ή-spirof cyclopropane- 1, 4 '-[2, 7] naphthyridine] -6'-yl)-lH-pyrazol-l-yl)azetidine-l- carboxylate
Figure imgf000120_0001
This compound was prepared using procedures analogous to those for example 1, step 7, with tert-butyl 3-(cyanomethyl)-3-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazol-l-yl)azetidine-l-carboxylate replacing (5-amino-2-methylphenyl)boronic acid. The crude product was used directly in the next step without further purification.
Step 3: 2-( l-acetyl-3-( 4-(2'-(2, 6-difluoro-3, 5-dimethoxyphenyl)-3 '-oxo-2 ', 3 '-dihydro-l Ή- spiro[cyclopropane-l ,4'-[2 7j ' naphthyridine] '-6'-yi)-lH-pyrazoi-l-yi)azetidin-3-yi)acetonitriie tert-Butyl 3-(cyanomethyl)-3-(4-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'- dihy dro- 1 Ή-spiro [cyclopropane- 1,4'- [2,7]naphthyridine]-6'-yl)- 1 H-pyrazol- 1 -yl)azetidine- 1 - carboxylate was dissolved in hydrogen chloride solution, 4.0 M in dioxane (1 mL), and the resulting mixture was stirred at room temperature for 1 hour. The crude reaction mixture was concentrated, and then dissolved in DCM (0.6 mL). After cooling to 0 °C, triethylamine (0.015 mL, 0.11 mmol) and acetyl chloride (0.010 mL, 0.140 mmol) were added slowly into the reaction mixture. The resulting solution was stirred at room temperature for 1 hour. The reaction was quenched with aq. NaHCC , (2 mL) and extracted with EtOAc (3 x 2 mL). The combined organic layers were dried over a2S04, and concentrated. The resulting material was purified via pH 2 preparative LC/MS (MeCN/water with TFA) to afford the product as a white solid (TFA salt). LC/MS calculated for C28H27F2 6O4 [M+H]+m/z: 549.2; found 549.2. Table 5. The compounds in Table 5 were prepared in an analogous fashion to Example 29 using the appropriate amine building block and using method A or B in Step 2 as noted below.
Table 5.
Figure imgf000121_0001
Figure imgf000122_0001
2(lH)-one
Figure imgf000123_0001
Figure imgf000124_0001
2(lH)-one
Figure imgf000125_0001
2(lH)-one
Figure imgf000126_0001
2(lH)-one
Figure imgf000127_0001
d]pyrimidin-2( 1 H)-one
Figure imgf000128_0001
-one
Figure imgf000129_0001
2(lH)-one
Figure imgf000130_0001
dimethylbenzamide
Figure imgf000131_0001
2(lH)-one
Figure imgf000132_0001
Example 122
Methyl 4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-2- 3,4-dihydropyrido[4,3-d]pyrim carboxylate
Figure imgf000132_0002
Step 1. Preparation of tert-butyl 4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl- lH-pyrazol-4-yl)-2-oxo-3, 4-dihydropyrido[ 4, 3-d]pyrimidin-l(2H)-yl)piperidine-l- carboxylate
Figure imgf000132_0003
This compound was prepared using procedures analogous to those for Example 29, Step 2 (Condition B) and Step 3, with tert-butyl 4-aminopiperidine-l-carboxylate replacing 4- aminomethyl pyridine in Step 2. LCMS calculated for C30H37F2N6O5 [M+H]+ m/z: 599.1; Found: 599.1. Step 2: 3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-(piperidin- 4-yl)-3, 4-dihydropyrido[ 4, 3-
Figure imgf000133_0001
To the crude residue from Step 1 above was added methanol (1 mL) and 4.0 M HC1 1,4-dioxane (1 mL) and the reaction mixture stirred at room temperature for lh, then concentrated. The crude product was purified on prep-HPLC (pH = 2,
acetonitrile/water+TFA) to give the desired product (24 mg) as its bis-TFA salt. LCMS calculated for C25H29F2N6O3 [M+H]+ m/z: 499.2; Found: 499.1. Step 3. Preparation of methyl 4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH- pyrazol-4-yl)-2-oxo-3, 4-dihydropyrido[4,3-d]pyrimidin-l(2H)-yl)piperidine-l-carboxylate
To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4- yl)-l-piperidin-4-yl-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one (7.00 mg, 0.0140 mmol) in tetrahydrofuran (500 μΚ) was added N,N-diisopropylethylamine (9.78 μί, 0.0562 mmol) and methyl chloro formate (1.63 \L, 0.0211 mmol). The reaction mixture was stirred overnight then diluted with methanol and purified directly by reverse phase HPLC (pH = 2, acetonitrile/water+TFA) to provide the desired product as the corresponding TFA salt. LCMS calculated for C27H31F2N6O5 [M+H]+ m/z: 557.2, found 557.2. Example 123
Methyl 4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-2-oxo- 3,4-dihydropyrido[4,3-d]pyri ate.
Figure imgf000133_0002
Step 1. tert-butyl 4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)- 2-oxo-3, 4-dihydropyrido[ 4, 3-d]pyrimidin-l(2H)-yl)phenylcarbamate
Figure imgf000134_0001
This compound was prepared using procedures analogous to those for Example 29, Step 2 (Condition B) and Step 3, with tert-butyl 4-aminophenylcarbamate replacing 4- aminomethyl pyridine in Step 2. LCMS calculated for C31H33F2N6O5 [M+H]+ m/z: 607.2; Found: 607.2
Step 2. Preparation of l-(4-aminophenyl)-3-(2, 6-difluoro-3,5-dimethoxyphenyl)-7-(l,3- dimethyl-lH-pyrazol-4-yl)-3, 4- -2(lH)-one.
Figure imgf000134_0002
To the crude residue from Step 1 above was added methanol (1 mL) and 4.0 M HC1 1,4-dioxane (1 mL) and the reaction mixture stirred at room temperature for lh, then concentrated. The crude product was purified by column chromatography (0-10% methanol in dichloromethane). LCMS calculated for C26H25F2 6O3 [M+H]+ m/z: 507.2; Found: 507.2. Step 3. Preparation of methyl 4-(3-(2, 6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH- pyrazol-4-yl)-2-oxo-3, 4-dihydropyrido[ 4, 3-d]pyrimidin-l(2H)-yl)phenylcarbamate.
To a solution of l-(4-aminophenyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3- dimethyl-lH-pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one (7.00 mg, 0.0140 mmol) in tetrahydrofuran (500 μΚ) was added N,N-diisopropylethylamine (9.78 μί, 0.0562 mmol) and methyl chloro formate (1.63 \L, 0.021 1 mmol). The reaction mixture was stirred overnight, then diluted with methanol and purified directly by reverse phase HPLC (pH = 2, acetonitrile/water+TFA) to provide the desired product as the corresponding TFA salt. LCMS calculated for C28H27F2N6O5 [M+H]+ m/z: 565.2, found 565.2. Example 124 l-((l-cyclopropyl-lH-pyrazol-4-yl)methyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3- dimethyl-lH-pyrazol-4-yl)-3,4 in-2(lH)-one
Figure imgf000135_0001
Step 1. Preparation of (l-((2-(trimethylsilyl)ethoxy)methyl)-lH-pyrazol-4-yl)methanamine
Figure imgf000135_0002
To a solution of ethyl l- {[2-(trimethylsilyl)ethoxy]methyl}-lH-pyrazole-4- carboxylate (500 mg, 2 mmol) in tetrahydrofuran (2 mL) was added 2.0 M lithium tetrahydroaluminate in tetrahydrofuran (1.1 1 mL, 2.22 mmol) and the mixture stirred at room temperature for 2h, then quenched by the addition of 20 water, 20 μΐ^ of a 15% aqueous NaOH solution, then an additional 60 μϊ^ of water. After stirring an additional lh, the reaction mixture was filtered through a plug of Celite and concentrated.
To the above residue in methylene chloride (10 mL) was added triethylamine (644 μί, 4.62 mmol) and the mixture cooled to 0 degrees. Methanesulfonyl chloride (143 μί, 1.85 mmol) was added dropwise and the mixture stirred at room temperature 30 min, then recooled to 0 degrees and quenched by the careful addition of 2 mL of water. The mixture was washed with brine and the aqueous layer extracted with additional methylene chloride. The combined organics were dried over sodium sulfate and concentrated.
The residue was dissolved in N,N-dimethylformamide (10 mL) and sodium azide (180 mg, 2.77 mmol) was added. The mixture was stirred overnight at room temperature, then quenched at 0 degrees by the addition of 1.5 mL of water. The mixture was diluted with diethyl ether and the layers separated. The organic layer was then washed with water and brine, then dried over sodium sulfate and concentrated.
The residue was dissolved in 1,4-Dioxane (1.5 mL) and resin bound
triphenylphosphine (924 mg, 2.77 mmol) was added. The mixture was stirred for lh, then a 4: 1 mixture of dioxane:water (1.5 mL total) was added and the mixture was stirred at room temperature overnight. The resin was removed by filtration and the filtrate concentrated to yield the desired compound, which was used without further purification in the next step. LC- MS calculated for C10H22N3OS1 [M+H]+ m/z: 228.2, found 228.2. Step 2. Preparation of l-((lH-pyrazol-4-yl)methyl)-3-(2, 6-difluoro-3,5-dimethoxyphenyl)-7- ( 1, 3-dimethyl-lH-pyrazol-4-yl)-3, -dihydropyrido[ 4, 3-d]pyrimidin-2( lH)-one
Figure imgf000136_0001
To a mixture of N- {[4-chloro-6-(l,3-dimethyl-lH-pyrazol-4-yl)pyridin-3-yl]methyl}-
2,6-difluoro-3,5-dimethoxyaniline (50 mg, 0.1 mmol), l-(l-{[2-
(trimethylsilyl)ethoxy]methyl}-lH-pyrazol-4-yl)methanamine (41.7 mg, 0.183 mmol), (2'- aminobiphenyl-2-yl)(chloro)[dicyclohexyl(2',6'-diisopropoxybiphenyl-2- yl)phosphoranyl]palladium (9.5 mg, 0.012 mmol) and cesium carbonate (120 mg, 0.367 mmol) was added tert-butyl alcohol (2 mL) and the reaction vessel evacuated and back filled with nitrogen three times. The mixture was then stirred at 100 degrees overnight, at which point LCMS showed complete conversion. The reaction mixture was diluted with dichloromethane and filtered through a pad of Celite. The filtrate was concentrated.
The residue was dissolved in tetrahydrofuran (2.2 mL) and triethylamine (68.2 μΐ,, 0.489 mmol) was added. After cooling to 0 degrees, triphosgene (36.3 mg, 0.122 mmol) was added in one portion and the reaction mixture allowed to stir at room temperature for lh, then quenched by the addition of IN NaOH and stirred for an additional lh. The mixture was then extracted with ethyl acetate and the organic layer dried over sodium sulfate and concentrated.
The residue was dissolved in trifluoroacetic acid (1.0 mL) and stirred at room temperature for lh. LCMS analysis showed complete conversion to the desired product. The mixture was concentrated, then purified by column chromatography (50-100% ethyl acetate in hexanes) to provide the desired product as a brown powder. LC-MS calculated for C24H24F2N7O3 [M+H]+ m/z: 496.2, found 496.2. Step 3. Preparation of l-((l-cyclopropyl-lH-pyrazol-4-yl)methyl)-3-(2,6-difluoro-3,5- dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-3, 4-dihydropyrido[4,3-d]pyrimidin- 2(lH)-on.
A mixture of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4- yl)-l-(lH-pyrazol-4-ylmethyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one (10 mg, 0.02 mmol), cyclopropylboronic acid (6.93 mg, 0.0807 mmol), sodium carbonate (8.56 mg, 0.0807 mmol), copper(II) diacetate (7.33 mg, 0.0404 mmol) and 2,2'-bipyridine (6.30 mg, 0.0404 mmol) was dissolved in 1 ,2-dichloroethane (200 μί) and the mixture was heated at 95 degrees overnight. The mixture was diluted with methanol and purified directly by reverse phase HPLC (pH = 2, acetonitrile/water+TFA) to provide the desired product as a white solid. LC-MS calculated for C27H28F2N7O3 [M+H]+ m/z: 536.2, found 536.2.
Example 125
2-(4-((3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-2- dihydropyrido[4,3-d]pyrimidi -l(2H)-yl)methyl)-lH-pyrazol-l-yl)acetonitrile
Figure imgf000137_0001
To a solution of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4- yl)- 1 -( 1 H-pyrazol-4-ylmethyl)-3 ,4-dihydropyrido[4,3 -d]pyrimidin-2( 1 H)-one (Example 124, Step 2; 11 mg, 0.034 mmol) in N,N-dimethylformamide (500 μΚ) at 0 degrees was added sodium hydride (4.12 mg, 0.172 mmol) and the mixture stirred at 0 degrees for 10 minutes. Bromoacetonitrile (23.9 \L, 0.343 mmol) was then added and the reaction mixture stirred for lh at room temperature. The reaction mixture was then diluted with methanol and purified directly by reverse phase HPLC (pH = 2, acetonitrile/water+TFA) to provide the desired product as the corresponding TFA salt. LC-MS calculated for C26H25F2 8O3 [M+H]+ m/z: 535.2, found 535.2.
Example 126
l-((l-(cyclopropylmethyl)-lH-pyrazol-4-yl)methyl)-3-(2,6-difluoro-3,5- dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin- 2(lH)-one
Figure imgf000138_0001
This compound was prepared using procedures analogous to those for Example 125, with cyclopropylmethyl bromide replacing bromoacetonitrile. LCMS calculated for
C28H30F2N7O3 [M+H]+ m/z: 550.2; Found: 550.2.
Example 127
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-((l- ((tetrahydrofuran-2-yl)methyl)-lH-pyrazol-4-yl)methyl)-3,4-dihydropyrido[4,3- d] pyrimidin-2 (1 H)-one
Figure imgf000138_0002
This compound was prepared using procedures analogous to those for Example 125, with 2-(bromomethyl)tetrahydrofuran replacing bromoacetonitrile. LCMS calculated for C29H32F2N7O4 [M+H]+ m/z: 580.2; Found: 580.2.
Example 128
3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-((l-(2,2-difluoroethyl)-lH-pyrazol-4-yl)methyl)- 7-(l,3-dimethyl-lH-pyrazol-4- -3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one
Figure imgf000138_0003
This compound was prepared using procedures analogous to those for Example 125, with 2-bromo-l, l-difluoroethane replacing bromoacetonitrile. LCMS calculated for
C26H26F4N7O3 [M+H]+ m/z: 560.2; Found: 560.2. Example 129
3- (2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-(lH-pyrazol-
4- yl)-3,4-dihydropyrido[4,3-d]
Figure imgf000139_0001
Step 1. Preparation of l-((2-(trimethylsilyl)ethoxy)methyl)-lH-pyrazol-4-amine
Figure imgf000139_0002
To a 0 degree solution of 4-nitro-lH-pyrazole (250 mg, 2.2 mmol) in tetrahydrofuran (10 rnL) was added sodium hydride (60wt% in mineral oil, 63.7 mg, 2.65 mmol) and the reaction mixture stirred for 10 minutes at this temperature. [ -(Trimethylsilyl)ethoxy]methyl chloride (430 \L, 2.43 mmol) was then added dropwise and the reaction mixture stirred for an additional lh at room temperature. The reaction mixture was quenched with brine and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated. The residue was purified by column chromatography (10-80% ethyl acetate in hexanes) to provide the intermediate protected nitro pyrazole.
The residue was dissolved in ethyl acetate (2.5 mL) and 10% palladium on carbon (240 mg, 0.1 1 mmol) was added. The reaction vessel was evacuated and backfilled with hydrogen gas (1 atm) and the reaction mixture stirred for 2h at room temperature. The mixture was filtered through a pad of Celite and concentrated. The residue was used without further purification in the next step. LCMS calculated for C9H20N3OS1 [M+H]+ m/z: 214.1 ; Found: 214.2.
Step 2. Preparation of 3-(2, 6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4- yl)-l-( lH-pyrazol-4-yl)-3, 4-dihydropyrido[ 4, 3-d]pyrimidin-2(lH)-one.
To a mixture of N- {[4-chloro-6-(l,3-dimethyl-lH-pyrazol-4-yl)pyridin-3-yl]methyl}-
2,6-difluoro-3,5-dimethoxyaniline (50 mg, 0.1 mmol), l- {[2-(trimethylsilyl)ethoxy]methyl}- lH-pyrazol-4-amine (39.1 mg, 0.183 mmol), RuPhos Pd G2 (9.5 mg, 0.012 mmol) and cesium carbonate (120 mg, 0.367 mmol) was added tert-butyl alcohol (2 mL) and the reaction vessel evacuated and back filled with nitrogen three times. The mixture was then stirred at 100 degrees overnight,. The reaction mixture was diluted with dichloromethane and filtered through a pad of Celite. The filtrate was concentrated.
The residue was dissolved in tetrahydrofuran (2.2 mL) and triethylamine (68.2 μΐ,, 0.489 mmol) was added. After cooling to 0 degrees, triphosgene (36.3 mg, 0.122 mmol) was added in one portion and the reaction mixture allowed to stir at room temperature for lh, then quenched by the addition of IN NaOH and stirred for an additional lh. The mixture was then extracted with ethyl acetate and the organic layer dried over sodium sulfate and concentrated. The residue was purified by column chromatography (0- 15% methanol in dichloromethane) to provide the desired product as a light brown solid. This solid was further purified by reverse phase HPLC (pH = 2, acetonitrile/water+TFA) to provide the desired product as the corresponding TFA salt. LCMS calculated for C23H22F2N7O3 [M+H]+ m/z: 482.2; Found:
482.2.
Example 130
l-(l-cyclopropyl-lH-pyrazol-4-yl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3- dimethyl-lH-pyrazol-4-yl)-3,4- in-2(lH)-one
Figure imgf000140_0001
This compound was prepared using procedures analogous to those for Example 124, Step 3 with the product of Example 129 serving as the starting material. LCMS calculated for C26H26F2N7O3 [M+H]+ m/z: 522.2; Found: 522.2.
Example 131
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-(l-ethyl-lH- pyrazol-4-yl)-3,4-dihydropyrido [4,3-d] pyrimidin-2(lH)-one
Figure imgf000141_0001
This compound was prepared using procedures analogous to those for Example 125 with 3-(2, 6-difluoro-3, 5-dimethoxyphenyl)-7-(l , 3-dimethyl-lH-pyrazol-4-yl)-l-( lH-pyrazol- 4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one (Example 129) replacing 3-(2,6-difluoro- 3, 5-dimethoxyphenyl)- 7-( 1, 3-dimethyl-lH-pyrazol-4-yl)-l-( lH-pyrazol-4-ylmethyl)-3, 4- dihydropyrido[4,3-d]pyrimidin-2(lH)-one and ethyl iodide replacing bromoacetonitrile. LCMS calculated for C25H26F2N7O3 [M+H]+ m/z: 510.2; Found: 510.2.
Example 132
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-(l-propyl-lH- pyrazol-4-yl)-3,4-dihydropyrido -d] pyrimidin-2(lH)-one
Figure imgf000141_0002
This compound was prepared using procedures analogous to those for Example 131 with propyl iodide replacing ethyl iodide. LCMS calculated for C26H28F2N7O3 [M+H]+ m/z: 524.2; Found: 524.2.
Example 133
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-(lH-indazol-6- yl)-3,4-dihydropyrido [4,3-d] p
Figure imgf000141_0003
Step 1. Preparation of 1 -((2-(trimethylsilyl)ethoxy)methyl)- lH-indazol-6-amine.
Figure imgf000142_0001
To a solution of 5-nitroindazole (250 mg, 1.5 mmol) in tetrahydrofuran (10 mL) at 0 degrees was added sodium hydride (60% suspension in mineral oil, 67 mg, 1.7 mmol) and the mixture stirred for 10 minutes at 0 degrees. [ -(Trimethylsilyl)ethoxy]methyl chloride (320xL, 1.8 mmol) was then added dropwise and the reaction mixture warmed to room temperature and stirred for lh, at which point LCMS confirmed complete conversion. The reaction mixture was quenched with water and diluted with ethyl acetate. The layers were separated and the aqueous layer extracted with additional ethyl acetate. The combined organics were dried over sodium sulfate and concentrated. The residue was purified by column (0-35% ethyl acetate in hexanes) to provide the desired intermediate.
The residue from above was dissolved in ethyl acetate (10 mL) and 10% palladium on carbon (0.16 g, 0.15 mmol) was added. The reaction was then placed under balloon pressure of hydrogen and stirred overnight then filtered and concentrated to provide the desired product, which was purified by column chromatography (0-20% methanol in
dichloromethane). LCMS calculated for C13H22N3OS1 [M+H]+ m/z: 264.2; Found: 264.2.
Step 2. Preparation of 3-(2, 6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4- yl)-l-( lH-indazol-6-yl)-3, 4-dihydropyrido[ 4, 3-d]pyrimidin-2( lH)-one.
This compound was prepared using procedures analogous to those for Example 29, Step 2 (Condition B) and Step 3, with the product from Step 1 replacing
cyclopropylmethylamine in Step 2. LCMS calculated for C27H24F2N7O3 [M+H]+ m/z: 532.2; Found: 532.2.
Example 134
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-(lH-indazol-5- yl)-3,4-dihydropyrido [4,3-d] p
Figure imgf000142_0002
This compound was prepared using procedures analogous to those for Example 133 with 4-nitroimidazole replacing 5-nitroimidazole. LCMS calculated for C27H24F2N7O3
[M+H]+ m/z: 532.2; Found: 532.2. Example 135
l-(5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-l-(pyrimidin-4-yl)-l,2,3,4- tetrahydropyrido[4,3-d]pyrim utanecarbonitrile
Figure imgf000143_0001
Step 1. Preparation of l-(5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin
yl)cyclobutanecarbonitrile.
Figure imgf000143_0002
A mixture of l-(6-bromopyridin-3-yl)cyclobutanecarbonitrile (500 mg, 2 mmol), 4,4, 5,5,4',4',5',5'-octamethyl-[2,2']bi[[l,3,2]dioxaborolanyl] (802 mg, 3.16 mmol), potassium acetate (621 mg, 6.33 mmol), and [l,l'-bis(diphenylphosphino)ferrocene] dichloropalladium (II) (92 mg, 0.13 mmol) in 1,4-dioxane (8 mL) was first purged with nitrogen gas, and then stirred at 90 °C overnight. The reaction mixture was then cooled to room temperature, diluted with ethyl acetate, filtered through a pad of celite, and concentrated. The crude material was then purified via column chromatography (0% to 30% EtOAc in hexanes) to give the product as a yellow solid. LCMS calculated for C10H12BN2O2 [M+H for boronic acid]+ m/z: 203.1 ; Found: 203.1.
Step 2. Preparation of l-(4-chloro-5-((2, 6-difluoro-3,5-dimethoxyphenylamino)methyl)-2,3'- bipyridin-6'-yi)cyciobutanecarbonitriie.
Figure imgf000144_0001
A mixture of N-[(4,6-dichloropyridin-3-yl)methyl]-2,6-difluoro-3,5-dimethoxyaniline (400 mg, 1 mmol), l-[5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl]cyclobutanecarbonitrile (330 mg, 1.2 mmol), tetrakis(triphenylphosphine)palladium(0) (120 mg, 0.10 mmol) and potassium carbonate (580 mg, 4.2 mmol) was dissolved in a mixture of 1,4-dioxane (5 mL) and water (1 mL). The reaction flask was evacuated and back filled with nitrogen, then heated to 120 degrees for 2h, at which point LCMS showed nearly complete conversion. The reaction mixture was quenched with saturated aqueous sodium bicarbonate and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated. The residue was purified by column chromatography (0-30% ethyl acetate in hexanes) to provide the desired product as a pale yellow solid. LCMS calculated for C24H22CIF2N4O2 [M+H]+ m/z: 471.1; Found: 471.1.
Step 3. Preparation of l-(5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-l-(pyrimidin-4-yl)- 1,2, 3, 4-tetrahydropyrido[ 4, 3-d]pyrimidin-7-yl)pyridin-2-yl)cyclobutanecarbonitrile.
A mixture of l-(4-chloro-5-{[(2,6-difluoro-3,5-dimethoxyphenyl)amino]methyl}-2,3'- bipyridin-6'-yl)cyclobutanecarbonitrile (30.0 mg, 0.0637 mmol), pyrimidin-4-amine (9.09 mg, 0.0956 mmol), RuPhos Pd G2 (4.9 mg, 0.0064 mmol) and cesium carbonate (62.3 mg, 0.191 mmol) was dissolved in tert-butyl alcohol (0.6 mL) and the reaction flask was evacuated and backfilled with nitrogen three times. The reaction was then stirred at 95 degrees overnight. The reaction was quenched by the addition of saturated aqueous sodium bicarbonate, then diluted with ethyl acetate. The layers were separated and the aqueous layer extracted with additional ethyl acetate. The combined organics were dried over sodium sulfate and concentrated.
The residue was dissolved in tetrahydrofuran (0.75 mL) and triethylamine (25.8 mg,
0.255 mmol) was added. After cooling to 0 degrees, triphosgene (18.9 mg, 0.0637 mmol) was added and the mixture stirred at room temperature for lh, then diluted with methanol and purified using reverse phase HPLC (pH = 2, acetonitrile/water+TFA) to provide the desired product as the corresponding TFA salt. LCMS calculated for C29H24F2N7O3 [M+H]+ m/z: 556.2; Found: 556.2.
Example 136
l-(5-(l-cyclobutyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-l,2,3,4- tetrahydropyrido[4,3-d]pyrim utanecarbonitrile
Figure imgf000145_0001
This compound was prepared using procedures analogous to those for Example 135, Step 3 with cyclobutylamine replacing pyrimidin-4-amine. LCMS calculated for
C29H28F2N5O3 [M+H]+ m/z: 532.2; Found: 532.2.
Example 137
l-(5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-l-(pyridin-2-yl)-l,2,3,4- tetrahydropyrido[4,3-d]pyrim utanecarbonitrile
Figure imgf000145_0002
This compound was prepared using procedures analogous to those for Example 135, Step 3 with 2-aminopyridine replacing pyrimidin-4-amine. LCMS calculated for
C30H25F2N6O3 [M+H]+ m/z: 555.2; Found: 555.2. Example 138
l-(5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-l-(pyridin-3-yl)-l,2,3,4- tetrahydropyrido[4,3-d]pyrimidin-7-yl)pyridin-2-yl)cyclobutanecarbonitrile
Figure imgf000146_0001
This compound was prepared using procedures analogous to those for Example 135, Step 3 with 3-aminopyridine replacing pyrimidin-4-amine. LCMS calculated for
C30H25F2N6O3 [M+H]+ m/z: 555.2; Found: 555.2.
Example 139
l-(5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-(2-methoxyethyl)-2-oxo-l,2,3,4- tetrahydropyrido[4,3-d]pyrim utanecarbonitrile
Figure imgf000146_0002
This compound was prepared using procedures analogous to those for Example 135, Step 3 with 2-methoxy ethylamine replacing pyrimidin-4-amine. LCMS calculated for C28H28F2N5O4 [M+H]+ m/z: 536.2; Found: 536.2.
Example 140
l-(5-(l-(cyclopropylmethyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-l,2,3,4- tetrahydropyrido[4,3-d]pyrim utanecarbonitrile
Figure imgf000146_0003
This compound was prepared using procedures analogous to those for Example 135, Step 3 with cyclopropylmethyl amine replacing pyrimidin-4-amine. LCMS calculated for C29H28F2N5O3 [M+H]+ m/z: 532.2; Found: 532.2. Example 141
3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(l-methyl-lH-pyrazol-3-yl)-3,4- dihydropyrido[4,3-d]pyrimidin-2 -one
Figure imgf000147_0001
Step 1. Preparation ofN-((4-chloro-6-(l-methyl-lH-pyrazol-3-yl)pyridin-3-yl)methyl)-2, 6- difluoro-3, 5-dimethoxyanilin.
Figure imgf000147_0002
This compound was prepared using procedures analogous to those for Example 135, Step 2 with l-methyl-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole replacing l-(5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-yl)cyclobutanecarbonitrile. LCMS calculated for C18H18CIF2N4O2 [M+H]+ m/z: 395.1 ; Found: 395.1.
Step 2. Preparation of 3-(2, 6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(l -methyl- lH-pyrazol- 3-yl)-3, 4-dihydropyrido[ 4, 3-dJpyrimidin-2( lH)-one.
This compound was prepared using procedures analogous to those for Example 135, Step 3 with N-((4-chloro-6-( l-methyl-lH-pyrazol-3-yl)pyridin-3-yl)methyl)-2, 6-difluoro-3, 5- dimethoxyanilin (Step 1) replacing l-(4-chloro-5-((2, 6-difluoro-3,5- dimethoxyphenylamino)methyl)-2, 3 '-bipyridin-6'-yl)cyclobutanecarbonitrile and ethylamine replacing pyrimidin-4-amine. LCMS calculated for C21H22F2N5O3 [M+H]+ m/z: 430.2; Found: 430.2. Example 142
4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l-methyl-lH-pyrazol-3-yl)-2-oxo-3,4- dihydropyrido[4,3-d]pyrimidin- -yl)benzonitrile
Figure imgf000148_0001
This compound was prepared using procedures analogous to those for Example 141, Step 2 with 4-amino benzonitrile replacing ethylamine. LCMS calculated for C26H21F2N6O3 [M+H]+ m/z: 503.2; Found: 503.2. Example 143
3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-((l-ethyl-lH-pyrazol-4-yl)methyl)-7-(l-methyl- lH-pyrazol-3-yl)-3,4-dihydropy -d]pyrimidin-2(lH)-one
Figure imgf000148_0002
This compound was prepared using procedures analogous to those for Example 141, Step 2 with (1 -ethyl- lH-pyrazol-4-yl)methanamine replacing ethylamine. LCMS calculated for C25H26F2N7O3 [M+H]+ m/z: 510.2; Found: 510.2.
Example 144
4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l-methyl-lH-pyrazol-4-yl)-2- dihydropyrido[4,3-d]pyrimidin-l(2H)-yl)benzonitrile
Figure imgf000149_0001
Step 1. Preparation ofN-((4-chloro-6-(l-methyl-lH-pyrazol-4-yl)pyridin-3-yl)methyl)-2, 6- difluoro-3, 5-dimethoxyaniUn.
Figure imgf000149_0002
This compound was prepared using procedures analogous to those for Example 135, Step 2 with l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole replacing l-(5-(4,4,5,5 etramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-yl)cyclobutanecarbonitrile. LCMS calculated for C18H18CIF2N4O2 [M+H]+ m/z: 395.1 ; Found: 395.1.
Step 2. Preparation of 4-(3-(2, 6-difluoro-3,5-dimethoxyphenyl)-7-(l-methyl-lH-pyrazol-4- yl)-2-oxo-3, 4-dihydropyrido[ 4, 3-d]pyrimidin-l(2H)-yl)benzonitrile.
This compound was prepared using procedures analogous to those for Example 135, Step 3 with 4-amino benzonitrile replacing pyrimidin-4-amine. LCMS calculated for C26H21F2N6O3 [M+H]+ m/z: 503.2; Found: 503.2.
Example 145
3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-((l-ethyl-lH-pyrazol-4-yl)methyl)-7-(l-methyl- lH-pyrazol-4-yl)-3,4-dihydropy -d]pyrimidin-2(lH)-one
Figure imgf000149_0003
This compound was prepared using procedures analogous to those for Example 144, Step 2 with (1 -ethyl- lH-pyrazol-4-yl)methanamine replacing 4-amino benzonitrile. LCMS calculated for C25H26F2N7O3 [M+H]+ m/z: 510.2; Found: 510.2.
Table 6. The compounds in Table 6 were prepared in accordance with the synthetic protocols set forth in Scheme 3 and Example 1, using the appropriate starting materials
Figure imgf000150_0001
Figure imgf000151_0001
[2,7]naphthyridin]-3'(2'H)-one
Figure imgf000152_0001
Figure imgf000153_0001
Table 7. The compounds in Table 7 were prepared in accordance with the synthetic protocols set forth in Scheme 4 and Example 22, using the appropriate starting materials
Figure imgf000153_0002
Figure imgf000154_0001
Example 171
S- '-i ^-difluoro-S^-dimethox phen ^-S'-oxo- '^'-dih dro-l'H-spiroIc clopropane- l,4'-[2,7]naphthyridine]-6'-yl)-l -pyrazole-4-carbonitrile
Figure imgf000154_0002
Step 1 : 5-(2'-(2, 6-difluoro-3, 5-dimethoxyphenyl)-3 '-oxo-2 ', 3 '-dihydro-l Ή- spiro[cyciopropane-l,4'-[2 JnaphthyridineJ-6'-yi)-l-((2-(trimethyisiiyi)ethoxy)methyi)-lH- pyrazole-4-carbonitrile
Figure imgf000155_0001
6'-chloro-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-r,2'-dihydro-3'H- spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'-one (0.507 g, 1.33 mmol), l- {[2- (trimethylsilyl)ethoxy]methyl}-lH-pyrazole-4-carbonitrile (0.342 g, 1.53 mmol), palladium acetate (29.9 mg, 0.133 mmol), trimethylacetic Acid (34.0 mg, 0.333 mmol), potassium carbonate (0.552 g, 4.00 mmol) and di-l-adamantyl(butyl)phosphine (71.6 mg, 0.200 mmol) were mixed in N,N-dimethylformamide (2.67 mL) and 1,4-dioxane (2.67 mL). The mixture was heated at 130 °C for 1.5 h. The crude was diluted with DCM, and filtered through Celite. The filtrate was concentrated. The residue was purified by chromatography on silica gel (35-60% EtO Ac/Hex) to give the desired coupling product 760 mg (not 100% pure). Rf = 0.41 (50% EtO Ac/Hex). LC/MS calculated for C28H32F2N5O4S1 [M+H]+ m/z: 568.2; found: 568.2.
Step 2: 5-(2'-(2, 6-difluoro-i, 5-dimethoxyphenyl)-3 '-oxo-2 ', 3 '-dihydro-l Ή- spiro[cyclopropane-l ,4'-[2 ] naphthyndine] -6'-yl)-lH-pyrazole-4-carbonitrile
Trifluoroacetic acid (0.464 mL, 6.02 mmol) was added to the solution of 5-[2'-(2,6- difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro-rH-spiro[cyclopropane-l,4'- [2,7]naphthyridin]-6'-yl]- 1 - { [2-(trimethylsilyl)ethoxy]methyl} - 1 H-pyrazole-4-carbonitrile (171 mg, 0.301 mmol) in DCM. The mixture was stirred at room temperature for 15 h. The resulting mixture was concentrated, and NH4OH in MeOH was added. The mixture was stirred at room temperature for 30 min. The crude was diluted with water and extracted with DCM. The organic phase was concentrated. The residue was purified by chromatography on silica gel (4-10% MeOH/DCM) to give the product 49.0 mg. LC/MS calculated for C22H18F2N5O3 [M+H]+ m/z: 438.1 ; found: 438.2. Example 172
S- '-i ^-difluoro-S^-dimethox hen ^-S'-oxo- '^'-dih dro-l'H-s iroIc clo ro ane- l,4'-[2,7]naphthyridine]-6'-yl)-l-methyl-lH-pyrazole-4-carbonitrile
Figure imgf000156_0001
Cesium Carbonate (13.1 mg, 0.0402 mmol) was added to the solution of 5-[2'-(2,6- difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro- H-spiro[cyclopropane-l,4'- [2,7]naphthyridin]-6'-yl]-lH-pyrazole-4-carbonitrile (Example 171: 8.8 mg, 0.020 mmol) in N,N-dimethylformamide (150 \\L), followed by methyl iodide (7.14 mg, 0.0503 mmol). The mixture was stirred at room temperature overnight. The crude was diluted with DCM and filtered. The filtrate was concentrated. The residue was diluted with MeOH and purified via pH 2 preparative LC/MS (MeCN/water with TFA) to afford the product as a white solid (TFA salt). LC/MS calculated for C23H20F2N5O3 [M+H]+ m/z: 452.2; found: 452.2.
Example 173
S- '-i ^-difluoro-S^-dimethox hen ^-S'-oxo- '^'-dih dro-l'H-s iroIc clo ro ane- l,4'-[2,7]naphthyridine]-6'-yl)-l-((tetrahydro-2H-pyran-4-yl)methyl)-lH-pyrazole-4- carbonitrile
Figure imgf000156_0002
Cesium Carbonate (10.4 mg, 0.0320 mmol) was added to the solution of 5-[2'-(2,6- difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro- rH-spiro[cyclopropane-l,4'- [2,7]naphthyridin]-6'-yl]-lH-pyrazole-4-carbonitrile (Example 171: 7.0 mg, 0.016 mmol) and 4-(bromomethyl)tetrahydro-2H-pyran (7.16 mg, 0.0400 mmol) in N,N-dimethylformamide (120 μΚ). The mixture was stirred at room temperature overnight. The crude was diluted with DCM and filtered. The filtrate was concentrated. The residue was diluted with MeOH and purified via pH 2 preparative LC/MS (MeCN/water with TFA) to afford the product as a white solid (TFA salt). LC/MS calculated for C28H28F2N5O4 [M+H]+ m/z: 536.2; found: 536.1. Example 174
l- c anometh ^-S- '-i ^-difluoro-S^-dimethox hen ^-S'-oxo- '^'-dih dro-l'H- spiro[cyclopropane-l,4'-[2,7]n azole-4-carbonitrile
Figure imgf000157_0001
Cesium Carbonate (10.4 mg, 0.0320 mmol) was added to the solution of 5-[2'-(2,6- difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro- H-spiro[cyclopropane-l,4'- [2,7]naphthyridin]-6'-yl]-lH-pyrazole-4-carbonitrile (Example 171: 7.0 mg, 0.016 mmol) and bromoacetonitrile (4.80 mg, 0.0400 mmol) in N,N-dimethylformamide (120 \L). The mixture was stirred at 40 °C for 2 h. The crude was diluted with DCM and filtered. The filtrate was concentrated. The residue was diluted with MeOH and purified via pH 2 preparative LC/MS (MeCN/water with TFA) to afford the product as a white solid (TFA salt). LC/MS calculated for C24H19F2N6O3 [M+H]+ m/z: 477.1 ; found: 477.2.
Example 175
5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l,2,3,4-tetrahydropyrido[4,3- d]pyrimidin-7-yl)-N-ethylpicolinamide
Figure imgf000157_0002
Step 1 : 5-( 3-(2, 6-difluoro-3, 5-dimethoxyphenyl)-l-ethyl-2-oxo-l, 2, 3, 4-tetrahydropyridof 4, 3- djpyrimidin- 7-yl)picolinic acid
Figure imgf000158_0001
This compound was prepared using procedures analogous to those for Example 22, Step 2, with 6-(methoxycarbonyl)pyridin-3-ylboronic acid replacing phenyl boronic acid. LC/MS calculated for C23H21F2N4O5 [M+H]+ m/z: 471.1 ; Found: 471.2.
Step 2: 5-( 3-(2, 6-difluoro-i, 5-dimethoxyphenyl)-l-ethyl-2-oxo-l, 2, 3, 4-tetrahydropyrido[ 4, 3- d]pyrimidin-7-yl)-N-ethylpicolinamide
To a mixture of 5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l,2,3,4- tetrahydropyrido[4,3-d]pyrimidin-7-yl)picolinic acid (10 mg, 0.021 mmol) from previous step, Benzotriazol- 1 -yloxytris(dimethylamino)phosphonium hexafluorophosphate (11 mg, 0.025 mmol), and EtsN (15 L, 0.1 1 mmol) in DMF (1.5 mL) at rt was added EfNH2 (2.0 M in THF, 53 xL, 0.1 1 mmol). The reaction mixture was stirred at rt overnight, diluted with MeOH, and directly purified via pH 2 preparative LC/MS (MeCN/water with TFA) to give the desired product as a white solid (TFA salt). LC/MS calculated for C25H26F2N5O4 [M+H]+ m/z: 498.2; Found: 498.2. XH NMR (600 MHz, DMSO) δ 9.32 (dd, J = 2.2, 0.7 Hz, 1H), 8.87 (t, J = 6.0 Hz, 1H), 8.67 (dd, J = 8.2, 2.2 Hz, 1H), 8.46 (s, 1H), 8.15 (dd, J = 8.2, 0.7 Hz, 1H), 7.72 (s, 1H), 7.07 (t, J = 8.1 Hz, 1H), 4.84 (s, 2H), 4.07 (q, J = 7.0 Hz, 2H), 3.90 (s, 6H), 3.42 - 3.32 (m, 2H), 1.23 (t, J= 7.0 Hz, 3H), 1.15 (t, J = 7.2 Hz, 3H). Example 176
N-cyclopropyl-5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l,2,3,4- tetr ahy dr opyrido [4,3-d] py rimidin-7-yl)picolinamide
Figure imgf000158_0002
This compound was prepared using procedures analogous to those for Example 175, Step 2, with cyclopropylamine replacing EfNEk (2.0 M in THF). LC/MS calculated for C26H26F2N5O4 [M+H]+ m/z: 510.2; Found: 510.2. Example 177
5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l,2,3,4-tetrahydropyrido[4,3- d]pyrimidin-7-yl)-N-(2-hydr
Figure imgf000159_0001
This compound was prepared using procedures analogous to those for Example 175, Step 2, with ethanolamine replacing EfNEk (2.0 M in THF). LC/MS calculated for C25H26F2N5O5 [M+H]+ m/z: 514.2; Found: 514.2.
Example 178
5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l,2,3,4-tetrahydropyrido[4,3- d]pyrimidin-7-yl)-N-isoprop
Figure imgf000159_0002
This compound was prepared using procedures analogous to those for Example 175, Step 2, with 2-propanamine replacing ΕΪΝΗ2 (2.0 M in THF). LC/MS calculated for C26H28F2N5O4 [M+H]+ m/z: 512.2; Found: 512.2.
Example 179 5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l,2,3,4-tetrahydropyrido[4,3- d]pyrimidin-7-yl)-N-propylpicolinamide
Figure imgf000160_0001
This compound was prepared using procedures analogous to those for Example 175, Step 2, with 1 -propanamine replacing EfNEk (2.0 M in THF). LC/MS calculated for C26H28F2N5O4 [M+H]+ m/z: 512.2; Found: 512.2.
Example 180
2-(4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l,2,3,4-tetrahydropyrido[4,3- d]pyrimidin-7-yl)phenyl)acetonitrile
Figure imgf000160_0002
This compound was prepared using procedures analogous to those for Example 22, step 2, with 4-(cyanomethyl)phenylboronic acid replacing phenyl boronic acid. LC/MS calculated for C25H23F2N4O3 [M+H]+ m/z: 465.2; Found: 465.1.
Example 181
l-(4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l,2,3,4-tetrahydropyrido[4,3- d]pyrimidin-7-yl)phenyl)cyclobutanecarbonitrile
Figure imgf000160_0003
This compound was prepared using procedures analogous to those for Example 22, Step 2, with 1 -(4-(4,4,5,5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)phenyl)cyclobutanecarbonitrile replacing phenyl boronic acid. LC/MS calculated for C28H27F2N4O3 [M+H]+ m/z: 505.2; Found: 505.2.
Example 182
3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(6-morpholinopyridin-3-yl)-3,4- dihydropyrido[4,3-d]pyrimidi -2(lH)-one
Figure imgf000161_0001
This compound was prepared using procedures analogous to those for Example 22, Step
2, with 4-(5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine replacing phenyl boronic acid. LC/MS calculated for C26H28F2N5O4 [M+H]+ m/z: 512.2; Found: 512.2.
Example 183
l-(4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l,2,3,4-tetrahydropyrido [4,3- d]pyrimidin-7-yl)phenyl)cyclo
Figure imgf000161_0002
This compound was prepared using procedures analogous to those for Example 22, Step 2, with 4-(l-cyanocyclopropyl)phenylboronic acid replacing phenyl boronic acid. LC/MS calculated for C27H25F2N4O3 [M+H]+ m/z: 491.2; Found: 491.2.
Example 184 5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l,2,3,4-tetrahydropyrido[4,3- d]pyrimidin-7-yl)picolinamide
Figure imgf000162_0001
Step 1 : 5-( 3-(2, 6-difluoro-i, 5-dimethoxyphenyl)-l-ethyl-2-oxo-l, 2, 3, 4-tetrahydropyrido[ 4, 3- d]pyrimidin-7-yl)picolinonitrile
Figure imgf000162_0002
This compound was prepared using procedures analogous to those for Example 22, Step 2, with 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)picolinonitrile replacing phenyl boronic acid. LC/MS calculated for C23H20F2N5O3 [M+H]+ m/z: 452.2; Found: 452.1.
Step 2: 5-( 3-(2, 6-difluoro-3, 5-dimethoxyphenyl)-l-ethyl-2-oxo-l, 2, 3, 4-tetrahydropyrido[ 4, 3- d]pyrimidin-7-yl)picolinamide
A mixture of 5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l,2,3,4- tetrahydropyrido[4,3-d]pyrimidin-7-yl)picolinonitrile (94 mg, 0.21 mmol) in NaOH solution (1.0 M in H2O) (1.20 mL) and ethanol (3.6 mL) was stirred at 80 °C overnight. The reaction mixture was cooled to rt, quenched with HCl solution (12.0 M in H2O, 120 μί), and concentrated. The crude material was then purified via pH 2 preparative LC/MS (MeCN/water with TFA) to give the desired product as a white solid (TFA salt). LC/MS calculated for C23H22F2N5O4 [M+H]+ m/z: 470.2; Found: 470.1.
Example 185
'-i ^-difluoro-S^-dimethox phen l^e'- p ridin^- ^-l'H-spiroIc clopropane-l^'- [2,7]naphthyridin]-3'(2'H)-one
Figure imgf000163_0001
This compound was prepared using procedures analogous to those for Example 1, Step 7, with 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine replacing (5-amino-2- methylphenyl)boronic acid. LC/MS calculated for C23H20F2N3O3 [M+H]+ m/z: 424.1; Found: 424.2.
Example 186
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(l-methyl-lH-pyrazol-4-yl)-l,,2,-dihydro-3,H- spiro[cyclopropane-l,4'-[2,7]n
Figure imgf000163_0002
This compound was prepared using procedures analogous to those for Example 1, Step 7, with l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole replacing (5-amino-2-methylphenyl)boronic acid. LC/MS calculated for C22H21F2N4O3 [M+H]+ m/z: 427.2; Found: 427.1.
Example 187
l-(5-{3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-[(5-methyl-l,3,4-oxadiazol-2-yl)methyl]-2- oxo-l,2,3,4-tetrahydropyrido[ -d]pyrimidin-7-yl}pyridin-2-yl)cyclobutanecarbonitrile
Figure imgf000163_0003
This compound was prepared using procedures analogous to those for Example 135, Step 3 with l-(5-methyl-l,3,4-oxadiazol-2-yl)methanamine replacing pyrimidin-4-amine. LCMS calculated for C29H26F2N7O4 [M+H]+ m/z: 574.2; Found: 574.2.
Example 188
l-{5-[3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-(l-methyl-lH-pyrazol-4-yl)-2-oxo- tetrahydropyrido [4,3-d] pyrim utanecarbonitrile
Figure imgf000164_0001
This compound was prepared using procedures analogous to those for Example 135, Step 3 with 1 -methyl- lH-pyrazol-4-amine replacing pyrimidin-4-amine. LCMS calculated for C29H26F2N7O3 [M+H]+ m/z: 558.2; Found: 558.1.
Example A
FGFR Enzymatic Assay
The inhibitor potency of the exemplified compounds was measured in an enzyme assay that measures peptide phosphorylation using FRET measurements to detect product formation. Inhibitors were serially diluted in DMSO and a volume of 0.5 μϊ^ was transferred to the wells of a 384-well plate. For FGFR3, a 10 μϊ^ volume of FGFR3 enzyme (Millipore) diluted in assay buffer (50 mM HEPES, 10 mM MgCl2, 1 mM EGTA, 0.01% Tween-20, 5 mM DTT, pH 7.5) was added to the plate and pre-incubated for a time between 5-10 minutes and up to 4 hours. Appropriate controls (enzyme blank and enzyme with no inhibitor) were included on the plate. The assay was initiated by the addition of a 10 μϊ^ solution containing biotinylated EQEDEPEGDYFEWLE peptide substrate (SEQ ID NO: 1) and ATP (final concentrations of 500 nM and 140 μΜ respectively) in assay buffer to the wells. The plate was incubated at 25 °C for 1 hr. The reactions were ended with the addition of 10 μΕΛνεΙΙ of quench solution (50 mM Tris, 150 mM NaCl, 0.5 mg/mL BSA, pH 7.8; 30 mM EDTA with Perkin Elmer Lance Reagents at 3.75 nM Eu-antibody PY20 and 180 nM APC-Streptavidin). The plate was allowed to equilibrate for ~1 hr before scanning the wells on a PheraStar plate reader (BMG Labtech).
FGFR1, FGFR2, and FGFR4 are measured under equivalent conditions with the following changes in enzyme and ATP concentrations: FGFR1, 0.02 nM and 210 uM respectively, FGFR2, 0.01 nM and 100 uM, respectively, and FGFR4, 0.04 nM and 600 uM respectively. The enzymes were purchased from Millipore or Invitrogen.
GraphPad prism3 was used to analyze the data. The ICso values were derived by fitting the data to the equation for a sigmoidal dose-response with a variable slope.
Y=Bottom + (Top-Bottom)/(l+10A((LogIC5o-X)*HillSlope)) where X is the logarithm of concentration and Y is the response. Compounds having an ICso of 1 μΜ or less are considered active.
The compounds of the invention were found to be selective inhibitors of FGFR3 and/or FGFR4 according to the FGFR Enzymatic Assays. Compouds of Formula (Γ) and (I) and all the compounds as described herein have been tested and exhibit an ICso of less than 1 μΜ.
Table 1 provides ICso data for compounds of the invention assayed in the FGFR Enzymatic Assay after dilution in assay buffer, added to the plate and pre-incubated for 4 hours. The symbol: "+" indicates an ICso less than 10 nM; "++" indicates an ICso greater than or equal to 10 nM but less than 30 nM; "+++" indicates an ICso greater than or equal to 30 nM but less than 200 nM; and "++++" indicates an ICso greater than or equal to 200 nM. Table 2 provides ICso ratios showing FGFR4 selectivity. Table 2A provides ICso ratios showing FGFR3 selectivity of the compounds.
Table 1
Example No. FGFR1 FGFR2 FGFR3 FGFR4
IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM)
1 ++++ ++++ ++++ +++
2 ++++ ++++ ++++ +++
3 ++++ ++++ ++++ ++
4 +++ +++ +++ +
5 +++ ++ ++ +
6 ++++ ++++ +++ +
7 ++++ ++++ ++++ +++
8 ++++ ++++ +++ ++
9 +++ +++ ++ ++
10 +++ ++ ++ +
11 ++++ ++++ ++++ ++
12 ++++ +++ +++ + 13 ++++ +++ +++ +
14 ++++ +++ +++ +
15 +++ +++ +++ +
16 ++++ +++ +++ +
17 ++++ +++ ++ ++
18 ++ + + ++
19 ++ + + +
20 +++ ++ ++ ++
21 ++ + + ++
22 +++ ++ ++ ++
23 +++ + + +
24 ++ + + ++
25 ++ + + ++
26 ++ + + ++
27 ++ + + ++
28
29 ++ + + ++
30 ++ + + ++
31 ++ + + ++
32 ++ + + ++
33 +++ + + +++
34 +++ ++ + +++
35 ++ + + ++
36 ++ + + ++
37 ++ + + +++
38 +++ ++ + +++
39 ++ + + +
40 +++ + + +++
41 +++ ++ ++ +++
42
43 ++
44 +++ ++ + +++
45 +++ ++ + +++
46 ++ + + ++
47 +++ + + +++
48 ++ + + ++
49 +++ + + +++
50 +++ ++ ++ ++
51
52 +++ ++ + ++
53 ++ + + ++
54 +++ + + ++
55 ++ + + +
56
57 ++
58 +++ + + ++
59 +++ ++ ++ +++ 60 +++ ++ + +++
61 ++
62 +++ ++ + +++
63 +++ ++ + +++
64 +++ ++ + +++
65 +++ + + +++
66 ++
67 +++ + + +++
68 +++ ++ + +++
69 +++ ++ + +++
70 +++ ++ ++ +++
71 +++ +++ ++ +++
72 + + + +
73 +++ ++ ++ +++
74 +++ +++ ++ +++
75 +++ +++ ++ +++
76 +++ +++ ++ +++
77 ++ + + +++
78 +++ ++ + +++
79 +++ + + +++
80 +++ ++ + +++
81 ++ ++
82 +++ + + +++
83 ++
84 +++ + + +++
85 +++ ++ + +++
86 +++ ++ ++ +++
87 +++ + + +++
88 + + + +
89 ++ + + +++
90 +++ ++ + +++
91 +++ + + +++
92 +++ ++ ++ +++
93 +++ + + +++
94 + + + ++
95 ++ + + +++
96 +++ ++ ++ +++
97 +++ + + +++
98 +++ ++ ++ +++
99 +++ + + +++
100 +++ ++ ++ +++
101 + + + ++
102 +++ ++ ++ +++
103 +++ ++ ++ +++
104 ++ + + +++
105 +++ ++ ++ +++
106 +++ +++ ++ +++ 107 +++ ++ ++ +++
108 +++ ++ ++ +++
109 ++ + + +++
1 10 ++ + + +++
1 11 ++ + + +++
1 12 +++ + + +++
1 13 +++ + ++ +++
1 14 +++ ++ ++ +++
1 15 +++ + + +++
122 +++ ++ ++ +++
123 +++ + + ++
124 + + + +
125 +++ + ++ +++
129 ++ + + +++
130 +++ ++ ++ +++
131 ++ ++
132 +++ ++ ++ +++
133 ++ + + +++
134 ++ + + +++
135 +++ + + +++
146 +++ ++ + +++
147 ++ + + +
148 +++ ++ + ++
149 +++ + + +++
150 + + + +
151 + + + +
152 ++ + + ++
153 +++ ++ + ++
154 +++ ++ ++ +++
155 +++ +++ ++ +++
156 +++ ++ + ++
157 ++ + + +
158 +++ + + ++
159 +++ ++ ++ +++
160 ++ + + ++
161 ++ + + ++
162 ++ + + +
163 +++ + + +++
164 +++ ++ ++ +++
165 ++ + + ++
166 ++ + + ++
167 + + + ++
168 ++ + + ++
169 + + + ++
170 ++ + + ++
171 +++ +++ +++ +
172 ++++ ++++ ++++ ++ 173 ++++ ++++ ++++ ++
174 ++++ ++++ ++++ ++
175 +++ + + +++
176 ++ + + ++
177 ++ + + ++
178 ++ + + ++
179 ++ + + ++
180 +++ + + ++
181 +++ + + +++
182 ++ + + ++
183 ++ + + +++
184 ++ + + ++
185 ++ + + ++
186 + + + +
187 +++ + + +++
188 +++ ++ ++ +++
Table 2
Figure imgf000169_0001
Table 2A
Figure imgf000169_0002
5 >3
6 >3
7 >1
8 >5
9 >3
10 >1
11 >1
12 >3
13 >3
14 >5
15 >3
16 >1
17 >10
18 >5
19 >5
20 >5
21 >5
22 >5
23 >5
24 >5
25 >5 >5
26 >5 >5
27 >10 >10
28 >10 >25
29 >1 >5
30 >1 >5
31 >5 >10
32 >1 >5
33 >5 >5
34 >5 >10
35 >5 >10
36 >5 >10
37 >1 >10
38 >5 >5
39 >10 >10
40 >10 >10
41 >1 >5
42 >5 >1
43 >10 >5
44 >10 >10
45 >10 >10
46 >10 >10
47 >10 >10
48 >10 >10
49 >5 >1
50 >1 >1
51 >1 >1 52 >10 >1
53 >5 >5
54 >5 >1
55 >10 >5
56 >5 >1
57 >10 >10
58 >10 >10
59 >10 >10
60 >10 >5
61 >10 >5
62 >10 >5
63 >10 >5 z64 >10 >10
65 >5 >10
66 >5 >5
67 >5 >10
68 >5 >5
69 >5 >5
70 >5 >5
71 >5 >3
72 >5 >10
73 >5 >10
74 >5 >5
75 >5 >3
76 >5 >5
77 >5 >10
78 >5 >3
79 >5 >3
80 >5 >10
81 >5 >10
82 >5 >5
83 >5 >5
84 >5 >5
85 >5 >10
86 >5 >10
87 >5 >10
88 >5 >10
89 >5 >10
90 >5 >5
91 >5 >5
92 >5 >10
93 >5 >5
94 >5 >10
95 >5 >10
96 >5 >5
97 >5 >10
98 >5 >10 99 >5 >5
100 >5 >5
101 >5 >10
102 >3 >10
103 >3 >5
104 >3 >5
105 >3 >5
106 >3 >5
107 >3 >10
108 >3 >3
109 >3 >10
110 >3 >5
111 >3 >5
112 >3 >5
113 >3 >5
114 >3 >5
115 >3 >5
122 >5 >5
123 >5 >3
124 >10 >10
125 >5 >5
129 >5 >10
130 >5 >5
131 >3 >10
132 >3 >5
133 >3 >5
134 >3 >5
135 >5 >10
146 >10 >5
147 >10 >3
148 >10 >3
149 >5 >3
150 >5 >5
151 >5 >5
152 >5 >3
153 >5 >3
154 >5 >3
155 >5 > 1
156 >5 > 1
157 >5 >3
158 >5 >3
159 >5 >3
160 >5 >5
161 >5 >3
162 >5 > 1
163 >3 >3
164 >3 >3 165 >3 >3
166 >3 >3
167 >3 >3
168 >5 >3
169 >3 >5
170 >3 >5
175 >10 >5
176 >10 >5
177 >5 >10
178 >5 >5
179 >5 >10
180 >5 >5
181 >5 >10
182 >5 >5
183 >3 >10
184 > 5 >5
185 >3 >3
186 >5 >5
187 >10 >10
188 >5 >5
Table 3 provides ICso data for compounds of the invention assayed in the FGFR Enzymatic Assay after dilution in assay buffer, added to the plate and pre-incubated for 5 to 10 minutes. The symbol: "+" indicates an ICso less than 10 nM; "++" indicates an ICso greater than or equal to 10 nM but less than 30 nM; "+++" indicates an ICso greater than or equal to 30 nM but less than 200 nM; and "++++" indicates an ICso greater than or equal to 200 nM. Table 4 provides ratios of ICso data, showing FGFR4 selectivity.
Table 3
Figure imgf000173_0001
13
14
15
16
57 1
58
59
69
116
117
118
119
120
121
126
127
128
136
137
138
139
140
141
142
143
144
145
168
169
170
175
186
187
Table 4
Figure imgf000174_0001
10 >25 >10 >10
1 1 >50 >20 >25
12 >50 >25 >20
13 >50 >20 >10
14 >25 >5 >5
15 >50 >25 >10
16 >25 >10 >10
Example B
FGFR4 Cellular and In Vivo Assays
The FGFR4 inhibitory activity of the example compounds in cells, tissues, and/or animals can be demonstrated according to one or more assays or models described in the art such as, for example, in French et al. "Targeting FGFR4 Inihibits Hepatocellular Carcinoma in Preclinical Mouse Models," PLoS ONE, May 2012, Vol. 7, Issue 5, e36713, which is incorporated herein by reference in its entirety. Example C
Cell-Based FGFR Phosphorylation Assays
The inhibitory effect of compounds on FGFR phosphorylation in relevant cell lines (Ba/F3-FGFR3, KMS-1 1, RT112, KatoIII, H-1581 cancer cell lines and HUVEC cell line) can be assessed using immunoassays specific for FGFR phosphorylation. Cells are starved in media with reduced serum (0.5%) and no FGF 1 for 4 to 18 h depending upon the cell line then treated with various concentrations of individual inhibitors for 1-4 hours. For some cell lines, such as Ba/F3-FGFR3 and KMS-11, cells are stimulated with Heparin (20 μg/mL) and FGF1 (10 ng/mL) for 10 min. Whole cell protein extracts are prepared by incubation in lysis buffer with protease and phosphatase inhibitors [50 mM HEPES (pH 7.5), 150 mM NaCl, 1.5 mM MgCk, 10% Glycerol, 1% Triton X-100, 1 mM sodium orthovanadate, 1 mM sodium fluoride, aprotinin (2 μg/mL), leupeptin (2 μg/mL), pepstatin A (2 μg/mL), and
phenylmethylsulfonyl fluoride (1 mM)] at 4°C. Protein extracts are cleared of cellular debris by centrifugation at 14,000 x g for 10 minutes and quantified using the BCA (bicinchoninic acid) microplate assay reagent (Thermo Scientific).
Phosphorylation of FGFR receptor in protein extracts was determined using immunoassays including western blotting, enzyme-linked immunoassay (ELISA) or bead- based immunoassays (Luminex). For detection of phosphorylated FGFR2, a commercial ELISA kit DuoSet IC Human Phospho-FGF R2a ELISA assay (R&D Systems, Minneapolis, MN) can be used. For the assay KatoIII cells are plated in 0.2% FBS supplemented Iscove's medium (50,000 cells / well/ per 100 μΐ,) into 96-well flat-bottom tissue culture treated plates (Corning, Corning, NY), in the presence or absence of a concentration range of test compounds and incubated for 4 hours at 37 °C, 5% CO2. The assay is stopped with addition of 200 μΐ, of cold PBS and centrifugation. The washed cells are lysed in Cell Lysis Buffer (Cell Signaling, #9803 ) with Protease Inhibitor (Calbiochem, #535140) and PMSF (Sigma, #P7626) for 30 min on wet ice. Cell lysates were frozen at -80 °C before testing an aliquot with the DuoSet IC Human Phospho-FGF R2a ELISA assay kit. GraphPad prism3 was used to analyze the data. The IC50 values were derived by fitting the data to the equation for a sigmoidal dose-response with a variable slope.
For detection of phosphorylated FGFR3, a bead based immunoassay was developed. An anti-human FGFR3 mouse mAb (R&D Systems, cat#MAB7661) was conjugated to Luminex MAGplex microspheres, bead region 20 and used as the capture antibody. RT-112 cells were seeded into multi-well tissue culture plates and cultured until 70% confluence. Cells were washed with PBS and starved in RPMI + 0.5% FBS for 18 hr. The cells were treated with 10 of 10X concentrations of serially diluted compounds for 1 hr at 37 °C, 5% CO2 prior to stimulation with 10 ng/niL human FGF1 and 20 μg/mL Heparin for 10 min. Cells were washed with cold PBS and lysed with Cell Extraction Buffer (Invitrogen) and centrifuged. Clarified supernatants were frozen at -80 °C until analysis.
For the assay, cell lysates are diluted 1 : 10 in Assay Diluent and incubated with capture antibody-bound beads in a 96-well filter plate for 2 hours at room temperature on a plate shaker. Plates are washed three times using a vacuum manifold and incubated with anti-phospho-FGF Rl-4 (Y653/Y654) rabbit polyclonal antibody (R&D Systems cat# AF3285) for 1 hour at RT with shaking. Plates are washed three times. The diluted reporter antibody, goat anti-rabbit-RPE conjugated antibody (Invitrogen Cat. # LHB0002) is added and incubated for 30 minutes with shaking. Plates are washed three times. The beads are suspended in wash buffer with shaking at room temperature for 5 minutes and then read on a Luminex 200 instrument set to count 50 events per sample, gate settings 7500-13500. Data is expressed as mean fluorescence intensity (MFI). MFI from compound treated samples are divided by MFI values from DMSO controls to determine the percent inhibition, and the IC50 values are calculated using the GraphPad Prism software. Compounds having an IC50 of 1 μΜ or less are considered active. Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference, including all patent, patent applications, and publications, cited in the present application is incorporated herein by reference in its entirety.

Claims

What is claimed is:
1. A compound of Formula (Γ):
Figure imgf000178_0001
or a pharmaceutically acceptable salt thereof, wherein:
ring A is a C6-10 aryl or 5- to 10-membered heteroaryl having carbon and 1 to 4 heteroatoms as ring members selected from O, N, and S, wherein the N and S are each optionally oxidized;
each R12 is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, ORa, SRa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NRaRa, NRORa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa, NRaC(=NRa)NRaRa,
NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, or 4 independently selected Rb substituents; or two adjacent R12 substituents on ring A taken together with the atoms to which they are attached form a fused 5- or 6-membered cycloalkyl ring, 5 to 6-membered
heterocycloalkyl ring, phenyl or 5 to 6-membered heteroaryl ring, wherein the
heterocycloalkyl or heteroaryl has 1 -2 heteroatoms as ring members selected from O, N, and
S;
each Ra is independently selected from H, Ci-6 alkyl, Ci-4haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Ra are each optionally substituted with 1, 2, 3, 4, or 5 independently selected Rd substituents;
or any two Ra substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each Rb is independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc, and S(0)2NRCRC; wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rb are each optionally substituted with 1, 2, 3, 4, or 5 independently selected Rf substituents;
each Rc is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-iocycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rc are each optionally substituted with 1, 2, 3, 4, or 5 independently selected Rf substituents;
or any two Rc substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each Rd is independently selected from C1-4 alkyl, C1-4 haloalkyl, halo, CN, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NReRe, NReC(0)Re, NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC(=NRe)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe;
each Rf is independently selected from Ci-4 alkyl, Ci-4 haloalkyl, halo, CN, ORs, SRS, C(0)R8, C(0)NR¾s, C(0)ORs, OC(0)Rs, OC(0)NR«R<% NR¾s, NRSC(0)RS,
RsC(0) R¾s, RsC(0)ORs, C(=NRs)NR¾s, NRsC(=NRs)NR¾s, S(0)R8, S(0)NR¾s, S(0)2Rs, NR¾(0)2Rs, NR¾(0)2NR¾s, and S(0)2NR¾s;
each Rh is independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-6 haloalkyl, halo, CN, OR1, SR1, C(0)R, C^N , C(0)OR, OC(0)R, OC^N , NRR, N C^ , N C^N , N CCO , C(=NR1)NRiR1, N C^NR N , S(0)R, S(0)NR1Ri, S(0)2R, RiS(0)2Ri, NRSiO^NRR, and SiO^NRR, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, Ce-ιο aryl, and 5-6 membered heteroaryl of Rh are optionally substituted by 1, 2, or 3 independentlys selected R> substituents;
each Rj is independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, CN, 0Rk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk, OC(0)Rk, OC(0)NRkRk, NRkRk, NRkC(0)Rk,
NRkC(0)NRkRk, NRkC(0)OR, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk, NRkS(0)2NRkRk, and S(0)2NRkRk;
each Re, Rg, R1 or Rk is independently selected from H, Ci-4 alkyl, C6-ioaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C6-ioaryl, C2-4 alkenyl or C2-4 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, Ci-4 alkyl, C1-4 alkoxy, Ci-4 alkylthio, Ci-4 alkylamino, di(Ci-4 alkyl)amino, Ci-4 haloalkyl, and Ci-4 haloalkoxy;
or any two Re substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rs substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R1 substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
X1 is -CR10Rn- or -NR7-
X2 is N or CR6; R13 is H, CN, NRc4Rd4, OR1 or -C(0)NHRe, wherein R1 is C1-3 alkyl or C1-3 haloalkyl; R2 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R3 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R14 is H, CN, NRc4Rd4, OR4 or -C(0)NHRs, wherein R4 is C1-3 alkyl or C1-3 haloalkyl; R5 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R6 is selected from H, halo, CN, ORa4, SRa4, C(0)NRc4Rd4, OC(0)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, NRc4S(0)RM, NRc4S(0)2RM,
NRc4S(0)2NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM, S(0)2NRc4Rd4, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl groups of R6 are each optionally substituted with 1, 2, or 3 substituents independently selected from R10A;
R7 is selected from H, C(0)NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM,
S(0)2NRc4Rd4, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, 5- to 10-membered heteroaryl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, 4- to 10-membered heterocycloalkyl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl- C1-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)- C1-4 alkyl-; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5- to 10-membered heteroaryl, 4-7 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- groups of R7 are each optionally substituted with 1, 2, or 3 substituents independently selected from R10A; or two R10A substituents attached to the adjacent ring atoms of the aryl or heteroaryl ring of R7, taken together with the atoms to which they are attached, form a fused C5-6 cycloalkyl ring or a fused 5- to 6-membered heterocycloalkyl ring having 1-2 heteroatoms as ring members independently selected from O, N and S, wherein the nitrogen and sulfur atoms are each optionally oxidized and the fused C5-6 cycloalkyl ring or fused 5 to 6-membered heterocycloalkyl is optionally substituted with 1 or 2 independently selected R19 groups;
R10 and R11 are each independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, a 5-10 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-10 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl groups of R10 and R11 are each optionally substituted with 1, 2, or 3, R10A;
alternatively, R10 and R11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group or a 4-, 5-, 6-, 7-, 8-, 9-, or 10- membered heterocycloalkyl group; wherein said 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group and 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group are each optionally substituted with 1, 2, 3 or 4 R10A;
each R10A is independently selected from halo, CN, NO2, ORa4, SRa4, C(0)RM, C(0)NRc4Rd4, C(0)ORa4, OC(0)RM, OC(0)NRc4Rd4, C(=NRe4)NRc4Rd4,
NRc4C(=NRe4)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, NRc4S(0)RM, NRc4S(0)2RM, NRc4S(0)2NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM,
S(0)2NRc4Rd4, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1 , 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of R10A are each optionally substituted with 1, 2, or 3 substituents independently selected from R19;
each Ra4, Rb4, Rc4, and Rd4 is independently selected from H, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci-4 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of Ra4, Rb4, Rc4, and Rd4 are each optionally substituted with 1, 2, or 3 substituents independently selected from R19;
alternatively, R04 and Rd4 together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group which is optionally substituted with 1, 2 or 3 substituents independently selected from R19;
each Re4 is independently H or Ci-4 alkyl; each R19 is independently selected from halo, CN, N02, ORa9, SRa9, C(0)Rb9, C(0)NRc9Rd9, C(0)ORa9, OC(0)Rb9, OC(0)NRc9Rd9, NRc9Rd9, NRc9C(0)Rb9,
NRc9C(0)ORa9, NRc9C(0)NRc9Rd9, NRc9S(0)Rb9, NRc9S(0)2Rb9, NRc9S(0)2NRc9Rd9, S(0)Rb9, S(0)NRc9Rd9, S(0)2Rb9, S(0)2NRc9Rd9, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Cs- 6cycloalkyl, 4- to 6-membered heterocycloalkyl and C1-4 haloalkyl, wherein the C1-4 alkyl, C2- 4 alkenyl, C2-4 alkynyl, C3-6cycloalkyl, 4- to 6-membered heterocycloalkyl and C1-4 haloalkyl of R19 are each further optionally substituted with 1 or 2 R20 substituents independently selected from H, halo, CN, N02, ORi, SRi, C(0)Ri, C(0)NRiRi, C(0)ORi, OC(0)Ri, OC(0)NRiRi, NRqRq, NR¾C(0)R¾, NR< (0)OR<i, NRiC(0)NRiRq, NR¾(0)Ri,
NR¾(0)2Ri, NRiS(0)2NRiRq, S(0)R¾, S(0)NRiRi, S(0)2R¾, S(0)2NRiRi, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl and C1-4 haloalkyl, wherein each Rq is independently H or Ci-4alkyl;
each Ra9, Rc9, and Rd9 is independently selected from H and C1-4 alkyl;
each Rb9 is independently C1-4 alkyl; and
the subscript n is 0, 1, 2 or 3.
2. A compound of Formula (Γ):
Figure imgf000183_0001
or a pharmaceutically acceptable salt thereof, wherein:
ring A is a C6-10 aryl or 5- to 10-membered heteroaryl having carbon and 1 to 4 heteroatoms as ring members selected from O, N, and S, wherein the N and S are each optionally oxidized;
each R12 is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, ORa, SRa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NRaRa, NRaORa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa, NRaC(=NRa)NRaRa,
NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, or 4 independently selected Rb substituents;
or two adjacent R12 substituents on ring A taken together with the atoms to which they are attached form a fused 5- or 6-membered cycloalkyl ring, 5 to 6-membered
heterocycloalkyl ring, phenyl or 5 to 6-membered heteroaryl ring, wherein the
heterocycloalkyl or heteroaryl has 1 -2 heteroatoms as ring members selected from O, N, and S;
each Ra is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Ra are each optionally substituted with 1, 2, 3, 4, or 5 independently selected Rd substituents;
or any two Ra substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each Rb is independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, N02, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC, NRCC(=NRC)NRCRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc, and S(0)2NRcRc; wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rb are each optionally substituted with 1, 2, 3, 4, or 5 independently selected Rf substituents;
each Rc is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-iocycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- of Rc are each optionally substituted with 1, 2, 3, 4, or 5 independently selected Rf substituents;
or any two Rc substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each Rd is independently selected from C1-4 alkyl, C1-4 haloalkyl, halo, CN, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NReRe, NReC(0)Re,
NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC(=NRe)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe;
each Rf is independently selected from C1-4 alkyl, C1-4 haloalkyl, halo, CN, ORs, SRS, C(0)R8, C(0)NR¾s, C(0)ORs, OC(0)Rs, OC(0)NR«R<% NR¾s, NRSC(0)RS,
NR8C(0)NR«R<% RsC(0)ORs, C(=NRs)NR¾s, NRsC(=NRs)NR¾s, S(0)R8, S(0)NR¾s, S(0)2Rg, NR¾(0)2Rg, R¾(0)2 RSRs, and S(0)2NR¾s;
each Rh is independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-6 haloalkyl, halo, CN, OR1, SR1, C(0)R;, C^NR'R1, C(0)OR, OC(0)R, 00(0)Ν^^, NRR, Ν^Ο(Ο)^, NRC C NRR, R'CCO R1, C(=NR1)NRiR1, R^ R^ R'R1, S(0)R, S C NRR, S^R1, RiS(0)2Ri, R'S^ R'R1, and S O^NRR1, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-10 aryl, and 5-6 membered heteroaryl of Rh are optionally substituted by 1, 2, or 3 independentlys selected R> substituents;
each Rj is independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, CN, ORk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk, OC(0)Rk, OC(0)NRkRk, NRkRk, NRkC(0)Rk,
NRkC(0)NRkRk, NRkC(0)OR, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk, NRkS(0)2NRkRk, and S(0)2NRkRk; each Re, Rs, R1 or Rk is independently selected from H, Ci-4 alkyl, C6-ioaryl, Ci-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C6-ioaryl, C2-4 alkenyl or C2-4 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, di(Ci-4 alkyl)amino, Ci-4 haloalkyl, and Ci-4 haloalkoxy;
or any two Re substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rs substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R1 substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
X1 is -CR10Rn- or -NR7-
X2 is N or CR6;
R13 is H, CN, NRc4Rd4, OR1 or -C(0)NHRe, wherein R1 is C1-3 alkyl or C1-3 haloalkyl; R2 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R3 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R14 is H, CN, NRc4Rd4, OR4 or -C(0)NHRs, wherein R4 is C1-3 alkyl or C1-3 haloalkyl; R5 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R6 is selected from H, halo, CN, ORa4, SRa4, C(0)NRc4Rd4, OC(0)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, NRc4S(0)RM, NRc4S(0)2RM,
NRc4S(0)2NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM, S(0)2NRc4Rd4, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl groups of R6 are each optionally substituted with 1, 2, or 3 substituents independently selected from R10A;
R7 is selected from H, C(0)NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM,
S(0)2NRc4Rd4, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, 5- to 10-membered heteroaryl having carbon and 1, 2, or 3 heteroatoms independently selected from , O and S, 4- to 10-membered heterocycloalkyl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, Ce-ιο aryl-Ci-4 alkyl-, C3-10 cycloalkyl- C1-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)- C1-4 alkyl-; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5- to 10-membered heteroaryl, 4-7 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- groups of R7 are each optionally substituted with 1, 2, or 3 substituents independently selected from R10A; or two R10A substituents attached to the adjacent ring atoms of the aryl or heteroaryl ring of R7, taken together with the atoms to which they are attached, form a fused C5-6 cycloalkyl ring or a fused 5- to 6-membered heterocycloalkyl ring having 1-2 heteroatoms as ring members independently selected from O, N and S, wherein the nitrogen and sulfur atoms are each optionally oxidized and the fused C5-6 cycloalkyl ring or fused 5 to 6-membered heterocycloalkyl is optionally substituted with 1 or 2 independently selected R19 groups;
R10 and R11 are each independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, a 5-10 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-10 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl groups of R10 and R11 are each optionally substituted with 1, 2, or 3, R10A;
alternatively, R10 and R11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group or a 4-, 5-, 6-, 7-, 8-, 9-, or 10- membered heterocycloalkyl group; wherein said 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group and 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group are each optionally substituted with 1, 2, 3 or 4 R10A;
each R10A is independently selected from halo, CN, NO2, ORa4, SRa4, C(0)RM, C(0)NRc4Rd4, C(0)ORa4, OC(0)RM, OC(0)NRc4Rd4, C(=NRe4)NRc4Rd4,
NRc4C(=NRe4)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, NRc4S(0)RM, NRc4S(0)2RM, NRc4S(0)2NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM,
S(0)2NRc4Rd4, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1 , 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of R10A are each optionally substituted with 1, 2, or 3 substituents independently selected from R19;
each Ra4, Rb4, Rc4, and Rd4 is independently selected from H, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, Ci-4 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of Ra4, Rb4, Rc4, and Rd4 are each optionally substituted with 1, 2, or 3 substituents independently selected from R19;
alternatively, R04 and Rd4 together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group which is optionally substituted with 1, 2 or 3 substituents independently selected from R19;
each Re4 is independently H or Ci-4 alkyl;
each R19 is independently selected from halo, CN, NO2, ORa9, SRa9, C(0)Rb9, C(0)NRc9Rd9, C(0)ORa9, OC(0)Rb9, OC(0)NRc9Rd9, NRc9Rd9, NRc9C(0)Rb9,
NRc9C(0)ORa9, NRc9C(0)NRc9Rd9, NRc9S(0)Rb9, NRc9S(0)2Rb9, NRc9S(0 NRc9Rd9, S(0)Rb9, S(0)NRc9Rd9, S(0)2Rb9, S(0)2NRc9Rd9, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3- 6cycloalkyl, and Ci-4 haloalkyl, wherein the Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6- cycloalkyl, and C1-4 haloalkyl of R19 are each further optionally substituted with 1 or 2 R20 substituents independently selected from H, halo, CN, NO2, OR\ SR\ C(0)R\ C(0)NRiRi, C(0)ORi, OC(0)Ri, OC(0)NRiRi, NRqRq, NR¾C(0)R¾, NRiC(0)ORi, NR< (0)NR<iRq, NR¾(0)Ri, NR¾(0)2Ri, NR¾(0)2NRqRq, S(0)R¾, S(0)NRiRi, S(0)2Ri, S(0)2NRiRq, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl and C1-4 haloalkyl, wherein each Rq is independently H or Ci-4alkyl;
each Ra9, Rc9, and Rd9 is independently selected from H and C1-4 alkyl;
each Rb9 is independently C1-4 alkyl; and
the subscript n is 0, 1, 2 or 3.
3. The compound of claim 1 or 2, having Formula (I):
Figure imgf000189_0001
or a pharmaceutically acceptable salt thereof, wherein:
ring A is a C6-10 aryl or 5- to 6-membered heteroaryl having carbon and 1 to 4 heteroatoms as ring members selected from O, N, and S;
each R12 is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, ORa, SRa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NRaRa, NRaORa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, C(=NRa)Ra, C(=NRa)NRaRa, NRaC(=NRa)NRaRa,
NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra, S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, or 4 independently selected Rb substituents; or two adjacent R12 substituents on ring A taken together with the atoms to which they are attached form a fused 5- or 6-membered cycloalkyl ring, 5 to 6-membered
heterocycloalkyl ring, phenyl or 5 to 6-membered heteroaryl ring, wherein the
heterocycloalkyl or heteroaryl has 1 -2 heteroatoms as ring members selected from O, N, and
S;
each Ra is independently selected from H, Ci-6 alkyl, Ci-4haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein Ci-6 alkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl- , (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- as Ra are each optionally substituted with 1, 2, 3, 4, or 5 independently selected Rd substituents;
or any two Ra substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each Rb is independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, CN, NO2, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, C(=NRC)NRCRC,
NRCC(=NRC)NRCRC, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc, S(0)NRcRc, S(0)2Rc, and S(0)2NRcRc;
each Rc is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered
heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-iocycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5 independently selected Rf substituents;
or any two Rc substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
each Rd is independently selected from C1-4 alkyl, C1-4 haloalkyl, halo, CN, ORe, SRe, C(0)Re, C(0)NReRe, C(0)ORe, OC(0)Re, OC(0)NReRe, NReRe, NReC(0)Re,
NReC(0)NReRe, NReC(0)ORe, C(=NRe)NReRe, NReC(=NRe)NReRe, S(0)Re, S(0)NReRe, S(0)2Re, NReS(0)2Re, NReS(0)2NReRe, and S(0)2NReRe;
each Rf is independently selected from C1-4 alkyl, C1-4 haloalkyl, halo, CN, ORs, SRS, C(0)R8, C(0)NR¾s, C(0)ORs, OC(0)Rs, OC(0)NR«R<% NR¾s, NRSC(0)RS,
NRsC(0)NR¾s, NRsC(0)ORs, C(=NRs)NR¾s, NRsC(=NRs)NR¾s, S(0)R8, S(0)NR¾s, S(0)2Rs, NR¾(0)2Rs, NR¾(0)2NR¾s, and S(0)2NR¾s;
each Rh is independently selected from Ci-6 alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, C6-io aryl, 5-6 membered heteroaryl, Ci-6 haloalkyl, halo, CN, OR1, SR1, C(0)R;, C^NR'R1, C(0)OR, OC(0)R, 00(0)Ν^^, NRR, NRiC(0)Ri, NRC C NRR1, R'CCO R1, C(=NR1)NRiR1, R^ R^ R'R1, S(0)R, S C NRR, S(0)2R, RiS(0)2Ri, NRiS(0)2NRiRi, and SCO^NRiR1, wherein said Ci-e alkyl, C3-7 cycloalkyl, 4-7 membered heterocycloalkyl, Ce-ιο aryl, and 5-6 membered heteroaryl are optionally substituted by 1, 2, or 3 independentlys selected Ri substituents;
each Ri is independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, CN, ORk, SRk, C(0)Rk, C(0)NRkRk, C(0)ORk, OC(0)Rk, OC(0)NRkRk, NRkRk, NRkC(0)Rk,
NRkC(0)NRkRk, NRkC(0)ORi, C(=NRk)NRkRk, NRkC(=NRk)NRkRk, S(0)Rk, S(0)NRkRk, S(0)2Rk, NRkS(0)2Rk, NRkS(0)2NRkRk, and S(0)2NRkRk;
each Re, Rs, R1 or Rk is independently selected from H, C1-4 alkyl, C6-ioaryl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein the C1-4 alkyl, C6-ioaryl, C2-4 alkenyl or C2-4 alkynyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, di(Ci-4 alkyl)amino, Ci-4 haloalkyl, and Ci-4 haloalkoxy;
or any two Re substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two Rs substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
or any two R1 substituents attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 independently selected Rh substituents;
X1 is -CR10Rn- or -NR7-
X2 is N or CR6;
R1 is Ci-3 alkyl or C1-3 haloalkyl;
R2 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R3 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R4 is Ci-3 alkyl or C1-3 haloalkyl;
R5 is H, halo, C1-3 alkyl, C1-3 haloalkyl, CN, or C1-3 alkoxy;
R6 is selected from H, halo, CN, ORa4, SRa4, C(0)NRc4Rd4, OC(0)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, NRc4S(0)RM, NRc4S(0)2RM,
NRc4S(0)2NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM, S(0)2NRc4Rd4, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl having carbon and 1, 2, or 3 heteroatoms independently selected from , O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl groups of R6 are each optionally substituted with 1, 2, or 3 substituents independently selected from R10A;
R7 is selected from H, C(0)NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM,
S(0)2NRc4Rd4, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, 5- to 6-membered heteroaryl having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5- to 6-membered heteroaryl and 4-7 membered heterocycloalkyl, groups of R7 are each optionally substituted with 1, 2, or 3 substituents independently selected from R10A;
R10 and R11 are each independently selected from H, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-6 haloalkyl, C6-10 aryl, C3-10 cycloalkyl, a 5-10 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-10 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl groups of R10 and R11 are each optionally substituted with 1, 2, or 3, R10A;
alternatively, R10 and R11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group or a 4-, 5-, 6-, 7-, 8-, 9-, or 10- membered heterocycloalkyl group; wherein said 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group and 4-, 5-, 6-, 7-, 8-, 9-, or 10-membered heterocycloalkyl group are each optionally substituted with 1, 2, 3 or 4 R10A;
each R10A is independently selected from halo, CN, NO2, ORa4, SRa4, C(0)RM, C(0)NRc4Rd4, C(0)ORa4, OC(0)RM, OC(0)NRc4Rd4, C(=NRe4)NRc4Rd4,
NRc4C(=NRe4)NRc4Rd4, NRc4Rd4, NRc4C(0)RM, NRc4C(0)ORa4, NRc4C(0)NRc4Rd4, NRc4S(0)RM, NRc4S(0)2RM, NRc4S(0)2NRc4Rd4, S(0)RM, S(0)NRc4Rd4, S(0)2RM,
S(0)2NRc4Rd4, Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci-e haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1 , 2, or 3 heteroatoms independently selected from N, O and S; wherein said Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of R10A are each optionally substituted with 1, 2, or 3 substituents independently selected from R19;
each Ra4, Rb4, Rc4, and Rd4 is independently selected from H, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, phenyl, C3-6 cycloalkyl, a 5-6 membered heteroaryl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S, and a 4-7 membered heterocycloalkyl moiety having carbon and 1, 2, or 3 heteroatoms independently selected from N, O and S; wherein said C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, phenyl, C3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl group of Ra4, Rb4, Rc4, and Rd4 are each optionally substituted with 1, 2, or 3 substituents independently selected from R19;
alternatively, R04 and Rd4 together with the nitrogen atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group which is optionally substituted with 1, 2 or 3 substituents independently selected from R19;
each Re4 is independently H or Ci-4 alkyl;
each R19 is independently selected from halo, CN, NO2, ORa9, SRa9, C(0)Rb9, C(0)NRc9Rd9, C(0)ORa9, OC(0)Rb9, OC(0)NRc9Rd9, NRc9Rd9, NRc9C(0)Rb9,
NRc9C(0)ORa9, NRc9C(0)NRc9Rd9, NRc9S(0)Rb9, NRc9S(0)2Rb9, NRc9S(0)2NRc9Rd9, S(0)Rb9, S(0)NRc9Rd9, S(0)2Rb9, S(0)2NRc9Rd9, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, and Ci-4 haloalkyl;
each Ra9, Rc9, and Rd9 is independently selected from H and C1-4 alkyl;
each Rb9 is independently Ci-4 alkyl; and
the subscript n is 0, 1, 2 or 3.
4. The compound of any one of claims 1-3, having Formula (la):
Figure imgf000193_0001
or a pharmaceutically acceptable salt thereof. compound of any one of claims 1-3, having Formula (lb):
Figure imgf000194_0001
or a pharmaceutically acceptable salt thereof. compound of any one of claims 1-3, having Formula (Ic)
Figure imgf000194_0002
(Ic) or a pharmaceutically acceptable salt thereof.
7. The compound of any one of claims 1-3, having Formula (Id):
Figure imgf000195_0001
(Id) or a pharmaceutically acceptable salt thereof.
8. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein ring A is Ce-ιο aryl.
9. The compound of any one of claim 1-5, or a pharmaceutically acceptable salt thereof, wherein ring A is phenyl.
10. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein ring A is 5-membered heteroaryl.
11. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein ring A is a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, thiophenyl, thiazolyl, isoxazolyl, isothiazolyl, and furanyl.
12. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein ring A is 6-membered heteroaryl.
13. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein ring A is a 6-membered heteroaryl selected from pyridyl, pyrazinyl, pyridazinyl, primidinyl, and triazinyl.
14. The compound of any one of claim 1-5, or a pharmaceutically acceptable salt thereof, wherein ring A is pyridyl.
15. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein ring A is phenyl or 6-membered heteroaryl.
16. The compound of any one of claim 1-5, or a pharmaceutically acceptable salt thereof, wherein ring A is phenyl or pyridyl.
17. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein R2 and R5 are halogen.
18. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein R2 and R5 are F.
19. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein R1 and R4 are each C1-3 alkyl.
20. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein R1 and R4 are each methyl.
21. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R10 and R11 are each Ci-6 alkyl.
22. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R10 and R11 are methyl.
23. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R10 and R11 together with the carbon atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group, which is optionally substituted with 1 or 2 independently selected R10A groups.
24. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R10 and R11 together with the carbon atom to which they are attached form a cyclopropyl, optionally substituted with 1 or 2 independently selected R10A groups.
25. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R10 and R11 together with the carbon atom to which they are attached form a cyclopropyl.
26. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R10 and R11 together with the carbon atom to which they are attached form 4-, 5-, 6-, or 7-membered heterocycloalkyl group, which is optionally substituted with 1 or 2 independently selected R10A groups.
27. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt thereof, wherein X2 is N or CH.
28. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt thereof, wherein each R12 is independently selected from halo, Ci-6 alkyl, C2-6 alkenyl, C2- 6 alkynyl, Ci-6 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, ORa, SRa, C(0)Ra, C(0)NRaRa, C(0)ORa, OC(0)Ra, OC(0)NRaRa, NRaRa, NRaORa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, NRaS(0)Ra, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)Ra,
S(0)NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C6- lo aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-io cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1, 2 or 3 Rb substituents.
29. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt thereof, wherein each R12 is independently selected from -NH2, -NHOH, -NHORa, - NHRa, -NHC(0)Ra, -NHC(0)NHRa, -NHS(0)2Ra, -C(0)Ra, -S(0)2Ra, Ci-e alkyl, Ci-6alkoxy, Ci-6 haloalkyl, Ci-4 haloalkoxy, halo, CN, C3-6 cycloalkyl, phenyl-Ci-4alkyl, 5-6 membered heteroaryl, 5- to 6-membered heteroaryl-Ci-4alkyl, 4- to 6-membered heterocycloalkyl, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, wherein the Ci-6 alkyl, C3-6 cycloalkyl, phenyl- Ci-4alkyl, 5-6 membered heteroaryl, 5- to 6-membered heteroaryl-Ci-4alkyl, 4 to 6-membered heterocycloalkyl, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- is optionally substituted with from 1-3 Rb; and Ci e alkoxy or C1-4 haloalkoxy is optionally substituted by 1-3 Rd.
30. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt thereof, wherein each R12 is independently selected from F, CI, CN, CH3, CEhCEb, NH2, OCH3, -C(0)NH(Ci-4 alkyl), NHC(0)CH3, NHS(0)2CH3, NHS(0)2Ra, C(0)Ra, -CH2C(0)Ra, -CH2CH2Ra, morpholinosulfonyl, imidazolyl, 4-morpholinyl, (3-cyanopyrrolidin-l-yl)methyl, 2-cyanoprop-2-yl, 1-cyanocyclobutyl, 1 -cyanocyclopropyl, benzyl, pyridylmethyl, 1, 1- dioxothiolan-3-yl, l-methylsulfonylazetidin-3-yl, l-acetyl-3-(cyanomethyl)azetidin-3-yl, and -CH2-(4-morpholinyl), wherein Ra is 4-morpholinyl.
31. The compound of any one of claims 1 and 6-30, wherein R13 and R14 are each independently selected from Ci-4 alkyl-NHC(O)- and OCH3.
32. The compound of any one of claims 1-3, 5 and 8-31, or a pharmaceutically acceptable salt thereof, wherein R7 is Ci-6 alkyl, phenyl, benzyl, C3-6 cycloalkyl, C3-10 cycloalkyl-Ci-4 alkyl-, 4- to 10-membered heterocycloalkyl, (4-10 membered
heterocycloalkyl)-Ci-4 alkyl-, 5- to 10-membered heteroaryl, or (5- to 10-membered heteroaryl)-Ci-4 alkyl-, each of which is optionally substituted with 1, 2, or 3 independently selected R10A substituents; or two R10A substituents attached to the adjacent ring atoms of the aryl or heteroaryl ring of R7 are optionally taken together with the atoms to which they are attached form a fused C5-6 cycloalkyl ring or a fused 5 to 6-membered heterocycloalkyl ring having 1 -2 heteroatoms as ring members independently selected from O, N and S, wherein the nitrogen and sulfur atoms are each optionally oxidized and the fused C5-6 cycloalkyl ring or fused 5 to 6-membered heterocycloalkyl is optionally substituted with 1 or 2 independently selected R19 groups.
33. The compound of any of claims 1-32, or a pharmaceutically acceptable salt thereof, wherein R10A is halo, CN, Ci-e alkyl, C3-6 cycloalkyl, -C(0)RM or -C(0)ORM; or two R10A substituents attached to the adjacent ring atoms of the aryl or heteroaryl ring of R7 are optionally taken together with the atoms to which they are attached form a 5- to 6-membered heterocycloalkyl ring having 1-2 heteroatoms as ring members independently selected from O, N and S, wherein the nitrogen and sulfur atoms are each optionally oxidized.
34. The compound of any of claims 1-32, or a pharmaceutically acceptable salt thereof, wherein R10A is F, CI, CH3, Ci-e alkyl, CN, -C(0)Ci-4 alkyl or -C(0)OCi-4 alkyl; or two R10A substituents attached to the adjacent ring atoms of the aryl or heteroaryl ring of R7 are optionally taken together with the atoms to which they are attached form a
tetrahydrofuran, tetrahydropyran, 1,4-dioxane, morpholine, tetrahydrothiopyran or tetrahydrothiophene ring, each of which is optionally substituted with 1 or 2 R19 substituents.
35. The compound of any one of claims 1-3, 5 and 8-34, or a pharmaceutically acceptable salt thereof, wherein R7 is Ci-6 alkyl, cyclopropylmethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-fluorobenzyl, tetrahydrofuran-3-yl, (3-methylisoxazol-5- yl)methyl, (tetrahydro-2H-pyran-4-yl)methyl, (5-cyclopropylisoxazol-3-yl)methyl, 5- methylisoxazol-3-yl)methyl, 4-fluorophenyl, (l-ethylpyrazol-4-yl)methyl, benzothiazol-6-yl, 1 -methyl-5 -oxopyrrolidin-3 -yl, 1 -acetylpiperidin-4-yl, 2,3 -dihydro- 1 ,4-benzodioxin-6- ylmethyl, l-t-butoxycarbonylpiperidin-4-yl, 4-cyanophenyl, 4-pyrimidinyl, 2-pyrimidinyl, 5- pyrimidinyl, l-methylpyrazol-3-yl, l-methylpyrazol-4-yl, (l,5-dimethylpyrazol-4-yl)methyl, or (5-methyl-l,3,4-oxadiazol-2-yl)methyl.
36. The compound of any one of claims 1-35, or a pharmaceutically acceptable salt thereof, wherein R3 is H.
37. The compound of any one of claims 1-36, or a pharmaceutically acceptable salt thereof, wherein subscript n is 0, 1 or 2.
38. The compound of any one of claims 1-5, wherein:
Ring A is phenyl or a 6-membered heteroaryl ring;
R10 and R11 are Ci-e alkyl;
alternatively, R10 and R11 together with the carbon atom to which they are attached form a a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group, which is optionally substituted with 1 or 2 independently selected R10A groups.
each R12 is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, C6-10 aryl, C3- 10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-Ci-4 alkyl-, C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, (4-10 membered heterocycloalkyl)-Ci-4 alkyl-, CN, NO2, ORa, C(0)Ra, C(0)NRaRa, C(0)ORa, NRaRa, NRaORa, NRaC(0)Ra, NRaC(0)ORa, NRaC(0)NRaRa, NRaS(0)2Ra, NRaS(0)2NRaRa, S(0)2Ra, and S(0)2NRaRa, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ιο aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, Ce-ιο aryl-Ci-4 alkyl- , C3-10 cycloalkyl-Ci-4 alkyl-, (5-10 membered heteroaryl)-Ci-4 alkyl-, and (4-10 membered heterocycloalkyl)-Ci-4 alkyl- are each optionally substituted with 1-3 independently selected Rb substituents;
each Rb is independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, CN, NO2, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, NRCRC, NRcC(0)Rc, NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2Rc, and S(0)2NRcRc;
each Rc is independently selected from H and Ci-6 alkyl; and
subscript n is 0, 1, 2, or 3.
39. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein,
X1 is CR10Rn;
X2 is CH;
Ring A is phenyl or a 6-membered heteroaryl ring;
R10 and R11 are Ci-6 alkyl;
alternatively, R10 and R11 together with the carbon atom to which they are attached form a a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group, which is optionally substituted with 1 or 2 independently selected R10A groups.
each R12 is independently selected from halo, CN, NRaRa, NRORa, NHC(0)Ra, NHS(0)2Ra, C(0)Ra, S(0)2Ra, ORa, Ci-e alkyl, Ci-e haloalkyl, 5-6 membered heteroaryl, and 4 to 6-membered heterocycloalkyl, wherein said Ci-6 alkyl, 5-6 membered heteroaryl, or 4 to 6- membered heterocycloalkyl is optionally substituted with from 1-3 Rb;
each Rb is independently selected from halo, Ci-4 alkyl, Ci-4 haloalkyl, CN, N02, ORc, SRC, C(0)Rc, C(0)NRcRc, C(0)ORc, OC(0)Rc, OC(0)NRcRc, NRCRC, NRcC(0)Rc,
NRcC(0)ORc, NRcC(0)NRcRc, NRcS(0)Rc, NRcS(0)2Rc, NRcS(0)2NRcRc, S(0)Rc,
S(0)NRcRc, S(0)2Rc, and S(0)2NRcRc;
each Rc is independently selected from H and Ci-6 alkyl; and
subscript n is 0, 1, 2, or 3.
40. The compound of claim any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein,
X1 is CR10Rn;
X2 is CH;
Ring A is phenyl or pyridyl;
R10 and R11 are Ci-e alkyl; alternatively, R10 and R11 together with the carbon atom to which they are attached form a a 3-, 4-, 5-, 6-, or 7-membered cycloalkyl group, which is optionally substituted with 1 or 2 independently selected R10A groups.
each R12 is independently selected from halo, Ci-6 alkyl, Ci-6 haloalkyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, (4-6 membered heterocycloalkyl)-Ci-2 alkyl-, CN, ORa, C(0)Ra, NRaRa, NRaS(0)2Ra, and S(0)2Ra;
each Ra is independently selected from H, Ci-6 alkyl, Ci-4 haloalkyl, C6-io aryl, C3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl; and
subscript n is 0, 1, 2, or 3.
41. The compound of claim 1, wherein the compound is selected from:
6'-(5-amino-2-methylphenyl)-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-l'H- spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one;
6'-(5-amino-4-fluoro-2-methylphenyl)-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-l'H- spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one;
4- amino-2-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro- H- spiro[cyclopropane-l,4'-[2,7]naphthyridine]-6'-yl)benzonitrile;
6'-(5-aminopyridin-3-yl)-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-rH- spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one;
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(5-fluoropyridin-3-yl)-rH- spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one;
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(5-morpholinopyridin-3-yl)-rH- spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one;
6'-(5-amino-2-methylpyridin-3-yl)-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-rH- spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one;
5- (2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro-rH- spiro[cyclopropane-l,4'-[2,7]naphthyridine]-6'-yl)nicotinonitrile;
2'-(2,6-difluoro-3 ,5-dimethoxyphenyl)-6'-(pyridin-3 -yl)- 1 'H-spiro[cyclopropane- 1 ,4'- [2,7]naphthyridin]-3'(2'H)-one;
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(5-methoxypyridin-3-yl)-rH- spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one;
6'-(5-chloropyridin-3-yl)-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-rH- spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one; 6'-(5-(lH-imidazol-l-yl)pyridin-3-yl)-2'-(2,6-difluoro-3,5-dimethoxyphenyl)-rH- spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one;
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(5-(morpholine-4-carbonyl)pyridin-3-yl)- rH-spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one;
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(5-(morpholinosulfonyl)pyridin-3-yl)- H- spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one;
N-(5-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro-l'H- spiro[cyclopropane-l,4'-[2,7]naphthyridine]-6'-yl)pyridin-3-yl)methanesulfonamide; and
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(5-(moφholinomethyl)pyridin-3-yl)-lΉ- spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one,
or a pharmaceutically acceptable salt thereof.
42. The compound of claim 1, wherein the compound is selected from:
3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(pyridin-3-yl)-3,4-dihydropyrido[4,3- d]pyrimidin-2(lH)-one;
5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l,2,3,4-tetrahydropyrido[4,3- d]pyrimidin-7-yl)-N-methylpicolinamide;
(S)-l-(4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l,2,3,4- tetrahydropyrido[4,3-d]pyrimidin-7-yl)benzyl)pyrrolidine-3-carbonitrile;
2- (5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l, 2,3,4- tetrahydropyrido[4,3-d]pyrimidin-7-yl)pyridin-2-yl)-2-methylpropanenitrile;
l-(5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l, 2,3,4- tetrahydropyrido[4,3-d]pyrimidin-7-yl)pyridin-2-yl)cyclobutanecarbonitrile;
3- (7-(6-(l-cyanocyclobutyl)pyridin-3-yl)-l-ethyl-2-oxo-l,2-dihydropyrido[4,3- d]pyrimidin-3(4H)-yl)-2-fluoro-5-methoxy-N-methylbenzamide;
1 -(cyclopropylmethyl)-3 -(2,6-difluoro-3 ,5 -dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H- pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-propyl- 3 ,4-dihydropyrido [4,3 -d]pyrimidin-2( 1 H)-one;
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-((5- methylisoxazol-3-yl)methyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
1 -cyclopentyl-3 -(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4- yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one; 3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (tetrahydrofuran-3-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 -(4- fluorobenzyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-((3- methylisoxazol-5-yl)methyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
l-((5-cyclopropylisoxazol-3-yl)methyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3- dimethyl- 1 H-pyrazol-4-yl)-3 ,4-dihydropyrido [4,3 -d]pyrimidin-2( 1 H)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ((tetrahydro-2H-pyran-4-yl)methyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-((2,3-dihydrobenzo[b][l,4]dioxin-6- yl)methyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-((l-ethyl- lH-pyrazol-4-yl)methyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3- (2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 -(4- fluorophenyl)-3 ,4-dihydropyrido [4,3 -d]pyrimidin-2( 1 H)-one;
l-(l,3-benzothiazol-6-yl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH- pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3 -(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 -( 1 -methyl- 5-oxopyrrolidin-3 -yl)-3 ,4-dihydropyrido [4,3 -d]pyrimidin-2( 1 H)-one;
1 -( 1 -acetylpiperidin-4-yl)-3 -(2,6-difluoro-3 ,5 -dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H- pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
4- (3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-2-oxo- 3,4-dihydropyrido[4,3-d]pyrimidin-l(2H)-yl)benzonitrile;
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-pyrimidin- 4-yl-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-[(5- methyl-l,3,4-oxadiazol-2-yl)methyl]-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-(l-methyl- lH-pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l-[(l,5- dimethyl-lH-pyrazol-4-yl)methyl]-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(3-methyl-l-(2-morpholinoethyl)- lH-pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3,5-dimethoxyphenyl)- 1 -ethyl-7-(3 -methyl- 1 -(pyridin-3-ylmethyl)- lH-pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(3-methyl-l-(2-morpholino-2- oxoethyl)-lH-pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(3-methyl-l-(2-morpholinoethyl)-lH- pyrazol-4-yl)-rH-spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one;
2'-(2,6-difluoro-3 ,5 -dimethoxyphenyl)-6'-( 1 -ethyl- 1 H-imidazol-4-yl)- 1 Ή- spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one;
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-[ 1 -(1 , 1 -dioxidotetrahydro-3-thienyl)-3- methyl- 1 H-pyrazol-4-yl] - 1 ',2'-dihydro-3 Ή-spiro [cyclopropane- 1 ,4'- [2,7]naphthyridin]-3 '- one;
2'-(2,6-difluoro-3 ,5 -dimethoxyphenyl)-6'-( 1 -( 1 -(methylsulfonyl)azetidin-3 -yl)- 1 H- pyrazol-4-yl)-rH-spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one; and
2- (l-acetyl-3-(4-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro-l'H- spiro[cyclopropane-l,4'-[2,7]naphthyridine]-6'-yl)-lH-pyrazol-l-yl)azetidin-3-yl)acetonitrile; or a pharmaceutically acceptable salt thereof.
43. The compound of claim 1, wherein the compound is selected from:
3- (2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (pyridazin-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ((2-methoxypyridin-4-yl)methyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ((6-methoxypyridin-3 -yl)methyl)-3 ,4-dihydropyrido [4,3 -d]pyrimidin-2( 1 H)-one;
3-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4- yl)-2-oxo-3 ,4-dihydropyrido [4,3 -d]pyrimidin- 1 (2H)-yl)benzonitrile;
3- (2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (pyrimidin-5 -yl)-3 ,4-dihydropyrido [4,3 -d]pyrimidin-2( 1 H)-one;
4- ((3 -(2,6-difluoro-3 ,5 -dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4- yl)-2-oxo-3 ,4-dihydropyrido [4,3 -d]pyrimidin- 1 (2H)-yl)methyl)-N- methylbenzamide; 3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (isoquinolin-7-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ((5 -ethylisoxazol-3 -yl)methyl)-3 ,4-dihydropyrido [4,3 -d]pyrimidin-2( 1 H)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (pyrimidin-4-ylmethyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4- yl)-2-oxo-3,4-dihydropyrido[4,3-d]pyrimidin-l(2H)-yl)-2-fluorobenzonitrile;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ((5 -ethyl- 1 ,3 ,4-oxadiazol-2-yl)methyl)-3 ,4-dihydropyrido [4,3 -d]pyrimidin-2( 1 H)- one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ((2-methylpyridin-4-yl)methyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (pyridin-4-ylmethyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (pyrazin-2-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ( 1 -(methylsulfonyl)piperidin-4-yl)-3 ,4-dihydropyrido [4,3 -d]pyrimidin-2( 1 H)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (( 1 -methyl- 1 H-pyrazol-4-yl)methyl)-3 ,4-dihydropyrido [4,3 -d]pyrimidin-2( 1 H)- one;
3 -(2,6-difluoro-3 ,5-dimethoxyphenyl)- 1 -(3 ,4-difluorobenzyl)-7-( 1,3- dimethyl-lH-pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
5-((3 -(2,6-difluoro-3,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4- yl)-2-oxo-3,4-dihydropyrido[4,3-d]pyrimidin-l(2H)-yl)methyl)picolinonitrile;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (2-methylbenzo [d] oxazol-6-yl)-3 ,4-dihydropyrido[4,3 -d]pyrimidin-2( 1 H)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - methyl-3 ,4-dihydropyrido [4,3 -d]pyrimidin-2( 1 H)-one;
1 -(4-( 1 H-pyrazol- 1 -yl)phenyl)-3 -(2,6-difluoro-3 ,5 -dimethoxyphenyl)-7- (l,3-dimethyl-lH-pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one; 3-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4- yl)-2-oxo-3,4-dihydropyrido[4,3-d]pyrimidin-l(2H)-yl)-5-fluorobenzonitrile;
6-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4- yl)-2-oxo-3 ,4-dihydropyrido [4,3 -d]pyrimidin- 1 (2H)-yl)nicotinonitrile;
3- (2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (oxazol-5-ylmethyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
4- (3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4- yl)-2-oxo-3,4-dihydropyrido[4,3-d]pyrimidin-l(2H)-yl)-2-methoxybenzonitrile;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ((5-methyloxazol-2-yl)methyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
1 -cyclopropyl-3 -(2,6-difluoro-3,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H- pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (pyrimidin-5-ylmethyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (pyrazin-2-ylmethyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (pyridin-3-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (6-methylpyrazin-2-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (pyridazin-3 -ylmethyl)-3 ,4-dihydropyrido[4,3 -d]pyrimidin-2( 1 H)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (3 -( 1 -methyl- 1 H- 1 ,2,3 -triazol-5-yl)phenyl)-3 ,4-dihydropyrido[4,3 -d]pyrimidin- 2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - isopropyl-3 ,4-dihydropyrido [4,3 -d]pyrimidin-2( 1 H)-one;
l-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4- yl)-2-oxo-3,4-dihydropyrido[4,3-d]pyrimidin-l(2H)-yl)cyclopropanecarbonitrile;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (pyridin-2-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one; 3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ((5 -isopropylisoxazol-3 -yl)methyl)-3 ,4-dihydropyrido[4,3 -d]pyrimidin-2( 1 H)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (pyridin-2-ylmethyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ((2-methylthiazol-4-yl)methyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ((l-methyl-5-oxopyrrolidin-3-yl)methyl)-3,4-dihydropyrido[4,3-d]pyrimidin- 2(lH)-one;
2- (4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4- yl)-2-oxo-3,4-dihydropyrido[4,3-d]pyrimidin-l(2H)-yl)phenyl)acetonitrile;
3- (2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (4-(methylsulfonyl)phenyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (3-fluorophenyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ( 1 -methyl- 1 H-pyrazol-3 -yl)-3 ,4-dihydropyrido[4,3 -d]pyrimidin-2( 1 H)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)methyl)-3 ,4-dihydropyrido [4,3 -d]pyrimidin- 2(lH)-one;
3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-(3,4-difluorophenyl)-7-(l,3- dimethyl-lH-pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-(3,5-difluorophenyl)-7-(l,3- dimethyl-lH-pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (4-methoxyphenyl)-3 ,4-dihydropyrido[4,3 -d]pyrimidin-2( 1 H)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (pyrimidin-2-yl)-3 ,4-dihydropyrido [4,3 -d]pyrimidin-2( 1 H)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (5-ethylpyrazin-2-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (5-methylpyrazin-2-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one; (R)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4- yl)-l-((tetrahydrofuran-3-yl)methyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)- one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (3 -methoxyphenyl)-3 ,4-dihydropyrido[4,3 -d]pyrimidin-2( 1 H)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (2-fluorophenyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4- yl)-2-oxo-3,4-dihydropyrido[4,3-d]pyrimidin-l(2H)-yl)-N- methylbenzenesulfonamide;
3- (2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (5-methoxypyrazin-2-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
4- (3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4- yl)-2-oxo-3,4-dihydropyrido[4,3-d]pyrimidin-l(2H)-yl)-N,N-dimethylbenzamide;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (2-( 1 -methyl- 1 H-pyrazol-4-yl)ethyl)-3 ,4-dihydropyrido [4,3 -d]pyrimidin-2( 1 H)- one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (4-(5-methyl-l,3,4-oxadiazol-2-yl)phenyl)-3,4-dihydropyrido[4,3-d]pyrimidin- 2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ((2-ethoxypyridin-4-yl)methyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ((l-methyl-2-oxo-l,2-dihydropyridin-4-yl)methyl)-3,4-dihydropyrido[4,3- d]pyrimidin-2( 1 H)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ((1 -methyl- lH-benzo[d][l,2,3]triazol-5-yl)methyl)-3,4-dihydropyrido[4,3- d]pyrimidin-2( 1 H)-one;
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l- (2-oxoindolin-5-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - (2-methyl-3-oxoisoindolin-5-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one; 3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ((2-methylpyrimidin-4-yl)methyl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
Methyl 4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH- pyrazol-4-yl)-2-oxo-3 ,4-dihydropyrido [4,3 -d]pyrimidin- 1 (2H)-yl)piperidine- 1 - carboxylate;
Methyl 4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH- pyrazol-4-yl)-2-oxo-3,4-dihydropyrido[4,3-d]pyrimidin-l(2H)- yl)phenylcarbamate;
1 -(( 1 -cyclopropyl- 1 H-pyrazol-4-yl)methyl)-3 -(2,6-difluoro-3 ,5 - dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-3,4-dihydropyrido[4,3- d]pyrimidin-2( 1 H)-one;
2- (4-((3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol- 4-yl)-2-oxo-3 ,4-dihydropyrido [4,3 -d]pyrimidin- 1 (2H)-yl)methyl)- 1 H-pyrazol- 1 - yl)acetonitrile;
1 -(( 1 -(cyclopropylmethyl)- 1 H-pyrazol-4-yl)methyl)-3 -(2,6-difluoro-3 ,5 - dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-3,4-dihydropyrido[4,3- d]pyrimidin-2( 1 H)-one;
3- (2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ((l-((tetrahydrofuran-2-yl)methyl)-lH-pyrazol-4-yl)methyl)-3,4- dihydropyrido[4,3 -d]pyrimidin-2( 1 H)-one;
3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-((l-(2,2-difluoroethyl)-lH- pyrazol-4-yl)methyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-3,4-dihydropyrido[4,3- d]pyrimidin-2( 1 H)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ( 1 H-pyrazol-4-yl)-3 ,4-dihydropyrido[4,3 -d]pyrimidin-2( 1 H)-one;
1 -( 1 -cyclopropyl- 1 H-pyrazol-4-yl)-3 -(2,6-difluoro-3 ,5 -dimethoxyphenyl)- 7-(l,3-dimethyl-lH-pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ( 1 -ethyl- 1 H-pyrazol-4-yl)-3 ,4-dihydropyrido[4,3 -d]pyrimidin-2( 1 H)-one;
3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ( 1 -propyl- 1 H-pyrazol-4-yl)-3,4-dihydropyrido[4,3 -d]pyrimidin-2(l H)-one; 3-(2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ( 1 H-indazol-6-yl)-3 ,4-dihydropyrido [4,3 -d]pyrimidin-2( 1 H)-one;
3- (2,6-difluoro-3 ,5-dimethoxyphenyl)-7-( 1 ,3 -dimethyl- 1 H-pyrazol-4-yl)- 1 - ( 1 H-indazol-5 -yl)-3 ,4-dihydropyrido [4,3 -d]pyrimidin-2( 1 H)-one;
l-(5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-l-(pyrimidin-4-yl)- l,2,3,4-tetrahydropyrido[4,3-d]pyrimidin-7-yl)pyridin-2- yl)cyclobutanecarbonitrile;
l-(5-(l-cyclobutyl-3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo- 1,2,3,4- tetrahydropyrido[4,3-d]pyrimidin-7-yl)pyridin-2-yl)cyclobutanecarbonitrile;
l-(5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-l-(pyridin-2-yl)-l,2,3,4- tetrahydropyrido[4,3-d]pyrimidin-7-yl)pyridin-2-yl)cyclobutanecarbonitrile;
l-(5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo-l-(pyridin-3-yl)-l,2,3,4- tetrahydropyrido[4,3-d]pyrimidin-7-yl)pyridin-2-yl)cyclobutanecarbonitrile;
l-(5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-(2-methoxyethyl)-2-oxo- l,2,3,4-tetrahydropyrido[4,3-d]pyrimidin-7-yl)pyridin-2- yl)cyclobutanecarbonitrile;
l-(5-(l-(cyclopropylmethyl)-3-(2,6-difluoro-3,5-dimethoxyphenyl)-2-oxo- l,2,3,4-tetrahydropyrido[4,3-d]pyrimidin-7-yl)pyridin-2- yl)cyclobutanecarbonitrile;
3 -(2,6-difluoro-3 ,5-dimethoxyphenyl)- 1 -ethyl-7-( 1 -methyl- 1 H-pyrazol-3 - yl)-3 ,4-dihydropyrido [4,3 -d]pyrimidin-2( 1 H)-one;
4- (3 -(2,6-difluoro-3 ,5 -dimethoxyphenyl)-7-( 1 -methyl- 1 H-pyrazol-3 -yl)-2- oxo-3,4-dihydropyrido[4,3-d]pyrimidin-l(2H)-yl)benzonitrile;
3- (2,6-difluoro-3,5-dimethoxyphenyl)-l-((l-ethyl-lH-pyrazol-4- yl)methyl)-7-( 1 -methyl- 1 H-pyrazol-3 -yl)-3 ,4-dihydropyrido[4,3 -d]pyrimidin- 2(lH)-one;
4- (3 -(2,6-difluoro-3 ,5 -dimethoxyphenyl)-7-( 1 -methyl- 1 H-pyrazol-4-yl)-2- oxo-3,4-dihydropyrido[4,3-d]pyrimidin-l(2H)-yl)benzonitrile;
3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-((l-ethyl-lH-pyrazol-4- yl)methyl)-7-(l-methyl-lH-pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin- 2(lH)-one; 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(3-methyl-l-(3- morpholinopropyl)- 1 H-pyrazol-4-yl)- 1 Ή-spiro [cyclopropane- 1 ,4'- [2,7]naphthyridin]-3'(2'H)-one;
2'-(2,6-difluoro-3 ,5 -dimethoxyphenyl)-6'-( 1 -( 1 -(methylsulfonyl)pyrrolidin- 3-yl)-lH-pyrazol-4-yl)-rH-spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)- one;
2'-(2,6-difluoro-3 ,5-dimethoxyphenyl)-6'-( 1 -(2-( 1 - (methylsulfonyl)piperidin-4-yl)ethyl)- lH-pyrazol-4-yl)- 1 'H-spiro[cyclopropane- l,4'-[2,7]naphthyridin]-3'(2'H)-one;
1- (4-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro-l'H- spiro[cyclopropane-l,4'-[2,7]naphthyridine]-6'-yl)-5-methyl-lH-pyrazol-l- yl)cyclobutanecarbonitrile;
6'-( 1 -( 1 -acetylpyrrolidin-3 -yl)- 1 H-pyrazol-4-yl)-2'-(2,6-difluoro-3 ,5 - dimethoxyphenyl)-rH-spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one;
2'-(2,6-difluoro-3 ,5 -dimethoxyphenyl)-6'-( 1 -(3 -morpholinopropyl)- 1 H- pyrazol-4-yl)-rH-spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one;
2'-(2,6-difluoro-3 ,5 -dimethoxyphenyl)-6'-( 1 -(2-(4-methoxypiperidin- 1 - yl)ethyl)-lH-pyrazol-4-yl)-rH-spiro[cyclopropane-l,4'-[2,7]naphthyridin]- 3'(2'H)-one;
2- (4-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro-l'H- spiro[cyclopropane-l,4'-[2,7]naphthyridine]-6'-yl)-3-methyl-lH-pyrazol-l- yl)acetonitrile;
2- (3-(4-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro-l'H- spiro[cyclopropane-l,4'-[2,7]naphthyridine]-6'-yl)-3-methyl-lH-pyrazol-l- yl)pyrrolidin- 1 -yl)acetonitrile;
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(3-methyl-l-(pyridin-3- ylmethyl)-lH-pyrazol-4-yl)-rH-spiro[cyclopropane-l,4'-[2,7]naphthyridin]- 3'(2'H)-one;
3- (4-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro-l'H- spiro[cyclopropane-l,4'-[2,7]naphthyridine]-6'-yl)-3-methyl-lH-pyrazol-l- yl)propanenitrile; 2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(l-(2-morpholinoethyl)-lH- pyrazol-4-yl)-rH-spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one;
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(l-ethyl-3 -methyl- 1 H-pyrazol-4- yl)-rH-spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one;
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(3 -methyl- 1 -(2-morpholino-2- oxoethyl)-lH-pyrazol-4-yl)-l'H-spiro[cyclopropane-l,4'-[2,7]naphthyridin]- 3'(2'H)-one;
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(2-(dimethylamino)thiazol-4-yl)- rH-spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one;
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(l-(2-(3-methoxypyrrolidin-l- yl)ethyl)-lH-pyrazol-4-yl)-l'H-spiro[cyclopropane-l,4'-[2,7]naphthyridin]- 3'(2'H)-one;
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-{ l-[(l,l-dioxido-l,2-thiazinan-3- yl)methyl]- lH-pyrazol-4-yl} - l'H-spiro[cyclopropane- 1 ,4'-[2,7]naphthyridin]- 3'(2'H)-one;
2'-(2,6-difluoro-3 ,5 -dimethoxyphenyl)-6'-(3 -methyl- 1 -( 1 -methylpyrrolidin- 3-yl)-lH-pyrazol-4-yl)-rH-spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)- one;
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(l-(2-(dimethylamino)ethyl)-3- methyl- lH-pyrazol-4-yl)- 1 Ή-spiro [cyclopropane- 1 ,4'-[2,7]naphthyridin]-3'(2'H)- one;
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(3-methyl-l-(2-(piperidin-4- yl)ethyl)-lH-pyrazol-4-yl)-l'H-spiro[cyclopropane-l,4'-[2,7]naphthyridin]- 3'(2'H)-one;
2'-(2,6-difluoro-3 ,5 -dimethoxyphenyl)-6'-( 1 -(( 1 -(methylsulfonyl)azetidin- 3-yl)methyl)-lH-pyrazol-4-yl)-rH-spiro[cyclopropane-l,4'-[2,7]naphthyridin]- 3'(2'H)-one;
6'-( 1 -(( 1 -acetylazetidin-3 -yl)methyl)- 1 H-pyrazol-4-yl)-2'-(2,6-difluoro-3 ,5 - dimethoxyphenyl)-rH-spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one;
3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(l-ethyl-3-methyl-lH- pyrazol-4-yl)-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one; 3-(2,6-difluoro-3,5-dimethoxyphenyl)- l-ethyl-7-(l -methyl- lH-pyrazol-4- yl)-3 ,4-dihydropyrido[4,3 -d]pyrimidin-2( 1 H)-one;
3-(2,6-difluoro-3,5-dimethoxyphenyl)-7-(l,3-dimethyl-lH-pyrazol-4-yl)-l- ethyl-3,4-dihydropyrido[4,3-d]pyrimidin-2(lH)-one;
5-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro- H- spiro[cyclopropane-l,4'-[2,7]naphthyridine]-6'-yl)-lH-pyrazole-4-carbonitrile;
3-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro- H- spiro [cyclopropane- 1 ,4'-[2,7]naphthyridine]-6'-yl)- 1 -methyl- 1 H-pyrazole-4- carbonitrile;
3-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'-dihydro- H- spiro[cyclopropane-l,4'-[2,7]naphthyridine]-6'-yl)-l-((tetrahydro-2H-pyran-4- yl)methyl)- 1 H-pyrazole-4-carbonitrile;
1- (cyanomethyl)-3-(2'-(2,6-difluoro-3,5-dimethoxyphenyl)-3'-oxo-2',3'- dihydro-rH-spiro[cyclopropane-l,4'-[2,7]naphthyridine]-6'-yl)-lH-pyrazole-4- carbonitrile;
5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l, 2,3,4- tetrahydropyrido[4,3-d]pyrimidin-7-yl)-N-ethylpicolinamide;
N-cyclopropyl-5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo- l,2,3,4-tetrahydropyrido[4,3-d]pyrimidin-7-yl)picolinamide;
5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l, 2,3,4- tetrahydropyrido[4,3-d]pyrimidin-7-yl)-N-(2-hydroxyethyl)picolinamide;
5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l, 2,3,4- tetrahydropyrido[4,3-d]pyrimidin-7-yl)-N-isopropylpicolinamide;
5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l, 2,3,4- tetrahydropyrido[4,3-d]pyrimidin-7-yl)-N-propylpicolinamide;
2- (4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo- 1,2,3,4- tetrahydropyrido[4,3-d]pyrimidin-7-yl)phenyl)acetonitrile;
l-(4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo- 1,2,3,4- tetrahydropyrido[4,3-d]pyrimidin-7-yl)phenyl)cyclobutanecarbonitrile;
3- (2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-7-(6-morpholinopyridin-3-yl)- 3 ,4-dihydropyrido [4,3 -d]pyrimidin-2( 1 H)-one; l-(4-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo- 1,2,3,4- tetrahydropyrido[4,3-d]pyrimidin-7-yl)phenyl)cyclopropanecarbonitrile;
5-(3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-ethyl-2-oxo-l, 2,3,4- tetrahydropyrido[4,3-d]pyrimidin-7-yl)picolinamide;
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(pyridin-4-yl)-rH- spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'(2'H)-one;
2'-(2,6-difluoro-3,5-dimethoxyphenyl)-6'-(l -methyl- lH-pyrazol-4-yl)- Γ,2'- dihydro-3'H-spiro[cyclopropane-l,4'-[2,7]naphthyridin]-3'-one;
l-(5-{3-(2,6-difluoro-3,5-dimethoxyphenyl)-l-[(5-methyl-l,3,4-oxadiazol-2- yl)methyl]-2-oxo-l,2,3,4-tetrahydropyrido[4,3-d]pyrimidin-7-yl}pyridin-2- yl)cyclobutanecarbonitrile; and
1 - { 5 -[3 -(2,6-difluoro-3 ,5 -dimethoxyphenyl)- 1 -( 1 -methyl- 1 H-pyrazol-4-yl)- 2-oxo- 1,2, 3,4-tetrahydropyrido[4,3-d]pyrimidin-7-yl]pyridin-2- yl}cyclobutanecarbonitrile; or a pharmaceutically acceptable salt thereof.
44. A pharmaceutical composition comprising a compound of any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
45. A method for inhibiting an FGFR3 or FGFR4 enzyme, said method comprising: contacting the FGFR3 or FGFR4 enzyme with a compound of any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof, or a composition of claim 44.
46. A method for treating cancer in a patient, said method comprising:
administering to said patient in need thereof a therapeutically effective amount of a compound of any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof, or a composition of claim 44.
47. The method of claim 46, wherein said cancer is selected from hepatocellular cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gall bladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, acute myelogenous leukemia, Hodgkin's or non-Hodgkin's lymphoma, Waldenstrom's Macroglubulinemia, hairy cell lymphoma, Burkett's lymphoma, glioblastoma, melanoma, and rhabdosarcoma.
48. The method of claim 46, wherein said cancer is selected from hepatocellular cancer, breast cancer, bladder cancer, colorectal cancer, melanoma, mesothelioma, lung cancer, prostate cancer, pancreatic cancer, testicular cancer, thyroid cancer, squamous cell carcinoma, glioblastoma, neuroblastoma, uterine cancer, and rhabdosarcoma.
49. A method for treating a myeloproliferative disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof.
50. The method of claim 49, wherein said myeloproliferative disorder is selected from polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
51. A method for treating a skeletal or chondrocyte disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof.
52. The method of claim 51 wherein said skeletal or chondrocyte disorder is selected from achrondroplasia, hypochondroplasia, dwarfism, thanatophoric dysplasia (TD), Apert syndrome, Crouzon syndrome, Jackson- Weiss syndrome, Beare-Stevenson cutis gyrate syndrome, Pfeiffer syndrome, and craniosynostosis syndrome.
53. A method for treating a hypophosphatemia disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 43, or a pharmaceutically acceptable salt thereof.
54. The method of claim 53 wherein said hypophosphatemia disorder is X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, autosomal dominant hypophosphatemic rickets, or tumor-induced osteromalacia.
PCT/US2016/018787 2015-02-20 2016-02-19 Bicyclic heterocycles as fgfr inhibitors Ceased WO2016134320A1 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
HK18106492.0A HK1246794B (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as fgfr inhibitors
SG11201706287PA SG11201706287PA (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as fgfr inhibitors
UAA201709221A UA121669C2 (en) 2015-02-20 2016-02-19 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
CN201680011332.7A CN107438607B (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as FGFR inhibitors
MYPI2017001121A MY197720A (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as fgfr inhibitors
BR112017017418-9A BR112017017418B1 (en) 2015-02-20 2016-02-19 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS, THEIR USE AND THE PHARMACEUTICAL COMPOSITION INCLUDING THEM
MX2017010673A MX373169B (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as fgfr inhibitors
NZ734586A NZ734586B2 (en) 2016-02-19 Bicyclic heterocycles as fgfr inhibitors
CR20170390A CR20170390A (en) 2015-02-20 2016-02-19 BICYCLE HETEROCICLES AS FGFR INHIBITORS
MX2020004108A MX388991B (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as fgfr inhibitors
EA201791866A EA038045B1 (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as fgfr inhibitors
EP19187640.8A EP3617205B1 (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as fgfr inhibitors
JP2017544021A JP6689871B2 (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as FGFR inhibitors
ES16706767T ES2751669T3 (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as FGFR inhibitors
AU2016219822A AU2016219822B2 (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as FGFR inhibitors
KR1020177026449A KR102632018B1 (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as FGFR inhibitors
CA2976790A CA2976790C (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as fgfr inhibitors
CN202110062229.8A CN113004278B (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as FGFR inhibitors
EP16706767.7A EP3259269B9 (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as fgfr inhibitors
IL253691A IL253691B (en) 2015-02-20 2017-07-27 Bicyclic heterocycles as fgfr inhibitors
PH12017501481A PH12017501481B1 (en) 2015-02-20 2017-08-15 Bicyclic heterocycles as fgfr inhibitors
CONC2017/0008795A CO2017008795A2 (en) 2015-02-20 2017-08-28 Bicyclic heterocycles as fgfr inhibitors
AU2020250211A AU2020250211B2 (en) 2015-02-20 2020-10-07 Bicyclic heterocycles as fgfr inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562118698P 2015-02-20 2015-02-20
US62/118,698 2015-02-20
US201562170936P 2015-06-04 2015-06-04
US62/170,936 2015-06-04

Publications (1)

Publication Number Publication Date
WO2016134320A1 true WO2016134320A1 (en) 2016-08-25

Family

ID=55442925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/018787 Ceased WO2016134320A1 (en) 2015-02-20 2016-02-19 Bicyclic heterocycles as fgfr inhibitors

Country Status (23)

Country Link
US (4) US9708318B2 (en)
EP (2) EP3259269B9 (en)
JP (2) JP6689871B2 (en)
KR (1) KR102632018B1 (en)
CN (2) CN107438607B (en)
AU (2) AU2016219822B2 (en)
CA (1) CA2976790C (en)
CL (1) CL2017002123A1 (en)
CO (1) CO2017008795A2 (en)
CR (1) CR20170390A (en)
EA (1) EA038045B1 (en)
EC (1) ECSP17062712A (en)
ES (2) ES2895769T3 (en)
IL (1) IL253691B (en)
MA (1) MA51229A (en)
MX (2) MX373169B (en)
MY (1) MY197720A (en)
PE (1) PE20171514A1 (en)
PH (1) PH12017501481B1 (en)
SG (2) SG11201706287PA (en)
TW (1) TWI712601B (en)
UA (1) UA121669C2 (en)
WO (1) WO2016134320A1 (en)

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
WO2018083603A1 (en) 2016-11-02 2018-05-11 Novartis Ag Combinations of fgfr4 inhibitors and bile acid sequestrants
US10196436B2 (en) 2012-07-11 2019-02-05 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US10221154B2 (en) 2013-10-25 2019-03-05 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2019047826A1 (en) 2017-09-05 2019-03-14 博奥阿迪斯生物科技公司 Aromatic derivative, preparation method for same, and medical applications thereof
WO2019089667A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Bridged bicyclic compounds as farnesoid x receptor modulators
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US11286248B2 (en) 2018-02-08 2022-03-29 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Pyrazine-2(1H)-ketone compound acting as FGFR inhibitor
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
EP4011866A4 (en) * 2019-08-08 2022-08-24 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd CRYSTALLINE FORM A AND CRYSTALLINE FORM B OF PYRAZINE-2(1H)-KETONE COMPOUND AND METHOD FOR PREPARING IT
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2022187443A1 (en) * 2021-03-04 2022-09-09 Eli Lilly And Company Fgfr3 inhibitor compounds
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11958844B2 (en) 2018-07-26 2024-04-16 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11976058B2 (en) 2019-03-05 2024-05-07 Bioardis Llc Aromatic derivatives, preparation methods, and medical uses thereof
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
US12440484B2 (en) 2019-05-31 2025-10-14 Chong Kun Dang Pharmaceutical Corporation 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2025232848A1 (en) * 2024-05-09 2025-11-13 Insilico Medicine Ip Limited Salt-inducible kinases (sik) inhibitors and methods of uses thereof
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026013630A1 (en) * 2024-07-10 2026-01-15 Best Agrolife Limited An improved process for preparation of broflanilide
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
RS58514B1 (en) 2012-06-13 2019-04-30 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI712601B (en) 2015-02-20 2020-12-11 美商英塞特公司 Bicyclic heterocycles as fgfr inhibitors
MA41551A (en) * 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
HRP20241288T1 (en) 2018-05-04 2024-12-06 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
CN113164478B (en) 2018-09-13 2024-10-11 南加州大学 Novel FGFR inhibitors and their uses
TWI829857B (en) * 2019-01-29 2024-01-21 美商英塞特公司 Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
PH12021551976A1 (en) * 2019-02-15 2022-07-04 Incyte Corp Cyclin-dependent kinase 2 biomarkers and uses thereof
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
TWI748492B (en) * 2019-05-31 2021-12-01 韓商鐘根堂股份有限公司 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN114269723B (en) * 2019-08-08 2023-09-12 漳州片仔癀药业股份有限公司 D crystal form of pyrazine-2 (1H) -ketone compound and preparation method thereof
US11680061B2 (en) 2019-08-08 2023-06-20 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Crystal forms C and E of pyrazin-2(1H)-one compound and preparation method therefor
CN114174272B (en) * 2019-08-08 2023-05-12 漳州片仔癀药业股份有限公司 Preparation method of pyrazin-2 (1H) -ketone compound
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3157361A1 (en) * 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7832891B2 (en) 2019-12-04 2026-03-18 インサイト・コーポレイション Derivatives of FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
MX2024006113A (en) 2021-11-22 2024-07-29 Incyte Corp Combination therapy comprising an fgfr inhibitor and a kras inhibitor.
WO2024112806A1 (en) * 2022-11-21 2024-05-30 Moonwalk Biosciences, Inc. Generation and use of epigenetic maps for drug discovery
WO2024114680A1 (en) * 2022-11-30 2024-06-06 海南先声再明医药股份有限公司 Heterocyclic compound, pharmaceutical composition, and application thereof
WO2025184010A1 (en) * 2024-03-01 2025-09-04 Merck Sharp & Dohme Llc N-biaryl sulfonamides as modulators of the hippo pathway

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011597A2 (en) * 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2015006492A1 (en) * 2013-07-09 2015-01-15 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease

Family Cites Families (772)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE280853C (en)
US850370A (en) 1906-06-05 1907-04-16 William L Hynes Water-automobile.
DE2156720A1 (en) 1971-11-16 1973-05-24 Bayer Ag Pyrimido(4,5-d) pyrimidines - prepd from polychloroalkylimino acid chloride and 4-amino uracils, are starting materials for plant
US3894021A (en) 1974-01-28 1975-07-08 Squibb & Sons Inc Derivatives of 1,7-dihydro-2H-pyrazolo{8 4{40 ,3{40 :5,6{9 pyrido{8 4,3-D{9 pyrimidine-2,4-(3H)-diones
JPS5120580B2 (en) 1974-06-19 1976-06-25
US4347348A (en) 1978-06-05 1982-08-31 Chernikhov Alexei Y Heat-resistant heterocyclic polymers and methods for producing same
FR2428654A1 (en) 1978-06-13 1980-01-11 Chernikhov Alexei Heat-stable heterocyclic polymer prepn. - by reacting polyfunctional nitrile with polyfunctional isocyanate opt. contg. silicon, halogen, nitrogen, phosphorus and/or boron atoms
CH641470A5 (en) 1978-08-30 1984-02-29 Ciba Geigy Ag SILANES CONTAINING IMID GROUPS.
CH635828A5 (en) 1978-08-30 1983-04-29 Ciba Geigy Ag N-SUBSTITUTED IMIDES AND BISIMIDS.
US4339267A (en) 1980-01-18 1982-07-13 E. I. Du Pont De Nemours And Company Herbicidal sulfonamides
US4405786A (en) 1980-10-22 1983-09-20 Plastics Engineering Company Addition products of di-acetylene-terminated polyimide derivatives and an dienophile having ethylene groups
US4405520A (en) 1980-10-22 1983-09-20 Plastics Engineering Company Addition products of di-acetylene-terminated polymide derivatives and dienophiles having terminal maleimide grops
US4405519A (en) 1980-10-22 1983-09-20 Plastics Engineering Company Di-Acetylene-terminated polyimide derivatives
US4402878A (en) 1980-10-22 1983-09-06 Plastics Engineering Company Addition products of di-acetylene-terminated polyimide derivatives with a polyimide having terminal non-conjugated acetylene groups
US4460773A (en) 1982-02-05 1984-07-17 Lion Corporation 1-Phenyl-1H-pyrazolo [3,4-b]pyrazine derivatives and process for preparing same
JPS59173203A (en) 1983-03-22 1984-10-01 Mitsubishi Metal Corp Shoeless sizing method
DE3432983A1 (en) 1983-09-07 1985-04-18 Lion Corp., Tokio/Tokyo 1,5-disubstituted 1H-pyrazolo[3,4-b]pyrazine derivatives and antitumour agents which contain them
JPS62273979A (en) 1986-05-21 1987-11-28 Lion Corp 1,5-substituted-1H-pyrazolo[3,4-b]pyrazine derivatives and antitumor agents containing the compounds
JPS6310630A (en) 1986-06-23 1988-01-18 Teijin Ltd Production of aromatic polyamide-imide ether
JPS6317882A (en) 1986-07-09 1988-01-25 Lion Corp 5-substituted-1H-pyrazolo[3,4-b]pyrazine derivatives and antitumor agents containing the compounds
US4859672A (en) 1986-10-29 1989-08-22 Rorer Pharmaceutical Corporation Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone
US4874803A (en) 1987-09-21 1989-10-17 Pennwalt Corporation Dianhydride coupled polymer stabilizers
DE3814549A1 (en) 1987-10-30 1989-05-18 Bayer Ag N-SUBSTITUTED DERIVATIVES OF 1-DESOXYNOJIRIMYCIN AND 1-DESOXYMANNONOJIRIMYCIN, METHOD FOR THE PRODUCTION AND USE THEREOF IN MEDICINAL PRODUCTS
JPH029895A (en) 1988-06-28 1990-01-12 Lion Corp Nucleoside analog compound and antitumor agent
DD280853A1 (en) 1989-03-21 1990-07-18 Akad Nauk Sssr BINDER FOR ELECTRODES, PREFERABLY FOR POLYMER ELECTRODES
US5159054A (en) 1989-05-16 1992-10-27 The United States Of America As Represented By The Secretary Of The Navy Synthesis of phthalonitrile resins containing ether and imide linkages
JP2845957B2 (en) 1989-07-17 1999-01-13 三井化学株式会社 Novel diphenols having imide ring and process for producing the same
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
DE3937633A1 (en) 1989-11-11 1991-05-16 Bayer Ag HETEROCYCLIC COMPOUNDS AND THEIR USE AS PIGMENTS AND DYES
WO1991009835A1 (en) 1989-12-28 1991-07-11 Hoechst Aktiengesellschaft Biscationic acid amide and acid imide derivatives and process for preparing them
DE59009701D1 (en) 1989-12-28 1995-10-26 Hoechst Ag BISCATIONIC ACID AMID AND IMID DERIVATIVES AS CHARGE CONTROL.
JP2883670B2 (en) 1990-03-23 1999-04-19 三井化学株式会社 Novel bisphenol having imide ring and method for producing the same
GB9113137D0 (en) 1990-07-13 1991-08-07 Ici Plc Thioxo heterocycles
EP0552197B1 (en) 1990-10-03 1999-01-13 Commonwealth Scientific And Industrial Research Organisation Epoxy resins based on diaminobisimide compounds
JPH04158084A (en) 1990-10-22 1992-06-01 Fuji Photo Film Co Ltd Recording material
JPH04179576A (en) 1990-11-14 1992-06-26 Fuji Photo Film Co Ltd Recording material
JPH04328121A (en) 1991-04-26 1992-11-17 Sumitomo Bakelite Co Ltd Epoxy resin composition for sealing semiconductor
KR100207360B1 (en) 1991-06-14 1999-07-15 돈 더블유. 슈미츠 Imidazon (1,5-a) quinoxalines
DE4119767A1 (en) 1991-06-15 1992-12-17 Dresden Arzneimittel Prepn. of (pyrimid-2-yl-thio- or seleno-) acetic acid derivs. - by reacting the corresp. chloro:alkanoyl-amino cpd. with a rhodanide and water or an alcohol
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
JP3279635B2 (en) 1992-05-18 2002-04-30 鐘淵化学工業株式会社 Hydrosilyl group-containing imide compound
JP3232123B2 (en) 1992-05-20 2001-11-26 鐘淵化学工業株式会社 Curable composition
WO1993024488A1 (en) 1992-05-28 1993-12-09 Commonwealth Scientific And Industrial Research Organisation Bismaleimide compounds
EP0672044A4 (en) 1992-12-07 1997-08-20 Commw Scient Ind Res Org Bisnadimides.
EP0678106A4 (en) 1993-01-11 1995-12-27 Univ Pennsylvania Polycyclic aromatic compounds having nonlinear optical properties.
AU4293193A (en) 1993-04-28 1994-11-21 Du Pont Merck Pharmaceutical Company, The Novel trisubstituted aromatic amines useful for the treatment of cognitive deficits
US5536725A (en) 1993-08-25 1996-07-16 Fmc Corporation Insecticidal substituted-2,4-diamino-5,6,7,8-tetrahydroquinazolines
DE69422306T4 (en) 1993-11-30 2000-09-07 G.D. Searle & Co., Chicago SUBSTITUTED PYRAZOLYL-BENZOLSULFONAMIDES FOR TREATING INFLAMMATION
EP0746320B1 (en) 1994-02-02 2001-01-31 Eli Lilly And Company Hiv protease inhibitors and intermediates
US5480887A (en) 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
PL181893B1 (en) 1994-11-14 2001-10-31 Warner Lambert Co Pyrimidine and naphthyridine derivative compounds and a pharmaceutical preparation containing them EN EN EN
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US5783577A (en) 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
JPH09188812A (en) 1996-01-11 1997-07-22 Mitsui Toatsu Chem Inc Crystallization accelerator
WO1997047601A1 (en) 1996-06-11 1997-12-18 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
BR9710808A (en) 1996-08-06 1999-08-17 Pfizer Bicyclic derivatives 6,6 or 6,7 containing substituted pyrite or pyrimido
WO1998006703A1 (en) 1996-08-14 1998-02-19 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
JP3669783B2 (en) 1996-08-21 2005-07-13 三井化学株式会社 Organic electroluminescence device
US5994364A (en) 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
WO1998018781A2 (en) 1996-10-28 1998-05-07 Versicor, Inc. Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents
EP0946523A1 (en) 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
WO1998033798A2 (en) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
CA2285263C (en) 1997-04-11 2009-03-10 Abbott Laboratories Furopyridine, thienopyridine, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission
SI0991628T1 (en) 1997-05-28 2005-06-30 Aventis Pharmaceuticals Inc QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES
GB9716231D0 (en) 1997-07-31 1997-10-08 Amersham Int Ltd Base analogues
JP2001512742A (en) 1997-08-11 2001-08-28 シーオーアール セラピューティクス インコーポレイテッド Selective factor Xa inhibitor
US6150359A (en) 1997-08-20 2000-11-21 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
JPH11171865A (en) 1997-12-04 1999-06-29 Yoshitomi Pharmaceut Ind Ltd Fused heterocyclic compound
AU4481899A (en) 1998-02-20 1999-09-06 Takeda Chemical Industries Ltd. Aminoguanidine hydrazone derivatives, process for producing the same and drugs thereof
AU9298798A (en) 1998-05-15 1999-12-06 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
TR200003429T2 (en) 1998-05-26 2001-07-23 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as cellular growth inhibitors.
US20040044012A1 (en) 1998-05-26 2004-03-04 Dobrusin Ellen Myra Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
JP2002517486A (en) 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド inhibitors of p38
PT1107964E (en) 1998-08-11 2010-06-11 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
JP2000123973A (en) 1998-10-09 2000-04-28 Canon Inc Organic light emitting device
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
HK1041483B (en) 1998-10-23 2004-12-24 霍夫曼-拉罗奇有限公司 Bicyclic nitrogen heterocycle
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
DE19912638A1 (en) 1999-03-20 2000-09-21 Bayer Ag Naphthylcarboxamide substituted sulfonamides
DE19920790A1 (en) 1999-05-06 2000-11-09 Bayer Ag Bis-sulfonamides with anti-HCMV activity
PE20010306A1 (en) 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
JP4041624B2 (en) 1999-07-21 2008-01-30 三井化学株式会社 Organic electroluminescence device
TR200200763T2 (en) 1999-09-24 2003-09-22 Janssen Pharmaceutica N.V. Antiviral compositions
DE19946289A1 (en) 1999-09-28 2001-03-29 Basf Ag Benzodiazepine derivatives, their production and use
AU776250B2 (en) 1999-10-21 2004-09-02 F. Hoffmann-La Roche Ag Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase
CZ20021743A3 (en) 1999-10-21 2002-08-14 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles substituted with alkylamino group functioning together with the group as P38 protein kinase inhibitors
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
DK1242382T3 (en) 1999-12-29 2007-05-07 Wyeth Corp Tricyclic protein kinase inhibitors
SK10572002A3 (en) 2000-01-24 2003-10-07 Warner-Lambert Company 3-Aminoquinazolin-2,4-dione antibacterial agents
JP2003523358A (en) 2000-01-27 2003-08-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Pyridopyrimidinone derivatives for the treatment of neurodegenerative diseases
DE50112961D1 (en) 2000-02-01 2007-10-18 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as PARP inhibitors
WO2001057037A1 (en) 2000-02-04 2001-08-09 Cor Therapeutics, Inc. Platelet adp receptor inhibitors
PT1254138E (en) 2000-02-09 2005-09-30 Novartis Ag PYRIDINE DERIVATIVES THAT INHIBIT ANGIOGENESE AND / OR VIRUS TYROSINE KINASE RECEPTOR
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU2001235804A1 (en) 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
DE10012549A1 (en) 2000-03-15 2001-09-20 Bayer Ag New heterocyclic-substituted dihydropyrimidine derivatives useful for treatment of viral infections, especially hepatitis B infections
JP2001265031A (en) 2000-03-15 2001-09-28 Fuji Xerox Co Ltd Electrophotographic photoreceptor, process cartridge and electrophotographic device
AR028385A1 (en) 2000-04-28 2003-05-07 Acadia Pharm Inc MUSCARINIC AGONISTS
JP2003532728A (en) 2000-05-05 2003-11-05 コー セラピューティックス， インコーポレイテッド Heterobicyclic sulfonamides and their use as platelet ADP receptor inhibitors
CN1439008A (en) 2000-06-23 2003-08-27 布里斯托尔-迈尔斯斯奎布药品公司 1-(heteroaryl-henyl)-condensed pyrazol derivatives as factor XA inhibitors
KR100786927B1 (en) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 Wet Grinding Method
PY0119496A (en) 2000-08-07 2003-11-03 Neurogen Corp HETEROCYCLIC COMPOUNDS AS GABAA RECEPTOR LIGANDS
EP1309593B1 (en) 2000-08-14 2006-03-15 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
JP2004531456A (en) 2000-09-06 2004-10-14 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド How to treat allergies with substituted pyrazoles
GB0025782D0 (en) 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
GB0100621D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
AP1699A (en) 2001-03-21 2006-12-26 Warner Lambert Co New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US6998408B2 (en) 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
JP2002296731A (en) 2001-03-30 2002-10-09 Fuji Photo Film Co Ltd Heat developable color image recording material
US7074801B1 (en) 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
DE60225127T2 (en) 2001-04-30 2009-02-19 Glaxo Group Ltd., Greenford CONDENSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF)
WO2002094825A1 (en) 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Novel spiropiperidine derivative
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
EP1401830A2 (en) 2001-06-19 2004-03-31 Warner-Lambert Company LLC Quinazolinediones as antibacterial agents
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000187A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
US20040235867A1 (en) 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
HUP0401108A2 (en) 2001-08-07 2004-09-28 Banyu Pharmaceutical Co., Ltd. Spiro compounds, process for their preparation and pharmaceutical compositions containing them
BR0212760A (en) 2001-09-19 2004-12-07 Aventis Pharma Sa Chemical compounds
DE60213842T2 (en) 2001-10-30 2007-09-06 Novartis Ag STAUROSPORINE DERIVATIVES AS INHIBITORS OF THE FLT3 RECEPTOR TYROSINE KINASE EFFECT
HUP0402106A3 (en) 2001-11-01 2009-07-28 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2003040131A1 (en) 2001-11-07 2003-05-15 F. Hoffmann-La Roche Ag Aminopyrimidines and pyridines
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
GB0129476D0 (en) 2001-12-10 2002-01-30 Syngenta Participations Ag Organic compounds
MXPA04005939A (en) 2002-01-22 2005-01-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES.
CN100430052C (en) 2002-03-05 2008-11-05 默克弗罗斯特加拿大有限公司 cathepsin cysteine protease inhibitor
US6815519B2 (en) 2002-03-22 2004-11-09 Chung-Shan Institute Of Science & Technology Acidic fluorine-containing poly (siloxane amideimide) silica hybrids
JP2006503802A (en) 2002-04-03 2006-02-02 エフ．ホフマン−ラ　ロシュ　アーゲー Imidazo condensation compounds
ES2323952T3 (en) 2002-05-15 2009-07-28 Janssen Pharmaceutica Nv 3-AMINOPIRAZOL SUBSTITUTED TRICYCLES IN N AS RECEIVING INHIBITORS OF PDFG.
JP4499342B2 (en) 2002-05-16 2010-07-07 株式会社カネカ Method for producing nitrogen-containing organic compound containing SiH group
PT1551834E (en) 2002-05-23 2010-09-30 Novartis Vaccines & Diagnostic Substituted quinazolinone compounds
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
PE20040522A1 (en) 2002-05-29 2004-09-28 Novartis Ag DIARYLUREA DERIVATIVES DEPENDENT ON PROTEIN KINASE
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
HRP20050089B1 (en) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
AU2003251661A1 (en) 2002-08-06 2004-02-25 F. Hoffmann-La Roche Ag 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
EP1388541A1 (en) 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
GB0220187D0 (en) 2002-08-30 2002-10-09 Novartis Ag Organic compounds
GB0223349D0 (en) 2002-10-08 2002-11-13 Merck Sharp & Dohme Therapeutic agents
TW200413381A (en) 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
US7112676B2 (en) 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
WO2004043367A2 (en) 2002-11-06 2004-05-27 Bristol-Myers Squibb Company Fused heterocyclic compounds and use thereof
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
KR20050075028A (en) 2002-11-18 2005-07-19 에프. 호프만-라 로슈 아게 Diazinopyrimidines
JP2006508997A (en) 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Chk-, Pdk- and Akt-inhibiting pyrimidines, their preparation and use as pharmaceuticals
EP1567497B1 (en) 2002-12-06 2009-09-23 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
EP1571146A4 (en) 2002-12-10 2010-09-01 Ono Pharmaceutical Co Nitrogen-containing heterocyclic compounds and medicinal use thereof
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
CN101899114A (en) 2002-12-23 2010-12-01 惠氏公司 Anti-PD-1 antibody and uses thereof
JP2004203749A (en) 2002-12-24 2004-07-22 Kanegafuchi Chem Ind Co Ltd Method for producing nitrogen-containing organic compound containing SiH group
MXPA05007503A (en) 2003-01-17 2005-09-21 Warner Lambert Co 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7135469B2 (en) 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
CA2518465A1 (en) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
WO2004089955A1 (en) 2003-04-10 2004-10-21 F.Hoffmann-La Roche Ag Pyrimido compounds
MXPA05011710A (en) 2003-05-05 2006-01-23 Hoffmann La Roche Fused pyrimidine derivatives with crf activity.
JP2004346145A (en) 2003-05-21 2004-12-09 Teijin Ltd Imide composition, resin composition comprising the same, and method for producing the same
CA2523015A1 (en) 2003-05-23 2004-12-29 Chiron Corporation Guanidino-substituted quinazolinone compounds as mc4-r agonists
SI1631295T1 (en) 2003-06-06 2010-06-30 Arexis Ab Use of condensed heterocyclic compounds as scce inhibitors for the treatment of skin diseases
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
WO2004113307A1 (en) 2003-06-18 2004-12-29 Ube Industries, Ltd. Process for producing pyrimidin-4-one compound
JP2005015395A (en) 2003-06-26 2005-01-20 Japan Science & Technology Agency A novel pyrimidopyrimidine nucleoside and its structural analogs
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
AR045037A1 (en) 2003-07-10 2005-10-12 Aventis Pharma Sa TETRAHIDRO-1H-PIRAZOLO [3,4-C] SUBSTITUTED PYRIDINS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE.
US7390820B2 (en) 2003-08-25 2008-06-24 Amgen Inc. Substituted quinolinone derivatives and methods of use
CA2537916A1 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
MXPA06002997A (en) 2003-09-18 2007-02-08 Conforma Therapeutics Corp Novel heterocyclic compounds as hsp90-inhibitors.
CA2537325A1 (en) 2003-09-19 2005-03-31 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
AR045944A1 (en) 2003-09-24 2005-11-16 Novartis Ag ISOQUINOLINE DERIVATIVES 1.4-DISPOSED
EP1670761B1 (en) 2003-10-01 2009-01-28 Xention Limited Tetrahydro-naphthalene and urea derivatives
AU2004279427B2 (en) 2003-10-08 2008-07-03 Irm Llc Compounds and compositions as protein kinase inhibitors
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
CN1897950A (en) 2003-10-14 2007-01-17 惠氏公司 Fused aryl and heteroaryl derivatives and methods of use
CA2546192C (en) 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
WO2005056524A2 (en) 2003-12-09 2005-06-23 Euro-Celtique S.A. Therapeutic agents useful for treating pain
WO2005066162A1 (en) 2003-12-23 2005-07-21 Human Biomolecular Research Institute Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
KR100703068B1 (en) 2003-12-30 2007-04-05 에스케이케미칼주식회사 Pyridine derivatives and preparation method thereof, and pharmaceutical composition
CA2553969A1 (en) 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EA011277B1 (en) 2004-01-23 2009-02-27 Янссен Фармацевтика Н.В. Quinoline derivatives and use thereof as mycobacterial inhibitors
CA2553670A1 (en) 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc. Anti-viral therapeutics
GB0402137D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
CN1918158B (en) 2004-02-14 2011-03-02 Irm责任有限公司 Compounds and compositions as protein kinase inhibitors
BRPI0507852A (en) 2004-02-18 2007-07-10 Warner Lambert Co 2- (pyridin-3-ylamino) -pyrido [2,3-d] pyrimidin-7-ones
WO2005085249A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
CN1934111A (en) 2004-02-27 2007-03-21 霍夫曼-拉罗奇有限公司 Heteroaryl-fused pyrazolo derivatives
WO2005087765A1 (en) 2004-03-04 2005-09-22 Arena Pharmaceuticals, Inc. Ligands of follicle stimulating hormone receptor and methods of use thereof
JPWO2005085210A1 (en) 2004-03-10 2008-01-17 小野薬品工業株式会社 Nitrile compound and pharmaceutical composition containing the compound as an active ingredient
CN1938321B (en) 2004-03-29 2010-05-05 三井化学株式会社 Novel compound and organic electronic device using the compound
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
JP2005320288A (en) 2004-05-10 2005-11-17 Mitsui Chemicals Inc Tetracarboxylic acid derivative, electrophotographic photoreceptor given by using the compound, and electrophotographic device
US20050256309A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
JP4842929B2 (en) 2004-05-27 2011-12-21 ファイザー・プロダクツ・インク Pyrrolopyrimidine derivatives useful for cancer treatment
PE20060426A1 (en) 2004-06-02 2006-06-28 Schering Corp TARTARIC ACID DERIVATIVES AS INHIBITORS OF MMPs, ADAMs, TACE AND TNF-alpha
RU2401265C2 (en) 2004-06-10 2010-10-10 Айрм Ллк Compounds and compositions as protein kinase inhibitors
SI1761528T1 (en) 2004-06-11 2008-06-30 Japan Tobacco Inc 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO?á2,3-D?åPYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
JP2006028027A (en) 2004-07-12 2006-02-02 Mitsui Chemicals Inc Tetracarboxylic acid derivative, electrophotographic photoconductor using the compound and electrohptographic apparatus
JP2008510690A (en) 2004-08-31 2008-04-10 エフ．ホフマン−ラ ロシュ アーゲー Amide derivatives of 3-phenyl-dihydropyrimido [4,5-d] pyrimidinone, their preparation and use as pharmaceuticals
CA2577275A1 (en) 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
AU2005279337A1 (en) 2004-08-31 2006-03-09 F. Hoffmann-La Roche Ag Amide derivatives of 7-amino-3-phenyl-dihydropyrimido [4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
DE102004042667A1 (en) 2004-09-01 2006-03-30 Ewald Dörken Ag Multilayered building wall
CN1980970B (en) 2004-09-10 2010-05-26 宇部兴产株式会社 Modified polyimide resin and curable resin composition
CA2584412C (en) 2004-09-14 2017-05-09 Minerva Biotechnologies Corporation Methods for diagnosis and treatment of cancer
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
FR2876582B1 (en) 2004-10-15 2007-01-05 Centre Nat Rech Scient Cnrse USE OF PYRROLO-PYRAZINE DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF MUCOVISCIDOSIS AND DISEASES ASSOCIATED WITH A DEFECT OF ADDRESSING PROTEINS IN CELLS
US20060135553A1 (en) 2004-10-28 2006-06-22 Campbell David A Imidazole derivatives
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
ES2424255T3 (en) 2004-11-08 2013-09-30 Baxter International Inc. Particulate compositions of tubulin inhibitors
CN101103016A (en) 2004-11-18 2008-01-09 因塞特公司 11-beta hydroxysteroid dehydrogenase type 1 inhibitors and methods of use thereof
WO2006058120A1 (en) 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
AU2005309019A1 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
US7767687B2 (en) 2004-12-13 2010-08-03 Biogen Idec Ma Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
WO2006074293A2 (en) 2005-01-07 2006-07-13 President And Fellows Of Harvard College Bicyclic dihydropyrimidines as eg5 inhibitors
DE102005008310A1 (en) 2005-02-17 2006-08-24 Schering Ag Use of CDKII inhibitors for fertility control
CA2599662A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of pde7 inhibitors for the treatment of neuropathic pain
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
EP2526957A3 (en) 2005-03-30 2013-02-20 Minerva Biotechnologies Corporation Proliferation of MUC1 expressing cells
JP2006284843A (en) 2005-03-31 2006-10-19 Mitsui Chemicals Inc Electrophotographic photoreceptor using tetracarboxylic acid derivative and electrophotographing device
US20060223993A1 (en) 2005-04-01 2006-10-05 Connor Daniel M Colorant compounds, intermediates, and compositions
JP2006316054A (en) 2005-04-15 2006-11-24 Tanabe Seiyaku Co Ltd High conductance calcium-sensitive K channel opener
KR100781704B1 (en) 2005-04-20 2007-12-03 에스케이케미칼주식회사 Novel pyridine derivatives, process for preparing thereof and pharmaceutical compositions containing them
MX2007013595A (en) 2005-05-04 2008-01-24 Renovis Inc Fused heterocyclic compounds, and compositions and uses thereof.
DK2439273T3 (en) 2005-05-09 2019-06-03 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES FOR PROGRAMMED DEATH-1 (PD-1) AND PROCEDURES FOR TREATMENT OF CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNTER APPLICATIONS
WO2006124731A2 (en) 2005-05-12 2006-11-23 Irm Llc Compounds and compositions as protein kinase inhibitors
US8183248B2 (en) 2005-05-13 2012-05-22 Irm Llc Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors
WO2006135821A2 (en) 2005-06-09 2006-12-21 Achille Carlisle Tisdelle Vehicular head and neck safety system and method
GB0512844D0 (en) 2005-06-23 2005-08-03 Novartis Ag Organic compounds
PT1907424E (en) 2005-07-01 2015-10-09 Squibb & Sons Llc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US7932257B2 (en) 2005-07-22 2011-04-26 Sunesis Pharmaceuticals, Inc. Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
EP1910369A1 (en) 2005-07-29 2008-04-16 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
ES2270715B1 (en) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. NEW DERIVATIVES OF PIRAZINA.
WO2007021795A2 (en) 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
US7589101B2 (en) 2005-08-16 2009-09-15 Irm Llc Compounds and compositions as protein kinase inhibitors
KR101011958B1 (en) 2005-08-25 2011-01-31 에프. 호프만-라 로슈 아게 ｐ38 fused pyrazoles as MAP kinase inhibitors
US7678917B2 (en) 2005-09-01 2010-03-16 Hoffman-La Roche Inc. Factor Xa inhibitors
MX2008003172A (en) 2005-09-06 2008-03-18 Smithkline Beecham Corp Regioselective process for preparing benzimidazole thiophenes.
KR20080046728A (en) 2005-09-15 2008-05-27 아스카 세이야쿠 가부시키가이샤 Heterocyclic Compounds, Methods for Making And Uses thereof
US20070116984A1 (en) 2005-09-21 2007-05-24 Doosan Corporation Spiro-compound for electroluminescent display device and electroluminescent display device comprising the same
US7482360B2 (en) 2005-09-23 2009-01-27 Schering Corporation Fused tetracyclic mGluR1 antagonists as therapeutic agents
DE102005048072A1 (en) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazoles as fungicides
US7989622B2 (en) 2005-10-07 2011-08-02 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
CN102746298A (en) 2005-10-07 2012-10-24 埃克塞里艾克西斯公司 Pyridopyrimidinone inhibitors of Pl3K[alpha]
WO2007061554A2 (en) 2005-10-21 2007-05-31 Purdue Research Foundation Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries
RU2008120619A (en) 2005-10-26 2009-12-10 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) (HETERO) ARILS WITH ANTAGONISTIC ACTIVITY AGAINST MELANINE-CONCENTRATING HORMONE
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
JP5191391B2 (en) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド Bi-aryl meta-pyrimidine inhibitors of kinases
JP5116687B2 (en) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト Pyrrolo [2,1-f] [1,2,4] triazin-4-ylamine IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
WO2007056075A2 (en) 2005-11-02 2007-05-18 Targegen, Inc. Six membered heteroaromatic inhibitors targeting resistant kinase mutations
ES2381205T3 (en) 2005-11-10 2012-05-24 Msd K.K. Aza-substituted spiro derivative
DK1954274T3 (en) 2005-11-10 2011-01-31 Chemocentryx Inc Substituted quinolones and methods of use
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
AR057986A1 (en) 2005-11-21 2008-01-09 Japan Tobacco Inc HETEROCICLICAL COMPOUND AND ITS PHARMACEUTICAL USE
WO2007064931A2 (en) 2005-12-02 2007-06-07 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PE20070855A1 (en) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp DERIVATIVES OF 4-AMINO-PYRROLOTRIAZINE SUBSTITUTE AS KINASE INHIBITORS
WO2007067444A1 (en) 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Bicyclic compounds with kinase inhibitory activity
WO2007066189A2 (en) 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
US20080318989A1 (en) 2005-12-19 2008-12-25 Burdick Daniel J Pyrimidine Kinase Inhibitors
GEP20105074B (en) 2005-12-21 2010-09-10 Novartis Ag Pyrimidinyl aryl urea derivatives being fgf inhibitors
WO2007084314A2 (en) 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
UY30118A1 (en) 2006-01-31 2007-06-29 Tanabe Seiyaku Co AMIS TRISUSTITUDE COMPUTER
WO2007092879A2 (en) 2006-02-08 2007-08-16 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
JP2009528989A (en) 2006-02-17 2009-08-13 ファイザー・リミテッド 3-Deazapurine derivatives as TLR7 modulators
WO2008117269A2 (en) 2007-03-28 2008-10-02 Atir Holding S.A. Heterotri cyciii c compounds as serotonergic and/or dopaminergic agents and uses thereof
EP2010505B1 (en) 2006-03-28 2012-12-05 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20100273776A1 (en) 2006-03-29 2010-10-28 FOLDRx PHARMACEUTICALS, INC Inhibition of alpha-synuclein toxicity
US7648973B2 (en) 2006-04-06 2010-01-19 Wisconsin Alumni Research Foundation 2-methylene-1α,25-dihydroxy-19,21-dinorvitamin D3 analogs and uses thereof
JP2009533426A (en) 2006-04-13 2009-09-17 アストラゼネカ・アクチエボラーグ Thioxanthine derivatives and their use as MPO inhibitors
GB0608386D0 (en) 2006-04-27 2006-06-07 Senexis Ltd Compounds
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
PL2027123T3 (en) 2006-05-11 2011-09-30 Irm Llc Compounds and compositions as protein kinase inhibitors
MX2008014618A (en) 2006-05-15 2008-11-28 Irm Llc Compositions and methods for fgf receptor kinases inhibitors.
US7910108B2 (en) 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
DE102006027156A1 (en) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag New sulfimide compounds are protein kinase inhibitors useful to treat e.g. cancer, Hodgkin's lymphoma, Kaposi's sarcoma, cardiovascular disease, Crohn's disease, endometriosis and hemangioma
US8163760B2 (en) 2006-06-22 2012-04-24 Prana Biotechnology Limited Use of pyridopyrimidine compounds in the treatment of gliomas
WO2008005877A2 (en) 2006-06-30 2008-01-10 Board Of Regents, The University Of Texas System Inhibitors of c-kit and uses thereof
TW200817391A (en) 2006-06-30 2008-04-16 Astrazeneca Ab Novel compounds
CA2654670A1 (en) 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh New compounds
WO2008008234A1 (en) 2006-07-07 2008-01-17 Targegen, Inc. 2-amino-5-substituted pyrimidine inhibitors
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
US20100222345A1 (en) 2006-08-09 2010-09-02 Caroline Jean Diaz Novel compounds as antagonists or inverse agonists for opioid receptors
CN101528231A (en) 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 Use of PI3K and MEK modulators in the treatment of cancer
DE102006041382A1 (en) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl sulfoximides as protein kinase inhibitors
BRPI0719123A2 (en) 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc SERINA-TREONINE PROTEIN KINASE AND PARP MODULATORS
US8268809B2 (en) 2006-09-05 2012-09-18 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
WO2008033858A2 (en) 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
WO2008034859A1 (en) 2006-09-21 2008-03-27 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
UY30600A1 (en) 2006-09-22 2008-05-02 Glaxo Group Ltd NEW COMPOUNDS
CN103739595A (en) 2006-10-02 2014-04-23 Irm责任有限公司 Compounds and compositions as protein kinase inhibitors
TW200825058A (en) 2006-10-30 2008-06-16 Glaxo Group Ltd Cysteine protease inhibitors
US7858645B2 (en) 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
US8148361B2 (en) 2006-11-10 2012-04-03 Bristol-Myers Squibb Company Kinase inhibitors
US7892454B2 (en) 2006-11-17 2011-02-22 Polyera Corporation Acene-based organic semiconductor materials and methods of preparing and using the same
WO2008063609A2 (en) 2006-11-17 2008-05-29 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
KR20080045536A (en) 2006-11-20 2008-05-23 에스케이케미칼주식회사 Pharmaceutical composition having a hepatitis treatment and prevention or hepatoprotective effect comprising a pyridine compound
RS54510B1 (en) * 2006-11-22 2016-06-30 Incyte Holdings Corporation IMIDAZOTRIAZINS AND IMIDAZOPYRIMIDINS AS KINASE INHIBITORS
EP2104501B1 (en) 2006-12-13 2014-03-12 Merck Sharp & Dohme Corp. Methods of cancer treatment with igf1r inhibitors
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
WO2008074068A1 (en) 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8513276B2 (en) 2006-12-22 2013-08-20 Astex Therapeutics Limited Imidazo[1,2-a]pyridine compounds for use in treating cancer
HRP20150642T1 (en) 2006-12-22 2015-08-14 Astex Therapeutics Limited BIKE HETEROCYCLIC SUBSTANCES AS FGFR INHIBITORS
CN101568529A (en) 2006-12-22 2009-10-28 诺瓦提斯公司 Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
FR2911140B1 (en) 2007-01-05 2009-02-20 Sanofi Aventis Sa NOVEL 2-ANILINO 4-HETEROARYL PYRIMIDES DERIVATIVES, THEIR PREPARATION AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS, AND IN PARTICULAR AS INHIBITORS OF IKK
KR20090117730A (en) 2007-01-08 2009-11-12 폴리에라 코퍼레이션 Arene-bis (dicarboximide) -based semiconductor materials, and methods of making related intermediates for making them
CN101007778A (en) 2007-01-10 2007-08-01 复旦大学 Chain-prolonged type fluorenyl bimaleimide and its preparation method
MX2009007333A (en) 2007-01-12 2009-08-31 Biocryst Pharm Inc Antiviral nucleoside analogs.
AR064879A1 (en) 2007-01-12 2009-04-29 Astellas Pharma Inc CONDENSED PYRIDINE COMPOUND
FR2911604B1 (en) 2007-01-19 2009-04-17 Sanofi Aventis Sa N- (HETEROARYL-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
JP5358962B2 (en) 2007-02-06 2013-12-04 住友化学株式会社 Composition and light-emitting device using the composition
JP2008198769A (en) 2007-02-13 2008-08-28 Nippon Steel Chem Co Ltd Organic electroluminescent device
CA2678492A1 (en) 2007-03-06 2008-09-12 Novartis Ag Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions
JP2010520293A (en) 2007-03-07 2010-06-10 アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド Metalloprotease inhibitors containing heterocyclic moieties
KR101566840B1 (en) 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 Phenylaminopyrimidine compounds and uses thereof
JP5191497B2 (en) 2007-03-21 2013-05-08 エピックス ファーマシューティカルズ，インコーポレイテッド S1P receptor modulating compounds and uses thereof
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
EP2132207A2 (en) 2007-03-23 2009-12-16 Amgen Inc. Heterocyclic compounds and their uses
KR20080091948A (en) 2007-04-10 2008-10-15 에스케이케미칼주식회사 Pharmaceutical composition for the prevention and treatment of ischemic diseases containing lactam type pyridine compound
WO2008128141A2 (en) 2007-04-12 2008-10-23 Advanced Technology Materials, Inc. Zirconium, hafnuim, titanium, and silicon precursors for ald/cvd
CN101754961A (en) 2007-04-20 2010-06-23 先灵公司 Pyrimidinone derivatives and methods of use thereof
EP1985612A1 (en) 2007-04-26 2008-10-29 Bayer Schering Pharma Aktiengesellschaft Arymethylen substituted N-Acyl-gamma-aminoalcohols
EP1990342A1 (en) 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
PE20090288A1 (en) 2007-05-10 2009-04-03 Smithkline Beecham Corp QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
GB2449293A (en) 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
KR20100033981A (en) 2007-06-03 2010-03-31 벤더르빌트 유니버시티 Benzamide mglur5 positive allosteric modulators and methods of making and using same
WO2008153852A1 (en) 2007-06-07 2008-12-18 Merck & Co., Inc. Tricyclic anilide heterocyclic cgrp receptor antagonists
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
JP5129812B2 (en) 2007-06-15 2013-01-30 Ｍｓｄ株式会社 Bicycloaniline derivatives
BR122017025062B8 (en) 2007-06-18 2021-07-27 Merck Sharp & Dohme monoclonal antibody or antibody fragment to human programmed death receptor pd-1, polynucleotide and composition comprising said antibody or fragment
EP2018859A1 (en) 2007-07-26 2009-01-28 Bayer Schering Pharma Aktiengesellschaft Arylmethylene substituted N-acyl-beta-amino alcohols
ATE522249T1 (en) 2007-07-26 2011-09-15 Novartis Ag ORGANIC COMPOUNDS
EP2020404A1 (en) 2007-08-01 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Cyanomethyl substituted N-Acyl Tryptamines
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
EP2173354A4 (en) 2007-08-09 2011-10-05 Glaxosmithkline Llc Quinoxaline derivatives as pi3 kinase inhibitors
US7960400B2 (en) 2007-08-27 2011-06-14 Duquesne University Of The Holy Ghost Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
WO2009029625A1 (en) 2007-08-27 2009-03-05 Kalypsys, Inc. 4- [heterocyclyl-methyl] -8-fluoro-quinolin-2-ones useful as nitric oxide synthase inhibitors
JP5611826B2 (en) 2007-09-04 2014-10-22 ザ スクリプス リサーチ インスティテュート Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009030871A1 (en) 2007-09-07 2009-03-12 Vernalis R & D Ltd Pyrrolopyrimidine derivatives having hsp90 inhibitory activity
TW200920357A (en) 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
WO2009046141A2 (en) 2007-10-01 2009-04-09 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
JP5470043B2 (en) 2007-10-05 2014-04-16 Ｍｓｄ株式会社 Benzoxazinone derivatives
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
WO2009049018A1 (en) 2007-10-10 2009-04-16 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
CN101821243B (en) 2007-10-11 2013-05-08 中国科学院上海药物研究所 A class of pyrimidine-substituted phenylpropionic acid derivatives and their use as PPAR agonists
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
JP5273052B2 (en) 2007-10-13 2013-08-28 コニカミノルタ株式会社 Organic electroluminescence element, display device and lighting device
EA201000484A1 (en) 2007-10-16 2010-12-30 ВАЙЕТ ЭлЭлСи THYENOPYRIMIDINE AND PYRAZOLOPIRIMIDIN COMPOUNDS AND THEIR APPLICATION AS INHIBITORS MTOR KINASE AND PI3 KINASE
JP2011500778A (en) 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ Pyridine and pyrazine derivatives-083
RU2007139634A (en) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) NEW THIAZOLE-, TRIAZOLE- OR OXADIAZOLE-CONTAINING TETRACYCLIC COMPOUNDS
WO2009056886A1 (en) 2007-11-01 2009-05-07 Astrazeneca Ab Pyrimidine derivatives and their use as modulators of fgfr activity
EA019869B1 (en) 2007-11-28 2014-06-30 Дана Фарбер Кансер Инститьют, Инк. Small molecule myristate inhibitors of tyrosine kinase bcr-abl and methods of use thereof
US8461147B2 (en) 2007-12-03 2013-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
EA201001030A1 (en) 2007-12-19 2011-02-28 Амген Инк. Condensed Compounds of Pyridine, Pyrimidine, and Triazine as Cellular Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Capsule inhibitors
WO2009086130A1 (en) 2007-12-21 2009-07-09 Wyeth Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009086509A2 (en) 2007-12-27 2009-07-09 Purdue Research Foundation Reagents for biomolecular labeling, detection and quantification employing raman spectroscopy
FR2926297B1 (en) 2008-01-10 2013-03-08 Centre Nat Rech Scient INHIBITORY CHEMICAL MOLECULES IN THE SPLICE MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICE ANOMALIES.
KR20100119776A (en) 2008-01-24 2010-11-10 알라 캠, 엘엘씨 2-alkylamino-3-arylsulfonyl-cycloalcano[e or d]pyrazolo[1,5-a]pyrimidines/antagonists of serotonin 5-ht6 receptors, methods for the production and the use thereof
WO2009092764A1 (en) 2008-01-24 2009-07-30 Ucb Pharma, S.A. Compounds comprising a cyclobutoxy group
US8629154B2 (en) 2008-01-24 2014-01-14 Andrey Alexandrovich Ivashchenko Substituted cycloalcano[e and d] pyrazolo [1,5-a]pyrimidines/antagonists of serotonin 5-HT6 receptors and methods for production and the use thereof
EA018462B1 (en) 2008-01-25 2013-08-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-α SYNTHESIS AND AS PDE4 INHIBITORS
US8987280B2 (en) 2008-01-30 2015-03-24 Genentech, Inc. Pyrazolopyrimidine PI3K inhibitor compounds and methods of use
EP2265270A1 (en) 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
JP5328816B2 (en) 2008-02-22 2013-10-30 エフ．ホフマン−ラ ロシュ アーゲー Modulator of amyloid β
JP2011513233A (en) 2008-02-22 2011-04-28 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and compositions as GPR119 activity modulators
JP5451646B2 (en) 2008-02-27 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Inhibitors of 11β-hydroxysteroid dehydrogenase type 1
WO2009108827A1 (en) 2008-02-29 2009-09-03 Wyeth Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme BINDING PROTEINS WITH PD-1
GB0804701D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EP2252293B1 (en) 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
US20100056524A1 (en) 2008-04-02 2010-03-04 Mciver Edward Giles Compound
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
WO2009124755A1 (en) 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Compounds with novel medical uses and method of identifying such compounds
WO2009125809A1 (en) 2008-04-11 2009-10-15 第一三共株式会社 Piperidine derivatives
WO2009125808A1 (en) 2008-04-11 2009-10-15 第一三共株式会社 Aminocyclohexyl derivative
EP2277881A4 (en) 2008-04-18 2011-09-07 Shionogi & Co Heterocyclic compound having inhibitory activity on p13k
AU2009238590A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
TWI526687B (en) 2008-04-29 2016-03-21 諾華公司 Biomarkers
CA2719868A1 (en) 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag Pyrimidinyl pyridone inhibitors of jnk.
AR071523A1 (en) 2008-04-30 2010-06-23 Merck Serono Sa FUSIONATED BICYCLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, THE COMPOSITE TO BE USED AS A MEDICINAL PRODUCT IN THE TREATMENT AND PROFILAXIS OF DISEASES, A PHARMACEUTICAL COMPOSITION AND A SET THAT INCLUDES SEPARATE PACKAGES OF THE COMPOUND AND OF AN INGREDIENT
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
ES2554513T3 (en) 2008-05-23 2015-12-21 Novartis Ag Quinoline and quinoxaline derivatives as protein tyrosine kinase inhibitors
WO2009144205A1 (en) 2008-05-30 2009-12-03 Basf Se Rylene-based semiconductor materials and methods of preparation and use thereof
KR101656793B1 (en) 2008-06-10 2016-09-12 유디씨 아일랜드 리미티드 - novel transition metal complexes and use thereof in organic light-emitting diodes -
WO2009151997A1 (en) 2008-06-12 2009-12-17 Merck & Co., Inc. Process for producing bicycloaniline derivatives
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
CA2728063A1 (en) 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436
JPWO2009157423A1 (en) 2008-06-24 2011-12-15 財団法人乙卯研究所 Oxazolidinone derivatives having fused rings
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8124764B2 (en) 2008-07-14 2012-02-28 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
WO2010007099A1 (en) 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
WO2010006947A1 (en) 2008-07-15 2010-01-21 F. Hoffmann-La Roche Ag Novel phenyl-imidazopyridines and pyridazines
JP2011528368A (en) 2008-07-16 2011-11-17 シェーリング コーポレイション Bicyclic heterocyclic derivatives and their use as GPCR modulators
UY31982A (en) 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVATIVES OF 1,2-DIHYDROPIRIDIN-3-CARBOXAMIDS N-SUBSTITUTED
MX2011000664A (en) 2008-07-16 2011-02-24 Schering Corp Bicyclic heterocycle derivatives and use thereof as gpr119 modulators.
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
JP2011530511A (en) 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション Therapeutic compounds
AR072906A1 (en) 2008-08-06 2010-09-29 Novartis Ag MODIFIED NUCLEOSIDS USEFUL AS ANTIVIRAL
AU2009282480B2 (en) 2008-08-11 2015-05-07 Children's Medical Center Corporation Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
UY32049A (en) 2008-08-14 2010-03-26 Takeda Pharmaceutical CMET INHIBITORS
EP2342191B1 (en) 2008-09-10 2013-03-20 Mitsubishi Tanabe Pharma Corporation Aromatic nitrogen-containing 6-membered ring compounds and their use
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
TW201016676A (en) 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
US20100267748A1 (en) 2008-10-15 2010-10-21 Gilead Palo Alto, Inc. HETEROCYCLIC COMPOUNDS USEFUL AS STEAROYL CoA DESATURASE INHIBITORS
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
UY32203A (en) 2008-10-29 2010-05-31 Astrazeneca Ab AMINO PIRIMIDINAS AND ITS USE IN THERAPY
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2010052448A2 (en) 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
WO2010059552A1 (en) 2008-11-18 2010-05-27 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
AR074199A1 (en) 2008-11-20 2010-12-29 Glaxosmithkline Llc COMPOSITE OF 6- (4-PYRIMIDINYL) -1H-INDAZOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OR DECREASE OF CANCER GRAVITY.
JP5522053B2 (en) 2008-12-03 2014-06-18 コニカミノルタ株式会社 ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, DISPLAY DEVICE AND LIGHTING DEVICE
KR101061599B1 (en) 2008-12-05 2011-09-02 한국과학기술연구원 Novel indazole derivatives that are protein kinase inhibitors for the treatment of abnormal cell growth diseases, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing the same as active ingredients
JP5752601B2 (en) 2008-12-08 2015-07-22 ブイエム ファーマ エルエルシー Composition of protein receptor tyrosine kinase inhibitor
US8110265B2 (en) 2008-12-09 2012-02-07 The Coca-Cola Company Pet container and compositions having enhanced mechanical properties and gas barrier properties
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
AU2009325398A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
AU2009325400A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
WO2010080503A1 (en) 2008-12-19 2010-07-15 Genentech, Inc. Heterocyclic compounds and methods of use
PA8852901A1 (en) 2008-12-22 2010-07-27 Lilly Co Eli PROTEIN CINASE INHIBITORS
TWI461410B (en) 2008-12-30 2014-11-21 Arqule Inc Substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
TW201035098A (en) 2008-12-30 2010-10-01 Arqule Inc Substituted imidazolyl-5,6-dihydrobenzo[n] isoquinoline compounds
EP3828185B1 (en) 2009-01-06 2024-11-20 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
TWI720517B (en) 2009-01-15 2021-03-01 美商英塞特公司 Processes for preparing jak inhibitors and related intermediate compounds
US8592425B2 (en) 2009-01-16 2013-11-26 Merck Sharp & Dohme Corp. Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors
DE102009007038A1 (en) 2009-02-02 2010-08-05 Merck Patent Gmbh metal complexes
JP2010180147A (en) 2009-02-04 2010-08-19 Mitsubishi Gas Chemical Co Inc Cyanic acid ester compound and cured product thereof
JP5844159B2 (en) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ PD-1 antibody and PD-L1 antibody and use thereof
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
TW201035102A (en) 2009-03-04 2010-10-01 Gruenethal Gmbh Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
US20100278835A1 (en) 2009-03-10 2010-11-04 Astrazeneca Uk Limited Novel compounds 660
JP5615261B2 (en) 2009-03-11 2014-10-29 学校法人関西学院 Polycyclic aromatic compounds
WO2010107768A1 (en) 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
JP2012521988A (en) 2009-03-23 2012-09-20 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド Imaging agents for detecting neurological disorders
WO2010111573A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2010117425A1 (en) 2009-03-31 2010-10-14 Biogen Idec Ma Inc. Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
ES2465971T3 (en) 2009-04-06 2014-06-09 University Health Network Kinase inhibitors and method to treat cancer with them
SG174463A1 (en) 2009-04-07 2011-10-28 Astrazeneca Ab Isoxazol-3(2h)-one analogs as therapeutic agents
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
JP5531446B2 (en) 2009-04-20 2014-06-25 コニカミノルタ株式会社 ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, DISPLAY DEVICE AND LIGHTING DEVICE
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
ES2347630B1 (en) 2009-04-29 2011-09-08 Universitat Ramon Llull SYNTHESIS AND USES OF 4-CIANOPENTANOATOS AND 4-CIANOPENTENOATS SUBSTITUTED.
US20100280067A1 (en) 2009-04-30 2010-11-04 Pakala Kumara Savithru Sarma Inhibitors of acetyl-coa carboxylase
AR078411A1 (en) 2009-05-07 2011-11-09 Lilly Co Eli IMIDAZOLIL VINYL COMPOUND AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
JP5600891B2 (en) 2009-05-15 2014-10-08 コニカミノルタ株式会社 Organic electroluminescence element, display device and lighting device
JP5604808B2 (en) 2009-05-20 2014-10-15 コニカミノルタ株式会社 Organic electroluminescence element, display device and lighting device
JP5629980B2 (en) 2009-05-22 2014-11-26 コニカミノルタ株式会社 Organic electroluminescence element, display device and lighting device
JP5568889B2 (en) 2009-05-22 2014-08-13 コニカミノルタ株式会社 ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, LIGHTING DEVICE, AND ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL
US8637465B2 (en) 2009-05-27 2014-01-28 Kobenhavns Universitet Fibroblast growth factor receptor-derived peptides binding to NCAM
JP5499519B2 (en) 2009-05-27 2014-05-21 コニカミノルタ株式会社 Organic electroluminescence element, display device and lighting device
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
JP5600894B2 (en) 2009-06-24 2014-10-08 コニカミノルタ株式会社 White organic electroluminescence element, display device and lighting device
US8431576B2 (en) 2009-06-25 2013-04-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
CN102471261B (en) 2009-06-30 2014-10-29 日本瑞翁株式会社 Novel diarylamine compound, and anti-aging agent, polymer composition, crosslinked rubber product and molded article thereof, and method for producing diarylamine compound
US20120135997A1 (en) 2009-07-17 2012-05-31 Shionogi & Co., Ltd. Pharmaceutical composition comprising a lactam or benzenesulfonamide compound
WO2011011597A1 (en) 2009-07-24 2011-01-27 Duke University Prochelators useful for inhibiting metal-associated toxicity
FR2948568B1 (en) 2009-07-30 2012-08-24 Sanofi Aventis PHARMACEUTICAL FORMULATION
TWI468402B (en) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 Compounds for the reduction of β-amyloid production
SG178106A1 (en) 2009-08-05 2012-03-29 Versitech Ltd Antiviral compounds and methods of making and using thereof
JP2012197231A (en) 2009-08-06 2012-10-18 Oncotherapy Science Ltd Pyridine and pyrimidine derivative having ttk-inhibiting action
HRP20151258T1 (en) 2009-08-07 2016-02-26 Chugai Seiyaku Kabushiki Kaisha AMINOPIRAZOLA DERIVATIVE
WO2011018894A1 (en) 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
JP5577650B2 (en) 2009-08-24 2014-08-27 コニカミノルタ株式会社 ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, DISPLAY DEVICE AND LIGHTING DEVICE
KR101184115B1 (en) 2009-08-31 2012-09-18 일동제약주식회사 New peptide deformylase inhibitor compounds and the manufacturing process thereof
AU2010289397B2 (en) 2009-09-03 2016-05-26 Bioenergenix Heterocyclic compounds for the inhibition of PASK
JP5728683B2 (en) 2009-09-04 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
WO2011031740A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
US9481675B2 (en) 2009-09-11 2016-11-01 Merck Sharp & Dohme Corp. Gyrase inhibitors
EP2483275B1 (en) 2009-10-01 2014-10-15 Merck Sharp & Dohme Corp. HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
US8466155B2 (en) 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
GB0917571D0 (en) 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
EP2308866A1 (en) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles and their use as fungicides
FR2951172B1 (en) 2009-10-13 2014-09-26 Pf Medicament PYRAZOLOPYRIDINE DERIVATIVES AS ANTI-CANCER AGENT
CN102666537A (en) 2009-10-20 2012-09-12 艾格尔生物制药股份有限公司 Azaindazoles to treat flaviviridae virus infection
KR20110043270A (en) 2009-10-21 2011-04-27 (주)씨에스엘쏠라 Organic light emitting compound and organic light emitting device having same
JP5694345B2 (en) 2009-10-22 2015-04-01 ギリアード サイエンシーズ， インコーポレイテッド Regulators of TOLL-like receptors
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
SG10201500511TA (en) 2009-10-26 2015-03-30 Signal Pharm Llc Methods Of Synthesis And Purification Of Heteroaryl Compounds
EP2493864B1 (en) 2009-10-30 2014-10-01 Novartis AG N-oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea
KR20110049217A (en) 2009-11-04 2011-05-12 다우어드밴스드디스플레이머티리얼 유한회사 Novel organic light emitting compound and organic electroluminescent device employing the same
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
CN106220623A (en) 2009-11-06 2016-12-14 普莱希科公司 Compounds and methods for and indication thereof for kinases regulation
EA024729B1 (en) 2009-11-13 2016-10-31 Джиноско Kinase inhibitors
ES2627911T3 (en) 2009-11-18 2017-08-01 Plexxikon, Inc. N- [2-Fluoro-3- (4-amino-7H-pyrrolo [2,3-d] pyrimidin-5-carbonyl) -phenyl] -4-benzenesulfonamide derivatives as modulators of the Raf protein kinase for the treatment of Cancer
JP2013032290A (en) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd Novel fused pyrimidine derivative
US20120232073A1 (en) 2009-11-23 2012-09-13 Santhosh Francis Neelamkavil Fused bicyclic pyrimidine derivatives and methods of use thereof
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
EP2332939A1 (en) 2009-11-26 2011-06-15 Æterna Zentaris GmbH Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
PH12012501000A1 (en) 2009-12-01 2013-02-11 Abbvie Inc Novel tricyclic compounds
JP2011116840A (en) 2009-12-02 2011-06-16 Fujifilm Corp Pigment fine particle dispersion, photocurable composition using the same, and color filter
AR079257A1 (en) 2009-12-07 2012-01-04 Novartis Ag CRYSTAL FORMS OF 3- (2,6-DICLORO-3-5-DIMETOXI-PHENYL) -1- {6- [4- (4-ETIL-PIPERAZIN-1-IL) -PENYL-AMINO] -PIRIMIDIN-4- IL} -1-METHYL-UREA AND SALTS OF THE SAME
KR101445012B1 (en) 2009-12-17 2014-09-26 머크 샤프 앤드 돔 코포레이션 Aminopyrimidines as syk inhibitors
WO2011075620A1 (en) 2009-12-18 2011-06-23 Novartis Ag Method for treating haematological cancers
KR101758046B1 (en) 2009-12-22 2017-07-14 버텍스 파마슈티칼스 인코포레이티드 Isoindolinone inhibitors of phosphatidylinositol 3-kinase
FR2954317B1 (en) 2009-12-23 2012-01-27 Galderma Res & Dev NOVEL PHENOLIC DERIVATIVES, AND THEIR PHARMACEUTICAL OR COSMETIC USE
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
FR2954315B1 (en) 2009-12-23 2012-02-24 Galderma Res & Dev NOVEL PHENOLIC DERIVATIVES, AND THEIR PHARMACEUTICAL OR COSMETIC USE
EP2519241A2 (en) 2009-12-28 2012-11-07 Afraxis, Inc. Methods for treating autism
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
US8440828B2 (en) 2009-12-29 2013-05-14 Polyera Corporation Organic semiconductors and devices incorporating same
WO2011080755A1 (en) 2009-12-29 2011-07-07 Advinus Therapeutics Private Limited Fused nitrogen heterocyclic compounds, process of preparation and uses thereof
WO2011082266A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted heterocyclic compounds
WO2011082267A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted triazolo-pyrazine compounds
AU2010339444A1 (en) 2009-12-30 2012-07-19 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds
CN102115026A (en) 2009-12-31 2011-07-06 清华大学 One-dimensional nano-structure, preparation method thereof and method for marking by using one-dimensional nano-structure
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
US20130109758A1 (en) 2010-01-06 2013-05-02 The University Of British Columbia Bisphenol derivative therapeutics and methods for their use
KR101483215B1 (en) 2010-01-29 2015-01-16 한미약품 주식회사 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinases
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CA2789344A1 (en) 2010-02-15 2011-08-18 Jeremy Earle Wulff Synthesis of bicyclic compounds and method for their use as therapeutic agents
WO2011103196A1 (en) 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
SA111320200B1 (en) 2010-02-17 2014-02-16 ديبيوفارم اس ايه Bicyclic Compounds and their Uses as Dual C-SRC / JAK Inhibitors
WO2011102441A1 (en) 2010-02-18 2011-08-25 Ntn株式会社 Thickener, grease, method for producing thickener, method for producing grease, and greased bearing
WO2011103460A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
WO2011103441A1 (en) 2010-02-18 2011-08-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
UY33227A (en) 2010-02-19 2011-09-30 Novartis Ag PIRROLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF THE CDK4 / 6
WO2011103557A1 (en) 2010-02-22 2011-08-25 Advanced Cancer Therapeutics, Llc Small molecule inhibitors of pfkfb3 and glycolytic flux and their methods of use as anti-cancer therapeutics
US8986858B2 (en) 2010-02-26 2015-03-24 Nippon Steel & Sumikin Chemical Co., Ltd. Organic electroluminescent device
US20130045203A1 (en) 2010-03-02 2013-02-21 Emory University Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP
WO2011111880A1 (en) 2010-03-08 2011-09-15 주식회사 메디젠텍 Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3
US20110237599A1 (en) 2010-03-10 2011-09-29 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
AU2011226689B2 (en) 2010-03-11 2016-09-01 Kronos Bio, Inc. Imidazopyridines Syk inhibitors
US8987275B2 (en) 2010-03-16 2015-03-24 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
US8957216B2 (en) 2010-03-24 2015-02-17 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
WO2011123493A1 (en) 2010-03-31 2011-10-06 Bristol-Myers Squibb Company Substituted pyrrolotriazines as protein kinase inhibitors
CN102153551B (en) 2010-04-02 2012-04-25 济南海乐医药技术开发有限公司 Indazole/azaindazole-based diarylcarbamide/thiocarbamide-structure antineoplastic drug
JP5724204B2 (en) 2010-04-07 2015-05-27 コニカミノルタ株式会社 Organic electroluminescence element, display device, and lighting device
CA2792278C (en) 2010-04-13 2019-05-14 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses
BR112012026289A2 (en) 2010-04-16 2016-07-12 Novartis Ag organic compound for use in treating liver cancer
US8822447B2 (en) 2010-04-22 2014-09-02 Janssen Pharmaceutica Nv Indazole compounds useful as ketohexokinase inhibitors
KR20130069640A (en) 2010-04-23 2013-06-26 키네타, 인크. Anti-viral compounds
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
CN103025744A (en) 2010-04-30 2013-04-03 百时美施贵宝公司 Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US8759398B2 (en) 2010-05-03 2014-06-24 Biolink Life Sciences, Inc. Phosphorus binder composition for treatment of hyperphosphatemia
WO2011140338A1 (en) 2010-05-05 2011-11-10 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
WO2011141848A1 (en) 2010-05-11 2011-11-17 Pfizer Inc. Morpholine compounds as mineralocorticoid receptor antagonists
TWI513694B (en) 2010-05-11 2015-12-21 Amgen Inc Pyrimidine compounds that inhibit anaplastic lymphoma kinase
RU2012153241A (en) 2010-05-11 2014-06-20 Авео Фармасьютикалз, Инк. ANTIBODIES TO FGFR2
ES2871021T3 (en) 2010-05-12 2021-10-28 Spectrum Pharmaceuticals Inc Lanthanum Carbonate Hydroxide, Lanthanum Oxycarbonate and Procedures for Manufacture and Use
MX2012013197A (en) 2010-05-12 2013-04-03 Abbvie Inc Indazole inhibitors of kinase.
GB201008134D0 (en) 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
WO2011147199A1 (en) 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treating viral infections
WO2011147198A1 (en) 2010-05-28 2011-12-01 Versitech Limited Compounds and methods for treatment of proliferative diseases
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
ES2577829T3 (en) 2010-06-04 2016-07-19 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as modulators of LRRK2
WO2011155983A1 (en) 2010-06-07 2011-12-15 Bikam Pharmaceuticals Inc. Opsin-binding ligands, compositions and methods of use
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
KR101486782B1 (en) 2010-06-27 2015-01-28 킹 사우드 유니버시티 One-time password authentication with infinite nested hash chains
ES2706066T3 (en) 2010-07-02 2019-03-27 Univ Health Network Procedure directed to mutant diseases with PTEN and compositions for them
FR2962437B1 (en) 2010-07-06 2012-08-17 Sanofi Aventis IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC APPLICATION
FR2962438B1 (en) 2010-07-06 2012-08-17 Sanofi Aventis INDOLIZINE DERIVATIVES, PREPARATION METHODS AND THERAPEUTIC APPLICATION
US20130109682A1 (en) 2010-07-06 2013-05-02 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
WO2012003544A1 (en) 2010-07-09 2012-01-12 The Walter And Eliza Hall Institute Of Medical Research Protein kinase inhibitors and methods of treatment
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
US20130210807A1 (en) 2010-07-14 2013-08-15 Nigel J Liverton Tricyclic Compounds as Allosteric Modulators of Metabotropic Glutamate Receptors.
TW201206946A (en) 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production
US20130225581A1 (en) 2010-07-16 2013-08-29 Kyowa Hakko Kirin Co., Ltd Nitrogen-containing aromatic heterocyclic derivative
WO2012008564A1 (en) 2010-07-16 2012-01-19 協和発酵キリン株式会社 Nitrogenated aromatic heterocyclic ring derivative
CA2806655A1 (en) 2010-07-28 2012-02-02 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
EP2413140A1 (en) 2010-07-29 2012-02-01 Sanofi Method for identifying a compound having an antiarrhythmic effect as well as uses relating thereto
TW201300501A (en) 2010-07-30 2013-01-01 羅門哈斯電子材料韓國公司 Electroluminescent device using electroluminescent compound as luminescent material
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012027239A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRROLO[3,2-e]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8975260B2 (en) 2010-09-01 2015-03-10 Genetech, Inc Pyridazinones, method of making, and method of use thereof
CA2809836C (en) 2010-09-01 2019-01-15 Gilead Connecticut, Inc. Pyridinones/pyrazinones, method of making, and method of use thereof for the treatment of disorders mediated by bruton's tyrosine kinase
AR082799A1 (en) 2010-09-08 2013-01-09 Ucb Pharma Sa DERIVATIVES OF QUINOLINE AND QUINOXALINE AS QUINASE INHIBITORS
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
RS54286B1 (en) 2010-09-08 2016-02-29 Glaxosmithkline Intellectual Property Development Limited POLYMORPHS AND SALTS N- [5- [4- (5 - {[(2R, 6S) -2,6-DIMETHYL-4-MORPHOLINYL] METHYL} -1,3-OXAZOL-2-yl) -1H-INDAZZOL- 6-IL] -2 (methyloxy) -3-pyridinyl] -methanesulfonamide
TWI541243B (en) 2010-09-10 2016-07-11 拜耳知識產權公司 Substituted imidazopyridazines
CN103238117A (en) 2010-09-14 2013-08-07 保土谷化学工业株式会社 Charge control agent and toner using same
CN102399220A (en) 2010-09-15 2012-04-04 黄振华 Tricyclic dual PI3K and mTOR inhibitors
CN102399233B (en) 2010-09-15 2014-08-13 山东轩竹医药科技有限公司 Dual PI3K and mTOR inhibitor compounds
WO2012036233A1 (en) 2010-09-17 2012-03-22 塩野義製薬株式会社 Condensed heterocyclic derivative having melanine-concentrating hormone receptor antagonistic activity
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
JO3062B1 (en) 2010-10-05 2017-03-15 Lilly Co Eli Crystalline (r)-(e)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1h-indazol-3-yl)vinyl)-1h-pyrazol-1-yl)ethanol
WO2012054364A2 (en) 2010-10-22 2012-04-26 Merck Sharp & Dohme Corp. Bicyclic diamines as janus kinase inhibitors
MX338327B (en) 2010-10-25 2016-04-12 G1 Therapeutics Inc Cdk inhibitors.
JP2012092049A (en) 2010-10-27 2012-05-17 Sumitomo Chemical Co Ltd Pest control composition and method for controlling pest
CA2816022C (en) 2010-10-29 2019-09-10 Emory University Quinazoline derivatives, compositions, and uses related thereto
WO2012061337A1 (en) 2010-11-02 2012-05-10 Exelixis, Inc. Fgfr2 modulators
JP2013545740A (en) 2010-11-10 2013-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Substituted heteroaromatic carboxamide derivatives and urea derivatives as vanilloid receptor ligands
CA2815179A1 (en) 2010-11-10 2012-05-18 Actelion Pharmaceuticals Ltd Lactam derivatives useful as orexin receptor antagonists
JP2012116825A (en) 2010-11-11 2012-06-21 Ehime Univ Method for producing acene diimide compound
KR101171232B1 (en) 2010-11-15 2012-08-06 단국대학교 산학협력단 Spiro Compound and Organic Light Emitting Device Including the Same
WO2012065297A1 (en) 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
MX2013005567A (en) 2010-11-17 2013-10-30 Amgen Inc Quinoline derivatives as pik3 inhibitors.
KR101817221B1 (en) 2010-11-18 2018-01-10 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
WO2012080729A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
EP2468258A1 (en) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
CA2822312A1 (en) 2010-12-22 2012-06-28 Gunnar Grue-Sorensen 3-acyl-ingenols ii
JP5845283B2 (en) 2010-12-22 2016-01-20 レオ・ラボラトリーズ・リミテッドＬｅｏ Ｌａｂｏｒａｔｏｒｉｅｓ Ｌｉｍｉｔｅｄ Ingenol-3-acylate III and ingenol-3-carbamate
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
WO2012083866A1 (en) 2010-12-22 2012-06-28 The Hong Kong Polytechnic University Quinoline derivatives as anti-cancer agents
MX2013007261A (en) 2010-12-23 2013-11-04 Amgen Inc Heterocyclic compounds and their uses.
JP5691508B2 (en) 2010-12-27 2015-04-01 Jnc株式会社 Diimide compound and inkjet ink and use thereof
KR101466150B1 (en) 2010-12-31 2014-11-27 제일모직 주식회사 Compound for organic photoelectric device and organic photoelectric device including the same
CN103328488B (en) 2011-01-06 2015-12-09 吉坤日矿日石能源株式会社 Imide compound and manufacture method, lubricating grease thickening material and grease composition
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
FR2970967B1 (en) 2011-01-27 2013-02-15 Pf Medicament AZAINDAZOLE OR DIAZAINDAZOLE DERIVATIVES AS A MEDICINAL PRODUCT
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
US9434747B2 (en) 2011-02-18 2016-09-06 Medivation Technologies, Inc. Methods of treating diabetes
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
TWI532742B (en) 2011-02-28 2016-05-11 艾伯維有限公司 Tricyclic inhibitors of kinases
AU2012229107A1 (en) 2011-03-17 2013-09-19 Novartis Ag FGFR and ligands thereof as biomarkers for breast cancer in HR positive subjects
EP2937349B1 (en) 2011-03-23 2016-12-28 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
ITPD20110091A1 (en) 2011-03-24 2012-09-25 Univ Padova USEFUL INHIBITORS FOR RELATED PATHOLOGIES: PHARMACOFORIC MODELS, IDENTIFIED COMPOUNDS BY THESE MODELS, METHODS FOR THEIR PREPARATION, THEIR FORMULATION AND THEIR THERAPEUTIC USE.
EP2688866A1 (en) 2011-03-25 2014-01-29 AbbVie Inc. Trpv1 antagonists
CA2828890A1 (en) 2011-04-07 2012-10-11 Genentech, Inc. Anti-fgfr4 antibodies and methods of use
FR2974088A1 (en) 2011-04-12 2012-10-19 Pf Medicament TRI- AND TETRACYCLIC PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS AS ANTI-CANCER AGENTS
EA030462B1 (en) 2011-05-16 2018-08-31 Дженентек, Инк. Fgfr1 agonists and methods of use thereof
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
US20140288069A1 (en) 2011-05-17 2014-09-25 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
MX2013013437A (en) 2011-05-19 2013-12-06 Novartis Ag 4-amino-5-fluoro-3- [6- (4 -methylpiperazin- 1 - yl) - 1h - benzimidazol - 2 - yl] - 1h - quinoli n-2-one for use in the treatment of adenoid cystic carcinoma.
WO2012163942A1 (en) 2011-06-01 2012-12-06 Bayer Intellectual Property Gmbh Substituted aminoimidazopyridazines
AR086656A1 (en) 2011-06-03 2014-01-15 Millennium Pharm Inc COMBINATION OF MEK INHIBITORS AND SELECTIVE INHIBITORS OF QUINASA AURORA A
EP2719742B1 (en) 2011-06-13 2016-04-27 LG Chem, Ltd. Novel compounds and organic electronic device using same
WO2012175591A1 (en) 2011-06-22 2012-12-27 Bayer Intellectual Property Gmbh Heterocyclyl aminoimidazopyridazines
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
AU2012295802B2 (en) 2011-08-12 2017-03-30 Nissan Chemical Industries, Ltd. Tricyclic heterocyclic compounds and JAK inhibitors
EP2742046A1 (en) 2011-08-12 2014-06-18 F.Hoffmann-La Roche Ag PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE
JP2013049251A (en) 2011-08-31 2013-03-14 Fujifilm Corp Relief printing plate original plate for laser engraving, and, relief printing plate and method for producing the same
WO2013033981A1 (en) 2011-09-06 2013-03-14 江苏先声药物研究有限公司 2,7-naphthyridine derivative, preparation method therefor and use thereof
WO2013039854A1 (en) 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
US9376435B2 (en) 2011-09-23 2016-06-28 Jawaharlal Nehru Centre For Advanced Scientific Research Chromophores for the detection of volatile organic compounds
CA2849345A1 (en) 2011-09-23 2013-03-28 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
CN103842364A (en) 2011-09-30 2014-06-04 奇尼塔公司 Anti-viral compounds
UA111382C2 (en) 2011-10-10 2016-04-25 Оріон Корпорейшн Protein kinase inhibitors
KR101897044B1 (en) 2011-10-20 2018-10-23 에스에프씨 주식회사 Organic metal compounds and organic light emitting diodes comprising the same
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
RU2014120792A (en) 2011-10-28 2015-12-10 Новартис Аг METHOD FOR TREATING STOMAL TUMORS OF THE GASTROINTESTINAL TRACT
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
FR2985258A1 (en) 2011-12-28 2013-07-05 Sanofi Sa FGFS RECEPTOR AGONISTIC DIMERS (FGFRS), PREPARATION METHOD AND THERAPEUTIC USE THEREOF
FR2985257B1 (en) 2011-12-28 2014-02-14 Sanofi Sa FGFS RECEPTOR AGONISTIC DIMERS (FGFRS), PREPARATION METHOD AND THERAPEUTIC USE THEREOF
US10026905B2 (en) 2012-01-18 2018-07-17 Duk San Neolux Co., Ltd. Compound, organic electric element using the same, and an electronic device thereof
WO2013109027A1 (en) 2012-01-18 2013-07-25 덕산하이메탈(주) Compound, organic electronic element using same and electronic device thereof
MY171055A (en) 2012-01-19 2019-09-23 Taiho Pharmaceutical Co Ltd 3,5-disubstituted alkynylbenzene compound and salt thereof
JP6082033B2 (en) 2012-02-23 2017-02-15 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Substituted benzothienyl-pyrrolotriazines and uses thereof
JP2013179181A (en) 2012-02-28 2013-09-09 Sumitomo Chemical Co Ltd Organic photoelectric conversion element
NZ629432A (en) 2012-03-14 2017-01-27 Lupin Ltd Heterocyclyl compounds as mek inhibitors
US20150072019A1 (en) 2012-03-30 2015-03-12 Novartis Ag Fgfr inhibitor for use in the treatment of hypophosphatemic disorders
JP5120580B1 (en) 2012-05-14 2013-01-16 Ｊｓｒ株式会社 Liquid crystal alignment agent
LT2852354T (en) 2012-05-20 2020-09-25 Tel Hashomer Medical Research Infrastructure And Services Ltd. MITRAL VALVE PROSTHESIS
RS58514B1 (en) 2012-06-13 2019-04-30 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
IN2014DN10801A (en) 2012-07-11 2015-09-04 Novartis Ag
SG11201500125QA (en) 2012-07-11 2015-02-27 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
WO2014019186A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015106909A (en) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. ANTI-DIABETIC TRICYCLIC COMPOUNDS
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
KR101985259B1 (en) 2012-08-10 2019-06-03 제이에스알 가부시끼가이샤 Liquid crystal aligning agent and compound
WO2014044846A1 (en) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
WO2014062454A1 (en) 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
KR102000211B1 (en) 2012-10-29 2019-09-30 삼성디스플레이 주식회사 Organometallic compound and organic light emitting diode comprising the same
RS56680B1 (en) 2012-11-28 2018-03-30 Merck Sharp & Dohme Compositions and methods for treating cancer
US20140148548A1 (en) 2012-11-28 2014-05-29 Central Glass Company, Limited Fluorine-Containing Polymerizable Monomer And Polymer Compound Using Same
CN104968664A (en) 2012-12-12 2015-10-07 山东亨利医药科技有限责任公司 Bicyclic compound functioning as tyrosine kinase inhibitor
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014105849A1 (en) 2012-12-28 2014-07-03 Xoma (Us) Llc Antibodies specific for fgfr4 and methods of use
TWI629266B (en) 2012-12-28 2018-07-11 藍印藥品公司 Inhibitors of the fibroblast growth factor receptor
KR102030587B1 (en) 2013-01-09 2019-10-10 에스에프씨주식회사 Asymmetric antracene derivatives having two naphthyl groups and organic light-emitting diode including the same
EP2945623B1 (en) 2013-01-15 2018-09-05 Suzhou Kintor Pharmaceuticals, Inc. Hedgehog pathway signaling inhibitors and therapeutic applications thereof
CN103694236B (en) 2013-01-15 2017-05-31 苏州开拓药业股份有限公司 A kind of pyrimidine scaffold has the antitumoral compounds of activity of hedgehog path antagonist
KR101456626B1 (en) 2013-02-01 2014-11-03 대영이앤비 주식회사 Apparatus for protecting negative pressure of refrigerator
JP6311093B2 (en) 2013-03-07 2018-04-18 国立大学法人九州大学 Sensor elements for detecting supramolecular complexes, light emitters, and organic compounds
WO2014138485A1 (en) 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
EP2968285A4 (en) 2013-03-13 2016-12-21 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
EP2970258B1 (en) 2013-03-14 2018-04-18 AbbVie Deutschland GmbH & Co KG Novel inhibitor compounds of phosphodiesterase type 10a
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
CN105307657B (en) 2013-03-15 2020-07-10 西建卡尔有限责任公司 Heteroaryl compounds and their uses
EP3943087A1 (en) 2013-03-15 2022-01-26 Celgene CAR LLC Heteroaryl compounds and uses thereof
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
TWI628176B (en) 2013-04-04 2018-07-01 奧利安公司 Protein kinase inhibitors
KR101573611B1 (en) 2013-04-17 2015-12-01 주식회사 엘지화학 Fullerene derivatives, organic solar cell using the same and fabricating method thereof
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
WO2014170063A1 (en) 2013-04-19 2014-10-23 Covagen Ag Novel bispecific binding molecules with antitumoral activity
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
WO2014182829A1 (en) 2013-05-09 2014-11-13 Principia Biopharma Inc. Quinolone derivatives as fibroblast growth factor inhibitors
EA030558B1 (en) 2013-06-14 2018-08-31 Санофи Pyrazolopyridine derivatives for use in the treatment of bladder cancer
EP3013797B1 (en) 2013-06-28 2018-01-03 BeiGene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
EA029412B1 (en) 2013-06-28 2018-03-30 Бейджин, Лтд. FUSED TRICYCLIC UREA COMPOUNDS AS Raf KINASE AND/OR Raf KINASE DIMER INHIBITORS
CA2917262A1 (en) 2013-07-02 2015-01-08 Syngenta Participations Ag Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents
KR102173433B1 (en) 2013-07-11 2020-11-04 에이시아 바이오사이언시스 인코포레이티드. Pyrimidine derivatives as kinase inhibitors
AR097455A1 (en) 2013-08-28 2016-03-16 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION CONTAINING PYRIMIDINE COMPOSITE AS AN ACTIVE INGREDIENT
PH12016500676B1 (en) 2013-10-18 2022-07-20 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
TN2016000115A1 (en) 2013-10-25 2017-07-05 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors.
RS63405B1 (en) 2013-10-25 2022-08-31 Blueprint Medicines Corp FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS
FR3012330B1 (en) 2013-10-29 2015-10-23 Oreal BIPHASE COMPOSITION COMPRISING AN ESTER OF FATTY ACID AND SUGAR OR A LIQUID ALKYLPOLYGLUCOSIDE OF HLB <8, AND A C8-C18 BRANCHED ALKANE
WO2015066452A2 (en) 2013-11-01 2015-05-07 Foundation Medicine, Inc. Methods of treating pediatric cancers
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
CN104262330B (en) 2014-08-27 2016-09-14 广东东阳光药业有限公司 A kind of urea substituted biphenyl compounds and combinations thereof thing and purposes
AU2015316796A1 (en) 2014-09-19 2017-03-30 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as Bub1 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US20160115164A1 (en) 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
TWI712601B (en) 2015-02-20 2020-12-11 美商英塞特公司 Bicyclic heterocycles as fgfr inhibitors
PE20180021A1 (en) 2015-02-20 2018-01-09 Univ Oregon Health & Science DERIVATIVES OF SOBETHROMA
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
IT201600073305A1 (en) 2015-07-15 2018-01-13 Cabot Corp Silica-reinforced elastomer composite and products containing it.
UA120463C2 (en) 2015-07-15 2019-12-10 Ф. Хоффманн-Ля Рош Аг ETHYNILE DERIVATIVES AS MODULATORS OF THE METABOTROPIC GLUTAMATE RECEPTOR
MX384213B (en) 2015-07-15 2025-03-14 Protagonist Therapeutics Inc PEPTIDE INHIBITORS OF THE INTERLEUKIN 23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES.
MY189596A (en) 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
HUE068868T2 (en) 2015-07-30 2025-02-28 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
US10208024B2 (en) 2015-10-23 2019-02-19 Array Biopharma Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
MA44075A (en) 2015-12-17 2021-05-19 Incyte Corp N-PHENYL-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS MODULATORS OF PROTEIN / PROTEIN PD-1 / PD-L1 INTERACTIONS
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
AR108396A1 (en) 2016-05-06 2018-08-15 Incyte Corp HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060256T2 (en) 2016-06-20 2023-02-28 Incyte Corp Heterocyclic compounds as immunomodulators
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
AU2017339890A1 (en) 2016-10-05 2019-04-11 Recurium Ip Holdings, Llc Spirocyclic compounds
KR101755556B1 (en) 2016-11-18 2017-07-07 주식회사 케마스 Pharmaceutical composition for prevention or treatment of brain cancer comprising polymorphic form of tetraarsenic oxide and preparation method thereof
KR101834366B1 (en) 2016-11-21 2018-03-05 주식회사 케마스 Pharmaceutical composition for prevention or treatment of breast cancer comprising polymorphic form of tetraarsenic oxide and preparation method thereof
KR101844049B1 (en) 2016-12-05 2018-03-30 주식회사 케마스 Pharmaceutical composition for prevention or treatment of liver cancer comprising polymorphic form of tetraarsenic oxide
KR101844050B1 (en) 2016-12-09 2018-05-14 주식회사 케마스 Pharmaceutical composition for prevention or treatment of cancer comprising polymorphic form of tetraarsenic oxide
LT3558990T (en) 2016-12-22 2022-12-27 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
ES2874756T3 (en) 2016-12-22 2021-11-05 Incyte Corp Triazolo [1,5-A] pyridine derivatives as immunomodulators
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
JP7101678B2 (en) 2016-12-22 2022-07-15 インサイト・コーポレイション Heterocyclic compounds as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
US11242334B2 (en) 2017-08-22 2022-02-08 Js Innopharm (Shanghai) Ltd. Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
EP3717471B1 (en) 2017-12-02 2022-01-05 Galapagos NV Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
SMT202500157T1 (en) 2018-03-30 2025-05-12 Incyte Corp Heterocyclic compounds as immunomodulators
HRP20241288T1 (en) 2018-05-04 2024-12-06 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
HUE061503T2 (en) 2018-05-11 2023-07-28 Incyte Corp Tetrahydroimidazo[4,5-C]pyridine derivatives as PD-L1 immunomodulators
US10947236B2 (en) 2018-08-14 2021-03-16 Osteoqc Inc. Pyrrolo-dipyridine compounds
CN112654396B (en) 2018-09-07 2025-07-01 默克专利股份公司 5-Morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives
US12351571B2 (en) 2018-12-19 2025-07-08 Array Biopharma Inc. Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011597A2 (en) * 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2015006492A1 (en) * 2013-07-09 2015-01-15 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"PDR", 1996, MEDICAL ECONOMICS COMPANY, article "Physicians' Desk Reference"
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1418
ESWARAKUMAR ET AL., CYTOKINE & GROWTH FACTOR REVIEWS, 2005
FRENCH ET AL.: "Targeting FGFR4 Inihibits Hepatocellular Carcinoma in Preclinical Mouse Models", PLOS ONE, vol. 7, no. 5, May 2012 (2012-05-01), pages E36713, XP055028245, DOI: doi:10.1371/journal.pone.0036713
HEINZLE ET AL., CUR. PHARM. DES., vol. 20, 2014, pages 2881
JOURNAL OFPHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2
K. BLOM: "Two-Pump At Column Dilution Configuration for Preparative LC-MS", J. COMBI. CHEM., vol. 4, 2002, pages 295
K. BLOM; B. GLASS; R. SPARKS; A. COMBS: "Preparative LCMS Purification: Improved Compound Specific Method Optimization", J. COMB. CHEM., vol. 6, 2004, pages 874 - 883
K. BLOM; B. GLASS; R. SPARKS; A. COMBS: "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", J. COMBI. CHEM., vol. 6, 2004, pages 874 - 883
K. BLOM; R. SPARKS; J. DOUGHTY; G. EVERLOF; T. HAQUE; A. COMBS: "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", J. COMBI. CHEM., vol. 5, 2003, pages 670
KNIGHTS; COOK, PHARMACOLOGY & THERAPEUTICS, 2010
T.W. GREENE; P.G.M. WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY & SONS, INC.
TAYLOR ET AL., JCI, vol. 119, 2009, pages 3395
TURNER; GROSE, NATURE REVIEWS CANCER, 2010

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10196436B2 (en) 2012-07-11 2019-02-05 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US10875837B2 (en) 2013-10-25 2020-12-29 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US10221154B2 (en) 2013-10-25 2019-03-05 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US10000490B2 (en) 2014-01-15 2018-06-19 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
WO2018083603A1 (en) 2016-11-02 2018-05-11 Novartis Ag Combinations of fgfr4 inhibitors and bile acid sequestrants
WO2019047826A1 (en) 2017-09-05 2019-03-14 博奥阿迪斯生物科技公司 Aromatic derivative, preparation method for same, and medical applications thereof
US11279697B2 (en) 2017-09-05 2022-03-22 Bioardis Llc Aromatic derivative, preparation method for same, and medical applications thereof
WO2019089667A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Bridged bicyclic compounds as farnesoid x receptor modulators
US11286248B2 (en) 2018-02-08 2022-03-29 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Pyrazine-2(1H)-ketone compound acting as FGFR inhibitor
US11958844B2 (en) 2018-07-26 2024-04-16 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11866432B2 (en) 2018-10-11 2024-01-09 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11976058B2 (en) 2019-03-05 2024-05-07 Bioardis Llc Aromatic derivatives, preparation methods, and medical uses thereof
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US12440484B2 (en) 2019-05-31 2025-10-14 Chong Kun Dang Pharmaceutical Corporation 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
US11603366B2 (en) 2019-08-08 2023-03-14 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Crystalline form and B crystalline form of pyrazine-2(1H)-ketone compound and preparation method thereof
EP4011866A4 (en) * 2019-08-08 2022-08-24 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd CRYSTALLINE FORM A AND CRYSTALLINE FORM B OF PYRAZINE-2(1H)-KETONE COMPOUND AND METHOD FOR PREPARING IT
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
US12312331B2 (en) 2019-08-14 2025-05-27 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
US12466828B2 (en) 2019-10-11 2025-11-11 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12209086B2 (en) 2021-03-04 2025-01-28 Eli Lilly And Company FGFR3 inhibitor compounds
AU2022229380B2 (en) * 2021-03-04 2025-05-08 Eli Lilly And Company Fgfr3 inhibitor compounds
US11878976B2 (en) 2021-03-04 2024-01-23 Eli Lilly And Company FGFR3 inhibitor compounds
WO2022187443A1 (en) * 2021-03-04 2022-09-09 Eli Lilly And Company Fgfr3 inhibitor compounds
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment
WO2025036876A2 (en) 2023-08-16 2025-02-20 ONA Therapeutics S.L. New anti-cancer approaches
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025232848A1 (en) * 2024-05-09 2025-11-13 Insilico Medicine Ip Limited Salt-inducible kinases (sik) inhibitors and methods of uses thereof
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026013630A1 (en) * 2024-07-10 2026-01-15 Best Agrolife Limited An improved process for preparation of broflanilide
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Also Published As

Publication number Publication date
KR20170127467A (en) 2017-11-21
US10632126B2 (en) 2020-04-28
US20190269693A1 (en) 2019-09-05
SG10201913036RA (en) 2020-02-27
CL2017002123A1 (en) 2018-03-16
PE20171514A1 (en) 2017-10-20
US9708318B2 (en) 2017-07-18
PH12017501481A1 (en) 2018-02-05
EP3259269B1 (en) 2019-09-04
US11173162B2 (en) 2021-11-16
BR112017017418A2 (en) 2018-04-10
US20160244449A1 (en) 2016-08-25
CN113004278B (en) 2023-07-21
CN107438607B (en) 2021-02-05
MX373169B (en) 2020-04-24
CN113004278A (en) 2021-06-22
CN107438607A (en) 2017-12-05
MX2020004108A (en) 2022-01-03
US10251892B2 (en) 2019-04-09
US20200306256A1 (en) 2020-10-01
EA201791866A1 (en) 2017-12-29
EP3259269A1 (en) 2017-12-27
JP2020121994A (en) 2020-08-13
IL253691B (en) 2020-11-30
CA2976790A1 (en) 2016-08-25
NZ773116A (en) 2024-05-31
AU2016219822B2 (en) 2020-07-09
AU2020250211A1 (en) 2020-11-05
UA121669C2 (en) 2020-07-10
BR112017017418A8 (en) 2023-01-24
HK1246794A1 (en) 2018-09-14
JP2018511573A (en) 2018-04-26
ECSP17062712A (en) 2017-11-30
EP3617205B1 (en) 2021-08-04
JP6689871B2 (en) 2020-04-28
EP3259269B9 (en) 2020-03-04
ES2751669T3 (en) 2020-04-01
EP3617205A1 (en) 2020-03-04
MX2017010673A (en) 2018-03-21
CR20170390A (en) 2017-10-23
CA2976790C (en) 2024-02-27
TW201639838A (en) 2016-11-16
ES2751669T9 (en) 2020-05-21
MX388991B (en) 2025-03-20
US20170290839A1 (en) 2017-10-12
NZ734586A (en) 2024-05-31
AU2016219822A1 (en) 2017-08-31
SG11201706287PA (en) 2017-09-28
EA038045B1 (en) 2021-06-28
ES2895769T3 (en) 2022-02-22
PH12017501481B1 (en) 2018-02-05
TWI712601B (en) 2020-12-11
CO2017008795A2 (en) 2018-01-16
MA51229A (en) 2021-03-24
IL253691A0 (en) 2017-09-28
KR102632018B1 (en) 2024-02-02
AU2020250211B2 (en) 2022-09-29
MY197720A (en) 2023-07-10

Similar Documents

Publication Publication Date Title
AU2020250211B2 (en) Bicyclic heterocycles as fgfr inhibitors
US9801889B2 (en) Bicyclic heterocycles as FGFR4 inhibitors
EP3318564B1 (en) Bicyclic heterocycles as fgfr inhibitors
HK40022691B (en) Bicyclic heterocycles as fgfr inhibitors
HK40022691A (en) Bicyclic heterocycles as fgfr inhibitors
HK1246794B (en) Bicyclic heterocycles as fgfr inhibitors
BR112017017418B1 (en) BICYCLIC HETEROCYCLES AS FGFR INHIBITORS, THEIR USE AND THE PHARMACEUTICAL COMPOSITION INCLUDING THEM

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16706767

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 253691

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2976790

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11201706287P

Country of ref document: SG

Ref document number: 12017501481

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 001424-2017

Country of ref document: PE

ENP Entry into the national phase

Ref document number: 2017544021

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/010673

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017017418

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: NC2017/0008795

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: CR2017-000390

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2016219822

Country of ref document: AU

Date of ref document: 20160219

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2016706767

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20177026449

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201709221

Country of ref document: UA

Ref document number: 201791866

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 112017017418

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170814